memoria 2012

Transcription

memoria 2012

SCIENTIFIC
R E P O R T
2012
SCIENTIFIC REPORT
2012
1
3
Published by:
Fundación Investigación Hospital Clínico Universitario of Valencia
INCLIVA Health Research Institute
Avd. Blasco Ibáñez, 17 – 46010 Valencia
Direction:
Dr. Josep Redón i Mas. Scientific Director.
Coordination and writing:
Scientific Management Department
Fundación Investigación Hospital Clínico Universitario of Valencia
Design and layout:
www.valledor.net
Printing:
Gráficas Papallona (Valencia)
Index
1.
Introduction ...............................................................................................................................
9
2.
2.1.
2.2.
2.2.1.
2.2.2.
2.2.3.
2.2.4.
2.2.5.
2.2.6.
2.2.7.
2.2.8.
2.2.9.
2.2.10.
INCLIVA Health Research Institute ........................................................................................
History ........................................................................................................................................
Organizational structure ............................................................................................................
Organization chart .....................................................................................................................
Board of Trustees .....................................................................................................................
Board of Governors ...................................................................................................................
General Director ........................................................................................................................
Scientific Director .......................................................................................................................
External Scientific Committee ....................................................................................................
Internal Scientific Committee .....................................................................................................
Ethical Committee in Clinical Research .....................................................................................
Ethical Committee in Animal Experimentation ...........................................................................
Management Structure..............................................................................................................
15
17
17
17
18
18
19
19
19
20
21
22
23
3.
3.1.
3.2.
3.3.
3.4.
Facilities, human, technological and financial resources ..................................................
Facilities .....................................................................................................................................
Human resources ......................................................................................................................
Research support platforms-Core Facilities ...............................................................................
Financial resources ...................................................................................................................
25
27
27
29
45
4.
4.1.
4.1.1.
4.1.2.
4.1.3.
4.1.4.
4.2.
Scientific activity .....................................................................................................................
47
Research Areas .........................................................................................................................
49
Cardiovascular Research Area ..................................................................................................
51
Oncology Research Area ...........................................................................................................
83
Research on Metabolism and Organic Damage Area .............................................................. 119
Research on Reproductive Medicine Area ................................................................................ 161
Other scientific contributions from the Hospital divisions
and the Clínico-Malvarrosa Health Department ......................................................................... 172
5.
5.1.
5.2.
5.3.
Clinical trials and other studies .............................................................................................
Activity of the Ethical Committee in Clinical Research (ECCR) ................................................
Assessment activity during last 5 years .....................................................................................
Ongoing studies in the Health Department Valencia Clínico-Malvarrosa ..................................
6.
6.1.
6.2.
Initiatives for research promotion .......................................................................................... 203
Grants for secondments in centers of excellence ...................................................................... 205
Training and Teaching Activities ................................................................................................ 206
7.
7.1.
7.2.
7.3.
7.4.
INCLIVA in figures ....................................................................................................................
Dissemination of scientific activity .............................................................................................
Networks of cooperative research .............................................................................................
National and international scientific collaborations ....................................................................
Knowledge transfer ....................................................................................................................
191
193
198
200
213
214
215
217
221
8
1
1
2
Introduction
9
1
9
Introduction
1
Once again, by means of this report, INCLIVA Health Research Institute provides an assessment of the scientific activities
carried out within the Hospital Clínico Universitario of Valencia and its Department of Health, and of those groups of excellence
of the University of Valencia and the Instituto Universitario IVI, which incorporated during 2012. The present year is the first
full one since receiving accreditation as a Health Research Institute by the Ministry of Science and Innovation via the Carlos III
Health Institute (Instituto de Salud Carlos III).
Following the efforts in the area of quality, and thanks to the aforementioned accreditation obtained in 2011, this year INCLIVA has won the ISO 9001:2008 certification. This award reinforces the Institute’s image of excellence, is in recognition of
the maturity and effectiveness of its quality management system and confirms its will to continually progress in order to give
a day by day response that meets the expectations of its customers. With respect to ISO 9001, INCLIVA not only meets the
requirements of the standard, but also raises, transforms and guarantees the quality of the R&D&I management services, thus
establishing the basis for a continual improvement in each and every one of the operations that it carries out.
Upon the certification of its Secretariat, INCLIVA has initiated the same process in the Ethical Committee in Clinical Research (ECCR) of the Hospital Clínico Universitario of Valencia and has collaborated with the certification of the Central
Research Unit laboratories of the Faculty of Medicine and Dentistry at the University of Valencia. The certification of these
activities is projected for the first half of next year.
Scientific production, moreover, has increased significantly in comparison to previous years. From the 491 papers published
in 2011, the total has risen to 512 this year, representing an increase of 4%. This increase in output has been accompanied by
an increase in cumulative impact factor, which is above 2000, an increase of nearly 5% over 2011. Furthermore, the number
of items published in cooperation with international authors has experienced an increase of over 50% from the previous year.
It is worth noting that papers published in journals within the first and second quartiles of their respective categories have represented 51% and 19% of the total production, respectively.
The associated research groups have competitively obtained and developed 170 research projects, both European (10
projects within the 7th Framework Programme), as well as national (94 projects under the National R&D&I Plan) and regional
(36 projects funded by the Generalitat Valenciana) ones. In addition to these research studies are those obtained from private
entities via concours, amounting to a total of 28 projects. Additionally, INCLIVA has been funded within the framework of the
Emerging Support Groups, with a total of 12 research initiatives proposed by young researchers. Furthermore, the groups have
been active in research networks of excellence (CAIBER, CIBER and RETICS).
11
Introduction
In the area of clinical research, the Ethical Committee in Clinical Research (ECCR) has processed a total of 114 trials, thus
continuing the upward trend of recent years. With the commencement of these studies, we have developed a total of 310
clinical trials and other studies during the year. In fact, 80% of these studies were clinical trials, and the remaining 20% were
observational studies or of other design. It is important to point out the importance of this early stage research to the clinical research center, since the number of Phase I and Phase II trials has represented almost 40% of those developed at the institute.
12
1
INCLIVA has competed for this year’s PROMIIS, which are directed exclusively at health research institutes, and is among
the top-ranked, ahead of other larger institutions. The funding received will go towards the development of a centralized bioinformatics platform in the new Institute building. Moreover, the INCLIVA has entered as a full member of the Network of Hospital
and Biomedical Clinical Research Management Entities (REGIC), an association that brings together the main organizations
managing R&D&I in the field of healthcare in Spain.
Among the activities to promote the culture of research, during 2012 the Institute continued with its Training Plan with the
objective of promoting educational activities by collaborating with the different hospital services in the organization and management of 25 courses, conferences and seminars. In addition, this year the Institute has funded a total of 15 stays in specialized centers of proven leadership in specific techniques or procedures.
Finally, the construction of the new Institute building will continue this year, which will mean an increase of 2,100 m² for
research. This new space will facilitate the growth in human resources, infrastructure and new technologies needed to expand
and strengthen the quantity and quality of the equipment utilized and the lines of research developed.
The present privileged position of INCLIVA, as much a result of its acknowledgements as it is the maintenance of its production, has been possible thanks to the efforts of everyone. Nevertheless, we face the challenge of continuing to generate
knowledge and guiding research excellence for the benefit of society.
Rafael Carmena Rodríguez
Josep Redón i Mas
General Director
Scientific Director
2
2
INCLIVA
Health
Research
Institute
15
2
15
2.1. History
The Foundation for the Research of the Hospital Clínico Universitario of Valencia was constituted in the year 2000,
being the first Valencian research foundation attached to a public hospital. In 2010, certain excellence groups in biomedical research from the University of Valencia and IUIVI (Valencian Infertility Institute) joined the Foundation through the
establishment of assignment agreements, thus creating the INCLIVA Health Research Institute.
INCLIVA manages biomedical research performed by the Hospital Clínico Universitario of Valencia and its Health Department and encourages teaching and scientific activities, thus improving patient treatment and knowledge sharing.
After being accredited, in 2011, as a Health Research Institute by the Ministry of Science and Innovation (Ministerio de
Ciencia e Innovación), INCLIVA obtained preferential by the Carlos III Health Institute (Instituto de Salud Carlos III), being
recognized its excellent research.
2.2. Organizational structure
2.2.1. Organization chart
Board of Trustees
Board of Governors
External Scientific Committee
General Director
External Associated Bodies
ECCR
ECAE
Financial Director
Internal Scientific Committee
Scientific Director
The Board of Trustees, the highest government body in the Foundation, is headed by the Honorable Conseller de Sanidad of the Valencian Governement. This body appoints a Board of Governors –headed by the Chief Executive Officer of
the Health Department– the General Director, the Scientific Director, and the Financial Director. All of them count on the
guidance of two Research Committees: the External Scientific Committee and the Internal Scientific Committee.
2
17
2.2.2. Board of Trustees
It is the highest collegiate body in the Institute. It establishes the action directives and has a high representation from
the Valencian society.
Dated December 31st 2012, its members are the following:
18
2
President
• Mr. Manuel Llombart, Honorable Conseller de Sanidad
Vice-president
• Mr. Luis Martí, Chief Executive Officer of the Hospital Clínico Universitario of Valencia
and of the Health Service Department in Valencia’s Clínico – Malvarrosa
Board members according to their positions
•Mr. Esteban Morcillo Sánchez, Lord Rector of the University of Valencia
• Mr. Federico Pallardó Calatayud, Most Illustrious Dean of the Faculty of Medicine
• Mr. Arturo Virosque Ruiz, Valencia Chamber of Commerce
• Mr. Martin Quirós Palau, Valencian Council of Culture
• Mr. Vicente Boquera Amil, Social Council of the University of Valencia
• Mr. Ángel Daniel Villanueva Pareja, Bancaja Foundation
• Mr. Juan López Trigo Pichó, Cañada Blanch Foundation
•Ms. Teresa de Rojas, General Director of planning, evaluation, research, quality and patients care of the
Consellería de Sanidad of the Valencian Government
• Mr. Carlos Simón Vallés, Scientific Director of the Valencian Infertility Institute
Board members in their names
• Mr. Carlos Pascual de Miguel
• Mr. Joaquín Ortega Serrano
• Mr. Tomás Trenor Puig
• Mr. Rubén Moreno Palanques (until December 2012)
The General Director, Financial Director, and Chief of Staff attend the meetings with right to speak but without a vote.
2.2.3. Board of Governors
The Board of Governors is responsible for preparing and passing the proposals of activities and research projects. It
also decides and allocates the budgetary means, and executes and enforces the Board of Trustees’ agreements, among
other duties.
Dated December 31st 2012, its members are the following:
President
• Dr. Luis Martí, Chief Executive Officer, Hospital Clínico Universitario of Valencia
Vice-president
• Dr. José Magraner, Head of the Pharmacy Service, Hospital Clínico Universitario of Valencia
General Director
• Prof. Rafael Carmena, Professor Emeritus of the Medicine Department, University of Valencia
Board members
• Prof. Josep Redón, INCLIVA Scientific Director
• Prof. Federico Pallardó, Dean of the Faculty of Medicine and Dentistry, University of Valencia
• Prof. Andrés Cervantes, Oncology Service, Hospital Clínico Universitario of Valencia
• Dr. Amparo Rufino, Medical Director, Hospital Clínico Universitario of Valencia
• Prof. Salvador Lluch, Department of Physiology, University of Valencia
• Dr. Rosana Espinosa, Director of Primary Health Care, Health Service Department in Valencia Clínico-Malvarrosa
• Prof. Carlos Simón, Scientific Director, Instituto Universitario IVI
• Prof. Carlos Hermenegildo, Coordinator of Research Support Platform, University of Valencia
2.2.4. General Director
The Foundation’s General Director is the highest person responsible for the execution
of scientific, economic and administrative policies fixed by the Board of Trustees. The
position has been held since May 2012 by Dr. Rafael Carmena Rodríguez.
Graduated with Distinction in Medicine from the Valencia’s Faculty of Medicine in
1964, and Doctor “cum laude” from the Universitat de València in 1966. Specialist in Internal Medicine and Endocrinology. Professor of Pathology and Medical Clinics (Internal
Medicine) at the universities of Valencia and Murcia, he has been Chief of the Internal
Medicine Department of the Ciudad Sanitaria “Virgen de la Arrixaca” of Murcia (19741982), and Chief of both the Welfare Department, and the Endocrinology and Nutrition
Service of the Hospital Clínico Universitario of Valencia for the last 28 years.
His research is focused on the lipid metabolism, the effects of dietary fats on cholesterolemia; conditions of resistance to insulin and its treatment; metabolic syndrome;
genetics of hypercholesterolemia and treatment of diabetes dyslipidemia.
2.2.5. Scientific Director
The Scientific Director is appointed by government bodies. The scientific direction has
been headed by Dr. Josep Redón since 2010. Dr. Redón is a specialist doctor of Internal
Medicine, Research Fellow in Hypertension in Northwestern University (Chicago), and
Fellow of the Council for High Blood Pressure of the American Heart Association. He is
currently Professor of Medicine, Chief of the Internal Medicine Service and Coordinator
of the Hypertension Unit of the Hospital Clínico Universitario of Valencia. Nowadays, he
heads the European Society of Hypertension, and he has authored many research works
on hypertension and diabetes. He is also a member of the editorial committees of several
international journals on the field of hypertension and cardiovascular risk.
2.2.6. External Scientific Committee
The External Scientific Committee is constituted by well-known standing professionals among the scientific community, and the national and international clinical medicine. Their members are appointed by the Board of Trustees, and it
counts at least on one expert in every INCLIVA priority area of research.
Its task is to assess and counsel the collegiate goverment bodies regarding to the research carried out. Furthermore,
it safeguards the quality of the research developed, and makes the required recommendations.
The composition of the External Scientific Committee, dated December 31st 2012, is the following:
President:
• Dr. Javier Díez
Professor of Medicine, University of Navarra. Director of the Cardiovascular Sciences Area,
Applied Medical Research Center (CIMA). University of Navarra.
Members:
• Dr. José Baselga
Director of the Division of Oncology in Massachusetts General Hospital, Boston (US).
Professor of Medicine, Autonomous University of Barcelona. Director of the Oncology Institute, Barcelona.
• Dr. Juan Carlos Lacal
Research Professor in CSIC. Biomedical Research Institute, Madrid.
2
19
• Dr. Nick S. Macklon
Professor in Obstetrics and Gynecology. Division of Developmental Origins of Adult Diseases (DOHaD).
University of Southampton. Princess Anne Hospital. Coxford Road, Southampton (United Kingdom).
• Dr. José María Medina
Professor in Biochemistry and Molecular Biology. University of Salamanca.
Castilla y León Neuroscience Institute (INCYL).
20
2
• Dr. Josep Tabernero
Chief of Medical Oncology Service. Hospital Vall d’Hebrón, Barcelona.
• Dr. Manuel Tena-Sempere
Professor in Cell Biology, Physiology, and Immunology Department. University of Córdoba.
• Dr. Antonio Vidal-Puig
Professor in Molecular Nutrition and Metabolism. University of Cambridge.
• Dr. Alberto Zanchetti
Professor Emeritus of Internal Medicine. Università di Milano.
Director of the Istituto Auxologico Italiano (Italy). Consultant in WHO.
The Committee’s intense activity along this year has been materialized in matters of scientific and strategic politics. In the
regular meeting held in November, INCLIVA’s advisors of the government bodies evaluated the scientific and financial reports,
and examined how the strategic, integration and training plans were put into practice.
As a result of this analysis, it was recommended to increase the participation in European projects, the establishment of
intramural transversal programs, and a resolute effort towards innovation.
2.2.7. Internal Scientific Committee
INCLIVA’s Internal Scientific Committee is the body that acts as a counsellor to the General Director and the Scientific Director. In order to achieve this, it evaluates, discusses, advises and supervises the scientific content of the research areas.
Dated December 31st 2012, the Committee composition is as follows:
President:
• Dr. Josep Redón i Mas
General Director:
• Dr. Rafael Carmena Rodríguez
Medical Director of the Hospital Clínico Universitario of Valencia:
• Dr. Amparo Rufino Valor
Coordinators of the priority areas of research:
• Dr. Andrés Cervantes Ruipérez
• Dr. José Viña Ribes
• Dr. Carlos Simón Vallés
• Dr. Javier Chorro Gascó
Board members:
• Dr. Esteban Morcillo Sánchez
• Dr. Pilar Eroles Asensio
• Dr. Carlos Hermenegildo Caudevilla
• Dr. Rafael Carmena Rodríguez
• Dr. Ana Lluch Hernández
• Dr. Javier Chaves Martínez
• Dr. Eduardo Otero Coto
• Dr. Gloria Ribas Despuig
• Dr. Irene Cervelló Alcaraz
• Dr. Felipe Vilella Mitjana
• Dr. Daniel Monleón Salvadó
• Dr. Fernando Martínez García
• Dr. Carlos Solano Vercet
• Dr. Rosa Zaragozá Colom
2.2.8. Ethical Committee in Clinical Research
The Ethical Committee in Clinical Research (ECCR) of the Hospital Clínico Universitario of Valencia is the independent
body whose task is to safeguard the protection of the rights, security, and welfare of the subjects taking part in a clinical
trial or research project.
Among others tasks, this Committee assesses the protocol, the aptitude of the participating researchers, the adequacy
of the center’s facilities, and ensures the use and quality of the Fact Sheet for Patients for securing the informed consent.
The members of the ECCR in the Hospital Clínico Universitario of Valencia, dated December 31st 2012, are the following:
President
•Dr. Antonio Peláez Hernández. Chief of the Allergy Unit
Vice-president
• Dr. José Magraner Gil. Chief of the Pharmacy Service
Secretary
• Dr. Manuel Labiós Gómez. Chief of Section of the Internal Medicine Service
Substitute Secretary
• Ms. Begoña Hernández Genovés. Chief of Supplies Service. Graduated in Law
Board members
• Dr. Luis Martí Moreno. Chief Executive Officer of Department of Health Clínico – Malvarrosa
Clinical Pharmacologist
• Dr. Esteban Morcillo Sánchez. Rector of the University of Valencia. Professor of Pharmacology
Members with assistance tasks
• Dr. Antonio Peláez Hernández. Chief of the Allergy Unit
• Dr. Manuel Labiós Gómez. Chief of Section of the Internal Medicine Service
• Dr. José Blanquer Olivas. Chief of Section of the Intensive-Care Medicine Service
• Dr. Miguel Mínguez Pérez. Chief of Section of Gastroenterology Service
• Dr. Andrés Cervantes Ruipérez. Chief of Section of Hematology and Oncology Service
• Dr. Ricardo Ruiz Granell. Chief of Section of Cardiostimulation Service
• Dr. Julio Palmero Da Cruz. Chief of the Radiology Service
• Dr. Alfonso Miguel Carrasco. Chief of the Nephrology Service
• Dr. Joaquín Ortega Serrano. Chief of the General Surgery Service
• Dr. Marina Soro Domingo. Chief of Section of Anesthesiology and Resuscitation
• Dr. Cristina Gomis Gozalbo. Assistant Obstetrics and Gynecology Service
2
21
Doctors with active assistance tasks in primary health care
• Dr. Nidia Ruiz Varea. Specialist doctor in Primary Health Care Specialist doctor in Pediatrics
• Dr. Rafael Fernández-Delgado. Specialist Doctor in Pediatrics
Pharmaceutics
• Dr. José Magraner Gil. Chief of the Pharmacy Service
22
2
• Mr. Diego V. Cano Blanquer. Primary Health Care Pharmaceutics
Graduated in Nursing
• Dr. Ms. Mª Ángeles Mora Plá. Outpatient Nursing Supervisor
Members unrelated to health professions
• Ms. Begoña Hernández Genovés. Chief of Supplies Service. Graduated in Law
• Mr. Carlos Pascual Vicens. Graduated in Law
Independent members
• Mr. Carlos Pascual Vicens. Graduated in Law
Other members
• Dr. Amparo Rufino. Medical Director of the Hospital Clínico Universitario of Valencia
• Dr. Marina Gisbert Grifo. Associate Professor of Preventive Medicine and Public Health in the University of Valencia
• Dr. Francisco Dasí Fernández. Miguel Servet Researcher
2.2.9. Ethical Committee in Animal Experimentation
The Ethical Committee in Animal Experimentation (ECAE) is part of the Ethics Committee for the Experimental Research in the University of Valencia. It is constituted by members that have the required experience and knowledge to
safeguard the welfare and care of animals.
Dated December 31st 2012, ECAE is constituted by the following members:
President
• Dr. Ms. María Dolores Real García, Director of the Central Service for Experimental Research Support (SCIE), University
of Valencia
Secretary
• Dr. Mr. Enrique Font Bisier. Instituto Cabanilles, University of Valencia
Members
• Dr. Mr. Antonio Alberola Aguilar, Physiology Department, University of Valencia
• Ms. María Carmen Recio Iglesias, Pharmacology Department, University of Valencia
• Ms. Alicia Salvador Fernández-Montejo, Psychobiology Department, University of Valencia
• Dr. Ms. Inmaculada Noguera Salvá, Veterinary Surgeon, Central Service for Experimental Research Support (SCIE),
University of Valencia
• Dr. Ms. Ana Díaz Cuevas, Veterinary Surgeon, Medical Research Central Unit, University of Valencia
2.2.10. Management Structure
INCLIVA Health Research Institute has an independent management structure where two big areas are distinguished:
General Director
Financial Director
Financial-Administrative Coordination
2
Scientific Director
Scientific Management Coordination
Scientific Activity
Records
Quality and Planning
CAIBER
Human Resources
European Projects
Biobank
Accounting and Invoicing
Innovation Management
Coordinators of Lines of Research
Financial
Projects
Other Researchers
Invoicing and Receiving
Clinical Trials
Primary Health Care
Training
Future Platforms
Financial-Administrative Area:
its tasks are framed in the economic administration, staff management, and general administration.
Financial-Administrative Manager: Mr. Juan Luis Huguet
Coordination: Ms. Consuelo López Riera
Accounting and Invoicing Unit: Ms. Mª José Rosalén
Financial Unit: Ms. Consuelo López and Ms. Karen Iglesias
Invoicing and Receiving Unit: Ms. Vera Marín
Records Unit: Ms. Alicia Belenguer
Human Resources Unit: Ms. Ruth Cano
Scientific Management Area:
it is responsible for the integral scientific management that includes controlling and monitoring clinical trials and research projects, organising courses, conferences and seminars, and several tasks related to general administration –
among others. Furthermore, it acts as an administrative support to the different scientific committees attached and to the
Medical Research Central Unit.
Coordination: Dr. Marta Peiró
Quality and Planning Unit: Mr. Enrique Cremades and Ms. Patricia Mañas
European Projects Unit: Dr. Marta Peiró
Innovation Management Unit: Mr. Enrique Cremades
Projects Unit: Ms. Mayca Román and Ms. Noemí Hidalgo
Clinical Trials Unit: Ms. Dolores Iglesias and Mr. Roberto Martínez
Training Unit: Mr. Justo Giner
General Secretary: Ms. Maite Sáenz
23
3
2
Facilities,
human,
technological
and financial
resources
25
3
25
Facilities, human, technological and financial resources
3.1. Facilities
INCLIVA carries out its task both in spaces located within the hospital grounds, where the Secretariat is located, and in
the Central Unit for Medical Research (UCIM). All of these spaces are located in Valencia, at Av. Blasco Ibáñez, n.15 and 17.
Under the signed attachment agreements, the University of Valencia assigns groups, spaces and equipment from the
Departments of Physiology, Pediatrics, Obstetrics and Gynecology, Pathology, Pharmacology, Biochemistry and Molecular
Biology and Medicine, and also from the UCIM Research Support Platforms.
Likewise, IVI assigns two research groups, their research foundation’s laboratories and the equipment located therein.
3
Night view of our new headquarters
Meeting room in the new headquarters
Thus, currently, INCLIVA has its own space for research in a hospital environment and under the Institute direct management. The space occupies 4.020,66 m2, 3.239,78 of those m2 are specifically used for research. In 2012, the new headquarters’
construction works has begun. This new headquarters will increase the space for research in over 2.100 m2.
3.2. Human resources
INCLIVA manages the scientific and support staff of the various research projects that are developed by both the attached
groups of the Hospital and its Department of Health, and by those of the University and IVI. INCLIVA has research management staff and research staff in several occupational categories to support research. The total number of researchers that
integrate our research groups was above 500 people in 2012.
In order to fulfill its functions, INCLIVA has research staff in all of the following categories, funded through grants via public
and private competitive calls:
• Heatlh Service Researchers
These researchers are hired through research grants from the Carlos III Health Institute (Instituto de Salud Carlos III),
as part of the Strategic Action in Health program. The aim of these actions is to incorporate doctors and other professionals with a proven research career in biomedical and health sciences, in order to develop new lines of research, or to
enhance those lines that already exist in the centers the researchers join to. These six-year grants allow a co-financing
of the recruitment costs.
Additionally, INCLIVA has Stabilized Researchers. These are the researchers that, after finishing the Miguel Servet
postdoctoral improvement program, have been favorably evaluated by the Carlos III Health Institute (Instituto de Salud
Carlos III), and whose link has been stabilized thanks to the Specific Collaboration Agreement between the Central
Government via the Carlos III Health Institute (Instituto de Salud Carlos III), and the Valencian Government, in the
National Health System Researcher Stabilization Program.
27
• Ramón y Cajal Researchers
These researchers are hired thanks to the Ramón y Cajal program, whose main aim is to strengthen the research
capacity of the R&D groups and institutions in both the public and the private sector, by hiring researchers that have
reached and hold the degree of Doctor, and that have presented a research line to develop. These grants are for a
five-year time and allow the co-financing of the hiring costs.
Just as it happens with the Miguel Servet researchers, INCLIVA has Ramón y Cajal Stabilized Researchers, those who
had been favorably evaluated by the program to promote the incorporation and intensification of research activities.
• Río Hortega Researchers
The aim of these grants is to hire, for a three-year period, professionals that have passed the Specializated Health
Training, for the development of a training plan on biomedicine and on health sciences within R&D centers.
• Juan de la Cierva Researchers
This subprogram is meant for the hiring of young doctors and pays special attention to the collective of researchers
that have recently obtained their doctoral degree, in order to help them to be incorporated into research teams for their
strengthening.
• Research Support Technicians
INCLIVA has two stabilized technicians that had been favorably evaluated by the Carlos III Health Institute (Instituto de
28
3
Salud Carlos III) and, therefore, stabilized through Specific Collaboration Agreement between the Central Government
via and the Valencian Government, in the National Health System Researcher Stabilization Program.
Futhermore, thanks to the specific call of the Research Support technicians program, INCLIVA counts on two technicians hired for a three-year term.
Additionally, within the frame of the grants for hiring support technicians in the National Health Service strategic Action
on health, INCLIVA counts on a technician hired for a three-year term.
• Trainee Research Staff
Thanks to the financing received through several calls for the hiring of trainee research staff, INCLIVA counts on staff
coming from the following programs:
· Program VAL+i for trainee researchers of the Conselleria de Educación, Formación y Empleo.
· Program FPU of the Ministry of Economy and Competitivity (former Ministry of Science and Innovation).
· Program of predoctoral grants for health research (PFIS) from the Carlos III Health Institute (Instituto de Salud
Carlos III).
• Other Research Support Staff
As a result of the research activities developed by the different research groups, INCLIVA has more research support
staff among its personnel. Depending on the financial source we can find the following ones:
-Hired staff funded under the Cooperative Research Thematic Networks (RETICs).
-Hired staff funded under CAIBER financing.
- Hired staff funded under the financing received by the Prometeo Program of the Conselleria d’Educació.
- Hired staff funded under the financing received from the Gerónimo Forteza Program of the Conselleria d’Educació.
- Hired staff funded under the financing received from the Program + i Comunidad Valenciana.
- Hired staff funded under the financing received from the Support of Research Program from the Fundación Bancaja.
-Hired staff funded under the financing received from the Health Research Fund projects (FIS).
-Support Staff for the Research Units: as a consequence of the research activity developed by the research groups,
the following units have been created:
· Oncological-Clinical Research Unit: the Hospital Clínico Universitario of Valencia is a reference regarding the
onco-hematologic area of research. It counts on a clinical research unit in which clinical trials are developed on
their different stages, aimed at developing new information about the state-of-the-art therapies.
· Basic Research of the Oncology-Haematology Service Unit: this unit counts on basic researchers and support
research technicians who cooperate in the development of the research projects.
· Pharmacy Service Clinical Trial Unit: as established by the Royal Decree 223/2004 for clinical trials, the Pharmacy Services are a key element for the development of the clinical trials in a health center. This is why the Pharmacy Service count on a Clinical Trial Unit in charge of bolstering the adequate development of these studies in
the hospital as well as the dispense, control and follow-up of the studies medication.
· Genotyping and Genetic Diagnosis Unit: this unit has the most advanced technology meant to perform genetic
studies for both diagnosis and research.
· Central Unit of Research Laboratories: since 2004 INCLIVA has subscribed a Specific Cooperative Agreement
with the Central Unit of Research Support of the Faculty of Medicine in the University of Valencia for the shared
use of this unit’s facilities. For the development of its activities, INCLIVA has hired the following technical staff to
ensure technical support for these units’ scientific-technical platforms.
· Molecular Imaging Lab: the molecular imaging lab of the Faculty of Medicine’s Pathologic Anatomy Department
is a national reference laboratory regarding the diagnosis of pediatric tumors.
• Staff funded under the Research projects
Additionally, INCLIVA has staff hired according to the needs of the diverse research programs performed by the institution.
3.3. Research support platforms-Core Facilities
On April 20th, 2004 it was signed the Collaboration Agreement between INCLIVA and the Central Service for Experimental research Support (SCIE) at the University of Valencia. This collaboration agreement – whose aim is to ease the
cooperation between both institutions, with special emphasis in the execution of research projects and collective research
activities – allows the access, stay and use of the Central Unit for Medical Research facilities to Hospital Clínico Universitario of Valencia staff.
The Central Unit for Medical Research (UCIM) was created thanks to FEDER funds in 1990. From its inception, it has
been granted with several infrastructure coming from both University of Valencia and INCLIVA funds, as well as from
external funds (Comisión Interministerial de Ciencia y Tecnología, Generalitat Valenciana and Fondo de Investigaciones
Sanitarias).
The gradual increase in the acquired scientific equipment has made possible that the UCIM supports a high number of
researchers. That support has allowed in the last years the provision of external services, consolidating the aforesaid unit as
a real support service to both internal and external research. In addition to these support units, INCLIVA has two additional
platforms: the Biobank and the Cytogenetics lab.
These laboratories have currently available several research technicians and technical assistants who have been included in the organization structure thanks to diverse grants from Conselleria, or directly to the University’s budget.
3
29
INCLIVA’ units for research support are the following:
BIOBANK
FUNCTIONS:
• To create and keep a critical mass of normal and pathological biological samples, collected and kept in optimal conditions, to be used in the field of biomedical research.
• To provide technical support to the institution’s units and research groups, becoming a tool of strategic development
for the aforesaid and improving the scientific and assistance quality of their activities.
• To increase the accessibility to biological samples for the research groups.
• To provide with the aforesaid material the research groups of the same institution, or groups unlinked to the institution, when meeting the scientific and ethical requirements.
30
3
• To drive translational research, assisting the incorporation of new techniques and new markers to diagnosis, prognosis, treatment, and patient monitoring.
• To guarantee the respect for the basic rights and freedoms, the protection of dignity and identity, and treatment of the
donors’ personal details.
• To establish collaborative networks with other biobanks that house samples similar to the ones of this Biobank.
EQUIPMENTS:
• Deep freezers in -80 °C (-112 °F), with base of CO2 and visual, acoustic and remote alarm system.
• COOLSAFE 110 (SCANVAC) freezing system for the immediate cryopreservation of biological samples in -110 °C
(-166 °F).
• Automated systems of nucleic acid extraction: QIAGEN’s QIAcube and CHEMAGEN’s Chemagic MSM I.
• Wireless computer system for data register, and for remote and telephonic management of alarms for the Biobank.
• Computer systems of associated samples and data management.
LOCATION:
INCLIVA Biobank is organized in four nodes: oncological, haematological, immunological diseases, and cardiovascular.
In turn, the nodes are constituted in diverse collections located in the following premises:
• Service of Pathological Anatomy at the Hospital Clínico Universitario of Valencia,1st floor of the Faculty of Medicine
building: the Oncological Node’s collection of solid tumors (Tumor Bank).
• Laboratory of Hematology at the Hospital Clínico Universitario of Valencia, 1st floor: the Hematological Node’s collection of hematological malignancies (Blood Bank).
• Premises of the Genotyping and Genetic Diagnoses Unit (UGDG), at the Faculty of Medicine and at the Laboratory of
Endocrinology in the Maternity building of the Hospital Clínico Universitario of Valencia, both in 2nd floor: collections
of the Oncological Node, the Immunological Diseases Node, and the Cardiovascular Node.
HUMAN RESOURCES:
• Scientific Director: Dr. Antonio Ferrández
• E-mail: [email protected]
• Contact phone: +34 963862600 ext: 51257
• Technician Coordinator: Dr. Lorena Peiró Chova
• Technician: Mrs. Olga Bahamonde Ponce
ACTIVITIES DEVELOPED IN 2012:
1. Incorporation of samples
1.1. Pre-existing samples:
• Collection of solid tumors (Tumor Bank): around 250 new cases.
• Collections of peripheral blood and derivative products in patients suffering from breast cancer (CM-S [Blood- Breast Cancer]) or lung cancer (CP-S [Blood- Lung Cancer): around 350 new cases.
• Hematological malignancies (Blood Bank): around 1,200 new cases.
• Collections from the cardiovascular node: around 30 new cases.
1.2. 2012 new collections:
• MM-S (Blood- Melanoma): peripheral blood and derivative products in patients suffering from melanoma (100 cases).
• SLE-B (Systemic Lupus Erythematosus): peripheral blood and derivative products in patients suffering from lung cancer (50 cases).
2. Transfer of samples
Project
Agency/Ref.
Principal
Researcher /
Institution
Samples
Deficiency in the homologous recombination FIS. ISCIII/
in sporadic breast cancer.
PI10/00347
Dr. Bolufer
(IIS La Fe)
Breast cancer:
paraffin embedded
tissue
Analysis of the miRNAs expression in tumor
Foundation Le
tissue of young women with breast cancer,
Cado against
without mutation in genes of high penetranbreast cancer
ce BRCA1 and 2.
Dr. Ribas
(INCLIVA)
Breast cancer: paraffin
embedded and frozen
tissue
3
31
Genomic alterations that refer to the pathogenesis of neuroendocrine tumors: Merkel
cell carcinoma. Analysis of the mutational
profiling of Merkel cell carcinoma for the
development of guided therapy.
Dr. Piris and Dr.
González-Vela
(HUMV/IFIMAV)
Merkel cell carcinoma:
paraffin embedded and
frozen tissue
Impact of the genetic susceptibility and sun
FIS. ISCIII/
exposure on vitamin D levels in patients with
PI10/00405
melanoma.
Dr. Ribas
(INCLIVA)
Melanoma: DNA and
peripheral blood plasma
Clinical and experimental study about the
influence that profiling of combined expression of cancer stem cell markers and
epithelial–mesenchymal transition markers
have on the malignant advance of “in vivo”
skin melanoma.
Dr. Monteagudo
(Universitat de
Melanoma: frozen tissue
València/Hospital
and RNA
Clínico Universitario/INCLIVA)
Intramural
funds IFIMAV
Generalitat
Valenciana/
PROMETEO
-2011/084
Evaluation of specific cancer biomarkers for
ISCIII/ PI10the diagnosis of prostate cancer, framed in
01206
an opportunistic early detection program.
32
3
Development of a new product for the
epigenetical diagnosis of unknown primary
cancer.
009/12. FIB115/ Ferrer
Internacional
S.A.
Dr. López-Guerrero (IVO)
Prostate cancer: frozen
tissue
Dr. Esteller
(IDIBELL)
Primary tumors: frozen
tissue
• Projects supported by collections of the Cardiovascular node:
Project
Identification of DM2-associated genetic variants in
the exome.
CIBER of Diabetes and Associated Metabolic Diseases “CIBERDEM”.
Agency/Ref.
FIS. ISCIII/ PI11/00726
ISCIII/ CB07/08/0018
PR/Institution
Dr. Chaves
(INCLIVA)
Dr. Carmena
(INCLIVA)
RNA expression profiling in lymphomonocytes after
oral overload with unsaturated fat in two resistantto-insulin models: abdominal obesity and type 2
FIS. ISCIII/ PI10/0511
Dr. Ascaso
(INCLIVA)
diabetes.
3. Register and authorization of Biobank INCLIVA
30
The Biobank INCLIVA submitteed the authorization application for its constitution and running on November
th
2012 (dossier code: BI/08/2012) before the Conselleria de Sanitat, Valencian Government, according to the
valid legislation (Ley 14/2007, Real Decreto 1716/2011, and Decreto 143/2008).
PARTICIPATION IN COOPERATIVE STRUCTURES
• NATIONAL NETWORK OF BIOBANKS (RETICS-BIOBANKS)
Reference: RD09/0076/00132.
Title: Red Temática de Investigación Cooperativa en Salud (RETICS). Biobank network.
Principal Investigator: Dr. Josep Redón i Mas.
Funding body: Instituto de Salud Carlos III
Beneficiary institution: Fundación Investigación Hospital Clínico Universitario of Valencia.
Duration: 2010-2013.
2012 funding: €106.932,09
• VALENCIAN NETWORK OF BIOBANKS
PUBLICATIONS
Publications of 2012, for which samples of the Biobank were used, and where the network has been cited in section Acknowledgements:
• Rojo F, García-Parra J, Zazo S, Tusquets I, Ferrer-Lozano J, Menendez S, Eroles P, Chamizo C, Servitja S,
Ramírez-Merino N, Lobo F, Bellosillo B, Corominas JM, Yelamos J, Serrano S, Lluch A, Rovira A, Albanell J.
Nuclear PARP-1 protein overexpression is associated with poor overall survival in early breast cancer.
Annals of Oncology: Official Journal of the European. 2012 May Volume: 23 Issue: 5 Pages: 1156-64.
Impact Factor (JCR 2011): 6.425
• Mansego ML, Martínez F, Martínez-Larrad MT, Zabena C, Rojo G, Morcillo S, Soriguer F, Martín-Escudero
JC, Serrano-Ríos M, Redon J, Chaves FJ.
Common variants of the liver fatty acid binding protein gene influence the risk of type 2 diabetes and insulin
resistance in Spanish population.
PloS One. 2012 Volume: 7 Issue: 3 Pages: e31853.
Impact Factor (JCR 2011): 4.092
3
33
GENOTYPING AND GENETIC DIAGNOSIS UNIT
FUNCTIONS:
• Research on the genetic bases of mono or oligogenetic and multifactorial diseases.
• Research and development of procedures to conduct of different types of genetic studies.
• Support to clinical practice by conducting genetic studies.
• Support to other research groups by conducting different genetic studies.
EQUIPMENTS:
• Illumina HiScanSQ System, for microarray of high capacity or own design chips of different capacities and nextgeneration sequencing.
• Roche 454’s Junior Sequencer of next-generation sequencing.
• Applied Biosystems Automated Sequencer 3730 (48 capillaries).
• Roche LightCycler 480 Quantitative Thermal Cycler and Standard Thermal Cycler (768, 385 or 96 samples).
LOCATION:
• UCIM, 2nd floor, Laboratories 14 and 23, Faculty of Medicine, University of Valencia.
34
3
• Laboratory of Endocrinology, Maternity building, 2nd floor, Hospital Clínico Universitario of Valencia.
• Laboratories 1 and 2, Department of Medicine, Faculty of Medicine, University of Valencia.
HUMAN RESOURCES:
• Head of the Unit: Dr. Felipe Javier Chaves Martínez
• Contact phone: +34 963983916
• Technicians:
• Dr. Sebastián Blesa Luján
• Mrs. Cristina Pérez Soriano
• Contact phone: +34 963864100 ext.51905
• Mrs. Verónica González Albert
• Mrs. Victoria Adam Felici
CELL CULTURE UNIT
FUNCTIONS:
• Maintenance of cell lines in primary and secondary cultures.
• Cultures at different oxygen percentages.
• Cryogenic storage and cataloguing of cell cultures.
EQUIPMENTS:
• CO2 Incubators (SANYO 18 AYC-UV, HERACELL 150iThermoscientific).
• Hypoxia Incubators, BINDER APTlineCB.
• Automated Cell Counter TC10, Biorad.
• Micro-volume spectrophotometer (Nanodrop 2000, Thermo Scientific).
• TELSTAR AV 30/70 Laminar Flow Cabinets.
• TELSTAR, BIO IIA (3 units) Biological Safety Laminar Flow Cabinets.
• Burdinola OR-ST1500 Fume Hood.
• Auxiliary equipment: N2 tank (cryopreservation team), ARPEGE 140, PERCISTERM 20L P-SELECTA Analog Precision Bath, HERAEUS-sepatech Megafuge Centrifuge, two P-SELECTA electrical autoclaves for sterilization, HERMLE Labortechnik refrigerated microcentrifuge, Thermoscientific HERAEUS Multifuge 3SR+ Centrifuge, ACCULAB
Sartorius Group precision balance, Moticam 2500 Camera.
• Molecular Devices ESPECTRAMAX GEMINI XPS Fluorometer.
• Molecular Devices ESPECTRA-MAX PLUS Spectrophotometer.
• NIKON Eclipse TS100 Microscope, precision shaking bath controlled by microprocessor UNITRONIC OR 20L, PSELECTA.
LOCATION:
• UCIM, 2nd floor, Laboratories 35 and 36, Faculty of Medicine, University of Valencia
PERSON IN CHARGE:
• Mr. Sergio Bañuls Sánchez de Cutanda
Fibroblasts taken with MOTICAM
(Motic Images Plus) with 20x lens.
3
35
FLOW CYTOMETRY UNIT
FUNCTIONS:
• Semi-quantitative, multi-parametric study of cell populations and subcellular structures using fluorescent probes.
EQUIPMENTS:
• Imagestream System Image Cytometer (AMNIS).
• FacsVerse Flow Cytometer (Becton Dickinson)
• FacsAriaIII Cell Separator (Becton Dickinson).
LOCATION:
• UCIM, 2nd floor, Laboratory 22, Faculty of Medicine, University of Valencia.
HUMAN RESOURCES:
• Dr. Guadalupe Herrera
36
3
• Dr. Jelena Markovic Djuric
Study of mitochondrial membrane potential and its
distribution through ImageStream (AMNIS). On the
left, control fibroblasts. On the right, fibroblasts from
a Kindler Syndrome patient.
CYTOGENETICS LABORATORY
FUNCTIONS:
• Application of conventional and molecular cytogenetic analysis techniques (FISH, multiFISH, CGH, Quantitative
Fluorescent PCR and Array CGH, etc.) to the study of different pathologies.
EQUIPMENTS:
• Cultivation room equipped with biological safety cabinet and CO2 incubators.
• Metafer System: automated system for the microscopic analysis and scanning of images obtained from both optical
and fluorescence microscopy.
• Optichrome: device to keep constant temperature and humidity conditions during the preparation of the slides.
• ThermoBrite: thermal Cycler for Slides.
• Hybridization oven: device for the DNA hybridization in CGH arrays.
LOCATION:
• Clinical Analysis and Clinical Biochemistry Service at the Hospital Clínico Universitario. Maternity building, 2nd floor.
HUMAN RESOURCES:
• Head of Unit: Dr. Ana Cuesta Peredo
• Technician: Dr. Rosario Abellán Sánchez
Study of 22g11 deletion: Di George Syndrome, normal
case. In red is shown the region of adjacent genes
whose deletion causes the desease. In green, control
hybridation probe.
3
37
MULTIGENIC ANALYSIS UNIT
FUNCTIONS:
• Whole genome expression profiling using Affymetrix biochips technology.
• MicroRNA expression profiling using Affymetrix biochips technology.
• Genotyping analysis using Affymetrix biochips technology.
EQUIPMENTS:
• Biochip system with fluid robotic station (Genechip Fluidics Station).
• Laser chip scanner with different computer applications to analyze the results achieved (Genechip Scanner 3000 7G).
• Genechip Hybridization Oven 640.
• Capillary electrophoresis (Agilent 2100 Bio analyzer).
LOCATION:
HUMAN RESOURCES:
• Head of Unit: Dr. Eva Serna García
38
3
• Technician: Mrs. Jésica Portero Trigo
•E-mail: [email protected]
Principal Component Analysis (PCA).
CONFOCAL MICROSCOPY UNIT
FUNCTIONS:
• Detection of tissue, cellular and sub-cellular processes using fluorescent probes.
• Study of markers placement.
• Material analysis.
• Molecule monitoring.
• Serial sequences detection and subsequent three-dimensional reconstruction.
EQUIPMENTS:
• Leica TCS SP2 Spectral Confocal microscope, ultraviolet laser, multiphoton system, temperature and CO2 control. It
has a DMIRB inverted microscope for transmitted light in brightfield and incident light fluorescence with optical components for interference contrast. With three fluorescent filter bocks: I3 (blue excitation BP 450-490; emission LP 515)
for FITC, Cy2, etc.; N2.1 (green excitation BP 515-560; emission LP 590) for TRITC, Cy3, etc.; and A (UV excitation
BP 340-380; emission LP 425) for HOECHST or DAPI, etc.
• System includes four laser sources: far-red (HeNe 633 nm), red (HeNe 543nm), green (HeNe 488 nm) and blue (Ar.
351nm, 364).
• Leica DMI3000 inverted research microscope, fluorescence system with power supply EL 6000 with long-life Halide
lamp (2000h) 100 Watt and fiber optic transmission for fluorescence. It has three filter blocks for TRITC (red), FITC
(green) and DAPI (blue), and it has four objectives: 10x, 20x, 40x and 63x.
LOCATION:
PERSON IN CHARGE:
• Mrs. Sonia Priego Villanueva
Hela Cells
Renal Tissue
Footh cut
Spermatozoa
Plant cells
Oocyte
3
39
TeJIEPIGENETICS
AND GENOTYPING UNIT (SEQUENOM PLATFORM)
FUNCTIONS:
• Quantitative analysis of the degree of DNA methylation.
• Quantitative analysis of gene expression.
• Genotyping services and study of polymorphism (SNPs).
EQUIPMENTS:
• Sequenom Platform includes a dispensing robot for the processing of DNA samples in 384-well plates, nanodispenser
that transfers PCR products to spectrochips and Mass Array analyzer that carries out the MALDI-TOF.
LOCATION:
PERSON IN CHARGE:
• Dr. Enrique José Busó Sáez
• Contact phone: +34 96 3864439 ext: 51138
40
3
Heat map of the methylation of a DNA region.
Mars spectrum a MRNA obtained by quantifying the expression degree technique (QGE) Sequenom.
LABORATORY OF MOLECULAR IMAGING AND METABOLOMICS
FUNCTIONS:
• Metabolic profiles using Nuclear Magnetic Resonance (NMR) in tissues, biopsies, bio-fluids and cultures.
• Microscopy imaging using Magnetic Resonance in tissues and small samples (insects, organs of animal models, etc.)
• Molecular imaging in tissues and small samples (insects, organs of animal models, etc.)
• Clinical Magnetic Resonance imaging using multivariate mathematical models.
EQUIPMENTS:
• Bruker AVANCE 600 MHz NMR Spectrometer with spectroscopic probes for determination in semi-solid (HR-MAS
1H/13C/15N) and liquid (QXI 1H/13C/15N/31P) systems and micro-imaging probes (10mm/5mm/2mm).
• BCU-Xtreme cooling unit for low-temperature measurements.
• Gilson 215 for automated sample preparation and pipetter, used for the automated preparation of liquid samples in
NMR tubes.
• Upright ultra-low temperature freezer (-112ºF) for the storage of samples and for longer terms. Cryogenic container
with liquid nitrogen (-320.8 ºF).
Current equipment allows the researchers to work with intact samples (500μ liquid or 10-40 mg tissue) so that, once
measured, it is possible to carry out other tests.
Probes available allow researchers to obtain the metabolic profile in liquid samples with a volume of 500μ (5mm tubes)
and with a volume of 50μ (1mm capillaries).
LOCATION:
• Faculty of Medicine, zone 6, -1 floor, Hospital Clínico Universitario of Valencia.
HUMAN RESOURCES:
• Head of Unit: Dr. Daniel Monleón Salvadó
• Head of Unit: Mr. José Manuel Morales Tatay
3
41
ANIMAL HOUSING AND EXPERIMENTAL OPERATING THEATERS UNIT
FUNCTIONS:
• Our facilities, with an area of approximately 500 m2, provide specific and centralized instrumentation for the breeding
and keeping of experimental animals. Additionally, these facilities provide space for housing experimental animals
(mice, rats, guinea-pigs, rabbits, pigs, etc.), for breeding and experimental animals keeping genetically modified mice,
counseling and training on experimentation aspects and monitoring the animal welfare.
EQUIPMENTS:
• Open-cage racks, filter-cage racks, ventilated racks, isolator cabinets. Washing and sterilization area with cage-washer, with a high cleaning and disinfection capacity, feeding bottle washer, animal sterilization autoclave, Window SAS
with ultraviolet light and Hydrogen peroxide SAS.
• Operating theaters for inferior mammals (rodents, lagomorphs and others) and for superior mammals (pig), equipped
with the material needed to carry out basic surgical procedures: inhalation anesthesia in rodents, fan for superior
mammals, gases, diagnostic imaging (ultrasound, scopy), etc.
• Procedure rooms to carry out experimental manipulation tasks, necropsies, etc.
• Behavior room to carry out behavioral studies.
42
3
LOCATION:
• UCIM, 3rd floor, Zone 2, Faculty of Medicine, University of Valencia.
PERSON IN CHARGE:
• Dr. Ana Díaz Cuevas
Superior mammal surgery in experimental
operating theater.
PROTEOMICS UNIT
FUNCTIONS:
• Two-dimensional Electrophoresis allows isolating proteins using a double separation in a 2D-PAGE gel based on the
isoelectric point (pI) in the first dimension and according to its molecular size (MS) in the second dimension.
• DIGE Technique (Differential in Gel Electrophoresis), by labeling with different fluorophores, allows to simultaneously
quantify in the same gel 2D separate samples. It includes the sample separation, labeling with three different fluorophores, 2D gel, imaging and automatic analysis with De Cyder (GE) software.
EQUIPMENTS:
• Bio Rad Isoelectric Focusing (IEF) unit and GE Ettan IPGphor 3 for the first dimension.
• Ettan DALTsix, for the second dimension, composed by an electrophoresis unit that runs up to six gels at the same time
while reproducing the experimental variability on each of those gels. Its gel mounting bracket is designed to polymerize
up to six gels at the same time.
• Typhoon Trio: scanner that detects gels.
• De Cyder: software for differential expression analysis of DIGE gels.
• Ettan Spot Picker: robotic instrument that picks spots from stained polyacrylamide gels or with proteins marked with
fluorochromes.
3
LOCATION:
PERSON IN CHARGE:
• Mrs. Estefanía Fernández García
Image from a human liver simple.
43
SMALL ANIMALS PET/CT CAMERA AND LABORATORY
FOR RADIOACTIVE ISOTOPES
FUNCTIONS:
This lab carries out functional studies “in vivo”, in a non-invasive way, to make known biochemical processes, monitored at molecular level.
Its usage is spreading to a wide range of applications, from developing new drugs, to studying human diseases on
animals (oncology, neurodegenerative diseases, etc.), or to the characterization of gene expression and phenotype
changes due to genetic manipulation.
Measures of “18-FDG” glucose analog can currently be done. However, and depending on the project, the PET/CT
team can determine any other positron-emitting radiopharmaceuticals.
Thanks to the addition of CT we are able to carry out studies on the anatomical morphology of animals and join those
studies with their matching metabolic image. Besides, soft- and bone-tissue studies, among others, can be carried out
given the advanced characteristics of the team.
LOCATION:
• UCIM, 2E floor, Zone 2, Faculty of Medicine, Isotopes Unit.
44
3
Regions of interest in the FDG-PET
SCAN (rats and mice).
3.4. Financial resources
The funding of INCLIVA during 2012 totalled €6.383.397. INCLIVA’s income in recent years has experienced an uptrend.
Evolution of the last four periods is shown in the chart below.
3
INCLIVA’s income trend.
33% of the € total obtained in 2012 corresponds to calls for research funding, that totalled €2,152,951.
The remaining income corresponds to private sources of funding, clinical trial revenues and grants among others. The
graph below shows this distribution.
Income distribution by funding source.
45
46
3
4
Scientific
activity
4
Scientific activity
4.1. Research areas
INCLIVA Health Research Institute organizes scientific activity in four research areas that, despite their independence, have
a common goal: to meet the health needs of the population and to improve R&D&i system.
Its main aim is to establish a common reference framework to promote collaboration between the attached researchers.
Each of the lines counts on the participation of one or several advisers from the External Scientific Committee, and these lines
are lead by the following coordinators:
Cardiovascular Research Area.
• Coordinator: Dr. Francisco Javier Chorro
Oncology Research Area.
• Coordinator: Dr. Andrés Cervantes Ruipérez
Research on Metabolism and Organic Damage Area.
• Coordinator: Dr. José Viña Ribes
Research on Reproductive Medicine Area.
• Coordinator: Dr. Carlos Simón Vallés
4
49
Scientific activity
4.1.1.
4
Cardiovascular
Research
Area
51
Scientific activity
Research Group on Cardiometabolic Risk
PI: Rafael Carmena Rodríguez (Department of Medicine University of Valencia).
Collaborating Researchers: Juan Francisco Ascaso Gimilio (Hospital), José Tomás Real Collado (Hospital), Sergio
Martínez Hervás (Hospital), Ana Bárbara García García (CIBERdem), Miguel Catalá Bauset (Hospital), Esther Benido
Casado (CIBERdem), Cristina Pérez Soriano (INCLIVA), Griselda de Marco Marco (INCLIVA), Marta Peiró Signes (INCLIVA / CIBERdem), Nieves Brito Domenech (CIBERdem).
Predoctoral Researchers: Javier Pérez Hernández (INCLIVA).
4
Strategic aims
• Study of autosomal dominant hypercholesterolemias and familial combined hyperlipidemia. An analysis of inflammation
markers has been performed, as well as a comprehensive biochemical profile and a collection of clinical and genetic characteristics.
• Effect of postprandial lipidemia on cardiovascular system, mainly on lipid profile, inflammation markers and oxidative stress
and the response of circulanting cells to stress caused by lipidemia. Studies of oral lipid overload in obese diabetic patients
have been carried out to study cell response to fatty acid delivery. Expression of all genes present in the lymphomonocytes
of these patients has been examined comparing with control subjects and the results are currently being analyzed.
• Study of insulin resistance and diabetes. The aim is to early detect insulin-resistance, identifying early detection markers and
risk and inflammatory factors linked to this condition.
• Diagnosis and treatment of diabetic foot. Confirmation of the connection between plasma homocysteine levels and risk for
diabetic foot ulceration.
• Genetic factors involved in the regulation of Body Mass Index (BMI), waist circumference, obesity development and central
obesity. Study of oxidative stress and other aspects of metabolism as factors able to modulate development of obesity. Levels of certain free radicals and oxidative stress regulate metabolism and energy homeostasis.
53
Scientific activity
Main lines of research
•
•
•
•
•
•
Genetic diagnosis of primary hyperlipidemias and cardiovascular risk.
Combination of primary hyperlipidemias with insulin resistance and diabetes mellitus.
Postprandial lipidemia and atherosclerosis in states of insulin resistance.
Insulin resistance, inflammation and oxidative stress.
Diagnosis, prevention and treatment of diabetic foot.
Genetic factors involved in the regulation of Body Mass Index and abdominal obesity.
Emerging Researcher
Sergio Martínez Hervás (Hospital).
The line of research is based on cardiovascular risk, essentially on insulin resistance and
diabetes, familial combined hyperlipidemia, inflammation, vitamin D, and atherosclerosis, just
like new markers of cardiovascular risk.
Emerging Researcher
Ana Bárbara García García (CIBERDEM).
54
The research is focused in an SREBF2 variant and its possible association with DM2, one of
the most frequent diseases of Western societies. SREBF2 is part of one of the most important
lipid and glucose metabolism regulatory systems.
4
PUBLICATIONS
Total Number of Publications: 16
Cumulative Impact Factor: 109,87
Original articles
1Martínez-Hervás
S, Priego A, Lorente R, Molina M,
Navarro-Hidalgo MI, Real JT. Subclinical carotid atherosclerosis in patients with familial combined hyperlipidemia. Two years follow-up after treatment with high
doses of atorvastatin. Medicina Clínica. 2012 Jan 21;
138(1): 1-6. IF: 1,385
2Soriguer F, Goday A, Bosch-Comas A, Bordiú E, CallePascual A, Carmena R , Casamitjana R, Castaño L,
Castell C, Catalá M, Delgado E, Franch J, Gaztambide S, Girbés J, Gomis R, Gutiérrez G, López-Alba
A, Martínez-Larrad MT, Menéndez E, Mora-Peces
I, Ortega E, Pascual-Manich G, Rojo-Martínez G,
Serrano-Ríos M, Valdés S, Vendrell J. Prevalence of
diabetes mellitus and impaired glucose regulation in
Spain: the [email protected] Study. Diabetologia. 2012 Jan;
55(1): 88-93. IF: 6,814
3Klop B, van den Berg TM, Rietveld AP, Chaves J, Real
JT, Ascaso JF, Carmena R, Elte JW, Castro Cabezas
M. AT1 Receptor Gene Polymorphisms in relation to
Postprandial Lipemia. International Journal of Vascular
Medicine. 2012: 271030.
4Bovenberg SA, Klop B, Alipour A, Martinez-Hervas S,
Westzaan A, van de Geijn GJ, Janssen HW, Njo T, Birnie E, van Mechelen R, Rietveld AP, Elte JW, Castro
Cabezas M. Erythrocyte-associated apolipoprotein B
and its relationship with clinical and subclinical atherosclerosis. European Journal of Clinical Investigation.
2012 Apr; 42(4): 365-70. IF: 3,018
5Caro J, Navarro-Hidalgo I, Civera M, Real JT, Ascaso JF. Severe, long-term hypoglycemia induced by
co-trimoxazole in a patient with predisposing factors.
Endocrinología y Nutrición: órgano de la Sociedad Española de Endocrinología y Nutrición. 2012 Feb; 59(2):
146-8.
Scientific activity
6
Martinez-Hervas S, Mansego ML, de Marco G, Martinez F, Alonso MP, Morcillo S, Rojo-Martínez G, Real
JT, Acaso JF, Redon J, Martin Escudero JC, Soriguer
F, Chaves FJ. Polymorphisms of the UCP2 gene are associated with body fat distribution and risk of abdominal
obesity in Spanish population. European Journal of Clinical Investigation. 2012 Feb; 42(2): 171-178. IF: 3,018
7Soriguer
F, García-Fuentes E, Gutierrez-Repiso C,
Rojo-Martínez G, Velasco I, Goday A, Bosch-Comas
A, Bordiú E, Calle A, Carmena R, Casamitjana R,
Castaño L, Castell C, Catalá M, Delgado E, Franch
J, Gaztambide S, Girbés J, Gomis R, Gutiérrez G, López-Alba A, Martínez-Larrad MT, Menéndez E, MoraPeces I, Ortega E, Pascual-Manich G, Serrano-Rios
M, Valdés S, Vázquez JA, Vendrell J. Iodine intake in
the adult population. [email protected] study. Clinical Nutrition. 2012 May 4. IF: 3,731
8
González R, Pedro T, Martinez-Hervas S, Civera M,
Antonia Priego M, Catalá M, Chaves FJ, Ascaso JF,
Carmena R, Real JT. Plasma homocysteine levels are
independently associated with the severity of peripheral polyneuropathy in type 2 diabetic subjects. Journal
of the Peripheral Nervous System: JPNS. 2012 Jun;
17(2): 191-196. IF: 2,8
9Marcuello C, Calle-Pascual AL, Fuentes M, Runkle I,
Soriguer F, Goday A, Bosch-Comas A, Bordiú E, Carmena R, Casamitjana R, Castaño L, Castell C, Catalá M, Delgado E, Franch J, Gaztambide S, Girbés J,
Gomis R, Gutiérrez G, López-Alba A, Martínez Larrad
MT, Menéndez E, Mora-Peces I, Ortega E, PascualManich G, Rojo-Martínez G, Serrano-Rios M, Valdés
S, Vázquez JA, Vendrell J. Evaluation of Health-Related Quality of Life according to Carbohydrate Metabolism Status: a Spanish Population-Based Study (Di@
bet.es Study). International Journal of Endocrinology.
2012: 872305. IF: 1,867
10Arbona C, Martinez-Hervás S, Goterris R, Montoro J,
Real JT, Ascaso JF. Low-density lipoprotein apheresis in familial hypercholesterolemia resistant to intensive medical treatment. Medicina Clínica. 2012 May 7.
IF: 1,385
11Bobes
J, Arango C, Aranda P, Carmena R, GarciaGarcia M, Rejas J, CLAMORS Study Collaborative
Group. Cardiovascular and metabolic risk in outpatients with schizoaffective disorder treated with antipsychotics: results from the CLAMORS study. European Psychiatry: the journal of the Association of
European Psychiatrists. 2012 May; 27(4): 267-74. IF:
2,766
12Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, Chaitman BR, Holme IM, Kallend D,
Leiter LA, Leitersdorf E, McMurray JJ, Mundl H, Nicholls SJ, Shah PK, Tardif JC, Wright RS, dal-OUTCOMES Investigators. Effects of dalcetrapib in patients
with a recent acute coronary syndrome. The New
England Journal of Medicine. 2012 Nov 29; 367(22):
2089-99. IF: 53,298
13Rossetti
P, Ampudia-Blasco FJ, Laguna A, Revert A,
Vehì J, Ascaso JF, Bondia J. Evaluation of a Novel
Continuous Glucose Monitoring-Based Method for
Mealtime Insulin Dosing-the iBolus-in Subjects with
Type 1 Diabetes Using Continuous Subcutaneous
Insulin Infusion Therapy: a Randomized Controlled
Trial. Diabetes Technology & Therapeutics. 2012 Nov;
14(11): 1043-52. IF: 19,31
Review
1Genser
B, Silbernagel G, De Backer G, Bruckert E,
Carmena R, Chapman MJ, Deanfield J, Descamps
OS, Rietzschel ER, Dias KC, März W. Plant sterols
and cardiovascular disease: a systematic review and
meta-analysis. European Heart Journal. 2012 Feb;
33(4): 444-51. IF: 10,478
Letter
1Caro
J, Inmaculada Navarro-Hidalgo M, Bonanad C,
Real JT, Ascaso JF. Mitral regurgitation of unknown
etiology in a 20-year-old patient. Endocrinología y Nutrición: órgano de la Sociedad Española de Endocrinología y Nutrición. 2012 May; 59(5): 333-5.
2 Molina M, García J, Civera M, Ortega J, Martínez-Valls
JF, Martínez-Hervás S, Real JT, Carmena R. Hypoglycemia after Roux-en-Y gastric bypass surgery. Endocrinología y Nutrición: Órgano de la Sociedad Española de Endocrinología y Nutrición. 2011 Apr Volume:
58 Issue: 4 Pages: 197-9.
THESIS
1Title of the thesis: Efecto de la sobrecarga oral con
grasa insaturada sobre los marcadores de estrés oxidativo e inflamación. Estudios de lipemia postprandial en
sujetos con hipercolesterolemia familiar heterocigota.
4
55
Scientific activity
Doctoral candidate: María Teresa Pedro Font
Director(s): José Tomás Real Collado and Rafael
Carmena Rodríguez
lución de la glándula mamaria tras la lactancia. Implicaciones biomédicas.
Date of the defense: 2012
Principal Investigator: Juan Viña Ribes (Marta Peiró
as collaborating researcher)
Grade: Summa cum laude
Funding Body: Ministerio de Ciencia e Innovación
Beneficiary Institution: Universitat de València
RESEARCH PROJECTS AND GRANTS FOR
RESEARCH
Reference: PI10/00511
Title: Perfil de expresión de ARN en linfomonocitos
tras sobrecarga oral con grasa insaturada en dos modelos con resistencia a la insulina: obesidad abdominal y diabetes tipo 2.
Principal Investigator: Juan Francisco Ascaso Gimilio
Funding Body: Instituto de Salud Carlos III
Beneficiary Institution: Fundación Investigación
Hospital Clínico Universitario de Valencia
Duration: 2011-2013
Duration: 2011-2013
Total Budget: €90.000
Reference: PROMETEO/2009/029
Title: Grupo de investigación en enfermedades de alto
riesgo cardiovascular.
Principal Investigator: Rafael Carmena Rodríguez
Funding Body: Conselleria d’Educació, Generalitat
Valenciana
Beneficiary Institution: Fundación de Investigación
del Hospital Clínico de Valencia
Duration: 2009-2012
Total Budget: €85.000 per year
Reference: CB07/08/0018
56
4
Title: CIBER de Diabetes y Enfermedades Metabólicas Asociadas.
Duration: 2008-2013
Reference: ESTUDIO Telemed-Diabetes
Title: Estudio multicéntrico, randomizado, prospectivo, abierto y comparativo para valorar la eficiencia de
la implantación en el entorno sanitario de un sistema
de telemedicina aplicado a un programa telemático de
optimización de control metabólico dirigido a pacientes con diabetes mellitus tipo 1 (DM1). Estudio TELEMED-DIABETES.
Principal Investigator: Enric Esmatjes (Sergio Martínez Hervás as collaborating researcher)
Funding Body: CIBERDEM
Beneficiary Institution: IDIBAPS
Duration: 2012-2013
Reference: BFU2010-18253
Title: El NF-KB como nodo de regulación en la invo-
Reference: ISIC/2012/018
Title: Instituto Superior de Investigaciones Científicas
INCLIVA
Valenciana
Duration: 2011-2012
Scientific activity
Research Group of the Genotiping and Genetic Diagnosis Unit (UGDG)
PI: Felipe Javier Chaves Martínez (INCLIVA).
Collaborating Researchers: Sebastián Blesa Luján (INCLIVA), Ana Bárbara García García (CIBERDEM), Pablo Marín
García (INCLIVA).
Predoctoral Researchers: Inmaculada Galan Chilet (INCLIVA), Pilar Rentero Garrido (INCLIVA), Vanessa Martínez
Barquero (INCLIVA).
Technicians: Verónica González Albert (INCLIVA), Victoria Adam Felici (INCLIVA), Cristina Pérez Soriano (INCLIVA).
Strategic aims
•
•
•
•
•
•
Identification of different genetic polymorphisms associated with:
- BMI and obesity, and waist perimeter and central obesity.
- Type 2 diabetes and insulin resistance.
- Kidney damage in hypertension (measured as microalbuminuria). In this case, new genes possibly associated with the development of kidney damage have been identified by means of a GWAS study and validation of the results in new samples.
The study of the exome related to the development of type 2 diabetes and its consecuences has been initiated.
The possible association between arsenic levels and elevation of blood pressure has been verified.
The importance of unsaturated oils in oxidative stress levels and the activity of some antioxidant systems by oral
overdose with this kind of fatty acids in hypercholesterolemic patients has been proved.
Identification of the correlation between the levels of C-reactive protein and the incidence of type 2 diabetes.
Identification of the correlation between levels of homocysteine and diabetic neuropathy.
• Detection of genetic alterations (mutations or polymorphisms) involved in the development of complex diseases with high
cardiovascular risk especially focused on genes related to oxidative stress, lipid metabolism, etc.
• Study of genetic variations present in the exome related to development of type 2 diabetes and its consecuences.
• Study of the importance of environmental pollutants in the development of human diseases, specially the connection between heavy metals and complex diseases with high cardiovascular risk.
4
57
Scientific activity
PUBLICATIONS
Original articles
Patents
Inventors: Felipe Javier Chaves, Ana Bárbara García-García and Sebastián Blesa
Title: Methods for DNA rearrengements analysis.
1Klop B, van den Berg TM, Rietveld AP, Chaves J, Real
JT, Ascaso JF, Carmena R, Elte JW, Castro Cabezas
M. AT1 Receptor Gene Polymorphisms in relation to
Postprandial Lipemia. International Journal of Vascular
Medicine. 2012: 271030.
2Martinez-Hervas
S, Mansego ML, de Marco G, Martinez F, Alonso MP, Morcillo S, Rojo-Martinez G, Real
JT, Ascaso JF, Redon J, Martin Escudero JC, Soriguer
F, Chaves FJ. Polymorphisms of the UCP2 gene are
associated with body fat distribution and risk of abdominal obesity in Spanish population. European Journal
of Clinical Investigation. 2012 Feb; 42(2): 171-178. IF:
3,018
3Ivorra C, García-Vicent C, Chaves FJ, Monleón D, Morales JM, Lurbe E. Metabolomic profiling in blood from
umbilical cords of low birth weight newborns. Journal
of Translational Medicine. 2012 Jul 9; 10(1): 142.
4Mansego ML, Martínez F, Martínez-Larrad MT, Zabe58
na C, Rojo G, Morcillo S, Soriguer F, Martín-Escudero
JC, Serrano-Ríos M, Redon J, Chaves FJ. Common
variants of the liver fatty acid binding protein gene influence the risk of type 2 diabetes and insulin resistance in Spanish population. PLoS One. 2012; 7(3):
e31853. IF: 4,092
4
5
6
Mitjavila MT, Fandos M, Salas-Salvadó J, Covas MI,
Borrego S, Estruch R, Lamuela-Raventós R, Corella D,
Martínez-González MA, Sánchez JM, Bulló M, Fitó M,
Tormos C, Cerdá C, Casillas R, Moreno JJ, Iradii A, Zaragoza C, Chaves J, Sáez GT. The Mediterranean diet
improves the systemic lipid and DNA oxidative damage
in metabolic syndrome individuals. A randomized, controlled, trial. Clinical Nutrition. 2012 Aug 31. IF: 3,731
González R, Pedro T, Martinez-Hervas S, Civera M,
Antonia Priego M, Catalá M, Chaves FJ, Ascaso JF,
Carmena R, Real JT. Plasma homocysteine levels are
independently associated with the severity of peripheral polyneuropathy in type 2 diabetic subjects. Journal
of the Peripheral Nervous System: JPNS. 2012 Jun;
17(2): 191-196. IF: 2,8
Application number: EP12382477.3
Priority date: 11/30/2012
Priority countries: Europe
RESEARCH
Title: Identificación de variantes genéticas en el exoma asociadas con DM2.
Principal Investigator: Javier Chaves Martínez
Duration: 2012-2014
Title: CIBER de Diabetes y Enfermedades Metabólicas Asociadas.
(Javier Chaves as collaborating researcher)
Duration: 2012-2013
Reference: PROMETEO/2009/029
Title: Grupo de investigación en enfermedades de alto
riesgo cardiovascular.
(Javier Chaves as collaborating researcher)
Valenciana
Duration: 2009-2012
Scientific activity
Reference: PS09/02014
Title: Interaction of genetic and adquired factors on
the risk to develop microalbuminuria in essential hypertension: a genomic and metabolomic approach.
Principal Investigator: Josep Redón i Mas (Verónica
González, Pablo Marín and Pilar Rentero as collaborating researchers)
Duration: 2010-2012
4
59
Scientific activity
Research Group on Cardiac Experimental Electrophysiology
PI: Francisco Javier Chorro Gascó (Department of Cardiology Hospital Clínico Universitario of Valencia / Department of
Medicine University of Valencia).
Collaborating Researchers: Luis Such Belenguer (University), Antonio Alberola Aguilar (University), Luis Such Miquel
(University), Isabel Trapero Gimeno (University), Luis Mainar Latorre (Hospital), Joaquín Cánoves Femenía (Hospital),
Laura López Bueno (Hospital).
60
4
Predoctoral Researchers: Germán Parra Giraldo (University), Laia Brines Ferrando (INCLIVA), Diana Gallego de Marco
(INCLIVA), Manuel Zarzoso Muñoz (University), Irene del Canto (INCLIVA), Natalia Gallego Rojas (INCLIVA).
Strategic aims
• To identify pharmacological agents able to block or counteract the pro-arrhythmogenic effects of mechanical stretching.
• To study the facilitation of myocardial capture during fibrillatory processes by electrical overstimulation.
• To characterize protective effects of physical activity in relation to induction, maintenance and cessation of ventricular
arrhythmias and analysis of the influence of autonomous nervous system.
• To perform an experimental study on the proarrhythmic and antiarrhythmic effects of thermal variations located in the
ventricular myocardium.
• To analyze the role played by IKATP currents and by their changes in electrophysiological heterogeneity during myocardial ischemia. An experimental study.
• To develop, update and integrate new and complementary instruments to improve and extend studies of experimental
cardiac electrophysiology. Incorporation of optical cartography techniques.
• Myocardial stress: analysis of electrophysiological changes induced by mechanical stretching. Autocrine/paracrine infuences and study of protective actions by means of drugs.
• Clinical and basic research on heart failure: role of calcium homeostasis in arrhythmogenesis. Study on the effects of
drugs acting on intracellular Ca2+ dynamics.
• Analysis of the effects of modifications in basic electrophysiological properties on the processes involved in beginning,
perpetuation and cessation of ventricular fibrillation.
• Study of electrophysiological effects of chronic physical activity by: a) analysis of the protection against arrhythmias or
Scientific activity
facilitation of its reversion; b) study of the influence of heart’s nervous system and mitochondrial oxidative stress; and c)
analysis of the effects on the electrical instability induced by myocardial ischemia and the implication of IKATP current.
• Development and extension of tools for the registration, processing and analysis of cardiac electrophysical signals based on multielectrodes and optical cartography systems able to analyze voltage and calcium signals.
PUBLICATIONS
tional Journal of Cardiology. 2012 Jun 8. IF: 7,078
6Brines L, Such-Miquel L, Gallego D, Trapero I, Del
Canto I, Zarzoso M, Soler C, Pelechano F, Cánoves
J, Alberola A, Such L, Chorro FJ. Modifications of
mechanoelectric feedback induced by 2,3-butanedione monoxime and Blebbistatin in Langendorff-perfused rabbit hearts. Acta Physioligica (Oxford). 2012
Sep; 206(1): 29-41. IF: 3,09
Original articles
1Chorro FJ, Pelechano F, Trapero I, Ibañez-Catalá X,
Such-Miquel L, Tormos A, Guerrero J, Mainar L, Millet J, Alberola A, Such L. Modifications in ventricular
fibrillation and capture capacity induced by a linear radiofrequency lesion. Revista Española de Cardiología.
2012 Feb; 65(2): 143-51. IF: 2,53
2
Bodi V, Husser O, Sanchis J, Núñez J, Monmeneu
JV, López-Lereu MP, Bosch MJ, Rumiz E, Miñana G,
García C, Diago JL, Chaustre F, Moratal D, Gómez C,
Aguilar J, Chorro FJ, Llácer A. Prognostic Implications
of Dipyridamole Cardiac MR Imaging: A Prospective
Multicenter Registry. Radiology. 2012 Jan; 262(1): 91100. IF: 5,726
3 Bodi V, Sanchis J, Morales JM, Marrachelli VG, Nuñez
J, Forteza MJ, Chaustre F, Gómez C, Mainar L, Miñana G, Rumiz E, Husser O, Noguera I, Diaz A, Moratal
D, Carratalá A, Bosch X, Llácer A, Chorro FJ, Viña JR,
Monleon D. Metabolomic profile of human myocardial
ischemia by nuclear magnetic resonance spectroscopy of peripheral blood serum: a translational study based on transient coronary occlusion models. Journal
of the American College of Cardiology. 2012 May 1;
59(18): 1629-41. IF: 14,156
4 Núñez J, Núñez E, Miñana G, Bodí V, Fonarow GC,
Bertomeu-González, Palau P, Merlos P, Ventura S,
Chorro FJ, Llàcer P, Sanchis J. Differential mortality
association of loop diuretic dosage according to blood
urea nitrogen and carbohydrate antigen 125 following
a hospitalization for acute heart failure. European Journal of Heart Failure. 2012 Jun 14(9):974-84. IF: 4,896
5 Husser O, Monmeneu JV, Sanchis J, Nuñez J, LopezLereu MP, Bonanad C, Chaustre F, Gómez C, Bosch
MJ, Hinarejos R, Chorro FJ, Riegger GA, Llácer A,
Bodi V. Cardiovascular magnetic resonance-derived
intramyocardial hemorrhage after STEMI: Influence on
long-term prognosis, adverse left ventricular remodeling
and relationship with microvascular obstruction. Interna-
7Husser O, Chaustre F, Sanchis J, Nuñez J, Monmeneu
JV, Lopez-Lereu MP, Bonanad C, Gómez C, Llácer A,
Riegger GA, Chorro FJ, Bodi V. Function of remote noninfarcted myocardium after STEMI: analysis with cardiovascular magnetic resonance. International Journal of
Cardiovascular Imaging. 2012. 28: 2057-64. IF: 2,285
8
Monmeneu JV, Bodí V, López-Lereu MP, Sanchis J,
Núñez J, Chaustre F, Husser O, Merlos P, Bonanad
C, Miñana G, Chorro FJ, Llácer A. Analysis of postinfarction salvaged myocardium by cardiac magnetic
resonance. Predictors and influence on adverse ventricular remodeling. Revista Española de Cardiología.
2012 Jul; 65(7): 634-41. IF: 2,53
9 Núñez J, Núñez E, Sanchis J, Bodí V, Fonarow GC,
Miñana G, Palau P, Bertomeu-Gonzalez V, Carratalá
A, Mainar L, Chorro FJ, Llàcer A. Antigen carbohydrate 125 and brain natriuretic peptide serial measurements for risk stratification following an episode of
acute heart failure. International Journal of Cardiology.
2012 Aug 9; 159(1): 21-8. IF: 7,078
10Zarzoso M, Such-Miquel L, Parra G, Brines-Ferrando L, Such L, Chorro FJ, Guerrero J, Guill A, O’Connor
JE, Alberola A. The training-induced changes on automatism, conduction and myocardial refractoriness are
not mediated by parasympathetic postganglionic neurons activity. European Journal of Applied Physiology.
2012 Jun; 112(6): 2185-93. IF: 2,147
11Chorro FJ, Ibañez-Catalá X, Trapero I, Such-Miquel
L, Pelechano F, Cánoves J, Mainar L, Tormos A, Cerdá JM, Alberola A, Such L. Ventricular Fibrillation
Conduction through an Isthmus of Preserved Myocardium between Radiofrequency Lesions. Pacing and
Clinical Electrophysiology. 2012 Dec 13. IF: 1,351
4
61
Scientific activity
12Such-Miquel
L, Chorro FJ, Guerrero J, Trapero I,
Brines L, Zarzoso M, Parra G, Soler C, Del Canto
I, Alberola A, Such L. Evaluation of the Complexity
of Myocardial Activation During Ventricular Fibrillation.
An Experimental Study. Revista Española de Cardiología. 2012 Dec 7. IF: 2,53
13Chorro FJ, Ibañez-Catalá X, Trapero I, Such-Miquel
L, Pelechano F, Cánoves J, Mainar L, Tormos A, Cerdá JM, Alberola A, Such L. Ventricular Fibrillation
Conduction through an Isthmus of Preserved Myocardium between Radiofrequency Lesions. Pacing and
Clinical Electrophysiology. 2012 Dec 13. IF: 1,351
14Such-Miquel
4
Doctoral candidate: Germán Parra Giraldo
Director(s): Luis Such Belenguer and Luis Such Miquel
2Title of the thesis: Efecto del ejercicio físico crónico
sobre las características de la fibrilación ventricular, la
refractariedad y el proceso de activación miocárdica
durante la arritmia, en el corazón normalmente oxigenado y tras isquemia regional aguda.
Doctoral candidate: Beatriz Díaz Díaz
L, Chorro FJ, Guerrero J, Trapero I,
Brines L, Zarzoso M, Parra G, Soler C, Del Canto
I, Alberola A, Such L. Evaluation of the Complexity
of Myocardial Activation During Ventricular Fibrillation.
An Experimental Study. Revista Española de Cardiología. 2012 Dec 7. IF: 2,53
Director(s): Luis Such Belenguer and Luis Such Miquel
15Borrás X, Garcia-Moll X, Gómez-Doblas JJ, Zapata A,
lógicos de la modificación local de la temperatura en
un modelo experimental de corazón aislado mediante
un electrodo específico de alta densidad con modulación térmica.
Artigas R, AVANCE study researchers. Stable angina in Spain and its impact on quality of life. The AVANCE registry. Revista Española de Cardiología. 2012
Aug; 65(8): 734-41. IF: 2,53
62
en corazón aislado de conejo.
16Zarzoso
M, Noujaim SF. Mission possible: RNA interference rescues the hERG current. Heart Rhythm.
2012 Oct 11. IF: 4,102
17Miñana G, Nuñez J, Sanchis J, Bodi V, Nuñez E, Chorro FJ, Llácer A. Carbohydrate antigen 125 serial measurements after an admission for acute heart failure
and risk of early readmission. Medicina Clínica 2012;
139 (11): 479-86. IF: 1,385
Letter
1Tormos A, Guill A, Millet J, Roses EJ, Trapero I, SuchMiquel L, Chorro FJ. New epicardial mapping electrode with warming/cooling function for experimental
electrophysiology studies. Medical Engineering & Physics. 2012 Jul; 34(6): 796. IF: 1,623
THESIS
1Title of the thesis: Estudio de los efectos del entrenamiento físico sobre algunas propiedades electrofisiológicas miocárdicas ventriculares, mediante el análisis
de la fibrilación ventricular inducida. Una investigación
3Title of the thesis: Estudio de los efectos electrofisio-
Doctoral candidate: Antonio Guill Ibáñez
Director(s): Álvaro Tormos Ferrando, José Millet Roig
and Francisco Javier Chorro Gascó
4Title of the thesis: Marcador tumoral antígeno carbohidrato 125 como marcador biológico en la insuficiencia cardiaca.
Doctoral candidate: Gema Miñana Escrivá
Director(s): Francisco Javier Chorro Gascó and Julio
Núñez Villota
5Title of the thesis: Estrategia invasiva en el síndrome coronario agudo sin elevación del segmento st.
Aspectos pronósticos. Análisis en población infrarrepresentada en estudios controlados.
Doctoral candidate: Patricia Palau Sampio
Director(s): Julio Núñez Villota, Juan Sanchis Forés
and Luis Such Belenguer
Scientific activity
RESEARCH
Title: Caracterización electrofisiológica y metabólica
de la repolarización cardiaca en el corazón humano
aislado.
Principal Investigator: Francisco Javier Chorro Gascó
Funding Body: Fundación “La Marató de TV3”
Duration: 2009-2012
Reference: RD06/0003/0010
Title: Red temática de investigación cooperativa en
salud (RETIC).
Reference: DEP 2010-22318-C02-01
Title: Efectos del entrenamiento sobre las modificaciones que la isquemia miocárdica produce en parámetros electrofisiológicos arritmogénicos. Implicación de
la corriente IKATP.
Principal Investigator: Luis Such Belenguer
Duration: 2011-2013
Title: Ayuda para la adquisición de equipamiento para
el microcluster “Protección Cardiovascular”.
Funding Body: International Campus of Excellence
VLC/CAMPUS
Duration: 2012
Duration: 2007-2012
Title: Modificaciones farmacológicas de los efectos
electrofisiológicos del estiramiento miocárdico.
Duration: 2010-2012
Reference: PROMETEO 2010/093
Title: Análisis de los efectos de las modificaciones
electrofisiológicas sobre los procesos fibrilatorios.
Valenciana
Duration: 2010-2012
Total budget: €55.300 per year
4
63
Scientific activity
Research Group on Endothelial Cells (LINCE)
PI: Carlos Hermenegildo Caudevilla (Department of Physiology University of Valencia).
Collaborating Researchers: Susana Novella del Campo (INCLIVA), Elena Monsalve Villalba (University).
Predoctoral Researchers: Andrés Laguna Fernández (INCLIVA), Carlos Bueno Betí (INCLIVA).
64
4
Strategic aims
• To identify new sex steroid-regulated endothelial signalling pathways. The analysis of the pathway for synthesis of angiotensin under exposure to estradiol is being completed.
• To study the role of estradiol in a model of murine senescence: there has been an advance in the identification of the
model and collection of blood pressure and biochemical data. A manuscript on the study has been completed.
• To compare the effects of steroid hormone on endothelial cells in relation with expression levels of estrogen receptors: the
group has published an article on the correlation between production of inflammatory mediators in human uterine artery
and increase of estrogen receptor beta expression related to time since menopause.
• Functional study in human endothelial progenitor cells (EPC): function tests have been performed in cell cultures from
blood of patients with acute myocardial infarction and two manuscripts are being prepared.
• Gender difference in cardiovascular area.
• Vascular effects of sex hormones.
• Identification of new hormone-regulated signalling pathways in endothelium.
• Interaction of sex hormones with pro-atherogenic factors.
• Determination of circulating endothelial progenitor cells and their link with hormone treatment.
Scientific activity
PUBLICATIONS
RESEARCH
Original articles
1Pineda B, Hermenegildo C, Tarín JJ, Cano A, GarcíaPérez MA. Effects of administration of hormone therapy or raloxifene on the immune system and on biochemical markers of bone remodeling. Menopause. 2012
Mar; 19(3): 319-27. IF: 3,758
2Novella S, Dantas AP, Segarra G, Medina P, Hermenegildo C. Vascular Aging in Women: is Estrogen the Fountain of Youth?. Frontiers in Physiology. 2012; 3: 165.
3Novella
S, Heras M, Hermenegildo C, Dantas AP.
Effects of estrogen on vascular inflammation: a matter
of timing. Arteriosclerosis, Thrombosis and Vascular
Biology. 2012 Aug; 32(8): 2035-42. IF: 6,368
4Fernández-Murga L, Hermenegildo C, Tarín JJ, García-Pérez MA, Cano A. Endometrial response to concurrent treatment with vaginal progesterone and transdermal estradiol. Climacteric. 2012 Feb 9. IF: 1,986
Title: Regulación por hormonas sexuales de diferentes rutas de señalización en células endoteliales humanas. Implicación en la fisiología y la fisiopatología
vasculares.
Principal Investigator: Carlos Hermenegildo Caudevilla
Institution: Universitat de València
Duration: 2011-2013
Budget: €142.780
Title: Nodo de la red de investigación cooperativa
(RETIC) HERACLES.
Duration: 2007-2012
5Pagán RM, Martínez AC, Hernández M, Martínez MP,
García-Sacristán A, Correa C, Novella S, Hermenegildo C, Prieto D, Benedito S. Endothelial and neural
factors functionally involved in the modulation of noradrenergic vasoconstriction in healthy pig internal mammary artery. Biochemical Pharmacology. 2012 Apr 1;
83(7): 882-92. IF: 4,705
Reference: ACOMP/2012/218
Title: Regulación por hormonas sexuales de diferentes rutas de señalización en células endoteliales humanas. Implicación en la fisiología y la fisiopatología
vasculares.
6 Tarín JJ, García-Pérez MA, Hermenegildo C, Cano A.
Unpredicted ovulations and conceptions during early
pregnancy: an explanatory mechanism of human superfetation. Reproduction, Fertility and Development.
2012 Oct 9. IF: 2,109
Valenciana
Beneficiary Institution: Departamento de Fisiología,
Universitat de València
Duration: 2012
THESIS
1Title of the thesis: Modificación de la expresión génica en células endoteliales humanas por factores aterogénicos y ateroprotectores.
Doctoral candidate: Andrés Laguna Fernández
Director(s): Carlos Hermenegildo Caudevilla
Reference: PRI-AIBDE-2011-0855
Title: Influencia del género en la vasodilatación mediada por Mas.
Duration: 2012-2013
4
65
Scientific activity
Reference: VA094A11-2
Title: Estudio de los mecanismos que asocian la expresión del canal Kv1.3 con la proliferación en tejidos
arteriales humanos.
Principal Investigator: José Ramón López López
(Carlos Hermenegildo and Susana Novella as collaborating researchers)
66
4
Funding Body: Consejería de Educación, Junta de
Castilla y León
Beneficiary Institution: Universidad de Valladolid
Duration: 2011-2013
Scientific activity
Research Group on Clinical Cardiology
PI: Juan Sanchis Forés (Department of Cardiology Hospital Clínico Universitario of Valencia / Department of Medicine
University of Valencia).
Collaborating Researchers: Julio Núñez Villota (Hospital), Luis Mainar Latorre (Hospital), Sergio García (Hospital),
Vicente Bodí Peris (Hospital), Anna Molla (INCLIVA), Estefanía Montalvo (INCLIVA).
Strategic aims
• To design a web tool for diagnosing chest pain of unclear origin.
• To question the benefits of ischemic postconditioning in reperfusion therapy for myocardial infarction.
• To identify subgroups of acute heart failure patients with risk of acute renal failure due to treatment with loop diuretics.
• Therapeutic and prognostic evaluation of acute coronary syndromes and secondary prevention.
• Ventricular dysfunction and myocardial perfusion in acute heart failure. Experimental model and clinical approach.
• Acute heart failure. New strategies for the evaluation of risk and treatment and new control programs.
Associated Emerging Group
Vicente Bodí Peris (Department of Cardiology Hospital Clínico Universitario of
Valencia / Department of Medicine University of Valencia).
The research lines are mainly focused on a prospective register of ST segment elevation acute myocardial infarction (STEMI) patients analyzed with cardiac magnetic resonance (CRM) during the first week and after six months post-infarction
and on a register of stress CRM patients. Another research project, which is currently active, is focused on the establishment of a swine model of ischemia-reperfusion by means of angioplasty balloon coronary occlusion. A relevant research
line is focused on the metabolomics profile of controlled and spontaneous myocardial ischemia. We are also interested in
the immunologic and molecular basis of myocardial infarction in swine and humans.
4
67
Scientific activity
Emerging Researcher
Julio Núñez Villota (Department of Cardiology Hospital Clínico Universitario of Valencia).
This research team has focused in the development of new clinical tools for improving diagnosis, risk stratification and treatment of patients with ischemic heart diseases and heart
failure. Specifically, we are working on finding new biomarkers that may be used for guiding
the therapy of these patients.
PUBLICATIONS
Original articles
1Nuñez J, Nuñez E, Fonarow G, Ventura S, Palau P,
Bodí V, Bertomeu V, Merlos P, Chorro FJ, Llácer P,
Miñana G, Sanchis J. Differential Mortality Association of Loop Diuretic Dosage According to Blood Urea
Nitrogen and Antigen Carbohydrate 125 Following
a Hospitalization for Acute Heart Failure. European
Journal of Heart Failure. 2012; 14(9): 974-84. IF:
4,896
2Consuegra-Sánchez L, Sanchis J, Núñez J, Cascón
68
4
JD, Villegas M, Picó F. Increased Mortality in Patients
With Diabetes Associated With Olmesartan for the
Prevention/Delay of Microalbuminuria Onset: a Matter of Concern?. Revista Española de Cardiología.
2012 Ap; 65(4): 378-380. IF: 2,53
3Bodi V, Husser O, Sanchis J, Núñez J, Monmeneu
JV, López-Lereu MP, Bosch MJ, Rumiz E, Miñana G,
García C, Diago JL, Chaustre F, Moratal D, Gómez
C, Aguilar J, Chorro FJ, Llácer A. Prognostic Implications of Dipyridamole Cardiac MR Imaging: A Prospective Multicenter Registry. Radiology. 2012 Jan;
262(1): 91-100. IF: 5,726
L, Miñana G, Rumiz E, Husser O, Noguera I, Diaz
A, Moratal D, Carratalá A, Bosch X, Llácer A, Chorro
FJ, Viña JR, Monleon D. Metabolomic profile of human
myocardial ischemia by nuclear magnetic resonance
spectroscopy of peripheral blood serum: a translational study based on transient coronary occlusion models. Journal of the American College of Cardiology.
2012 May 1; 59(18): 1629-41. IF: 14,156
7Núñez J, González M, Miñana G, Garcia-Ramón R,
Sanchis J, Bodí V, Núñez E, Puchades MJ, Palau
P, Merlos P, Llácer A, Miquel A. Continuous ambulatory peritoneal dialysis as a therapeutic alternative in
patients with advanced congestive heart failure. European Journal of Heart Failure. 2012 May; 14(5): 540-8.
IF: 4,896
8Miñana
Escrivá G, Núñez J, Sanchis J, Bodi V,
Núñez E, Chorro FJ, Llàcer A. Carbohydrate antigen
125 serial measurements after an admission for acute heart failure and risk of earlyreadmission. Medicina
Clinica (Barc). 2012 Nov 3; 139(11):479-86. IF: 1,385
9Husser
J, Heras M. Arrhythmias: Introduction. Revista Española de Cardiología. 2012 Jan; 65 (1): 91. IF: 2,53
O, Monmeneu JV, Sanchis J, Nuñez J,
Lopez-Lereu MP, Bonanad C, Chaustre F, Gómez
C, Bosch MJ, Hinarejos R, Chorro FJ, Riegger GA,
Llácer A, Bodí V. Cardiovascular magnetic resonance-derived intramyocardial hemorrhage after STEMI:
Influence on long-term prognosis, adverse left ventricular remodeling and relationship with microvascular
obstruction. International Journal of Cardiology. 2012
Jun 8. IF: 7,078
5Avanzas P, Bayes-Genis A, Pérez de Isla L, Sanchis
10Husser O, Chaustre F, Sanchis J, Nuñez J, Monme-
4Bayes-Genis A, Avanzas P, Pérez de Isla L, Sanchis
J, Heras M. Summary of the Clinical Studies Reported in the Annual Scientific Sessions of the American
Heart Association. Revista Española de Cardiología.
2012 Jan; 65(1): 71.e1-71.e9. IF: 2,53
6Bodi V, Sanchis J, Morales JM, Marrachelli VG, Nuñez J, Forteza MJ, Chaustre F, Gómez C, Mainar
neu JV, Lopez-Lereu MP, Bonanad C, Gómez C, Oltra
R, Llácer A, Riegger GA, Chorro FJ, Bodi V. Function
of remote non-infarcted myocardium after STEMI:
analysis with cardiovascular magnetic resonance. International Journal of Cardiovascular Imaging. 2012;
28(8): 2057-64. IF: 2,285
Scientific activity
11Núñez J, González M, Miñana G, Garcia-Ramón R,
Sanchis J, Bodí V, Núñez E, Puchades MJ, Palau
P, Merlos P, Mascarell B, Miquel A. Continuous Ambulatory Peritoneal Dialysis and Clinical Outcomes in
Patients With Refractory Congestive Heart Failure.
Revista Española de Cardiología. 2012; 65: 986-995.
IF: 2,53
A, Mainar L, Chorro FJ, Llàcer A. Antigen carbohydrate 125 and brain natriuretic peptide serial measurements for risk stratification following an episode of
acute heart failure. International Journal of Cardiology. 2012 Aug 9; 159(1): 21-8. IF: 6,802
19Palau
P, Núñez J, Sanchis J, Husser O, Bodí V,
Núñez E, Miñana G, Boesen L, Ventura S, Llàcer
A. Differential prognostic effect of revascularization
according to a simple comorbidity index in high-risk
non-ST-segment elevation acute coronary syndrome.
Clinical Cardiology. 2012 Apr; 35(4): 237-43. IF: 2,151
12Sanchis J, Bardají A, Bosch X, Loma-Osorio P, Marín F, Sánchez PL, Núñez J, Carratalá A, Barrabés
JA. Usefulness of high-sensitivity troponin T for the
evaluation of patients with acute chest pain and no or
minimal myocardial damage. American Heart Journal.
2012 Aug; 164(2): 194-200.e1. IF: 4,651
Letter
1Núñez J, Chilet M, Blasco ML, Clari MA, Sanjuan R,
13Heras M, Avanzas P, Bayes-Genis A, de Isla LP, San-
Muñoz-Cobo B, Bodí V, Costa E, Bravo D, Sanchis
J, Miñana G, Navarro D. Low rate of detection of active cytomegalovirus (CMV) infection early following
acute myocardial infarction. Atherosclerosis. 2012
May; 222(1): 295-7. IF: 3,794
chis J. Current Topics in Cardiology in 2011. Introduction: developments in 2011. Revista Española de Cardiología. 2012 Jan; 65 Suppl 1: 1-3. IF: 2,53
14 Husser O, Rauch S, Endemann DH, Resch M, Nuñez
J, Bodi V, Hilker M, Schimd C, Riegger GA, Luchner
A, Henstenberg C. Impact of three-dimensional transesophageal echocardiography on prosthesis sizing for
transcatheter aortic valve implantation. Catheterization
and Cardiovascular Interventions. 2012 Mar 14. IF: 2,29
Editorial
1Grupo
de Trabajo de SEC para Guía ESC2011 de
SCASEST, Fernández-Ortiz A, Pan M, Alfonso F,
Arós F, Barrabés JA, Bodí V, Cegueira A, García-Moll
X, Jiménez-Candil J, López-Palop R, Peña C, Worner F, Comité de Guías de Práctica Clínica de SEC,
Alonso Gómez AM, Anguita M, Cequier A, Comín J,
Fernández-Ortiz A, Pan M, Worner F, Alonso J, Bardají A, Barón-Esquivias G, Bover R, Angel-Ferrer J,
Goicolea J, Gómez-Doblas JJ, Iñiquez A, Mainar V,
Marín F, Pedreira M, Roldán I, Sabaté M, Sánchez
PL, Sanchis J. Comments on the ESC guidelines for
the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. A report of the Task Force of the Clinical Practice Guidelines Committee of the Spanish Society of
Cardiology. Revista Española de Cardiología. 2012
Feb; 65(2): 125-30. IF: 2,53
15Fernández-Ortiz A, Jiménez-Candil J, Bodí V, Barrabés JA. Update on ischemic heart disease. Revista
Española de Cardiología. 2012 Jan; 65 Suppl 1: 42-9.
IF: 2,53
16Monmeneu JV, Bodí V, López-Lereu MP, Sanchis J,
Núñez J, Chaustre F, Husser O, Merlos P, Bonanad
C, Miñana G, Chorro FJ, Llácer A. Analysis of postinfarction salvaged myocardium by cardiac magnetic
resonance. Predictors and influence on adverse ventricular remodeling. Revista Española de Cardiología.
2012 Jul; 65(7):634-41. IF: 2,53
17Anguita
M, Castillo JC, Ruiz M, Castillo F, JiménezNavarro M, Crespo M, Alonso-Pulpón L, de Teresa E,
Castro-Beiras A, Roig E, Artigas R, Zapata A, de Ullibarri IL, Muñiz J, OBELICA Study researches. Differences in outcome of heart failure with preserved or
depressed systolic function in patients older than 70
years who receive beta blockers. Revista Española de
Cardiología. 2012 Jan; 65(1): 22-8. IF: 2,53
THESIS
1Title of the thesis: Estrategia invasiva en el síndrome coronario agudo sin elevación del segmento ST.
Aspectos pronósticos. Análisis en población infrarrepresentada en estudios controlados.
18 Núñez J, Núñez E, Sanchis J, Bodí V, Fonarow GC,
Doctoral candidate: Patricia Palau Sampio
Miñana G, Palau P, Bertomeu-González V, Carratalá
Director(s): Julio Núñez Villota, Juan Sanchis Forés
4
69
Scientific activity
and Luis Such Belenguer
2Title of the thesis: Marcador tumoral antígeno carbohidrato 125 como marcador biológico en la insuficiencia cardiaca.
Doctoral candidate: Gema Miñana Escrivá
Director(s): Francisco Javier Chorro Gascó and Julio
Núñez Villota
Duration: 2009-2012
Reference: EC10-108
Title: Terapia guiada mediante los valores plasmáticos
del antígeno carbohidrato 125 tras un ingreso hospitalario por insuficiencia cardiaca aguda. Estudio randomizado y controlado.
Principal Investigator: Julio Núñez Villota
Funding Body: Ministerio de Sanidad, Servicios Sociales e Igualdad. Instituto de Salud Carlos III
del Hospital Clínico Universitario de Valencia
RESEARCH
Duration: 2012
Title: Comparación aleatoria entre las estrategias
invasiva y conservadora en pacientes con síndrome
coronario agudo sin elevación de segmento ST y comorbilidades.
Principal Investigator: Juan Sanchis Forés
70
4
Title: La metabolómica en el diagnóstico y el pronóstico de las enfermedades cardiovasculares. Una aproximación traslacional.
Principal Investigator: Vicent Bodí Peris
Duration: 2012-2014
Duration: 2012-2014
Title: RED HERACLES.
Duration: 2007-2012
Reference: EAHC-20081312
Title: European Hospital Benchmarking by Outcomes
in Acute Coronary Syndrome Procedures -EURHOBOP-.
Funding Body: European Commission EAHC. Public
Health Executive Agency
Scientific activity
Research Group on the Study of Cardiovascular Risk in Children and Adolescents
PI: Empar Lurbe i Ferrer (Department of Pediatrics, Obstetrics and Gynecology University of Valencia).
Collaborating Researchers: Isabel Torró Doménech (University), José Luis Fayos Soler (University), Julio Álvarez Pitti (University), Francisco Aguilar Bacallado (University), Carmen Ivorra Ivorra (CIBERobn).
Administrative assistants: Rachel Dix (CIBERobn).
Strategic aims
• To conduct an in-depth study of the impact of low birth weight on development of obesity and cardiometabolic risk.
• To study new biomarkers of cardiometabolic risk in umbilical cord vessels (cell growth, epigenetics, metabolomics and
proteomics).
• To improve the knowledge of cardiometabolic risk in obese children and teenagers.
• To extend the application of new technologies of Smart e-Therapy in obesity and related eating disorders.
• Physical activity and obesity.
• New technologies applied to the detection of congenital heart diseases and sepsis in asymptomatic newborn babies.
• Childhood obesity.
• New technologies applied to the treatment of obesity.
• Impact of intrauterine life in development of cardiometabolic disease.
• Arterial hypertension in children.
• Cardiovascular and kidney risk in diabetes.
PUBLICATIONS
Original articles
1Maravall M, Lurbe E. Left ventricular characteristics in
obesity and hypertension. Anales de Pediatría (Barc).
2012 Jan; 76(1): 1-3. IF: 0,77
2Ivorra
C, García-Vicent C, Chaves FJ, Monleón D,
Morales JM, Lurbe E. Metabolomic profiling in blood
from umbilical cords of low birth weight newborns.
Journal of Translational Medicine. 2012 Jul 9; 10(1):
142. IF: 3,474
3Lurbe E, Grassi G. Uncertainty in the assessment of
trends in childhood blood pressure. Journal of Hyper-
4
71
Scientific activity
J Transl Med. 2012 Jul 9; 10:142
Superposed 1H NMR spectra for the spectra of umbilical cord blood plasma (Panel A), Principal Component Analysis scores plot (PCA, panel B), and Projection
to Latent Structures for Discriminant Analysis scores plot (PLS-DA, panel C) showing the global metabolic differences between low birth weight (open circles,
blue spectra) and control birth weight (black triangles and red spectra) newborns. Although an unsupervised analysis by PCA does not show differences between
groups, a supervised classification method (PLS-DA) provides a differential global metabolic profile. The cross-validated error percentage of the model for the
classification of low weight at birth samples is 8%.
tension. 2012 Sep; 30(9): 1697-8. IF: 4,021
4Lurbe E, Torro I, Garcia-Vicent C, Alvarez J, Fernández-Fornoso JA, Redon J. Blood pressure and obesity
exert independent influences on pulse wave velocity in
youth. Hypertension. 2012 Aug; 60(2): 550-5. IF: 6,207
5Lisón
72
4
JF, Real-Montes JM, Torró I, Arguisuelas MD,
Alvarez-Pitti J, Martínez-Gramage J, Aguilar F, Lurbe E. Exercise intervention in childhood obesity: a
randomized controlled trial comparing hospital-versus
home-based groups. Academic Pediatrics. 2012 Jul;
12(4): 319-25. IF: 2,398
6Cebolla A,
Perpiñá C, Lurbe E, Alvarez-Pitti J, Botella C. Prevalence of binge eating disorder among a
clinical sample of obese children. Anales de Pediatría
(Barc). 2012 Aug; 77(2): 98-102. IF: 0,77
Editorial
1Lurbe
E. Reference blood pressure values in childhood: an issue to be solved. Journal of Hypertension.
2012 Oct; 30(10): 1911-2. IF: 4,021
Beneficiary Institution: Consorcio Hospital General
Universitario de Valencia
Duration: 2012-2014
Title: CIBER de obesidad y trastornos de la nutrición.
Principal Investigator: Empar Lurbe
Universitario de Valencia and Fundación de Investigación del Hospital Clínico de Valencia
Duration: 2007-2013
Reference: IPT-2011-0824-900000
Title: INNPACTO Plataforma IntegNeo.
Principal Investigator: Empar Lurbe i Ferrer
Duration: 2012-2014
RESEARCH
Title: Estudio de impacto de la vida intrauterina en el
desarrollo de la enfermedad cardiometabólica: de los
biomarcadores en cordón umbilical a fenotipos intermedios en época pediátrica.
Reference: IntecMedic
Title: Investigación clínica y tecnología médica personalizada para prevención, diagnóstico y terapia.
Funding Body: International Campus of Excellence
VLC/CAMPUS
Duration: 2011-2014
Scientific activity
Cardiometabolic Research Group on Primary Care
PI: Jorge Navarro Pérez (Department of Health Clínico-Malvarrosa (Primary Care) / Department of Medicine University
of Valencia).
Collaborating Researchers: José Vicente Lozano Vidal (Department of Health Clínico-Malvarrosa), Álvaro Bonet Pla
(Deparment of Health Clínico-Malvarrosa), Victoria Gosalbes (Deparment of Health Clínico-Malvarrosa), Carlos Fluixá
(Deparment of Health Clínico-Malvarrosa), Daniel Matoses (Deparment of Health Clínico-Malvarrosa), Nidia Ruiz Varea (Deparment of Health Clínico-Malvarrosa), Pilar Roca (Deparment of Health Clínico-Malvarrosa), Gaspar Sánchez
Vela (Hospital).
4
Strategic aims
• To consolidate the current lines of research which are based on epidemiological and qualitative studies.
• To start a cross-cutting integration able to allow cooperation with the rest of groups in cardiovascular and metabolic lines
of research.
• Observational studies:
- Estudio Cardiometabólico Valenciano (ESCARVAL project)
• Intervention studies:
- Euroaction Plus
- Programa Prevención Secundaria (PROPRESE program)
• Cost-effectiveness qualitative studies:
- Antiaggregation
• Research studies on evaluation of health technologies:
- Systematic reviews on cardiovascular procedures.
73
Scientific activity
PUBLICATIONS
Original articles
1 Millán J, Alegría E, Guijarro C, Lozano JV, Vitale GC,
González-Timón B, González-Juanatey JR. Dyslipemia in diabetics treated with statins. Results of the
Dyslipidemia International Study in Spain. Medicina
Clínica. 2012 Dec 12. IF: 1,385
2 Carratalá-Munuera MC, Orozco-Beltrán D, Gil-Guillen
VF, Navarro-Perez J, Quirce F, Merino J, Basora J.
BibliometricanalysisofInternationalScientificproduction on Primary Care. Atención Primaria. 2012 Jan 30.
IF: 0,627
THESIS
1 Title of the thesis: Estudio epidemiológico de incidencia y análisis de costes de herpes zóster y neuralgia
posherpética en atención primaria en la Comunidad
Valenciana.
Doctoral candidate: Ana Mª Cebrián Cuenca
74
4
Director(s): Jorge Navarro Pérez and Javier Díez Domingo
RESEARCH
Title: CIBER en Epidemiología y Salud Pública (CIBERESP).
Principal Investigator: María Manuela Morales Suárez-Varela (Jorge Pérez as collaborating researcher)
Duration: 2007-2013
Scientific activity
Research Group on the Study of Cardiometabolic and Renal Risk
PI: Josep Redón i Mas (Department of Internal Medicine Hospital Clínico Universitario of Valencia / Department of
Medicine University of Valencia).
Collaborating Researchers: María José García-Fuster González-Alegre (Hospital), María José Galindo Puerto (Hospital), María José Forner Giner (Hospital), Fernando Martínez García (INCLIVA), Elena Solaz Moreno (Hospital), María
José Fabiá Valls (INCLIVA), José Vicente Lozano Vidal (Department of Health Clínico-Malvarrosa).
Predoctoral Researchers: Oscar Calaforra Juan (CIBERobn).
Strategic aims
• Studies of relation and functional significance between genetic polymorphisms and risk of obesity, type 2 diabetes, hypertension, microalbuminuria and oxidative stress have been completed.
• Studies of metabolomics and its connection with obesity and microalbuminuria have been completed.
• Studies of “in vitro” inflammation in autoimmune pathologies and venous thromboembolic disease are being developed.
• Studies of genetic association of markers with risk of venous thromboembolic disease and its recurrence are being conducted.
• Development of clinical trials.
• To start participating in ECROS (Early Cardiometabolic Risk in Overweight Subjects) cross-cutting program.
• Defense of two theses, specially the one related to resistant HTN.
• Environmental and genetic factors involved in development of arterial hypertension and early vascular damage.
• Mechanisms of development of kidney damage associated with HTN.
• Inflammation and oxidative stress in the development of cardiovascular disease.
• Genomics, proteomics and metabolomics of early cardiometabolic and renal alterations.
• Mechanisms of cell adhesion to endothelium and determination of circulating endothelial progenitor cells in patients with:
HTN, lupus erythematosus and venous thrombosis.
• Identification of polymorphisms and genes related to control of BMI, waist perimeter and risk of obesity.
• Venous thrombosis in young patients: factors associated with its development.
• Relationship between risk of venous thromboembolic disease and arteriosclerosis.
4
75
Scientific activity
Emerging Researcher
Fernando Martínez García (Hospital).
The main line of this research focuses on the study of the major genetic factors involved
in the development of microalbuminuria and kidney damage in hypertensive patients and
the mechanisms involved (disorders of lipid metabolism, inflammation, oxidative stress and
intracellular signaling pathways). By means of a GWAS we have discovered some potential
candidate genes for the development of microalbuminuria in hypertensives and we are now
performing functional studies to address the potential role of these associated genes.
A better understanding of the underlying factors may facilitate the early detection of individuals at high risk of developing vascular complications and help to improve their treatment.
PUBLICATIONS
Original articles
1Redon
J, Mancia G, Sleight P, Schumacher H, Gao
P, Pogue J, Fagard R, Verdecchia P, Weber M, Böhm
M, Williams B, Yusoff K, Teo K, Yusuf S, ONTARGET
Investigators. Safety and Efficacy of Low Blood Pressures Among Patients With Diabetes Subgroup Analyses From the ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint
Trial). Journal of American College of Cardiology. 2012
Jan 3; 59(1): 74-83. IF: 14,156
76
4
2Manolis AJ, Rosei EA, Coca A, Cifkova R, Erdine SE,
Kjeldsen S, Lip GY, Narkiewicz K, Parati G, Redon J,
Schieder R, Tsioufis C, Mancia G. Hypertension and
atrial fibrillation: diagnostic approach, prevention and
treatment. Position paper of the Working Group ‘Hypertension Arrhythmias and Thrombosis’ of the European Society of Hypertension. Journal of Hypertension. 2012 Feb; 30(2): 239-252. IF: 4,021
3Neisius U, Bilo G, Taurino C, McClure JD, Schneider
MP, Kawecka-Jaszcz K, Stolarz-Skrzypek K, Klima Ł,
Staessen JA, Kuznetsova T, Redon J, Martinez F, Rosei EA, Muiesan ML, Melander O, Zannad F, Rossignol
P, Laurent S, Collin C, Lonati L, Zanchetti A, Dominiczak AF, Delles C. Association of central and peripheral
pulse pressure with intermediate cardiovascular phenoytpes. Journal of Hypertension. 2012 Jan; 30(1): 6774. IF: 4,021
4Parati G, Bilo G, Redon J. The effects of telmisartan
alone or with hydrochlorothiazide on morning and 24-h
ambulatory BP control: results from a practice-based
study (SURGE 2). Hypertension Research. 2012 Nov
15. IF: 2,576
5Mancia G, Parati G, Bilo G, Gao P, Fagard R, Redon
J, Czuriga I, Polák M, Ribeiro JM, Sanchez R, Trimarco B, Verdecchia P, van Mieghem W, Teo K, Sleight
P, Yusuf S. Ambulatory Blood Pressure Values in the
Ongoing Telmisartan Alone and in Combination with
Ramipril Global Endpoint Trial (ONTARGET). Hypertension. 2012 Dec; 60(6): 1400-6. IF: 6,207
6Redon
J, Martinez F. Microalbuminuria as surrogate endpoint in therapeutic trials. Current Hypertension
Reports. 2012 Aug; 14(4): 345-9. IF: 2,504
7Garrido
C, de Mendoza C, Alvarez E, García F, Morello J, Garcia S, Ribera E, Rodríguez-Novoa S, Gutierrez F, Soriano V, Sinres Team. Plasma raltegravir
exposure influences the antiviral activity and selection
of resistance mutations. AIDS Research and Human
Retroviruses. 2012 Feb; 28(2): 156-64. IF: 2,246
8Redon J. Necessity of add-on therapy in the treatment
of hypertension: a new marker of high cardiovascular risk?. Journal of Hypertension. 2012 Nov; 30(11):
2085-7. IF: 4,021
9Martinez-Hervas S, Mansego ML, de Marco G, Martinez F, Alonso MP, Morcillo S, Rojo-Martinez G, Real
JT, Ascaso JF, Redon J, Martin Escudero JC, Soriguer
F, Chaves FJ. Polymorphisms of the UCP2 gene are
associated with body fat distribution and risk of abdominal obesity in Spanish population. European Journal
of Clinical Investigation. 2012 Feb; 42(2): 171-178. IF:
3,018
10Mansego ML, Martínez F, Martínez-Larrad MT, Zabena C, Rojo G, Morcillo S, Soriguer F, Martín-Escudero
JC, Serrano-Ríos M, Redon J, Chaves FJ. Common
variants of the liver fatty acid binding protein gene influence the risk of type 2 diabetes and insulin resistance in Spanish population. PloS One. 2012; 7(3):
Scientific activity
e31853. IF: 4,092
11Lurbe E, Torro I, Garcia-Vicent C, Alvarez J, Fernández-Fornoso JA, Redon J. Blood pressure and obesity
exert independent influences on pulse wave velocity in
youth. Hypertension. 2012 Aug; 60(2): 550-5. IF: 6,207
12Erdine S, Redon J, Böhm M, Ferri C, Kolloch R, Kreutz R, Laurent S, Persu A, Schmieder RE. Are physicians underestimating the challenges of hypertension
management? Results from the Supporting Hypertension Awareness and Research Europe-wide (SHARE)
survey. European Journal of Preventive Cardiology.
2012 May 30.
13Gabriel Botella F, Labiós Gómez M, Corella Piquer D.
Chronic thromboembolic pulmonary hypertension. Medicina Clínica. 2012 May 5. IF: 1,385
14Santos JR, Llibre JM, Imaz A, Domingo P, Iribarren JA,
Mariño A, Miralles C, Galindo MJ, Ornelas A, Moreno
S, Schapiro JM, Clotet B, Call Conference Group. Mutations in the protease gene associated with virological
failure to lopinavir/ritonavir-containing regimens. Journal of Antimicrobial Chemotherapy. 2012 Jun; 67(6):
1462-9. IF: 5,068
15Berenguer J, Rodríguez E, Miralles P, Von Wichmann
MA, López-Aldeguer J, Mallolas J, Galindo MJ, Van
Den Eynde E, Téllez MJ, Quereda C, Jou A, Sanz J,
Barros C, Santos I, Pulido F, Guardiola JM, Ortega E,
Rubio R, Jusdado JJ, Montes ML, Gaspar G, Esteban
H, Bellón JM, González-García J, GESIDA HIV/HCV
Cohort Study Group. Sustained Virological Response
to Interferon Plus Ribavirin Reduces Non-Liver-Related Mortality in Patients Coinfected With HIV and Hepatitis C Virus. Clinical Infectious Diseases. 2012 Sep;
55(5): 728-736. IF: 9,154
16Garrido
C, de Mendoza C, Alvarez E, García F, Morello J, Garcia S, Ribera E, Rodríguez-Novoa S, Gutierrez F, Soriano V, Sinres Team. Plasma raltegravir
exposure influences the antiviral activity and selection
of resistance mutations. AIDS Research and Human
Retroviruses. 2012 Feb; 28(2): 156-64. IF: 2,246
17Redon J, Bilo G, Parati G, SURGE Steering Committee. Home blood pressure control is low during the critical morning hours in patients with hypertension: the
SURGE observational study. Family Practice. 2012
Aug; 29(4): 421-6. IF: 1,503
18Tsiachris
D, Tsioufis C, Syrseloudis D, Thomopoulos
C, Mpafakis I, Michaelides A, Redon J, Stefanadis C.
Impaired exercise tolerance is associated with increased urine albumin excretion in the early stages of essential hypertension. European Journal of Preventive
Cardiology. 2012 Jun; 19(3): 452-9.
19Coca
A, Mazón P, Aranda P, Redón J, Divisón JA,
Martínez J, Calvo C, Galcerán JM, Barrios V, Coll AR.
Role of dihydropyridinic calcium channel blockers in
the management of hypertension. Expert Review of
Cardiovascular Therapy. 2013 Jan; 11(1): 91-105.
20Parving HH, Brenner BM, McMurray JJ, de Zeeuw D,
Haffner SM, Solomon SD, Chaturvedi N, Persson F,
Desai AS, Nicolaides M, Richard A, Xiang Z, Brunel
P, Pfeffer MA, ALTITUDE Investigators. Cardiorenal
end points in a trial of aliskiren for type 2 diabetes.
New England Journal of Medicine. 2012 Dec; 367(23):
2204-13. IF: 53,298
21Merchante
N, Merino E, López-Aldeguer J, Jover F,
Delgado-Fernández M, Galindo MJ, Ortega E, Rivero A, Mínguez C, Romero-Palacios A, Padilla S, Márquez-Solero M, Amador C, Ríos-Villegas MJ, Téllez F,
Portilla J, Pineda JA. Increasing Incidence of Hepatocellular Carcinoma in HIV-Infected Patients in Spain.
Clinical Infectious Diseases. 2013 Jan; 56(1): 143-50.
IF: 9,154
22Betancor G, Garriga C, Puertas MC, Nevot M, Anta L,
Blanco JL, Pérez-Elías MJ, de Mendoza C, Martínez
MA, Martinez-Picado J, Menéndez-Arias L, Resistance Platform of the Spanish AIDS Research Network
(ResRIS), Iribarren JA, Caballero E, Ribera E, Llibre
JM, Clotet B, Jaén A, Dalmau D, Gatel JM, Peraire J,
Vidal F, Vidal C, Riera M, Córdoba J, López Aldeguer J,
Galindo MJ, Gutiérrez F, Álvarez M, García F, PérezRomero P, Viciana P, Leal M, Palomares JC, Pineda
JA, Viciana I, Santos J, Rodríguez P, Gómez Sirvent
JL, Gutiérrez C, Moreno S, Pérez-Olmeda M, Alcamí J,
Rodríguez C, del Romero J, Cañizares A, Pedreira J,
Miralles C, Ocampo A, Morano L, Aguilera A, Garrido
C, Manuzza G, Poveda E, Soriano V. Clinical, virological and biochemical evidence supporting the association of HIV-1 reverse transcriptase polymorphism
R284K and thymidine analogue resistance mutations
M41L, L210W and T215Y in patients failing tenofovir/
emtricitabine therapy. Retrovirology. 2012 Aug; 13(9):
68. IF: 6,47
4
77
Scientific activity
23Grupo de trabajo de la Cohorte VACH. Budget impact analysis of antiretroviral therapy. A reflection based on the GESIDA guidelines. Gaceta Sanitaria. 2012
Nov-Dec; 26(6): 541-6. IF: 1,326
Clinical guidelines
1Schmieder RE, Redon J, Grassi G, Kjeldsen SE, Mancia G, Narkiewicz K, Parati G, Ruilope L, van de Borne
P, Tsioufis C. ESH position paper: renal denervation - an
interventional therapy of resistant hypertension. Journal
of Hypertension. 2012 May; 30(5): 837-41. IF: 4,021
Title: Interaction of genetic and adquired factors on
the risk to develop microalbuminuria in essential hypertension: a genomic and metabolomic approach.
Principal Investigator: Josep Redón i Mas
Duration: 2010-2012
Reference: RD09/0076/00132.
THESIS
1Title of the thesis: Monitorización ambulatoria de la
presión arterial: valor pronóstico en el seguimiento de
pacientes con hipertensión arterial resistente.
Doctoral candidate: María Rosa Oltra Sempere
Director(s): Josep Redón i Mas and José María Pascual Izuel
Duration: 2009-2012
78
4
salud (RETIC) Biobanco.
Title: CIBER de obesidad y trastornos de la nutrición.
2Title of the thesis: Influencia de los biomarcadores de
Principal Investigator: Empar Lurbe i Ferrer (Josep
Redón i Mas as collaborating researcher)
lesión cerebral BNP, DD, MMP-9 y S-100 y de marcadores de la inflamación, en el pronóstico de la hemorragia cerebral espontánea en fase aguda.
Doctoral candidate: Ainhoa Serrano Lázaro
Director(s): Alfonso Mesejo Arizmendi and Josep Redón i Mas
Universitario de Valencia and Fundación de Investigación del Hospital Clínico de Valencia
Duration: 2007-2013
RESEARCH
Reference: HEALTH 2011.2.4.2-2
INCLIVA
(Josep Redon as collaborating researcher)
Valenciana
Title: EU-MASCARA: Markers for Subclinical Cardiovascular Risk Assessment.
Duration: 2011-2012
Funding Body: European Commission
Duration: 2011-2015
Scientific activity
Research Group on Vascular Function
PI: José María Vila Salinas (Department of Physiology University of Valencia).
Collaborating Researchers: Salvador Lluch López (University), Martín Aldasoro Celaya (University), Pascual Medina
Bessó (University), Gloria Segarra Irles (University), María Dolores Mauricio Aviñó (University).
Strategic aims
The studies of this group show that basal liberation of nitric oxide (NO) is higher in small mesenteric arteries of rats with
portal hypertension and cirrhosis. However, inhibition of NO synthase (NOS) does not have any effect on endotheliumdependent relaxation induced by acetylcholine. Futhermore, dimethylarginine dimethylaminohydrolase (DDAH-1) and
DDAH-2 protect NOS from high circulating levels of asymmetric dimethylarginine (ADMA) associated with cirrhosis. Decrease of ADMA contractile effects and increase of DDAH expression in mesenteric arteries suggest that DDAHs have a
role in hyperdynamic circulation and high plasma levels of NO observed in cirrhosis and portal hypertension.
• Vascular alterations associated with portal hypertension and experimental cirrhosis.
• Characterization of alterations in the control of vascular tone and endothelial function induced by aging.
• Role of VEGF in tumor growth.
• Alterations of ADMA-NO system and EDHF in obese patients with steatosis and steatohepatitis.
• Effects of physical training on vascular response. Vascular effects of ranolazine.
PUBLICATIONS
RESEARCH
Original articles
1Novella S, Dantas AP, Segarra G, Medina P, Hermenegildo C. Vascular Aging in Women: is Estrogen the
Fountain of Youth?. Frontiers in Physiology. 2012; 3:
165.
Title: Factores endoteliales en la obesidad mórbida
con estatosis o esteatohepatitis no alcohólica.
Principal Investigator: José María Vila Salinas
4
79
Scientific activity
(José María Vila as collaborating researcher)
Funding Body: Fundación de la Investigación Médica
de la Mutua Madrileña
Duration: 2010-2012
Beneficiary Institution: Universidad Autónoma de
Madrid
Title: Farmacología experimental del tracto digestivo.
Duration: 2009-2012
Principal Investigator: Ángel Luis García Villalón
80
4
Scientific activity
Research Group on Pedriatric Nutrition
PI: Cecilia Martínez Costa (Department of Pediatrics Hospital Clínico Universitario of Valencia / Department of Pediatrics, Obstetrics and Gynecology University of Valencia).
Collaborating Researchers: Francisco Núñez Gómez (Hospital), María José López García (Hospital), Parisá Khodayar Pardo (Hospital), Mª Ángeles Montal Navarro (Hospital), Mª Ángeles Tormos Muñoz (Hospital), Pablo García
Molina (Hospital), Evelin Balaguer López (Hospital), Ana Gómez Lacasa (Hospital), Carolina Castaño Vicente-Gella
(Hospital), Carmen Ruiz Piña (Hospital).
Strategic aims
• Line of research on prevention of cardiovascular risk in children and teenagers:
- To evaluate vascular alterations by Doppler ultrasonography in children with cardiovascular risk factors (obesity and
dyslipidemia).
- To analyze correlation of arterial stiffness parameters with metabolic alterations and genetic factors.
- To determine intensity and duration of daily exercise and their influence on energy consumption and arterial stiffness
parameters.
- To adjust nutritional intervention in dyslipidemic obese children depending on vascular and metabolic alterations.
• Line of research on defensive factors of human breast milk:
- To identify intestinal microbiota and inflammatory mediators in human milk. Relate the results with the ABO blood
group, secretory phenotype of the mother and the Lewis antigen.
• Line of research on hospital pediatric malnutrition:
- To determine a screening procedure to detect risk of hospital malnutrition in children.
- To analyze the connection between hospital malnutrition and pressure sores.
• Line of research on artificial pedriatric nutrition:
- To determine nutritional response of home nutrition in children.
• Cardiovascular area:
- Study of early markers of vascular damage in dyslipidemic obese children by Doppler ultrasonography to establish a
correlation with insulin resistance and other metabolic markers.
4
81
Scientific activity
- Monitoring exercise and energy consumption in obese schoolchildren and teenagers to adjust nutritional intervention.
• Area of human milk:
- Analysis of defensive factors against norovirus infections and its relationship with histo-blood group antigens and FUT
genotype.
- Analysis of mother-fetal microbiome and cold preservation methods.
• Area of hospital malnutrition and artificial nutrition:
- Screening procedures for detecting the risk of malnutrition linked to chronic disease and pediatric hospitalization.
- Multicenter study of acceptance and quality of life in children treated with home enteral nutrition.
PUBLICATIONS
Original articles
1Puche M, Guijarro-Martínez R, Pérez-Herrezuelo G, Miragall L, Iglesias ME, Martínez-Costa C. The hypothetical role of congenital hypotonia in the development of
early coronoid hyperplasia. Journal of Craniomaxillofacial Surgery. 2012 Sep; 40(6): e155-8. IF: 1,643
82
4
2Title of the thesis: Nutrición artificial domiciliaria pediátrica mediante gastrostomía. Análisis de la respuesta nutricional y de la aceptación familiar del procedimiento.
Doctoral candidate: Soraya Borraz Gracia
Director(s): Martínez Costa Cecilia, Consuelo Pedrón
Giner and Caterina Calderón Garrido
2Martínez-Costa C, Calderón C, Pedrón-Giner C, Bo-
Year of the defense: 2012
rraz S, Gómez-López L. Psychometric properties of
the structured Satisfaction Questionnaire with Gastrostomy Feeding (SAGA-8) for caregivers of children
with gastrostomy tube nutritional support. Journal of
Human Nutrition and Dietetics. 2012 Nov 29. IF: 1,738
3de
Onis M, Martínez-Costa C, Núñez F, NguefackTsague G, Montal A, Brines J. Association between
WHO cut-offs for childhood overweight and obesity
and cardiometabolic risk. Public Health Nutrition. 2012
Oct 31: 1-6. IF: 2,169
4García-Molina P, Balaguer-López E, Torra I, Bou JE,
Alvarez-Ordiales A, Quesada-Ramos C, Verdú-Soriano J. A prospective, longitudinal study to assess use
of continuous and reactive low-pressure mattresses to
reduce pressure ulcer incidence in a pediatric intensive care unit. Ostomy Wound Management. 2012 Jul;
58(7): 32-9. IF: 1,076
THESIS
1Title of the thesis: Capacidad protectora de la leche
materna frente a las infecciones por norovirus.
Doctoral candidate: Parisá Khodayar Pardo
Director(s): Cecilia Martínez Costa and Francisco Javier Buesa Gómez
RESEARCH
Title: Calicivirus humanos causantes de gastroenteritis: Análisis de la prevalencia, epidemiología molecular
e interacciones virus-receptor.
Principal Investigator: Javier Buesa Gómez (Cecilia
Martínez Costa as collaborating researcher)
Duration: 2010-2012
Scientific activity
4.1.2.
4
Oncology
Research
Area
83
Scientific activity
Research Group on Histopathology and Tissue Engineering
PI: Carmen Carda Batalla (Department of Pathology University of Valencia).
Collaborating Researchers: Amando Peydró Olaya (Hospital), Amparo Ruiz Saurí (University), María Sancho-Tello
Valls (University), José Javier Martín de Llano (University), Noemí Rojas Lara (University), Carmina Montoliu Feliu
(University).
Technician: José Benavent Seguí (University).
Strategic aims
84
4
• Regenerative medicine: new tissues with structural and functional quality to be used as a therapeutic tool, particularly in
muscular-eskeletic, mucous and corneal tissues.
• Odontology: contributions to odontologic therapy in the areas of new biomaterials, tissue engineering and use of pulpal
precursors.
• Study of morphological basis in ocular pathologies: morphological study of corneas in experimental animals after combined administration of UV radiation and riboflavin.
• Vascularization in renal tumors: structural markers for diagnosis of renal tumors in relation with the morphometric parameters of vascularization.
• Studies of myocardial infarction in pigs and rats: diagnosis of recurrent myocardial infarction and its determining factors
in pigs; and regenerative mechanisms after using stem cells in myocardial infarction in rats.
Regenerative Medicine
• Study of cartilage regeneration
• Study of bone regeneration
• Study of use of pulpal precursors in regenerative therapies
• Study of regeneration of dental and periodontal tissues
• Study of corneal induction and regeneration
Histopathology
• Study of recurrent myocardial infarction and its determinants
• Study of vascularization in renal tumors
• Study of ciliary pathology
• Study of endometriosis
Image of neo-dentin pulp obtained after co-culturing human precursor dentin disks obtained from Young teeth. 5 micres thick
sections obtained with masson trichroner.
Scientific activity
PUBLICATIONS
Original articles
1Armengot
M, Bonet M, Carda C, Gómez MJ, Milara
J, Mata M, Cortijo J. Development and validation of a
method of cilia motility analysis for the early diagnosis
of primary ciliary dyskinesia. Acta Otorrinolaringológica Española. 2012 Jan-Feb; 63(1): 1-8.
THESIS
1Title of the thesis: Estudio estructural de la mucosa
respiratoria postintubación orotraqueal.
Doctoral candidate: Alberto Alfaro Rubio
Director(s): Carmen Carda Batalla and Miguel Armengot Carceller
2Mata M, Lluch-Estellés J, Armengot M, Sarrión I, Carda
C, Cortijo J. New adenylate kinase 7 (AK7) mutation in
primary ciliary dyskinesia. American Journal of Rhinology and Allergy. 2012 Jul; 26(4): 260-4. IF: 2,302
3Calabuig-Fariñas S, Benso RG, Szuhai K, Machado I,
López-Guerrero JA, de Jong D, Peydró A, San Miguel
T, Navarro L, Pellín A, Llombart-Bosch A. Characterization of a New Human Cell Line (CH-3573) derived from
a Grade II Chondrosarcoma with Matrix Production.
Pathology Oncology Research. 2012 Oct; 18(4):793802. IF: 1,366
4Cerrada I, Ruiz-Saurí A, Carrero R, Trigueros C, Dorronsoro A, Sánchez-Puelles JM, Diez-Juan A, Montero
JA, Sepúlveda P. Hypoxia-inducible factor 1 alpha contributes to cardiac healing in mesenchymal stem cells
mediated cardiac repair. Stem Cells and Development.
2012 Aug 8. IF: 4,459
5Romanenko
AM, Ruiz-Saurí A, Morell-Quadreny L,
Valencia G, Vozianov AF, Llombart-Bosch A. Microvessel density is high in clear-cell renal cell carcinomas of
Ukrainian patients exposed to chronic persistent lowdose ionizing radiation after the Chernobyl accident.
Virchows Archiv. 2012 Jun; 460(6): 611-9. IF: 2,491
6Mata M, Sarrion I, Armengot M, Carda C, Martinez I,
Melero JA, Cortijo J. Respiratory syncytial virus inhibits
ciliagenesis in differentiated normal human bronchial
epithelialcells: effectiveness of N-acetylcysteine. PloS
One. 2012; 7(10). IF: 4,092
7Carrero R, Cerrada I, Lledó E, Dopazo J, García-García F, Rubio MP, Trigueros C, Dorronsoro A, Ruiz-Sauri A, Montero JA, Sepúlveda P. IL1 induces mesenchymal stem cells migration and leucocyte chemotaxis
through NF-kB. Stem Cells Reviews. 2012 Sep; 8(3):
905-16. IF: 3,739
8Novella-Maestre
E, Herraiz S, Vila-Vives JM, Carda C,
Ruiz-Sauri A, Pellicer A. Effect of antiangiogenic treatment
on peritoneal endometriosis-associated nerve fibers. Fertility and Sterility. 2012 Nov; 98(5): 1209-17. IF: 3,775
RESEARCH
Reference: MAT2010-21611-C03-03
Title: Evaluación biológica y morfológica de andamiajes sintéticos en el cartílago articular. Síntesis y evaluación de la respuesta biológica de nuevos soportes
biorreabsorbibles para la regeneración del cartílago
articular.
Principal Investigator: Carmen Carda Batalla
Funding Body: Ministerio de Educación, Cultura y
Deporte
Duration: 2011-2013
Reference: UV-SFPIE_DOCE12-81018
Title: Realización de prácticas microscópicas y videos
multimedia para la asignatura de Inmunología e Inmunopatología impartida por Histología.
Principal Investigator: Amparo Ruiz Saurí
Funding Body: Universitat de València
Duration: 2012-2013
Reference: UV-INV-AE11-41831
Title: Alteraciones del tráfico intracelular en la enfermedad de Parkinson.
Principal Investigator: Mónica Tomás Caballero (María Sancho-Tello, José Javier Martín de Llano, David
Ramos as collaborating researchers)
Duration: 2011-2013
Total budget: €10.500
4
85
Scientific activity
Research Group on Central Nervous System Tumors
PI: José Miguel Cerdá Nicolas (Department of Pathology Hospital Clínico Universitario of Valencia / Department of
Pathology University of Valencia).
Collaborating Researchers: José Manuel González Darder (Hospital), Rosario Gil Benso (University), Daniel Monleón
Salvadó (INCLIVA), Concepción López Ginés (University), José Manuel Almerich Silla (University), Robert Callaghan
(University), M. Aurelia Gregori Romero (University), Pablo Cerdá Durán (University).
Predoctoral Researchers: Teresa San Miguel Díez (University), Lara Navarro Cerveró (University), Lisandra Muñoz
Hidalgo (INCLIVA).
Technicians: Ana María Clari (University), Mercedes Salinas Erastoff (University), Amparo Andrés Bordería (INCLIVA).
86
4
Strategic aims
• Genetic/molecular characterization of primary Glioblastoma Multiforme (GBM) regarding amplification status of EGFR.
Study and analysis of gene and molecular profiles in primary GBM using MLPA techniques (100 cases).
• Elaboration of clinical–radiological protocols. Protocol analysis of 140 GBM cases.
• Analysis of morphological and immunohistologic patterns (100 GBM cases).
• Morphometric data collection and analysis of heterogeneity in the proliferative patterns of GBMs (50 cases).
• Completing microRNA analysis. Analysis of gene regulation and protein expression in 50 GBM cases.
• MicroRNA transfection in tissue cultures of primary GBMs.
• Primary GBM. Amplification status of EGFR and angiogenic/infiltrative phenotypes. Molecular networks responsible for
the processes of tumor modulation/reprogramming.
• Role of microRNAs in the regulation of EGFR-dependent signalling pathways in “high-grade astrocytic gliomas”.
• Development of a model of modulation of gene activity by microRNAs in GBM cell cultures.
• Development of a model of population analysis and geographical distribution in these neoplasms.
• Metabolomic and microvascular environmental characterization of aggressive human glioma by means of DCE-MRI and
genetic study of biopsies.
Scientific activity
Associated Emerging Group
Daniel Monleón Salvadó (INCLIVA)
This line of research is focused on the effect of alterations in the delivery of nutrients and vascularization in cell metabolism. The research is centered in two areas of large clinical relevance: cancer
(interaction between angiogenesis, hypoxia and tumor metabolism) and cardiovascular diseases
(cardiac metabolism in coronary ischemia and metabolic risk factors of cardiovascular disease).
PUBLICATIONS
Original articles
1Martínez-Martín N, Blas-García A, Morales JM, MartiCabrera M, Monleón D, Apostolova N. Metabolomics
of the effect of AMPK activation by AICAR on human
umbilical vein endothelial cells. International Journal of
Molecular Medicine. 2012 Jan; 29(1): 88-94. IF: 1,573
2 Bodi V, Sanchis J, Morales JM, Marrachelli VG, Nunez
J, Forteza MJ, Chaustre F, Gómez C, Mainar L, Minana G, Rumiz E, Husser O, Noguera I, Diaz A, Moratal
D, Carratalá A, Bosch X, Llacer A, Chorro FJ, Viña JR,
ischemia by nuclear magnetic resonance spectroscopy
of peripheral blood serum: a translational study based
on transient coronary occlusion models. Journal of the
American College of Cardiology. 2012 May 1; 59(18):
1629-41. IF: 14,156
3Ivorra
C, García-Vicent C, Chaves FJ, Monleón D,
Morales JM, Lurbe E. Metabolomic profiling in blood
from umbilical cords of low birth weight newborns.
Journal of Translational Medicine. 2012 Jul 9; 10(1):
142. IF: 3,474
4Quilis-Quesada
V, Botella-Maciá L, González-Darder
JM. Transzygomatic pterional approach. Part 1: anatomical study. Neurocirugía. 2012 Mar; 23(2): 47-53. IF:
0,54
5González-Darder JM, Quilis-Quesada V, Botella-Maciá
L. Transzygomatic pterional approach. Part 2: Surgical
experience in the management of skull base pathology.
Neurocirugía. 2012 May; 23(3): 96-103. IF: 0,54
6Gil-Benso R, Monteagudo C, Cerdá-Nicolás M, Callaghan RC, Pinto S, Martínez-Romero A, Pellín-Carcelén A, San-Miguel T, Cigudosa JC, López-Ginés C.
Characterization of a new human melanoma cell line
with CD133 expression. Human Cell. 2012 Jun; 25(2):
61-7. IF: 0,75
7 Eustaquio-Raga MV, Montiel-Company JM, AlmerichSilla JM. Factors associated with edentulousness in
an elderly population in Valencia (Spain). Gaceta Sanitaria. 2012 May 14. IF: 1,326
8Bellot-Arcís
C, Montiel-Company JM, Almerich-Silla
JM, Paredes-Gallardo V, Gandía-Franco JL. The use
of occlusal indices in high-impact literature. Community Dental Health. 2012 Mar; 29(1): 45-8. IF: 0,753
9Bellot-Arcís C, Montiel-Company JM, Manzanera-Pastor D, Almerich-Silla JM. Orthodontic treatment need
in a Spanish young adult population. Medicina Oral,
Patología Oral, Cirugía Bucal. 2012 Jul 1; 17(4): e63843. IF: 1,13
10Marrachelli VG, Centeno JM, Miranda I, Castelló-Ruiz
M, Burguete MC, Jover-Mengual T, Salom JB, Torregrosa G, Miranda FJ, Alborch E. Diabetes impairs the atrial
natriuretic peptide relaxant action mediated by potassium channels and prostacyclin in the rabbit renal artery. Pharmacology Research. 2012 Aug 8. IF: 4,436
Letter
1González-Darder JM. Management of neurovascular
disease in Neurosurgical Departments in Spain. Neurocirugia. 2012 Sep; 23(5): 216-7. IF: 0,54
THESIS
1Title of the thesis: Caracterización de tumores del sistema nervioso central mediante el análisis de imágenes de microscopía de resonancia magnética nuclear.
Doctoral candidate: Ana González Segura
Director(s): Daniel Monleón Salvadó, José Manuel
4
87
Scientific activity
González Darder and Miguel Cerdá Nicolás
RESEARCH
Title: Papel de los microRNA en la regulación de las
vías de señalización dependientes de EGFR en “gliomas astrocitarios de alto grado”. Desarrollo de un modelo poblacional de análisis poblacional y de distribución espacial de estas neoplasias.
Principal Investigator: Miguel Cerdá Nicolás
Valenciana
Duration: 2011-2015
Reference: SAF2011-23029
88
4
Title: Interplay between microvasculature, metabolic
reprogramming and tumor aggressiveness in hig grade glioma
Principal Investigator: Daniel Monleón Salvadó
Funding Body: Ministerio de Ciencia e innovación
Duration: 2012-2014
Scientific activity
Research Group on Colorectal Cancer and New Therapeutical Developments
in Solid Tumors
PI: Andrés Cervantes Ruipérez (Department of Oncology and Hematology Hospital Clínico Universitario of Valencia /
Department of Medicine University of Valencia).
Collaborating Researchers: José Antonio Pérez Fidalgo (Hospital), Amelia Insa Mollá (Hospital), Susana Roselló
Keranen (Hospital), Estefanía García Botello (Hospital), Desamparados Roda Pérez (INCLIVA), Alejandro Espí Macías
(Hospital).
Technicians: Cristina Mongort (INCLIVA).
Data managers: Amparo Domingo Lacasa (INCLIVA), Inma Blasco Blasco (INCLIVA).
Administrative assistants: Gabriela Pérez Garity (INCLIVA).
Strategic aims
• To determine the importance of complete mesocolic excision as a parameter related to a more accurate staging and a
higher probability of healing after resection.
• To stablish the role of acetylated proteins in the development of resistance to treatment with anti-EGFR effect drugs, in
mutated tumors as well as in absence of KRAS mutations.
• To develop therapeutic association between m-TOR inhibitors and IGFR-1 blocking antibodies.
• To develop drugs in initial phase which can advance to further phases of development as Aurora-A kinase inhibitors antitumor drugs.
• To validate the administration of siRNAs as antitumor agents in patients with hepatic metastases.
• Bio-pathological evaluation of mesorectal surgery in rectal cancer.
• Evaluation of mesocolon as a quality parameter in colon cancer surgery.
• Mechanisms of resistance to drugs against epidermal growth factor receptor (EGFR).
• Development of phase I trials with drugs against molecular therapies applied for the first time in humans affected by
solid tumors, with analysis of pharmacokinetic and pharmacodynamic parameters.
4
89
Scientific activity
PUBLICATIONS
Original articles
1Cervantes A,
Elez E, Roda D, Ecsedy J, Macarulla
T, Venkatakrishnan K et al. Phase I Pharmacokinetic/
Pharmacodynamic Study of MLN8237, an Investigational, Oral, Selective Aurora A Kinase Inhibitor, in
Patients with Advanced Solid Tumors. Clinical Cancer
Research. 2012 Sep 1; 18(17): 4764-74. IF: 7,742
2Díaz-Rubio
E, Gómez-España A, Massutí B, Sastre
J, Abad A, Valladares M, Rivera F, Safont MJ, Martínez de Prado P, Gallén M, González E, Marcuello E,
Benavides M, Fernández-Martos C, Losa F, Escudero
P, Arrivi A, Cervantes A, Dueñas R, López-Ladrón A,
Lacasta A, Llanos M, Tabernero JM, Antón A, Aranda
E, Spanish Cooperative Group for the Treatment of
Digestive Tumors. First-Line XELOX Plus Bevacizumab Followed by XELOX Plus Bevacizumab or Single-Agent Bevacizumab as Maintenance Therapy in
Patients with Metastatic Colorectal Cancer: The Phase
III MACRO TTD Study. The Oncologist. 2012; 17(1):
15-25. IF: 3,812
90
4
3Frasson M, Faus C, Garcia-Granero A, Puga R, FlorLorente B, Cervantes A, Navarro S, Garcia-Granero
E. Pathological evaluation of mesocolic resection quality and ex vivo methylene blue injection: what is the
impact on lymph node harvest after colon resection
for cancer?. Diseases of the Colon and Rectum. 2012
Feb; 55(2): 197-204. IF: 3,132
4Pavlidis
N, Vermorken JB, Stahel R, Bernier J, Cervantes A, Pentheroudakis G, Audisio RA, Costa A. Undergraduate training in oncology: An ESO continuing
challenge for medical students. Surgical Oncology.
2012 Mar; 21(1): 15-21. IF: 2,444
5Golfinopoulos V, Pentheroudakis G, Goussia A, Siozopoulou V, Bobos M, Krikelis D, Cervantes A, Ciuleanu
T, Marselos M, Fountzilas G,Malamou-Mitsi V, Pavlidis
N. Intracellular signalling via the AKT axis and downstream effectors is active and prognostically significant
in cancer of unknown primary (CUP): a study of 100
CUP cases. Annals of Oncology. 2012 May 6. IF: 6,425
6Krikelis D, Pentheroudakis G, Goussia A, Siozopoulou
V, Bobos M, Petrakis D, Stoyianni A, Golfinopoulos V,
Cervantes A, Ciuleanu T, Fountzilas G, Malamou-Mitsi V, Pavlidis N. Profiling immunohistochemical expression of NOTCH1-3, JAGGED1, cMET, and phosphoMAPK in 100 carcinomas of unknown primary. Clinical
& Experimental Metastasis. 2012 Aug; 29(6): 603-14.
IF: 3,524
7Stoyianni A, Goussia A, Pentheroudakis G, Siozopoulou V, Ioachim E, Krikelis D, Golfinopoulos V, Cervantes A, Bobos M, Fotsis T, Bellou S, Fountzilas G, Malamou-Mitsi V, Pavlidis N. Immunohistochemical study
of the epithelial-mesenchymal transition phenotype in
cancer of unknown primary: incidence, correlations
and prognostic utility. Anticancer Research. 2012 Apr;
32(4): 1273-81. IF: 1,725
8Dewdney A, Cunningham D, Tabernero J, Capdevila J,
Glimelius B, Cervantes A, Tait D, Brown G, Wotherspoon A, Gonzalez de Castro D, Chua YJ, Wong R,
Barbachano Y, Oates J, Chau I. Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy
with or without cetuximab followed by total mesorectal
excision in patients with high-risk rectal cancer (EXPERT-C). Journal of Clinical Oncology. 2012 May 10;
30(14): 1620-7. IF: 18,372
9Trama A, Mallone S, Nicolai N, Necchi A, Schaapveld
M, Gietema J, Znaor A, Ardanaz E, Berrino F, RARECARE Working Group. Burden of testicular, paratesticular and extragonadal germ cell tumours in Europe.
European Journal of Cancer. 2012 Jan; 48(2): 159-69.
IF: 5,536
10Mallone S, De Vries E, Guzzo M, Midena E, Verne J,
Coebergh JW, Marcos-Gragera R, Ardanaz E, Martinez R, Chirlaque MD, Navarro C, Virgili G, RARECARE WG. Descriptive epidemiology of malignant
mucosal and uveal melanomas and adnexal skin carcinomas in Europe. European Journal of Cancer. 2012
May; 48(8): 1167-75. IF: 5,536
11Visser O, Adolfsson J, Rossi S, Verne J, Gatta G, Maffezzini M, Franks KN, RARECARE WC. Incidence
and survival of rare urogenital cancers in Europe. European Journal of Cancer. 2012 Mar; 48(4): 456-64. IF:
5,536
12Santibañez M, Alguacil J, de la Hera MG, NavarreteMuñoz EM, Llorca J, Aragonés N, Kauppinen T, Vio-
Scientific activity
que J, PANESOES Study Group. Occupational exposures and risk of stomach cancer by histological type.
Occupational and Environmental Medicine. 2012 Apr;
69(4): 268-75. IF: 3,02
13Van
Dijk BA, Gatta G, Capocaccia R, Pierannunzio
D, Strojan P, Licitra L, RARECARE Working Group.
Rare cancers of the head and neck area in Europe.
European Journal of Cancer. 2012 Apr; 48(6): 783-96.
IF: 5,536
14Rosell R, Carcereny E, Gervais R, Cervantes A, et al.
Erlotinib versus standard chemotherapy as first-line
treatment for European patients with advanced EGFR
mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3
trial. The Lancet Oncology. 2012 Mar; 13(3): 239-46.
IF: 22,589
15Garcés-Albir M, García-Botello SA, Esclapez-Valero P,
Sanahuja-Santafé A, Raga-Vázquez J, Espi-Macías
A, Ortega-Serrano J. Quantifying the extent of fistulotomy. How much sphincter can we safely divide?. A
three-dimensional endosonographic study. International Journal of Colorectal Disease. 2012 Aug; 27(8):
1109-16. IF: 2,385
16Eroles P, Bosch A, Pérez-Fidalgo JA, Lluch A. Molecular biology in breast cancer: intrinsic subtypes and
signaling pathways. Cancer Treatment Reviews. 2012;
38(6): 698-707. IF: 6,054
17Pentheroudakis G, Krikelis D, Cervantes A, Vermorken
J, Pavlidis N. Profiling clinical cancer research across
the Atlantic: a review of research and its characteristics
presented at ASCO and ESMO Congresses during the
last decade. Cancer Treatment Reviews. 2012; 38(6):
560-5. IF: 6,054
18Faivre J, Trama A, De Angelis R, Elferink M, Siesling
S, Audisio R, Bosset JF, Cervantes A, Lepage C, RARECARE Working Group. Incidence, prevalence and
survival of patients with rare epithelial digestive cancers diagnosed in Europe in 1995-2002. European
Journal of Cancer. 2012 Jul; 48(10): 1417-24. IF: 5,536
19Dasí F, Navarro-García MM, Jiménez-Heredia M, Magraner J, Viña JR, Pallardó FV, Cervantes A, Morcillo
E. Evaluation of the quality of publications on randomized clinical trials using the consolidated standards of
reporting trials (CONSORT) statement guidelines in a
spanish tertiary hospital. Journal of Clinical Pharmacology. 2012 Jul; 52(7): 1106-14. IF: 2,911
20Pearse RM, Moreno RP, Bauer P, Pelosi P, Metnitz P,
Spies C, Vallet B, Vincent JL, Hoeft A, Rhodes A, European Surgical Outcomes Study(EuSOS) group
for the Trials groups of the European Society of Intensive Care Medicine and the European Society of
Anaesthesiology. Mortality after surgery in Europe: a
7 day cohort study. Lancet. 2012 Sep 22; 380 (9847):
1059-65. IF: 38,278
21Garcia-Granero E, Frasson M, Pous S, Cervantes A.
T4a and t4b colorectal cancer: what does this mean
nowadays?. Diseases of the Colon and Rectum. 2012
Nov; 55(11): e367. IF: 3,132
22Golfinopoulos V, Pentheroudakis G, Goussia A, Siozopoulou V, Bobos M, Krikelis D, Cervantes A, Ciuleanu
T, Marselos M, Fountzilas G,Malamou-Mitsi V, Pavlidis
N. Intracellular signalling via the AKT axis and downstream effectors is active and prognostically significant
in cancer of unknown primary (CUP): a study of 100
CUP cases. Annals of Oncology. 2012 Oct; 23(10):
2725-30. IF: 6,425
23Díaz-Rubio
E, Gómez-España A, Massutí B, Sastre
J, Reboredo M, Manzano JL, Rivera F, Safont MJ,
Montagut C, González E, Benavides M, Marcuello E,
Cervantes A, Martínez de Prado P, Fernández-Martos
C, Arrivi A, Bando I, Aranda E, Spanish Cooperative
Group for the Treatment of Digestive Tumors (TTD).
Role of Kras Status in Patients with Metastatic Colorectal Cancer Receiving First-Line Chemotherapy plus
Bevacizumab: A TTD Group Cooperative Study. PLoS
One. 2012; 7(10): e47345. IF: 4,092
24Van der Zwan JM, Mallone S, van Dijk B, Bielska-Lasota M, Otter R, Foschi R, Baudin E, Links TP, RARECARE WG. Carcinoma of endocrine organs: results of
the RARECARE project. European Journal of Cancer.
2012 Sep; 48(13): 1923-31. IF: 5,536
25Schmoll HJ, Van Cutsem E, Stein A, Valentini V, Glimelius B, Haustermans K, Nordlinger B, van de Velde
CJ, Balmana J, Regula J, Nagtegaal ID, Beets-Tan
RG, Arnold D, Ciardiello F, Hoff P, Kerr D, Köhne CH,
Labianca R, Price T, Scheithauer W, Sobrero A, Tabernero J, Aderka D,Barroso S, Bodoky G, Douillard JY,
El Ghazaly H, Gallardo J, Garin A, Glynne-Jones R,
Jordan K, Meshcheryakov A, Papamichail D, Pfeiffer
4
91
Scientific activity
P,Souglakos I, Turhal S, Cervantes A. ESMO Consensus Guidelines for management of patients with colon
and rectal cancer. A personalized approach to clinical decision making. Annals of Oncology. 2012 Oct;
23(10): 2479-516. IF: 6,425
Clinical guidelines
1Pérez Fidalgo JA, García Fabregat L, Cervantes A,
Margulies A, Vidall C, Roila F, ESMO Guidelines Working Group. Management of chemotherapy extravasation: ESMO-EONS Clinical Practice Guidelines. Annals of Oncology. 2012 Oct; 23 Suppl 7: vii167-73. IF:
6,425
Editorial
1Cervantes
A. Preoperative chemotherapy for colon
cancer is getting closer. Lancet Oncology. 2012 Sep
24. IF: 22,589
2Pavlidis N, Stahel R, Pentheroudakis G, Cervantes A.
ESMO Guidelines Working Group. ESMO Consensus
Conferences: another source of ESMO Clinical Practice Guidelines. Annals of Oncology. 2012 Oct; 23 Suppl
7: vii7-10. IF: 6,425
92
4
3Perez-Fidalgo
JA, Caballero A, Lluch A. Integrating
radical local treatment of the primary in the management of stage IV breast cancer. When is the best moment for the resection of the primary tumor?. European
Journal of Surgical Oncology. 2012 Aug; 38(8): 643-4.
IF: 2,499
Title: Mecanismos de resistencia a inhibidores de
EGFR. Estudio epigenómico y de acetilación de proteínas en líneas celulares Kras mutado y salvaje, y su
evaluación en pacientes con cáncer de colon.
Principal Investigator: Andrés Cervantes Ruipérez
Duration: 2010-2012
Funding Body: Fundación Gent per Gent
Duration: 2010-2012
Reference: EC11-243
Title: Ensayo fase III multicéntrico randomizado de
radioterapia de curso corto seguido de quimioterapia
preoperatoria prolongada y cirugía en cáncer de recto
localizado de alto preoperatoria riesgo frente a quimioradioterapia estándar.
Funding Body: Ministerio de Sanidad, Servicios Sociales e Igualdad
RESEARCH
Duration: 2011-2012
Reference: CAI08/01/0039
Title: Consorcio de Apoyo a la Investigación Biomédica en Red Unidad Central de Investigación Clínica y
Ensayos Clínicos en pacientes.
Duration: 2009-2012
Title: Demora diagnóstica y estrategias de seguimiento
en el cáncer colorrectal: su influencia en el pronóstico.
Principal Investigator: Alejandro Espí Macías
Duration: 2010-2012
Scientific activity
Title: Identificacióndeperfilesdeexpresióneneladenocarcinoma ductal de páncreas. Implicaciones clínicas en relación con la supervivencia.
Principal Investigator: Luis Sabater Ortí
Duration: 2012
Duration: 2012
Valenciana
cáncer.
Principal Investigator: Ana Lluch Hernández (Andrés
Cervantes as collaborating researcher)
Duration: 2007-2012
Total Budget: 173.823,50 €
4
93
Scientific activity
Research Group on Breast Cancer Biology
PI: Ana Lluch Hernández (Department of Oncology and Hematology Hospital Clínico Universitario of Valencia / Department of Medicine University of Valencia).
Collaborating Researchers: Isabel Chirivella González (Hospital), Begoña Bermejo de las Heras (Hospital), Ana
Magro Molina (Hospital), Vanesa Pons Sanz (Hospital), Octavio Burgués Gasión (Hospital), Antonio Caballero Gárate
(Hospital), Ángel Martínez Agullo (Hospital), Gloria Ribas Despuig (INCLIVA), Jessica Furriol Palmer (INCLIVA), Jaime
Ferrer Lozano (INCLIVA), Antonio Millet Serrano (Hospital), Pilar Eroles Asensio (INCLIVA), Begoña Pineda (INCLIVA),
Joan Climent (INCLIVA).
94
4
Predoctoral Researchers: Maider Ibarrola Villava (INCLIVA), Eduardo Tormo Martín (INCLIVA), Patricia Rodrígues
(INCLIVA).
Technicians: Estela Contel Martín (INCLIVA), Isabel Domenech Catoira (INCLIVA), Patricia Martínez Belenguer (INCLIVA), Vicenta Garces (Hospital), Elisa Alonso Yuste (INCLIVA).
Administrative assistants: Yolanda de la Cruz Robles (INCLIVA).
Strategic aims
Activity focused on the diagnosis and treatment of breast cancer. Research has been centered in the in-depth study of
genetic and genomic bases of breast cancer, identification of genes involved in tumor processes, application and development of new technologies of genomic screening to contribute to a faster and more efficient diagnosis and a better
understanding of cancer. Also, this research aims at finding new biological strategies able to individualize treatment.
• Study of the predictive value of NF-kappaB in breast cancer treated with anthracyclines and sensitization to anthraciclines by inhibition of NF-kappaB.
• Clinical-pathological and molecular evaluation of breast cancer response to neoadjuvant therapy; study of the predictive value of CD44+/CD24- overpopulation in residual disease.
• Mamographic density, genetic susceptibility and breast cancer in high-risk women (dm-BRCA project).
• Validation of the molecular study of sentinel lymph nod by One Step Nucleic acid Amplification (OSNA) technique.
• Modulation of VEGFR1s/VEGF levels in breast cancer treated with doxorubicin.
• Breast cancer susceptibility gene testing.
• Relationship between polymorphisms in p53 gene and VEGFR1 gene promoter and response to treatment with
Scientific activity
doxorubicin in breast cancer.
• Study of the influence of genetic predisposition to develop breast cancer associated with folate metabolism genes
(MTHFR, DHFR, TS, SHMT1 y MS).
• Analysis of angiogenic factors in breast cancer.
• Analysis of genetic markers in breast cancer tumors in young women (aged under 35).
Emerging Researcher
Isabel Chirivella González (Department of Oncology and Hematology Hospital Clínico Universitario of Valencia).
The research line suggests a possible relation between mammographic density, as a genetic susceptibility marker and the risk to suffer breast cancer in women with a mutation
in BRCA (hereditary breast cancer). Women with a mutation in genes BRCA1 or BRCA2
have a higher risk of developing breast cancer (40-70%) and the risk could possibly be
modified by genetic variations related to mammographic density.
Emerging Researcher
Pilar Eroles Asensio (INCLIVA).
The line of research aims at deepening the knowledge of some of the molecular subtypes
of breast cancer, especially HER2 + and triple negative, through studies of expression and
post-transcriptional changes (microRNAs, methylation) to decipher the possible mechanisms of resistance to current treatments. Among the processes under study are the angiogenic factors. The importance of genetic modifications in these factors in the development
of the disease will be evaluated as well.
4
PUBLICATIONS
Original articles
1Albanell J, González A, Ruiz-Borrego M, Alba E, García-Saenz JA, Corominas JM, Burgues O, Furio V,
Rojo A, Palacios J, Bermejo B, Martínez-García M, Limon ML, Muñoz AS, Martín M, Tusquets I, Rojo F, Colomer R, Faull I, Lluch A. Prospective transGEICAM
study of the impact of the 21-gene Recurrence Score
assay and traditional clinicopathological factors on adjuvant clinical decision making in women with estrogen
receptor-positive (ER+) node-negative breast cancer.
Annals of Oncology. 2012 Mar; 23(3): 625-31. IF: 6,425
2Avilés
JA, Lázaro P, Fernández LP, Benítez J, Ibarrola-Villava M, Ribas G. Phenotypic and histologic
characteristics of cutaneous melanoma in patients with
melanocortin-1 receptor polymorphisms. Actas Dermosifiliográficas. 2012 Jan-Feb; 103(1): 44-50.
3Blanco A, de la Hoya M, Balmaña J, Ramón y Cajal T,
Teulé A, Miramar MD, Esteban E, Infante M, Benítez
J, Torres A, Tejada MI, Brunet J, Graña B, Balbín M,
Pérez-Segura P, Osorio A, Velasco EA, Chirivella I,
Calvo MT, Feliubadaló L, Lasa A, Díez O, Carracedo
A, Caldés T, Vega A. Detection of a large rearrangement in PALB2 in Spanish breast cancer families with
male breast cancer. Breast Cancer Research and
Treatment. 2012 Feb; 132(1): 307-15. IF: 4,431
4Gianni
L, Pienkowski T, Im YH, Roman L, Tseng
LM, Liu MC, Lluch A, Staroslawska E, de la HabaRodriguez J, Im SA, Pedrini JL, Poirier B,Morandi P,
Semiglazov V, Srimuninnimit V, Bianchi G, Szado T,
Ratnayake J, Ross G, Valagussa P. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in
women with locally advanced, inflammatory, or early
HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. The Lancet
Oncology. 2012 Jan; 13(1): 25-32. IF: 22,589
5Estévez L, Alvarez I, Tusquets I, Seguí MA, Muñoz M,
95
Scientific activity
Fernández Y, Lluch A. Finding the right dose of fulvestrant in breast cancer. Cancer Treatment Reviews.
2012 Jul 13. IF: 6,054
6Alba E, Calvo L, Albanell J, De la Haba JR, Arcusa Lanza A, Chacon JI, Sanchez-Rovira P, Plazaola A, Lopez
Garcia-Asenjo JA, Bermejo B,Carrasco E, Lluch A,
GEICAM. Chemotherapy (CT) and hormonotherapy
(HT) as neoadjuvant treatment in luminal breast cancer
patients: results from the GEICAM/2006-03, a multicenter, randomized, phase-II study. Annals of Oncology.
2012 Dec; 23(12): 3069-74. IF: 6,425
7Bartholomeusz C, Gonzalez-Angulo AM, Liu P, Hayashi N, Lluch A, Ferrer-Lozano J, Hortobágyi GN. High
ERK protein expression levels correlate with shorter
survival in triple-negative breast cancer patients. The
Oncologist. 2012; 17(6): 766-74. IF: 3,812
8Martín M, Makhson A, Gligorov J, Lichinitser M, Lluch
A, Semiglazov V, Scotto N, Mitchell L, Tjulandin S.
Phase II study of bevacizumab in combination with
trastuzumab and capecitabine as first-line treatment
for HER-2-positive locally recurrent or metastatic
breast cancer. The Oncologist. 2012; 17(4): 469-75.
IF: 3,812
96
4
9Ibarrola-Villava M, Hu HH, Guedj M, Fernandez LP,
Descamps V, Basset-Seguin N, Bagot M, Benssussan
A, Saiag P, Fargnoli MC, Peris K, Aviles JA, Lluch A,
Ribas G, Soufir N. MC1R, SLC45A2 and TYR genetic variants involved in melanoma susceptibility in
Southern European populations: Results from a Metaanalysis. European Journal of Cancer. 2012 Mar 28.
IF: 5,536
10Cortés J, Fumoleau P, Bianchi GV, Petrella TM, Gelmon K, Pivot X, Verma S, Albanell J, Conte P, Lluch
A, Salvagni S, Servent V, Gianni L, Scaltriti M, Ross
GA, Dixon J, Szado T, Baselga J. Pertuzumab monotherapy after trastuzumab-based treatment and
subsequent reintroduction of trastuzumab: activity and
tolerability in patients with advanced human epidermal
growth factor receptor 2-positive breast cancer. Journal of Clinical Oncology. 2012 May 10; 30(14): 1594600. IF: 18,372
11Rodrigues P, Furriol J, Tormo E, Ballester S, Lluch
A, Eroles P. The single-nucleotide polymorphisms
+936 C/T VEGF and -710 C/T VEGFR1 are associated with breast cancer protection in a Spanish popu-
lation. Breast Cancer Research and Treatment. 2012
Jun; 133(2): 769-78. IF: 4,431
12Ibarrola-Villava
M, Martin-Gonzalez M, Lazaro P,
Pizarro A, Lluch A, Ribas G. Role of glutathione Stransferases in melanoma susceptibility: association
with GSTP1 rs1695 polymorphism. British Journal of
Dermatology. 2012 Jun; 166(6): 1176-83. IF: 3,666
13Baselga J, Segalla JG, Roché H, Del Giglio A, Pinczowski H, Ciruelos EM, Filho SC, Gómez P, Van Eyll
B, Bermejo B, Llombart A, Garicochea B, Durán MÁ,
Hoff PM, Espié M, de Moraes AA, Ribeiro RA, Mathias
C, Gil Gil M, Ojeda B, Morales J, Kwon Ro S, Li S,
Costa F. Sorafenib in combination with capecitabine:
an oral regimen for patients with HER2-negative locally advanced or metastatic breast cancer. Journal of
Clinical Oncology. 2012 May 1; 30(13): 1484-91. IF:
18,372
14Raimondi S, Gandini S, Fargnoli MC, Bagnardi V, Maisonneuve P, Specchia C, Kumar R, Nagore E, Han J,
Hansson J, Kanetsky PA, Ghiorzo P,Gruis NA, Dwyer
T, Blizzard L, Fernandez-de-Misa R, Branicki W, Debniak T, Morling N, Landi MT, Palmieri G, Ribas G,
Stratigos A, Cornelius L,Motokawa T, Anno S, Helsing
P, Wong TH, Autier P, García-Borrón JC, Little J, Newton-Bishop J, Sera F, Liu F, Kayser M, Nijsten T, GEM
StudyGroup, M-SKIP Study Group. Melanocortin-1
receptor, skin cancer and phenotypic characteristics
(M-SKIP) project: study design and methods for pooling results of genetic epidemiological studies. BMC
Medical Research Methodology. 2012 Aug 3; 12(1):
116. IF: 2,668
15Avilés
JA, Lázaro P, Fernández LP, Benítez J, Ibarrola-Villava M, Ribas G. Phenotypic and histologic
characteristics of cutaneous melanoma in patients
with melanocortin-1 receptor polymorphisms. Actas
Dermosifiliográficas. 2012 Jan; 103(1): 44-50.
16Eroles P, Bosch A, Pérez-Fidalgo JA, Lluch A. Molecular biology in breast cancer: intrinsic subtypes and
signaling pathways. Cancer Treatment Reviews. 2012
Oct; 38(6): 698-707. IF: 6,054
17Zambetti M, Mansutti M, Gómez P, Lluch A, Dittrich
C, Zamagni C, Ciruelos E, Pavesi L, Semiglazov V, De
Benedictis E, Gaion F, Bari M, Morandi P, Valagussa
P, Luca G. Pathological complete response rates following different neoadjuvant chemotherapy regimens
Scientific activity
for operable breast cancer according to ER status, in
two parallel, randomized phase II trials with an adaptive study design (ECTO II). Breast Cancer Research
and Treatment. 2012 Apr; 132(3): 843-51. IF: 4,431
18Rayson D, Suter TM, Jackisch C, van der Vegt S, Bermejo B, van den Bosch J, Vivanco GL, van Gent AM,
Wildiers H, Torres A, Provencher L,Temizkan M, Chirgwin J, Canon JL, Ferrandina G, Srinivasan S, Zhang
L, Richel DJ. Cardiac safety of adjuvant pegylated liposomal doxorubicin with concurrent trastuzumab: a
randomized phase II trial. Annals of Oncology. 2012
Jul; 23(7): 1780-8. IF: 6,425
19Rojo F, García-Parra J, Zazo S, Tusquets I, Ferrer-Lozano J, Menendez S, Eroles P, Chamizo C, Servitja S,
Ramírez-Merino N, Lobo F, Bellosillo B, Corominas JM,
Yelamos J, Serrano S, Lluch A, Rovira A, Albanell J.
Nuclear PARP-1 protein overexpression is associated
with poor overall survival in early breast cancer. Annals
of Oncology. 2012 May; 23(5): 1156-64. IF: 6,425
20Cortés
J, Calvo E, González-Martín A, Dawood S,
Llombart-Cussac A, De Mattos-Arruda L, Gómez P,
Silva O, Perez EA, Rugo HS, Lluch A, Hortobagyi GN.
Progress against solid tumors in danger: the metastatic breast cancer example. Journal of Clinical Oncology. 2012 Oct 1; 30(28): 3444-7. IF: 18,372
21Meric-Bernstam F, Chen H, Akcakanat A, Do KA, Lluch
A, Hennessy BT , Hortobagyi GN, Mills GB, GonzalezAngulo AM. Aberrations in translational regulation are
associated with poor prognosis in hormone receptorpositive breast cancer. Breast Cancer Research. 2012
Oct 26; 14(5): R138. IF: 5,245
22Alba E, Chacon JI, Lluch A, Anton A, Estevez L, Cirauqui B, Carrasco E, Calvo L, Segui MA, Ribelles N, Alvarez R, Sanchez-Muñoz A, Sanchez R,Garcia-Asenjo
JA, Rodriguez-Martin C, Escudero MJ, Albanell J. A
randomized phase II trial of platinum salts in basallike breast cancer patients in the neoadjuvant setting.
Results from the GEICAM/2006-03, multicenter study.
Breast Cancer Research and Treatment. 2012 Nov;
136(2): 487-93. IF: 4,431
23Carles J, Chirivella I, Climent MA, Gallardo E, González
del Alba A, Maroto JP, Mellado B, García del Muro FX.
Evaluation of patients with metastatic renal cell carcinoma after failure of first-line treatment. Cancer Metastasis
Reviews. 2012 Sep; 31 Suppl 1: S3-9. IF: 10,573
24Mao JH, Wu D, Kim IJ, Kang HC, Wei G, Climent J,
Kumar A, Pelorosso FG, DelRosario R, Huang EJ,
Balmain A. Hipk2 cooperates with p53 to suppress-ray
radiation-induced mouse thymic lymphoma. Oncogene. 2012 Mar 1; 31(9): 1176-80. IF: 6,373
25De Semir D, Nosrati M, Bezrookove V, Dar AA, Federman S, Bienvenu G, Venna S, Rangel J, Climent J,
Meyer Tamgüney TM, Thummala S, Tong S, Leong SP,
Haqq C, Billings P, Miller JR 3rd, Sagebiel RW, Debs
R, Kashani-Sabet M. Pleckstrin homology domaininteracting protein (PHIP) as a marker and mediator
of melanoma metastasis. Proceedings of the National
Academy of Sciences of the United States of America.
2012 May 1; 109(18): 7067-72. IF: 9,681 26Esteban
Cardeñosa E, de Juan Jiménez I, Palanca
Suela S, Chirivella González I, Segura Huerta A,
Santaballa Beltran A, Casals El Busto M,Barragán
González E, Fuster Lluch O, Bermúdez Edo J, Bolufer
Gilabert P. Low penetrance alleles as risk modifiers in
familial and sporadic breast cancer. Familiar Cancer.
2012 Dec; 11(4): 629-36. IF: 1,302
27Rodrigues P, Furriol J, Bermejo B, Chaves FJ, Lluch
A, Eroles P. Identification of candidate polymorphisms
on stress oxidative and DNA damage repair genes related with clinical outcome in breast cancer patients.
International Journal of Molecular Sciences. 2012 Dec
5; 13(12): 16500-13
Letter
1Báguena
Requena G, Calvete Chornet J, Caballero
Gárate A, Burgues Gasión O, Martínez Agulló A.
Granular cell tumours: An uncommon lesion in the
breast. Cirugía Española. 2012 Oct; 90(8): 537-539.
IF: 0,874
Editorial
1Lluch A, Bosch A. Evolution of tumour biology upon
progression. Do we know our enemy?. Clinical Translational Oncology. 2012 Jun; 14(6): 399-400. IF: 1,327
2Perez-Fidalgo
JA, Caballero A, Lluch A. Integrating
radical local treatment of the primary in the management of stage IV breast cancer. When is the best moment for the resection of the primary tumor?. European
Journal on Surgical Oncology. 2012 Aug; 38(8): 643-4.
IF: 2,499
4
97
Scientific activity
THESIS
Duration: 2011-2013
1Title of the thesis: Búsqueda de genes de suscepti-
bilidad a melanoma esporádico: análisis de genes implicados en las rutas de pigmentación, reparación del
ADN y procesos de estrés oxidativo.
Title: Modulación de los niveles de VEGFR1s/VEGF
en cáncer de mama tratado con doxorubicina.
Doctoral candidate: Maider Ibarrola Villava
Principal Investigator: Ana Lluch Hernández
Director(s): Gloria Ribas Despuig
Duration: 2009-2012
RESEARCH
Title: Caracterización de MKP-1 y MKP-3 en cáncer
de mama: valor predictivo y potencial diana terapéutica.
98
4
cáncer.
Duration: 2007-2012
Duration: 2010-2012
Title: Densidad mamográfica, susceptibilidad genética
y cáncer de mama en mujeres de familias de alto riesgo (Proyecto DM-BRCA).
Principal Investigator: Isabel Chirivella González
Duration: 2010-2012
Title: Impacto de la susceptibilidad genética y de la
exposición solar sobre los niveles de vitamina D en
pacientes con melanoma.
Principal Investigator: Gloria Ribas Despuig
Scientific activity
Research Group on Skin Cancer
PI: José Carlos Monteagudo Castro (Department of Pathology Hospital Clínico Universitario of Valencia / Department
of Pathology University of Valencia).
Collaborating Researchers: Antonio Pellín Pérez (University), Esperanza Jordá Cuevas (Hospital), David Ramos
Soler (Hospital), José María Martín Hernández (Hospital), Liria Terrádez Mas (Hospital), Gabriela Avram (Hospital
Craiova).
Predoctoral Researchers: Ana Pellín Carcelén (University), Miguel Martínez Rodríguez (Hospital), Verónica López
Castillo (INCLIVA), Beatriz Sánchez Sendra (INCLIVA).
Technicians: Mercedes Salinas Erastoff (University), Daniel Sanchis Castellanos (INCLIVA).
Strategic aims
• Publication of results in:
- proposal of the expression quotient of chemokine and receptors as new prognostic factor in skin melanoma.
- characterization of a new human melanoma cell line with CD133 expression.
- partial publication of results in clinicopathological and immunohistochemical factors involved in melanocytic lesions.
- new pathogen virulence mechanisms in systemic candidiasis.
- preliminary work for the study of Birt-Hogg-Dubé syndrome.
• To finish the study of epithelial–mesenchymal transition markers and tumor initiating cells in melanoma progression.
Pending statistical study.
• To make progress in the study of the expression of microRNAs in human melanomas. The experimental study in immunodeficient mice is currently being prepared.
• To make progress in the drafting of two doctoral theses on melanocytic regression and prognostic value of markers of
lymphocyte activation and CCL27 in skin melanoma.
• Expression of epithelial–mesenchymal transition markers and tumor initiating cells (tumor stem cells) in tumor progression of human skin melanoma and in xenotransplantation in immunodeficient mice.
• Epidemiology and genetics of Birt-Hogg-Dubé familial cancer syndrome.
• Implication of certain microRNAs in tumor progression of melanoma.
4
99
Scientific activity
PUBLICATIONS
R, Callaghan RC, Martín JM. CCL27-CCR10 and
CXCL12-CXCR4 chemokine ligand-receptor mRNA
expression ratio: new predictive factors of tumor progression in cutaneous malignant melanoma. Clinical &
Experimental Metastasis. 2012 Aug; 29(6): 625-37. IF:
3,524
Original articles
1López
V, Jordá E, Monteagudo C. Birt-Hogg-Dubé
Syndrome: An Update. Actas Dermosifiliográficas.
2012 Apr; 103(3): 198-206.
2
Felipo V, Urios A, Montesinos E, Molina I, Garcia-Torres ML, Civera M, Olmo JA, Ortega J, Martinez-Valls
J, Serra MA, Cassinello N, Wassel A, Jordá E, Montoliu C. Contribution of hyperammonemia and inflammatory factors to cognitive impairment in minimal hepatic
encephalopathy. Metabolic Brain Disease. 2012 Mar;
27(1): 51-8. IF: 2,198
3 Martí N, Monteagudo C, Alonso V. Generalized Erup-
10Martín JM, Rubio M, Bella R, Jordá E, Monteagudo
C. Complete regression of melanocytic nevi: correlation between clinical, dermoscopic, and histopathologic findings in 13 patients. Actas Dermosifiliográficas.
2012 Jun; 103(5): 401-10.
11Martín
JM, Bella-Navarro R, Jordá E. Vascular patterns in dermoscopy. Actas Dermosifiliográficas. 2012
Jun; 103(5): 357-75.
12Giner F, Compañ A, Monteagudo C. Uterine glomeruloid hemangioma in a patient without POEMS syndrome. International Journal of Surgical Pathology. 2012
Aug; 20(4): 407-10. IF: 1,00
tion in a Child. Actas Dermosifiliográficas. 2012 Mar;
103(2): 153-154.
4 Reig I, Monteagudo C, Gámez L, Martí N, Martín JM,
Jorda E. Follicular mucinosis with loss of ephelides.
International Journal of Dermatology. 2012 Mar; 51(3):
332-4. IF: 1,142
100
4
13Uppuluri P, Chaturvedi AK, Jani N, Pukkila-Worley R,
Monteagudo C, Mylonakis E, Köhler JR, Lopez Ribot
JL. Physiologic Expression of the Candida albicans
Pescadillo Homolog Is Required for Virulence in a Murine Model of Hematogenously Disseminated Candidiasis. Eukaryotic Cell. 2012 Dec; 11(12): 1552-6. IF:
3,604
5González-Rodríguez
AJ, Gutiérrez-Paredes EM, Revert Fernández A, Jordá-Cuevas E. Allergic Contact
Dermatitis to Benzocaine: The Importance of Concomitant Positive Patch Test Results. Actas Dermosifiliográficas. 2012 Apr 30.
6
14Díaz Beveridge R, Aparicio J, Tormo A, Estevan R, Artes J, Giménez A, Segura Á, Roldán S, Palasí R, Ramos D. Long-term results with oral fluoropyrimidines
and oxaliplatin-based preoperative chemoradiotherapy in patients with resectable rectal cancer. A singleinstitution experience. Clinical & Translational Oncology. 2012 Jun; 14(6): 471-80. IF: 1,327
Cleary IA, Lazzell AL, Monteagudo C, Thomas DP,
Saville SP. BRG1 and NRG1 form a novel feedback
circuit regulating Candida albicans hypha formation
and virulence. Molecular Microbiology. 2012 Aug;
85(3): 557-73. IF: 5,01
Letters
7Martín JM, Monteagudo C, Bella R, Reig I, Jordá E.
Complete Regression of a Melanocytic Nevus under
Intense Pulsed Light Therapy for Axillary Hair Removal
in a Cosmetic Center. Dermatology. 2012; 224(3): 1937. IF: 2,053
1López V, Giner F. Nodular Lesion in a Woman’s Earlobe. Actas Dermosifiliográficas. 2012 Nov 16.
2López V, Alonso V, Jordá E. Efficacy of topical imiquimod 5% in a patient with chronic radiodermatitis on the
hands. Actas Dermosifiliográficas. 2012 Jun; 103(5):
441-2.
8Gil-Benso
R, Monteagudo C, Cerdá-Nicolás M, Callaghan RC, Pinto S, Martínez-Romero A, Pellín-Carcelén A, San-Miguel T, Cigudosa JC. Characterization
of a new human melanoma cell line with CD133 expression. Human Cell. 2012 Jun; 25(2): 61-7. IF: 0,75
9Monteagudo
3Martí
N, Alonso V, Jordá E. Encephalocraniocutaneous lipomatosis and didymosis aplasticopsilolipara.
Actas Dermosifiliográficas. 2012 May; 103(4): 341-2.
C, Ramos D, Pellín-Carcelén A, Gil
Scientific activity
4 González-Rodríguez AJ, Gutiérrez-Paredes EM, Montesinos-Villaescusa E, Burgués Gasión O, Jordá-Cuevas
E. Subungual Keratoacanthoma: the Importance of Distinguishing it From Subungual Squamous Cell Carcinoma.
Actas Dermosifiliográficas. 2012 Aug 3.
RESEARCH
Title: Estudioclínicoyexperimentaldelainfluenciade
los perfiles de expresión combinada de marcadores
de célula madre cancerosa y de transición epiteliomesenquimal en la progresión tumoral del melanoma
cutáneo in vivo.
Principal Investigator: Carlos Monteagudo Castro
Valenciana
Doubleimmunofluorescenceshowingco-expressionofCXCL12andCXCR4
(a-d) as well as CCL27 and CCR10 (e-m) in melanoma tumor cells.
Duration: 2011-2014
4
Predictive value for distant metastasis of CCL27-CCR10 intratumoral mRNA
ratio in primary melanomas with Breslow ≤4 mm: ROC curves (a) and area
under curve (b).
101
Scientific activity
Translational Research Group on Pediatric Solid Tumors
PI: Samuel Navarro Fos (Department of Pathology Hospital Clínico Universitario of Valencia / Department of Pathology
Collaborating Researchers: Rosa Noguera Salvá (University), Marta Piqueras Franco (University), Eva Villamón
Ribate (University), Antonio Llombart Bosch (University), Francisco Giner Segura (Hospital), Nuria Santonja López
(Hospital), Isidro Machado Puerto (University).
Predoctoral Researchers: Ana Pilar Berbegall Beltrán (University), Irene Tadeo Cervera (University).
Technicians: Alejo Miguel Sempere Crespo (University).
102
4
Strategic aims
• Genetic analyses of neuroblastoma. At European level, the group is participating in the establishment of a standardized
nomenclature, a standard operating procedure and studies of quality validation, critical tools to obtain and maintain a high
quality in the results of FISH, MLPA y SNPs used in therapeutic stratification.
• Identification of new genetic factors with prognostic value in malignant pediatric neuroblastic and skeletogenic tumors.
• Obtention and characterization of cell lines from fresh tumors of pediatric skeletogenic tumors.
• Establishment and characterization of in vivo models of malignant skeletogenic tumors.
• Expression studies of markers in colorectal carcinoma and pediatric solid tumors.
• Results from the study of tumor microenvironment in neuroblastoma.
• Analysis of histopathological and genetic prognostic factors in neuroblastoma (NB).
• Development of high-throughput pan-genomic techniques in NB and sarcomas.
• Study of apoptosis, proliferation, angiogenesis and hypoxia in pediatric tumors, soft-tissue sarcomas, skeletogenic tumors and gynecologic mesenchymal tumors.
• ALK as a prognostic factor in NB.
• Identification and isolation of stem cells in NB.
• Establishment and characterization of in vitro and in vivo models of malignant skeletogenic tumors. Cell line extraction in
these tumors.
• Expression study of immunohistochemistry and Western blot markers in the described tumors for the identification of
possible therapeutic targets.
• Study of NB hyperstructure.
Scientific activity
PUBLICATIONS
Original articles
1Fieuw A, Kumps C, Schramm A, Pattyn F, Menten B,
Antonacci F, Sudmant P, Schulte JH, Van Roy N, Vergult S, Buckley PG, De Paepe A, Noguera R, Versteeg
R, Stallings R, Eggert A, Vandesompele J, De Preter K, Speleman F. Identification of a novel recurrent
1q42.2-1qter deletion in high risk MYCN single copy
11q deleted neuroblastomas. International Journal of
Cancer. 2012 Jun 1; 130(11): 2599-606. IF: 5,444
2Mackintosh
C, Ordóñez JL, García-Domínguez DJ,
Sevillano V, Llombart-Bosch A, Szuhai K. 1q gain
and CDT2 overexpression underlie an aggressive and
highly proliferative form of Ewing sarcoma. Oncogene.
2012 Mar 8; 31(10): 1287-98. IF: 6,373
3Illueca
C, Machado I, Cruz J, Almenar S, Noguera
R, Navarro S, Llombart-Bosch A. Pleomorphic hyalinizing angiectatic tumor: a report of 3 new cases, 1
with sarcomatous myxofibrosarcoma component and
another with unreported soft tissue palpebral location.
Applied Immunohistochemistry & Molecular Morphology. 2012 Jan; 20(1): 96-101.
4Frasson M, Faus C, Garcia-Granero A, Puga R, FlorLorente B, Cervantes A, Navarro S, Garcia-Granero
E. Pathological evaluation of mesocolic resection quality and ex vivo methylene blue injection: what is the
impact on lymph node harvest after colon resection
for cancer?. Diseases of the Colon and Rectum. 2012
Feb; 55(2): 197-204. IF: 3,132
5Alemany L, Pérez C, Tous S, Llombart-Bosch A, Lloveras B, Lerma E, Guarch R, Andújar M, Pelayo A, Alejo
M, Ordi J, Klaustermeier J, Velasco J, Guimerà N, Clavero O, Castellsagué X, Quint W, Muñoz N, Bosch FX,
de Sanjosé S, Spanish study group RIS HPV TT. Human
papillomavirus genotype distribution in cervical cancer
cases in Spain. Implications for prevention. Gynecologic
Oncology. 2012 Mar; 124(3): 512-7. IF: 3,888
6Kresse SH, Meza-Zepeda LA, Machado I, LlombartBosch A, Myklebost O. Preclinical xenograft models of
human sarcoma show nonrandom loss of aberrations.
Cancer. 2012 Jan 15; 118(2): 558-70. IF: 4,771
7Calabuig-Fariñas S, Benso RG, Szuhai K, Machado I,
López-Guerrero JA, de Jong D, Peydró A, San Miguel
T, Navarro L Pellín A Llombart-Bosch A. Characterization of a New Human Cell Line (CH-3573) Derived
from a Grade II Chondrosarcoma with Matrix Production. Pathology Oncology Research. 2012 Feb 15. IF:
1,366
8Romanenko AM, Ruiz-Saurí A, Morell-Quadreny L, Valencia G, Vozianov AF, Llombart-Bosch A. Microvessel density is high in clear-cell renal cell carcinomas of
Ukrainian patients exposed to chronic persistent lowdose ionizing radiation after the Chernobyl accident.
Virchows Archiv. 2012 Jun; 460(6): 611-9. IF: 2,491
9Baselga J, Segalla JG, Roché H, Del Giglio A, Pinczowski H, Ciruelos EM, Filho SC, Gómez P, Van Eyll,
B Bermejo B, Llombart A, Garicochea B, Durán MÁ,
Hoff PM, Espié M, de Moraes AA, Ribeiro RA, Mathias
C, Gil Gil M, Ojeda B, Morales J, Kwon Ro S, Li S,
Costa F. Sorafenib in combination with capecitabine:
an oral regimen for patients with HER2-negative locally advanced or metastatic breast cancer. Journal of
Clinical Oncology. 2012 May 1; 30(13): 1484-91. IF:
18,372
10Machado I, López-Guerrero JA, Navarro S, Alberghini
M, Scotlandi K, Picci P, Llombart-Bosch A. Epithelial
cell adhesion molecules and epithelial mesenchymal
transition (EMT) markers in Ewing’s sarcoma family of
tumors (ESFTs). Do they offer any prognostic significance?. Virchows Archiv. 2012 Aug 17. IF: 2,491
11García-Alfonso P, Salazar R, García-Foncillas J, Musulén E, García-Carbonero R, Payá A , Pérez-Segura P,
Ramón y Cajal S, Navarro S. Guidelines for biomarker
testing in colorectal carcinoma (CRC): a national consensus of the Spanish Society of Pathology (SEAP) and the
Spanish Society of Medical Oncology (SEOM). Clinical &
Translational Oncology. 2012 Jul 27. IF: 1,327
12Noguera
R, Nieto OA, Tadeo I, Fariñas F, Alvaro T.
Extracellular matrix, biotensegrity and tumor microenvironment. An update and overview. Histology & Histopathology. 2012 Jun; 27(6): 693-705. IF: 2,48
13 Kovar H, Alonso J, Aman P, Aryee DN, Ban J, Burchill
SA, Burdach S, De Alava E, Delattre O, Dirksen U,
Fourtouna A, Fulda S, Helman LJ, Herrero-Martin D,
Hogendoorn PC, Kontny U, Lawlor ER, Lessnick SL,
Llombart-Bosch A, Metzler M, Moriggl R, Niedan S,
Potratz J, Redini F, Richter GH, Riedmann LT, Rossig
C, Schäfer BW, Schwentner R, Scotlandi K, Soren-
4
103
Scientific activity
sen PH, Staege MS, Tirode F, Toretsky J, Ventura S,
Eggert A, Ladenstein R. The first European interdisciplinary ewing sarcoma research summit. Frontiers in
Oncology. 2012; 2: 54.
14Stacchiotti S, Verderio P, Messina A, Morosi C, Collini
P, Llombart-Bosch A, Martin J, Comandone A, Cruz
J, Ferraro A, Grignani G, Pizzamiglio S, Quagliuolo V,
Picci P, Frustaci S, Dei Tos AP, Casali PG, Gronchi A.
Tumor response assessment by modified Choi criteria
in localized high-risk soft tissue sarcoma treated with
chemotherapy. Cancer. 2012 May 17. IF: 4,771
15
Mosakhani N, Guled M, Leen G, Calabuig-Fariñas
S, Niini T, Machado I, Savola S, Scotlandi K, LópezGuerrero JA, Llombart-Bosch A, Knuutila S. An integrated analysis of miRNA and gene copy numbers in
xenografts of Ewing’s sarcoma. Journal of Experimental & Clinical Cancer Research. 2012 Mar 20; 31: 24.
16Bennani-Baiti IM, Machado I, Llombart-Bosch A, Kovar H. Lysine-specific demethylase 1 (LSD1/KDM1A/
AOF2/BHC110) is expressed and is an epigenetic drug
target in chondrosarcoma, Ewing’s sarcoma, osteosarcoma, and rhabdomyosarcoma. Human Pathology.
2012 Aug; 43(8): 1300-7. IF: 2,876
104
4
17Giner F, Compañ A, Monteagudo C.
Uterine glomeruloid hemangioma in a patient without POEMS syndrome. International Journal of Surgical Pathology. 2012
Aug; 20(4): 407-10. IF: 1,00
18Schramm A, Schowe B, Fielitz K, Heilmann M, Martin
M, Marschall T, Köster J, Vandesompele J, Vermeulen
J, de Preter K, Koster J, Versteeg R, Noguera R, Speleman F, Rahmann S, Eggert A, Morik K, Schulte JH.
Exon-level expression analyses identify MYCN and
NTRK1 as major determinants of alternative exon usage and robustly predict primary neuroblastoma outcome. British Journal of Cancer. 2012 Oct 9; 107(8):
1409-17. IF: 5,042
19Schleiermacher G, Mosseri V, London WB, Maris JM,
Brodeur GM, Attiyeh E, Haber M, Khan J, Nakagawara A, Speleman F, Noguera R, Tonini GP, Fischer M,
Ambros I, Monclair T, Matthay KK, Ambros P, Cohn
SL, Pearson AD. Segmental chromosomal alterations
have prognostic impact in neuroblastoma: a report
from the INRG project. British Journal of Cancer. 2012
Oct 9; 107(8):1418-22. IF: 5,042
20Decock A, Ongenaert M, Hoebeeck J, De Preter K, Van
Peer G, Van Criekinge W, Ladenstein R, Schulte JH,
Noguera R, Stallings RL, Van Damme A, Laureys G,
Vermeulen J, Van Maerken T, Speleman F, Vandesompele J. Genome-wide promoter methylation analysis
in neuroblastoma identifies prognostic methylation biomarkers. Genome Biology. 2012 Oct 3; 13(10): R95.
IF: 9,036
21Navarro S, Piqueras M, Villamon E, Yáñez Y, Balaguer J, Cañete A, Noguera R. New prognostic markers in neuroblastoma. Expert Opinion on Medical
Diagnosis. 2012. 6: 555-567.
22Bohn
OL, León EA, Lezama O, Rios-Luna NP, Sánchez-Sosa S, Llombart-Bosch A. Pulmonary artery
sarcoma with angiosarcoma phenotype mimicking
pleomorphic malignant fibrous histiocytoma: a case report. Diagnostic Pathology. 2012 Nov 7; 7(1): 154. IF:
1,638
23Van Oosterwijk JG, de Jong D, van Ruler MA, Hogendoorn PC, Dijkstra PS, van Rijswijk CS, Machado I,
Llombart-Bosch A, Szuhai K, Bovée JV. Three new
chondrosarcoma cell lines: one grade III conventional central chondrosarcoma and two dedifferentiated
chondrosarcomas of bone. BMC Cancer. 2012 Aug;
28(12): 375. IF: 3,011
RESEARCH
Reference: 20090840
Title: Estudios retrospectivo (1992-2005) y prospectivo (2006-2011) con técnicas semigenómicas de los
tumores neuroblásticos.
Principal Investigator: Rosa Noguera Salvá
Funding Body: Asociación Española Contra el Cáncer (AECC)
Duration: 2009-2012
cáncer (RTICC).
Scientific activity
Principal Investigator: Samuel Navarro Fos
Duration: 2007-2012
Title: Modelo in silico de la hiperestructura de los tumores neuroblásticos. Integración génica, microscópica y clínica.
Duration: 2011-2013
Reference: 261474
Title: European network for cancer in children and
adolescent (ENCCA).
Funding Body: European Commission
Duration: 2011-2015
Total Budget: €11.997.958
Title: Modelo in silico de la hiperestructura de los tumores neuroblásticos. Integración génica, microscópica y clínica.
Valenciana
Duration: 2012
4
105
Scientific activity
Research Group on Hematopoietic Transplantation
PI: Carlos Solano Vercet (Department of Oncology and Hematology Hospital Clínico Universitario of Valencia / Department of Medicine University of Valencia).
Collaborating Researchers: Cristina Arbona Castaño (Hospital), Maribel Marugán de la Concha (Hospital), María
José Remigia Pellicer (Hospital), Rosa Goterris Vicedo (Hospital), David Navarro Ortega (Hospital), María Ángeles
Clari (Hospital), Julia Peláez González (INCLIVA), Paula Amat Martínez (INCLIVA).
Predoctoral Researchers: María Collado Díaz (INCLIVA).
Technicians: Joana Hernández Martín (INCLIVA).
Administrative assistants: Gabriela Pérez Garity (INCLIVA).
106
4
Strategic aims
• To develop projects, publish articles and present papers at conferences related to research on specific immune recovery,
early detection of infections after hematopoietic transplantation and new strategies in prevention or treatment of infections after hematopoietic transplantation.
• To conduct research projects on genetic predisposition and on new drugs or strategies in prevention and treatment of
graft-versus-host disease after allogeneic transplantation.
• To make progress in the study of the value of mesenchymal stem cells for the treatment of chronic graft-versus-host disease thanks to a collaborative study with CABIMER, a center resulting from an agreement between Junta de Andalucía,
CSIC, Universidad de Sevilla and Universidad Pablo de Olavide.
• Biology of hematopoietic implant.
• Cell therapy with adult stem cells in relation with hematopoietic transplantation.
• Translational research on complications of allogeneic hematopoietic transplantation: graft-versus-host disease.
• Infection and immune reconstitution after hematopoietic transplantation.
Scientific activity
PUBLICATIONS
Original articles
1Muñoz-Cobo B, Solano C, Benet I, Costa E, Remigia
MJ, de la Cámara R, Nieto J, López J, Amat P, GarciaNoblejas A, Bravo D, Clari MÁ, Navarro D. Functional profile of cytomegalovirus (CMV)-specific CD8(+)
T cells and kinetics of NKG2C(+) NK Cells associated
with the resolution of CMV DNAemia in allogeneic stem
cell transplant recipients. Journal of Medical Virology.
2012 Feb; 84(2): 259-67. IF: 2,82
2Guillem V, Amat P, Cervantes F, Alvarez-Larrán A, Cervera J, Maffioli M, Bellosillo B, Collado M, Marugán I,
Martínez-Ruiz F, Hernández-Boluda JC. Functional polymorphisms in SOCS1 and PTPN22 genes correlate
with the response to imatinib treatment in newly diagnosed chronic-phase chronic myeloid leukemia. Leukemia
Research. 2012 Feb; 36(2): 174-81. IF: 2,923
3Bosch-Vizcaya A, Pérez-García A, Brunet S, Solano C,
Buño I, Guillem V, Martínez-Laperche C, Sanz G, Barrenetxea C, Martínez C, Tuset E, Lloveras N, Coll R,
Guardia R, González Y, Roncero JM, Bustins A, Gardella S, Fernández C, Buch J, Gallardo D, GvHD/Immunotherapy committee of the Spanish Group for Hematopoietic Transplant (GETH). Donor CTLA-4 Genotype
Influences Clinical Outcome after T Cell-Depleted Allogeneic Hematopoietic Stem Cell Transplantation from
HLA-Identical Sibling Donors. Biology of Blood and Marrow Transplantation. 2012 Jan; 18(1): 100-5. IF: 3,873
4Hernández-Boluda JC, Pereira A, Cervantes F, AlvarezLarrán A, Collado M, Such E, Arilla MJ, Boqué C, Xicoy
B, Maffioli M, Bellosillo B, Marugán I, Amat P, Besses
C, Guillem V. A polymorphism in the XPD gene predisposes to leukemic transformation and new nonmyeloid
malignancies in essential thrombocythemia and polycythemia vera. Blood. 2012 May 31; 119(22): 5221-8.
IF: 9,898
5Arbona C, Martinez-Hervás S, Goterris R, Montoro J,
Real JT, Ascaso JF. Low-density lipoprotein apheresis in
familial hypercholesterolemia resistant to intensive medical treatment. Medicina Clínica. 2012 May 7. IF: 1,385
6Clari
MÁ, Muñoz-Cobo B, Solano C, Benet I, Costa
E, Remigia MJ, Bravo D, Amat P, Navarro D. Performance of the QuantiFERON-cytomegalovirus (CMV)
assay for detection and estimation of the magnitude and
functionality of the CMV-specific gamma interferon-producing CD8(+) T-cell response in allogeneic stem cell
transplant recipients. Clinical and Vaccine Immunology.
2012 May; 19(5): 791-6. IF: 2,546
7Sanz
J, Boluda JC, Martín C, González M, Ferrá C,
Serrano D, de Heredia CD, Barrenetxea C, Martinez
AM, Solano C, Sanz MA, Sanz GF. Single-unit umbilical cord blood transplantation from unrelated donors in
patients with hematological malignancy using busulfan,
thiotepa, fludarabine and ATG as myeloablative conditioning regimen. Bone Marrow Transplantation. 2012
Feb 13. IF: 3,746
8Montoro J, Hernández-Boluda JC, Arbona C, Solano
C. Polymyositis after donor lymphocyte infusion. International Journal of Hematology. 2012 Aug 19. IF: 1,268
9Blanes M, Lahuerta JJ, González JD, Ribas P, Solano
C, Alegre A, Bladé J, San Miguel JF, Sanz MA, de la
Rubia J. Intravenous busulfan and melphalan as conditioning regimen for autologous stem cell transplantation
in patients with newly diagnosed multiple myeloma: a
matched comparison to a melphalan-only approach.
Biology of Blood and Marrow Transplantation. 2012 Aug
13. IF: 3,873
10Aguado JM, Navarro D, San Juan R, Castón JJ. Cytomegalovirus infection in solid organ transplantation. Enfermedades Infecciosas y Microbiología Clínica. 2012
Mar; 30 Suppl 2: 57-62. IF: 1,491
11Rodríguez
A, Alvarez-Rocha L, Sirvent JM, Navarro
D et al. Recommendations of the Infectious Diseases
Work Group (GTEI) of the Spanish Society of Intensive
and Critical Care Medicine and Coronary Units (SEMICYUC) and the Infections in Critically Ill Patients Study
Group (GEIPC) of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) for the diagnosis and treatment of influenza A/H1N1 in seriously
ill adults admitted to the Intensive Care Unit. Medicina
Intensiva. 2012 Mar; 36(2): 103-37. IF: 1,072
12Paiva
B, Gutiérrez NC, Chen X, Vídriales MB, Montalbán MÁ, Rosiñol L, Oriol A, Martínez-López J, Mateos MV, López-Corral L, Díaz-Rodríguez E, Pérez JJ,
Fernández-Redondo E, de Arriba F, Palomera L, Bengoechea E, Terol MJ, de Paz R, Martin A, Hernández
J, Orfao A, Lahuerta JJ, Bladé J, Pandiella A, Miguel
JF, GEM (Grupo Español de Mieloma)/PETHEMA
4
107
Scientific activity
(Programa para el Estudio de la Terapéutica en Hemopatías Malignas) cooperative. Clinical significance
of CD81 expression by clonal plasma cells in high-risk
smoldering and symptomatic multiple myeloma patients. Leukemia. 2012 Aug; 26(8): 1862-9. IF: 9,561
13Barona-Vilar
C, Giménez-Martí MJ, Fraile T, González-Steinbauer C, Parada C, Gil-Brusola A, Bravo D,
Gómez MD, Navarro D, Perez-Tamarit A, FernandezSilveira L, Fullana-Montoro A, Borrás R. Prevalence of
Trypanosoma cruzi infection in pregnant Latin American
women and congenital transmission rate in a non-endemic area: the experience of the Valencian Health Programme (Spain). Epidemiology and Infection. 2012 Oct;
140(10): 1896-903. IF: 2,843
14Perez-Simón
JA, Martino R, Parody R, Cabrero M,
Lopez-Corral L, Valcarcel D, Martinez C, Solano C,
Vazquez L, Márquez-Malaver FJ, Sierra J, Caballero D.
The combination of Sirolimus plus Tacrolimus improves
outcome after reduced-intensity conditioning unrelated
donor hematopoietic stem cell transplantation compared with Cyclosporine plus Mycofenolate. Haematologica. 2012 Dec 14. IF: 6,424
Letter
108
4
1Meza
LD, Sancho-Tello S, Muñoz-Cobo B, Costa E,
Bravo D, Pazos JM, Corrales I, Marcano X, Tohalino
M, Navarro D. Performance of an immunofiltration assay detecting IgM antibodies against ZEBRA and viral
capsid p18 proteins (Immunoquick(®) filtration EBV M)
for the diagnosis of heterophile antibody-negative primary Epstein-Barr virus infection in children. Journal of
Clinical Virology. 2012 Mar; 53(3): 270-1. IF: 3,969
Muñoz-Cobo B, Bodí V, Costa E, Bravo D, Sanchis J,
Miñana G, Navarro D. Low rate of detection of active
cytomegalovirus (CMV) infection early following acute myocardial infarction. Atherosclerosis. 2012 May;
222(1): 295-7. IF: 3,794
RESEARCH
Reference: EC10-317
Title: Estudio del tratamiento anticipado de la infección por citomegalovirus guiado por la reconstitución
inmune específica en el TPH alogénico.
Principal Investigator: Carlos Solano Vercet
Duration: 2011-2012
Title: Marcadores inmunológicos y genotípicos de protección frente al citomegalovirus en el trasplante alogénico de precursores hematopoyéticos. Aplicabilidad en
el manejo terapéutico de la infección activa virémica.
Principal Investigator: David Navarro Ortega
Duration: 2010-2012
Reference: EC10-317
Title: Estudio en fase II, multicéntrico, prospectivo,
abierto, de tratamiento anticipado de la infección por
citomegalovirus guiado por la monitorización virológica y la cuantificación de linfocitos T CD8 pp65/IE1IFNgamma+ en el trasplante de progenitores hematopoyéticos alogénicos.
Principal Investigator: Carlos Solano Vercet
Duration: 2011-2013
Reference: SAS, CMM/EICH/2008. EudraCT:
200004014-27
Title: Ensayo clínico multicéntrico fase I/II aleatorizado
y controlado, para la evaluación de seguridad y factibilidad de la terapia con dos dosis distintas de células
madre mesenquimales procedentes de tejido adiposo
en pacientes con Enfermedad injerto contra huésped
crónica extensa.
Principal Investigator: Manuel Jurado (Carlos Solano as Main Researcher of the Center)
Scientific activity
Duration: 2010-2013
4
109
Scientific activity
Research Group on Lymphoproliferative Disorders
PI: María José Terol Casterá (Department of Oncology and Hematology Hospital Clínico Universitario of Valencia /
Department of Medicine University of Valencia).
Collaborating Researchers: Isabel Benet Montforte (Hospital), Antonio Ferrández Izquierdo (Hospital), Ana Isabel
Teruel Casaús (Hospital).
Predoctoral Researchers: Sandra Ballester García (INCLIVA), Lucía Brines Sirerol (INCLIVA).
Strategic aims
110
4
• The knowledge of VEGF stimulation pathway and its interaction with CXCR4 pathway in Chronic Lymphocytic Leukemia
(CLL) has been expanded and the research has confirmed an increase in CXCR4 expression and a rise in cell migration
of CLL neoplastic cells in response to VEGF stimulation.
• The group has achieved the goal of publishing guides for healthcare clinical practice in Chronic Lymphocytic Leukemia
at regional and national levels.
• The participation in clinical research projects on resistant lymphomas and multiple myeloma has widely increased with
the inclusion of new drugs and also with the design and development of new therapeutic options.
• In the context of an international collaboration, the group has contributed to the identification of new prognostic factors in
diffuse large-cell lymphoma in the era of chemoimmunotherapy.
• Analysis of the interactions of the cells of CLL with their cellular microenvironment: further study of the intracellular
mechanisms triggered by VEGF in the cells of CLL. Analysis of the possible correlation with CXCR4/CCR7 cytokines
pathway. Transactivation mechanisms of the aforementioned receptors.
• Development of new ex-vivo co-culture models of the cells of CLL with bone marrow stroma and dendritic cells for the
efficacy analysis of new kinase inhibitor drugs. Drug resistance effect mediated by microcellular environment.
• Identification and analysis of VEGF polymorphisms in CLL progression: study of samples from CLL patients obtained at
diagnosis and controlled at the institution.
• Study of polymorphisms in folate pathway genes (MTHFR, DHFR, TS) and predisposition to develop lymphomas. Correlation with the clinical and biological characteristics of the disease, response to treatment, toxicity and survival.
• Study of polymorphisms of circadian rhythm-regulating genes in follicular lymphomas: correlation with the clinical and
biological characteristics of the disease, response to treatment, toxicity and survival.
• New therapeutic options for CLL/MM patients who are resistant to chemoimmunotherapy.
Scientific activity
PUBLICATIONS
Original articles
1Paiva B, Gutiérrez NC, Rosiñol L, Vídriales MB, Montalbán MA, Martínez-López J, Mateos MV, Cibeira MT,
Cordón L, Oriol A, Terol MJ, Echeveste MA, de Paz R,
de Arriba F, Palomera L, de la Rubia J, Díaz-Mediavilla
J, Sureda A, Gorosquieta A, Alegre A, Martin A, Hernández MT, Lahuerta JJ, Bladé J, San Miguel JF, on
behalf of the PETHEMA/GEM (Programa para el Estudio de la Terapéutica en Hemopatías Malignas/Grupo Español de Mieloma) Cooperative Study Groups.
High-risk cytogenetics and persistent minimal residual
disease by multiparameter flow cytometry predict unsustained complete response after autologous stem
cell transplantation in multiple myeloma. Blood. 2012
Jan 19; 119(3): 687-691. IF: 9,898
2Rodrigues P, Furriol J, Tormo E, Ballester S, Lluch A,
Eroles P. The single-nucleotide polymorphisms +936
C/T VEGF and -710 C/T VEGFR1 are associated
with breast cancer protection in a Spanish population.
Breast Cancer Research and Treatment. 2012 Jun;
133(2): 769-78. IF: 4,431
3Ugarte-Berzal E, Bailón E, Amigo-Jiménez I, Vituri CL,
Del Cerro MH, Terol MJ. A 17-residue Sequence from
the Matrix Metalloproteinase-9 (MMP-9) Hemopexin
Domain Binds α4β1 Integrin and Inhibits MMP-9-induced Functions in Chronic Lymphocytic Leukemia B
Cells. The Journal of Biological Chemistry. 2012 Aug
10; 287(33): 27601-13. IF: 4,773
4Mateos
MV, Oriol A, Martínez-López J, Gutiérrez N,
Teruel AI, López de la Guía A, López J, Bengoechea
E, Pérez M, Polo M, Palomera L, de Arriba F, González
Y, Hernández JM, Granell M, Bello JL, Bargay J, Peñalver FJ, Ribera JM, Martín-Mateos ML, García-Sanz
R, Lahuerta JJ, Bladé J, San-Miguel JF. Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma
patients included in the GEM2005MAS65 trial. Blood.
2012 Aug 13. IF: 9,898
5Rosiñol
L, Oriol A, Teruel AI, Hernández D, LópezJiménez J, de la Rubia J, Granell M, Besalduch J, Palomera L, González Y, Etxebeste MA, Díaz-Mediavilla
J, Hernández MT, de Arriba F, Gutiérrez NC, Martín-
Ramos ML, Cibeira MT, Mateos MV, Martínez J, Alegre A, Lahuerta JJ, San Miguel J, Bladé J, on behalf
of the Programa para el Estudio y la Terapéutica de
las Hemopatías Malignas/Grupo Español de Mieloma
(PETHEMA/GEM) group. Superiority of bortezomib,
thalidomide, and dexamethasone (VTD) as induction
pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study. Blood. 2012
Aug 23; 120(8): 1589-1596. IF: 9,898
6Paiva
B, Gutiérrez NC, Chen X, Vídriales MB, Montalbán MÁ, Rosiñol L, Oriol A, Martínez-López J, Mateos MV, López-Corral L, Díaz-Rodríguez E, Pérez JJ,
Fernández-Redondo E, de Arriba F, Palomera L, Bengoechea E, Terol MJ, de Paz R, Martin A, Hernández
J, Orfao A, Lahuerta JJ, Bladé J, Pandiella A, Miguel
JF. Clinical significance of CD81 expression by clonal
plasma cells in high-risk smoldering and symptomatic multiple myeloma patients. Leukemia. 2012 Aug;
26(8): 1862-9. IF: 9,561
7Van
Den Neste E, Cazin B, Janssens A, GonzálezBarca E, Terol MJ, Levy V, Pérez de Oteyza J, Zachee
P, Saunders A, de Frias M, Campàs C. Acadesine for
patients with relapsed/refractory chronic lymphocytic
leukemia (CLL): a multicenter phase I/II study. Cancer
Chemotherapy and Pharmacology. 2012 Dec 11. IF:
2,833
8Paiva B, Vídriales MB, Montalbán MÁ, Pérez JJ, Gutiérrez NC, Rosiñol L, Martínez-López J, Mateos MV,
Cordón L, Oriol A, Terol MJ, Echeveste MA, De Paz R,
De Arriba F, Palomera L, de la Rubia J, Díaz-Mediavilla
J, Sureda A, Gorosquieta A, Alegre A, Martin A, Lahuerta JJ, Bladé J, Orfao A, San Miguel JF. Multiparameter
Flow Cytometry Evaluation of Plasma Cell DNA Content and Proliferation in 595 Transplant-Eligible Patients with Myeloma Included in the Spanish GEM2000
and GEM2005<65y Trials. The American Journal of
Pathology. 2012 Nov; 181(5): 1870-8. IF: 4,89
9Clari MÁ, Muñoz-Cobo B, Solano C, Benet I, Costa E,
Remigia MJ, Bravo D, Amat P, Navarro D. Performance
of the QuantiFERON-cytomegalovirus (CMV) assay for
detection and estimation of the magnitude and functionality of the CMV-specific gamma interferon-producing
CD8(+) T-cell response in allogeneic stem cell transplant recipients. Clinical and Vaccine Immunology: CVI.
2012 May; 19(5): 791-6. IF: 2,546
4
111
Scientific activity
MJ, de la Cámara R, Nieto J, López J, Amat P, GarciaNoblejas A, Bravo D, Clari MÁ, Navarro D. Functional
profile of cytomegalovirus (CMV)-specific CD8+ T cells
and kinetics of NKG2C+ NK cells associated with the
resolution of CMV DNAemia in allogeneic stem cell
transplant recipients. Journal of Medical Virology. 2012
Feb; 84(2): 259-67. IF: 2,82
11Mateos
MV, Oriol A, Martínez-López J, Gutiérrez N,
Teruel AI, López de la Guía A, López J, Bengoechea
E, Pérez M, Polo M, Palomera L, de Arriba F, González
Y, Hernández JM, Granell M, Bello JL, Bargay J, Peñalver FJ, Ribera JM, Martín-Mateos ML, García-Sanz
R, Lahuerta JJ, Bladé J, San-Miguel JF. Maintenance
therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial. Blood.
2012 Sep 27; 120(13): 2581-8. IF: 9,898
12Rosiñol
112
4
L, Oriol A, Teruel AI, Hernández D, LópezJiménez J, de la Rubia J, Granell M, Besalduch J, Palomera L, González Y, Etxebeste MA, Díaz-Mediavilla
J, Hernández MT, de Arriba F, Gutiérrez NC, MartínRamos ML, Cibeira MT, Mateos MV, Martínez J, Alegre
A, Lahuerta JJ, San Miguel J, Bladé J; Programa para
el Estudio y la Terapéutica de las Hemopatías Malignas/Grupo Español de Mieloma (PETHEMA/GEM)
group. Superiority of bortezomib, thalidomide, and
dexamethasone (VTD) as induction pretransplantation
therapy in multiple myeloma: a randomized phase 3
PETHEMA/GEM study. Blood. 2012 Aug 23; 120(8):
1589-96. IF: 9,898
RESEARCH
Reference: FIS 10/02095
Title: Efecto sobre la supervivencia y migración celular
de los inhibidores de quinasas sorafebib y everolimus
en la Leucemia Linfática Crónica (LLC-B). Implicación
del microambiente celular.
Principal Investigator: María José Terol Casterá
Duration: 2011-2013
de los inhibidores de quinasas sorafenib y everolimus
en la Leucemia Linfática Crónica-B (LLC-B). Implicación del microambiente celular.
Valenciana
Duration: 2012
cáncer.
Principal Investigator: Ana Lluch Hernández (Ana
Isabel Teruel, Antonio Fernández and Mª José Terol
Casterá as collaborating researchers)
Duration: 2007-2012
Scientific activity
4
113
Scientific activity
Research Group on Myeloid Neoplasms
PI: Mar Tormo Díaz (Department of Oncology and Hematology Hospital Clínico Universitario of Valencia / Department
of Medicine University of Valencia).
Collaborating Researchers: Juan Carlos Hernández Boluda (Hospital), Vicente Martín Guillem Primo (INCLIVA),
Blanca Navarro Cubells (Hospital), Marisa Calabuig Muñoz (Hospital), Paula Amat Martínez (INCLIVA).
Strategic aims
• Study of genetic polymorphisms involved in the response to imanitib in patients with chronic myeloid leukemia.
• Study of genetic polymorphisms involved in the development of acute leukemias in patients with Philadelphia-negative
chronic myeloproliferative disorders.
114
4
• Clinical evaluation of response criteria to treatment of polycythemia vera.
• Clinical guidelines for diagnosis, prognosis and treatment of myelodysplastic syndromes.
• Studies of genetic polymorphisms involved in the development of:
- Acute leukemias and secondary to toxic myelodysplastic syndromes.
- Acute leukemias in patients with Philadelphia-negative chronic myeloproliferative disorders.
- Toxicity of autologous hematopoietic transplantation in lymphomas.
• Studies of genetic polymorphisms involved in the response to imanitib in patients with chronic myeloid leukemia:
- in maintaining DNA integrity and the response to imanitib treatment.
- in relation with phosphatase genes and the response to imanitib in chronic myeloid leukemia.
• Studies of new biological prognostic factors in acute myeloblastic leukemia.
• Clinical guides of response evaluation in chronic myeloblastic leukemia.
• Study of factors influencing the risk of thrombosis in Philadelphia-negative chronic myeloproliferative disorders.
Emerging Researcher
Juan Carlos Hernández Boluda (Department of Oncology and Hematology Hospital Clínico Universitario of Valencia / Department of Medicine University of Valencia).
The research is focused on the potential role of single nucleotide polymorphisms on the predisposition to develop chronic myeloproliferative neoplasms as well as on their influence on the natural
history of these diseases. In this sense, we have currently identified that a polymorphism in a DNA
repair gene involved in the nucleotide excision repair pathway is associated with the risk of leukemic transformation of patients with essential thrombocythemia and polycythemia vera.
Scientific activity
PUBLICATIONS
Original articles
1Alvarez-Larrán A, Pereira A, Cervantes F, Arellano-Rodrigo E, Hernández-Boluda JC, Ferrer-Marín F, Angona A, Gómez M, Muiña B, Guillén H, Teruel A, Bellosillo
B, Burgaleta C, Vicente V, Besses C. Assessment and
prognostic value of the European LeukemiaNet criteria
for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera. Blood.
2012 Feb 9; 119(6): 1363-9. IF: 9,898
2Such E, Cervera J, Ibáñez M, Gómez-Seguí I, Luna I,
López-Pavía M, Mallo M, Collado R, Vicente A, Hernández-Boluda JC, Luño E, Andreu R, Sanz GF, Sanz
MA. Absence of mutations in the activation loop and
juxtamembrane domains of VEGFR-1 and VEGFR-2
gene in chronic myelomonocytic leukemia (CMML).
Leukemia Research. 2012 Mar; 36(3): e50-1. IF: 2,923
3Guillem
V, Amat P, Cervantes F, Alvarez-Larrán A,
Cervera J, Maffioli M, Bellosillo B, Collado M, Marugán
I, Martínez-Ruiz F, Hernández-Boluda JC. Functional
polymorphisms in SOCS1 and PTPN22 genes correlate with the response to imatinib treatment in newly
diagnosed chronic-phase chronic myeloid leukemia.
Leukemia Research. 2012 Feb; 36(2): 174-81. IF:
2,923
4Valcárcel D, Montesinos P, Sánchez-Ortega I, Brunet
S, Esteve J, Martínez-Cuadrón D, Ribera JM, Tormo
M, Bueno J, Duarte R, Llorente A, Torres JP, Guardia R, Sanz MA, Sierra AJ, on behalf of the CETLAM
Group. A scoring system to predict the risk of death
during induction with anthracycline plus cytarabinebased chemotherapy in patients with de novo acute
myeloid leukemia. Cancer. 2012 Jan 15; 118(2): 410417. IF: 4,771
5Cordoba
I, González-Porras JR, Nomdedeu B, Luño
E, de Paz R, Such E, Tormo M, Vallespi T, Collado R,
Xicoy B, Andreu R, Muñoz JA, Solé F, Cervera J, Del
Cañizo C, on behalf of the Spanish Myelodysplastic
Syndrome Registry. Better prognosis for patients with
del(7q) than for patients with monosomy 7 in myelodysplastic syndrome. Cancer. 2012 Jan 1; 118(1): 127133. IF: 4,771
6Hernández-Boluda JC, Pereira A, Cervantes F, Alva-
rez-Larrán A, Collado M, Such E, Arilla MJ, Boqué C,
Xicoy B, Maffioli M, Bellosillo B, Marugán I, Amat P,
Besses C, Guillem V. A polymorphism in the XPD gene
predisposes to leukemic transformation and new nonmyeloid malignancies in essential thrombocythemia
and polycythemia vera. Blood. 2012 May 31; 119(22):
5221-8. IF: 9,898
7Montoro J, Hernández-Boluda JC, Arbona C, Solano
C. Polymyositis after donor lymphocyte infusion. International Journal of Hematology. 2012; 96(3): 386-9. IF:
1,268
8Santamaría C, Ramos F, Puig N, Barragán E, de Paz
R, Pedro C, Insunza A, Tormo M, Del Cañizo C, DiezCampelo M, Xicoy B, Salido E, Sánchez del Real J,
Hernández M, Chillón C, Sanz GF, García-Sanz R, San
Miguel JF, González M. Simultaneous analysis of the
expression of 14 genes with individual prognostic value in myelodysplastic syndrome patients at diagnosis:
WT1 detection in peripheral blood adversely affects
survival. Annals of Hematology. 2012;91(12):1887-95.
IF: 2,615
9Sanz J, Boluda JC, Martín C, González M, Ferrá C,
Serrano D, de Heredia CD, Barrenetxea C, Martinez
AM, Solano C, Sanz MA, Sanz GF; Grupo Español de
Trasplante Hematopoyético y Terapia Celular (GETH).
Single-unit umbilical cord blood transplantation from
unrelated donors in patients with hematological malignancy using busulfan, thiotepa, fludarabine and ATG
as myeloablative conditioning regimen. Bone Marrow
Transplantation. 2012 Oct; 47(10): 1287-93. IF: 3,743
MJ, de la Cámara R, Nieto J, López J, Amat P, GarciaNoblejas A, Bravo D, Clari MÁ, Navarro D. Functional profile of cytomegalovirus (CMV)-specific CD8+ T
cells and kinetics of NKG2C+ NK Cells associated with
the resolution of CMV DNAemia in allogeneic stem
cell transplant recipients. Journal of Medical Virology.
2012 Feb; 84(2): 259-67. IF: 2,82
11Clari
MÁ, Muñoz-Cobo B, Solano C, Benet I, Costa
E, Remigia MJ, Bravo D, Amat P, Navarro D. Performance of the QuantiFERON-Cytomegalovirus (CMV)
Assay for Detection and Estimation of the Magnitude
and Functionality of the CMV-Specific Gamma Interferon-Producing CD8+ T-Cell Response in Allogeneic
Stem Cell Transplant Recipients. Clinical and Vaccine
Immunology. 2012 May; 19(5): 791-6. IF: 2,546
4
115
Scientific activity
12Bosch-Vizcaya A,
Pérez-García A, Brunet S, Solano
C, Buño I, Guillem V, Martínez-Laperche C, Sanz G,
Barrenetxea C, Martínez C, Tuset E, Lloveras N, Coll
R, Guardia R, González Y, Roncero JM, Bustins A,
Gardella S, Fernández C, Buch J,Gallardo D; GvHD/
Immunotherapy committee of the Spanish Group for
Hematopoietic Transplant (GETH). Donor CTLA-4 genotype influences clinical outcome after T cell-depleted allogeneic hematopoietic stem cell transplantation
from HLA-identical sibling donors. Biology of Blood
and Marrow Transplantation. 2012 Jan; 18(1): 100-5.
IF: 3,873
Letter
1Ribera JM, García O, Fernández-Abellán P, Lavilla E,
Bernal MT, González-Campos J, Brunet S, Monteserín MC, Montesinos P, Sarrá J, Calbacho M, AlvarezLarrán A, Tormo M, Oriol A. Lack of negative impact
of Philadelphia chromosome in older patients with
acute lymphoblastic leukaemia in the thyrosine kinase
inhibitor era: comparison of two prospective parallel
protocols. British Journal of Haematology. 2012 Nov;
159(4): 485-8. IF: 4,941
Editorial
116
4
1Tormo
Díaz M. Liposomal cytarabine in central nervous system disease of haematological malignancies:
more effective but more toxic?. Clinical and Translational Oncology. 2012 Apr; 14(4): 241-2. IF: 1,327
RESEARCH
de los inhibidores de quinasas sorafenib y everolimus
en la Leucemia Linfática Crónica-B (LLC-B). Implicación del microambiente celular.
(Blanca Navarro and Marisa Calabuig as collaborating
researchers)
Duration: 2011-2013
cáncer.
Principal Investigator: Ana Lluch Hernández (Juan
Carlos Hernández, Vicente Martín Guillem and Mar Tormo
as collaborating researchers)
Duration: 2007- 2012
Title: Estudio de la predisposición genética individual
a desarrollar leucemia aguda en los pacientes con síndromes mieloproliferativos crónicos Ph-negativos.
Principal Investigator: Juan Carlos Hernández Boluda
Duration: 2010-2012
Title: Estudio del significado pronóstico de la expresión de VEGF y genes implicados en las vías de señalización del VEGF en pacientes con leucemia aguda
mieloblástica.
Principal Investigator: Mar Tormo Díaz
Duration: 2012-2013
Scientific activity
Research Group on Epigenetics and Chromatin
PI: Luis Franco Vera (Department of Biochemistry and Molecular Biology University of Valencia).
Collaborating Researchers: Gerardo López Rodas (University), M. Isabel Rodrigo Aleixandre (University), Josefa
Castillo Aliaga (University), Ángela L. Riffo Campos (University).
Strategic aims
• Research of resistance mechanisms to anti-EGFR drugs of a mutant cell line in KRAS derived from colon cancer.
• Study of molecular mechanisms in connection with the clinical data obtained by the Research Group on Colorectal Cancer and New Therapeutical Developments in Solid Tumors.
• Participation of chromatin in the regulation of EGR1 to study the changes in chromatin linked to the expression of EGR1
during the proliferation induced by phorbol esters in a cell line and in mouse liver in vivo after partial hepatectomy. Changes have been studied at epigenetic and nucleosome positioning level.
• Potential use of Gas1 overexpression in size reduction of hepatic tumors to study the effects of Gas1 overexpression in
HCC-carrier mice in two aspects: size reduction of tumors and reduction of their metastatic potential and normalization of
expression levels of genes involved in cell proliferation.
• Epigenetics of acute pancreatitis.
• Epigenetics of mRNA splicing and its involvement in the resistance to anti-EGFR drugs in colorectal cancer.
PUBLICATIONS
Original articles
1Escobar J, Pereda J, López-Rodas G, Sastre J. Redox signaling and histone acetylation in acute pancreatitis. Free Radical Biology & Medicine. 2012;
52(5): 819-837. IF: 5,423
2Escobar
J, Pereda J, Arduini A, Sandoval J, Moreno ML, Pérez S, Sabater L, Aparisi L, Cassinello N,
Hidalgo J, Joosten LA, Vento M, López-Rodas G y
Sastre J. Oxidative and nitrosative stress in acute pancreatitis. Modulation by pentoxifylline and oxypurinol.
Biochemical Pharmacology. 2012; 83(1): 122-130. IF:
4,705
4
117
Scientific activity
RESEARCH
Reference: CSD2006-49
Title: Epigenética: mecanismos y enfermedad.
Principal Investigator: Gerardo López Rodas
Duration: 2007-2012
Reference: UV-INV-AE112-66203
Title: ID2 y proliferación celular: respuestas en el contexto de la cromatina.
Principal Investigator: Gerardo López Rodas
Duration: 2012-2013
Reference: DO 02-310
Title: Molecular pathways involved in breast carcinogenesis.
118
4
Principal Investigator: Elena Georgieva (Gerardo
López and Luis Franco as collaborating researchers)
Funding Body: Bulgarian Ministry of Education and
Science
Duration: 2010-2013
Reference: OTR2012-10320INVES
Title: Validación y ensayo de nuevas formulaciones
para evaluar la reproducibilidad experimental de la
efectividad y toxicidad del fármaco BO-110 en diversas líneas celulares
Principal Investigator: Gerardo López-Rodas
Funding body: Biooncotech Diagnostics
Duration: 2012-2013
Scientific activity
4.1.3.
Research on
Metabolism
and Organic
Damage
Area
4
119
Scientific activity
Research Group on Genetics of Osteoporosis
MR: Miguel Ángel García Pérez (Department of Genetics University of Valencia).
Collaborating Researchers: Inmaculada Noguera Salvá (University), Rosa María Aliaga Corachán (University), Damian Mifsut Miedes (Hospital).
Predoctoral Researchers: Layla Panach González (INCLIVA).
Strategic aims
• Analysis of the effect on immune and bone systems of treatments (HRT and raloxifene) acting through the estrogen
receptor in a group of women compared with a control group. The main conclusion was that both treatments inhibit bone
resorption in a similar way and that they do not affect selected parameters of the immune system.
120
4
• Description of the function of NR5A2 nuclear receptor, which regulates gene expression in osteoblasts and certain genetic variants associated to bone mass, in populations of Spanish postmenopausal women.
• Study of the implication of Wnt pathways in osteoblast cell differentiation. It is believed that strontium ranelate activates
canonic (beta-catenin) and Wnt/PCP pathways. Also, it is considered that, in the activation of osteogenesis by IGF1, NFKbeta pathway is active but NFAT pathway is not.
• Colaboration in studies on the endometrial response to a simultaneous treatment of progesterone and estradiol; in a
study of the effects of paternal aging on embryo development and postnatal life of the offspring in murine models; and
colaboration in a theoretical study on the possible causes for superfetation in humans.
• Research and analysis of polymorphisms in estrogen-regulated genes of immune system and Wnt/beta-catenin pathway associated with
postmenopausal osteoporosis.
• Role of NR5A2 nuclear receptor in bone metabolism.
• Identification of new estrogen-regulated genes by using microarrays in
murine models of accelerated bone loss.
• Role of B cells and CD40/CD40L system in postmenopausal bone loss.
• Role of RUNX2 transcription factor in bone metabolism. Functional
analysis of polymorphisms by quantification of in vitro transcription
rate.
• Effect of strontium ranelate on bone metabolism in postmenopausal
women, on bone microstructure in ovariectomized mice, and on cell
models of osteoblastogenesis.
Primary osteoblasts
Scientific activity
PUBLICATIONS
Original articles
Valenciana
Duration: 2012
1Pineda B, Hermenegildo C, Tarín JJ, Cano A, GarcíaPérez MA. Effects of administration of hormone therapy or raloxifene on the immune system and on biochemical markers of bone remodeling. Menopause. 2012.
193. 319-27. IF: 3,758
2Riancho JA, Liu Y, Sainz J, Garcia-Pérez MA, Olmos
JM, Bolado-Carrancio A, Valero C, Perez-Lopez J, Cano
A, Yang T, Sañudo C, Deng HW, Rodríguez-Rey JC. Nuclear receptor NR5A2 and bone: gene expression and
association with bone mineral density. European Journal
of Endocrinology. 2012; 166: 69-75. IF: 3,423
3Tarín JJ, García-Pérez MA, Hermenegildo C, Cano A.
Unpredicted ovulations and conceptions during early
pregnancy: an explanatory mechanism of human superfetation. Reproduction, Fertility and Development.
2012 Oct 9. IF: 2,109
Reference: FPA/2012/082
Title: Ayudas para grupos de investigación de calidad
contrastada. Programa Gerónimo Forteza. Ayudas
para la contratación de personal de soporte en organismos de investigación de la Comunidad Valenciana.
Principal Investigator: Miguel Ángel García Pérez
Funding Body: Conselleria d’ Educació, Generalitat
Valenciana
Duration: 2012
4Fernandez-Murga L, Hermenegildo C, Tarin JJ, GarciaPerez MA, Cano. Endometrial response to concurrent
treatment with vaginal progesterone and transdermal
estradiol. Climacteric. 2012; 15(5): 455-9. IF: 1,986
RESEARCH
Title: Identificación de genes del sistema inmune implicados en la osteoporosis posmenopáusica.
Duration: 2010-2012
Title: Ayudas para grupos de investigación de calidad
contrastada. Ayudas complementarias para proyectos
I+D.
4
121
Scientific activity
Translational Research Group on Nutrition and Metabolism
PI: Antonio Hernández Mijares (Department of Medicine University of Valencia).
Collaborating Researchers: Milagros Rocha Barajas (University), Víctor Manuel Víctor González (University), Juan
Vicente Esplugues Monta (University), Ana Jover Fernández (University), Marcelino Gómez Balguer (University), Carlos Morillas Ariño (University), Celia Bañuls Morant (University), Lorena Bellod Lázaro (University), Nadezda Apostolova Atanasovska (CIBERehd).
122
4
Strategic aims
• It has been found out that simvastatin has a beneficial effect to reduce the most atherogenic lipoprotein subfractions of
LDL and HDL, as well as an anti-inflammatory effect mediated by significant reduction of TNF-alpha levels.
• Patients with subclinical hypothyroidism and TSH>10mUI/L show a lipid profile characteristic of atherogenic dyslipidemia.
• In a model of tolerance, nitroglycerin induces mitochondrial dysfunction at complex I level. Mitochondrial antioxidants
would prevent these effects.
• A VLCD administered to morbidly obese patients for 6 weeks is associated with a reduction in levels of C3-fraction of the
complement, reducing the CVR linked to this biomarker.
• Insulin resistance and associated pathologies (diabetes mellitus, obesity, metabolic syndrome, polycystic ovary, familial
combined hyperlipidemia).
• Diabetes mellitus and cardiovascular risk.
• Obesity, inflammation and endothelial dysfunction.
• Dyslipidemias and residual cardiovascular risk.
• Functional foods and their influence on cardiovascular risk factors.
• Mitochondrial dysfunction and oxidative stress.
• Characterization of new cellular mechanisms of antiretroviral-related hepatotoxicity.
Scientific activity
PUBLICATIONS
Original articles
1Millán J, Pedro-Botet J, Muñoz A, Corbella E, Mangas
A, Zúñiga M, Hernández-Mijares A, Pintó X. Residual
lipid profile in recurrent ischemic cardiopathy. Medicina Clinica. 2012 Mar 17; 138(6): 238-41. IF: 1,385
2Bañuls C, Bellod L, Jover A, Martínez-Triguero ML,
Víctor VM, Rocha M, Hernández-Mijares A. Comparability of two different polyacrylamide gel electrophoresis methods for the classification of LDL pattern type.
Clinica Chimica Acta. 2012 Jan 18; 413(1-2): 251-7. IF:
2,535
3Martínez-Martín N, Blas-García A, Morales JM, MartiCabrera M, Monleón D, Apostolova N. Metabolomics
of the effect of AMPK activation by AICAR on human
umbilical vein endothelial cells. International Journal of
Molecular Medicine. 2012 Jan; 29(1): 88-94. IF: 1,573
4De la Sierra A, Alegría E, Martínez-Castelao A, Morillas C, González-Segura D. Characteristics of patients
with hypertension and metabolic syndrome attended
by different specialists. Medicina Clinica. 2012 Feb 25;
138(4): 145-50. IF: 1,385
5Rocha M, Herance R, Rovira S, Hernández-Mijares
A, Victor VM. Mitochondrial dysfunction and antioxidant therapy in sepsis. Infectious Disorderds Drug Targets. 2012 Apr; 12(2): 161-78.
6Garcia-Bou R, Rocha M, Apostolova N, Herance R,
Hernandez-Mijares A, Victor VM. Evidence for a relationship between mitochondrial Complex I activity
and mitochondrial aldehyde dehydrogenase during
nitroglycerin tolerance: Effects of mitochondrial antioxidants. Biochimica et Biophysica Acta. 2012 May;
1817(5): 828-37.
7Llambés F, Silvestre FJ, Hernández-Mijares A, Guiha
R, Bautista D, Caffesse R. Efect of periodontal disease
and non surgical periodontal treatment on C-reactive
protein. Evaluation of type 1 diabetic patients. Medicina oral, patología oral y cirugía bucal. 2012 Jul 1;
17(4): e562-8. IF: 1,13
8Menchón C, Martín R, Apostolova N, Victor VM, Alvaro M, Herance JR, García H. Gold nanoparticles supported on nanoparticulate ceria as a powerful agent
against intracellular oxidative stress. Small. 2012 Jun
25; 8(12): 1895-903. IF: 8,349
9Gómez-Sucerquia LJ, Blas-Garcia A, Marti-Cabrera M,
Esplugues JV, Apostolova N. Profile of stress and
toxicity gene expression in human hepatic cells treated
with Efavirenz. Antiviral Research. 2012 Jun; 94(3):
232-41. IF: 4,301
10Martínez-Castelao A,
Górriz JL, Sola E, Morillas C,
Jover A, Coronel F, Navarro-González J, De Álvaro
F. About the discrepancies between consensus documents, clinical practice guidelines, and legal regulations in the treatment of type 2 diabetes. Nefrologia.
2012 Jul 17; 32(4): 419-426. IF: 1,00
11Hoekzema E, Rojas S, Herance R, Pareto D, Abad S,
Jiménez X, Figueiras FP, Popota F, Ruiz A, Flotats N,
Fernández FJ, Rocha M, Rovira M, Víctor VM, Gispert JD. In vivo molecular imaging of the GABA/benzodiazepine receptor complex in the aged rat brain.
Neurobiology of Aging. 2012 Jul; 33(7): 1457-65. IF:
6,189
12Hernández-Mijares
A, Bañuls C, Bellod L, Jover
A, Solá E, Morillas C, Víctor VM, Rocha M. Effect of
weight loss on C3 and C4 components of complement
in obese patients. European Journal of Clinical Investigation. 2012 May; 42(5): 503-9. IF: 3,018
13Vayá A, Rivera L, Hernández-Mijares A, de la Fuente
M, Solá E, Romagnoli M, Alis R, Laiz B. Homocysteine
levels in morbidly obese patients: its association with
waist circumference and insulin resistance. Clinical
Hemorheology and Microcirculation. 2012; 52(1): 4956. IF: 3,398
14Hernández-Mijares
A, Jover A, Bellod L, Bañuls
C, Solá E, Veses S, Víctor VM, Rocha M. Relation
between lipoprotein subfractions and TSH levels in the
cardiovascular risk among women with subclinical hypothyroidism. Clinical Endocrinology. 2012 Oct 8. IF:
3,168
15Bergoglio
MT, Gómez-Balaguer M, Almonacid Folch
E, Hurtado Murillo F, Hernández-Mijares A. Symptomatic meningioma induced by cross-sex hormone
treatment in a male-to-female transsexual. Endocrinología y Nutrición. 2012 Sep 26.
16Rojas
S, Gispert JD, Abad S, Buaki-Sogo M, Victor
VM, Garcia H, Herance JR. In Vivo Biodistribution of
4
123
Scientific activity
Amino-Functionalized Ceria Nanoparticles in Rats
Using Positron Emission Tomography. Molecular Pharmaceutics. 2012 Nov 20. IF: 4,782
17Ortiz-Masià D, Díez I, Calatayud S, Hernández C, CosínRoger J, Hinojosa J, Esplugues JV, Barrachina MD. Induction of CD36 and Thrombospondin-1 in Macrophages
by Hypoxia-Inducible Factor 1 and Its Relevance in the
Inflammatory Process. PLoS One. 2012; 7(10): e48535.
IF: 4,092
18Górriz JL, Martínez-Castelao A, Sola E, Morillas C,
Jover A, Coronel F, Navarro-González J, De Álvaro
F. Author Reply: Discrepancies between the summary of characteristics and the recommended use of
metformin in the treatment of type 2 diabetes mellitus
patients. Nefrologia. 2012 Nov 21; 32(6):8 387-838.
IF: 1,00
19Martínez-Castelao A,
Górriz JL, Sola E, Morillas C,
Jover A, Coronel F, Navarro-González J, de Álvaro F.
Author Reply: About the discrepancies between consensus documents, clinical practice guidelines, and
legal regulations in the treatment of type 2 diabetes.
Nefrologia. 2012 Nov 21; 32(6): 835-837. IF: 1,00
20Moreno-Pérez
124
4
O, Esteva De Antonio I, Grupo de
Identidad y Diferenciación Sexual de la SEEN (GIDSEEN). Clinical practice guidelines for assessment
and treatment of transsexualism. SEEN Identity and
Sexual Differentiation Groupd (GIDSEEN). Endocrinología y Nutrición. 2012 Jun-Jul; 59(6): 367-82.
Letters
1Vayá A, Suescun M, Solá E, Romagnoli M, Hernández-Mijares A. Rheological blood behaviour is not
related to gender in morbidly obese subjects. Clinical
Hemorheology and Microcirculation. 2012; 50(3): 2279. IF: 3,398
2Bergoglio MT, Solá Izquierdo E, Veses Martin S, Hernández Mijares A. Acute severe hyponatremia induced by aceclofen in a male patient with central diabetes insipidus. Endocrinología y Nutrición. 2012 Sep 26.
THESIS
1Name
of the thesis: Mecanismos celulares y moleculares implicados en la hepatotoxicidad inducida por
efavirenz.
Doctoral candidate: Ana Blas García
Director(s): Juan Vicente Esplugues Mot and Nadezda Apostolova Atanasovska
2Name of the thesis: Esteroles vegetales en bebidas
lácteas: efecto sobre el perfil lipídico y estimación de
su biodisponibilidad.
Doctoral candidate: Celia Bañuls Morant
Director(s): Antonio Hernández Mijares and Mª Jesús
Lagarda Blanch
21Esteva de Antonio I, Gómez-Gil E, Almaraz MC, Martí-
nez-Tudela J, Bergero T, Olveira G, Soriguer F, Grupo
GIDSEEN. Organization of healthcare for transsexual
persons in the Spanish national health system. Gaceta
Sanitaria. 2012 May-Jun; 26(3): 203-9. IF: 1,326
22De Pablo C, Orden S, Calatayud S, Martí-Cabrera M,
Esplugues JV, Alvarez A. Differential effects of tenofovir/emtricitabine and abacavir/lamivudine on human
leukocyte recruitment. Antiviral Therapy. 2012; 17(8):
1615-9. IF: 3,161
Clinical guidelines
1Klionsky DJ, Abdalla FC, Abeliovich H., Apostolova N
et al. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy. 2012 Apr;
8(4): 445-544. IF: 7,453
RESEARCH
Name: Disfunción mitocondrial y diabetes tipo 2: implicaciones patofisiológicas y clínicas.
Principal Investigator: Víctor Manuel Víctor González
Beneficiary institution: Fundación para la Investigación Hospital Universitario Dr. Peset
Duration: 2011-2013
Scientific activity
Reference: CP10/00360
Title: Papel de la disfunción mitocondrial en las complicaciones macrovasculares de los diabéticos tipo 2:
efecto de la mitoquinona - un antioxidante mitocondrial-.
peso y moderadamente hipercolesterolémicos sobre
parámetros de riesgo cardiovascular.
Principal Investigator: Antonio Hernández Mijares
Funding body: AINIA
Principal Investigator: Milagros Rocha Barajas
Duration: 2010-2012
Benefitiary institution: Fundación para la Investigación Hospital Universitario Dr. Peset
Duration: 2011-2013
Title: Evaluación de la glucosa postpandrial, parámetros de estrés oxidativo y función endotelial en pacientes con síndrome metabólico y diabetes tipo 2 tras el
consumo de un producto edulcorante.
Title: Farmacología experimental del tracto digestivo.
Funding body: WILD Valencia S.A.
Principal Investigator: Juan Vicente Esplugues Mota
Funding body: Conselleria d’Educació, Generalitat
Valenciana
Beneficiary institution: Universitat de València
Duration: 2010-2014
Reference: Beca Invest Cli-Epid (3)
Duration: 2011-2013
Title: Estudio aleatorizado, doble ciego y controlado
con placebo, sobre la influencia de FRUIT UP® en los
parámetros del metabolismo hidrocarbonato y lipídico,
así como sobre los marcadores de inflamación, función endotelial y estrés oxidativo, en un grupo de sujetos con diabetes mellitus, intolerantes a la glucosa y
en controles sanos (FRUIT UP/01).
Title: Estudio de la función endotelial en pacientes
hiperlipémicos antes y después del tratamiento con
simvastatina más Ezetimiba.
Funding body: WILD Valencia S.A.
Funding body: SEA - Sociedad Española de Arteriosclerosis
Duration: 2010-2012
Title: Síndrome de ovario poliquístico, resistencia a la
insulina y disfunción mitocondrial: implicaciones fisiopatológicas y terapéuticas.
Duration: 2011-2013
Reference: AP-192/11
Title: Factores de riesgo cardiovascular en pacientes
con diabetes mellitus tipo 2 y relación con la disfunción
eréctil.
Funding body: Conselleria de Sanitat, Generalitat Valenciana
Duration: 2011-2012
Duration: 2010-2012
Title: Evaluación de un producto de panificación enriquecido en fibra y L-carnitina en pacientes con sobre-
Title: Síndrome de ovario poliquístico, resistencia a la
insulina y disfunción mitocondrial: implicaciones fisiopatológicas y terapéuticas.
4
125
Scientific activity
Valenciana
Duration: 2012
Title: Disfunción mitocondrial y diabetes tipo 2: implicaciones patofisiológicas y clínicas.
Funding body: Conselleria d’ Educació, Generalitat
Valenciana
Duration: 2012
126
4
Scientific activity
Research Group on Hepatology and Hepatic Encephalopathy
PI: Carmina Montoliu Félix (INCLIVA).
Contributor Researchers: Amparo Urios Lluch (INCLIVA), Abdullah Wassel (Hospital), Miguel Ángel Serra Desfilis
(Hospital), Juan Ángel del Olmo Puchalt (Hospital), Amparo Escudero García (Hospital), María Luisa García Torres (Hospital), Paloma Lluch García (Hospital), José Manuel Rodrigo Gómez (University), Mª Jesús Andrés Costa (INCLIVA).
Predoctoral Researchers: Carla Giménez Garzó (INCLIVA).
Strategic aims
• Characterization of the neuropsychological deficit in patients with minimum hepatic encephalopathy (MHE).
• Study of the alterations in the brain mechanisms involved in tasks execution.
• Study of the brain connectivity in the neural network by defect, in patients with minimum hepatic encephalopathy through
the BOLD MR functional study in basal stadium.
• Study of the density patterns of the cerebral cortex and the volume of different cerebral areas in controls and cirrhotic
patients with and without MHE.
• Study of functional MR done while performing attention tests.
• Characterization of sleep disorders in cirrhotic patients. Comparison of sleep disorders in patients with and without MHE.
Link to disorders in the Neural Network by defect and with attention and coordination disorders.
• Evaluation of the swelling and parameters linked to the oxidative and nitrosative stress in blood. Identifying of peripheral
biomarkers in order to diagnose the presence of MHE and specific neuropsychological disorders in cirrhotic patients.
• Correlations among the different analyzed parameters.
• Hepatic encephalopathy. Clinical, diagnostic and biochemical aspects.
• Detection of the presence of Minimum Hepatic Encephalopathy (MHE) in cirrhotic patients. Comparison of biometrical
tests and blinking critical frequency. Study of the peripheral parameters related to the homeostasis of the cyclic GMP and
swelling as possible indicators for the presence of MHE.
• Biomarkers of the Minimum Hepatic Encephalopathy. Recognition of useful metabolites in the diagnosis for Minimum
Hepatic Encephalopathy.
• MR study of brain disorders (including edema, cerebral atrophy, disorders in neural tracts) in patients with hepatic cirrhosis.
• Usefulness in the diagnosis of minimum hepatic encephalopathy.
4
127
Scientific activity
• Study of attention disorders, quality and rhythm of the sleep in patients with hepatic cirrhosis with or without minimum
hepatic encephalopathy.
• Study of the disorders in the ability to drive vehicles in patients with hepatic cirrhosis. Correlation with the presence of
MHE.
• Analysis of the synergic cooperation between hyperammonemia and swelling in the induction of the cognitive decay of
the Minimum Hepatic Encephalopathy.
• Hepatitis virus. Epidemiologic, therapeutic and immune prophylactic aspects.
• Development and characterization of an animal model with alcohol-induced hepatic encephalopathy.
• Molecular and cellular mechanisms in the hepatic injury in obesity: pathogenic, diagnostic and therapeutic implications.
• NGAL value, KIM-1, L-FABP and Interleukin-18 as precocious markers for acute kidney failure in critical patients and
after surgery and cardiac catheterization.
PUBLICATIONS
Original articles
1Felipo
V, Ordoño JF, Urios A, El Mlili N, GiménezGarzó C, Aguado C, González-Lopez O, Giner-Duran
R, Serra MA, Wassel A, Rodrigo JM, Salazar J, Montoliu C. Patients with minimal hepatic encephalopathy
show impaired mismatch negativity correlating with
reduced performance in attention tests. Hepatology.
2012; 55(2): 530-9. IF: 11,665
128
4
2Torregrosa I, Montoliu C, Urios A, Elmlili N, Puchades MJ, Solís MA, Sanjuán R, Blasco ML, Ramos C,
Tomás P, Ribes J, Carratalá A, Juan I, Miguel A. Early
biomarkers of acute kidney failure after heart angiography or heart surgery in patients with acute coronary
syndrome or acute heart failure. Nefrologia. 2012;
32(1): 44-52. IF: 1,00
3Felipo
V, Urios A, Montesinos E, Molina I, GarciaTorres ML, Civera M, Olmo JA, Ortega J, MartinezValls J, Serra MA, Cassinello N, Wassel A, Jordá E,
Montoliu C. Contribution of hyperammonemia and inflammatory factors to cognitive impairment in minimal
hepatic encephalopathy. Metabolonic Brain Disease.
2012; 27(1): 51-8. IF: 2,198
4Montoliu C, Gonzalez-Escamilla G, Atienza M, Urios
A, Gonzalez O, Wassel A, Aliaga R, Giner-Duran R,
Serra MA, Rodrigo JM, Belloch V, Felipo V, Cantero
JL. Focal cortical damage parallels cognitive impairment in minimal hepatic encephalopathy. Neuroimage.
2012; 61(4): 1165-75. IF: 5,895
5Llansola M, Montoliu C, Cauli O, Hernández-Rabaza
V, Agustí A, Cabrera-Pastor A, Giménez-Garzó C,
González-Usano A, Felipo V. Chronic hyperammonemia, glutamatergic neurotransmission and neurological alterations. Metabolic Brain Disease. 2012 Sep 26.
IF: 2,198
6Miro
JM, Montejo M, Castells L, Rafecas A, Moreno
S, Agüero F, Abradelo M, Miralles P, Torre-Cisneros J,
Pedreira JD, Cordero E, de la Rosa G, Moyano B, Moreno A, Perez I, Rimola A, Spanish OLT in HIV-Infected Patients Working Group investigators. Outcome of HCV/HIV-coinfected liver transplant recipients:
a prospective and multicenter cohort study. American
Journal of Transplantion. 2012 Jul; 12(7): 1866-76. IF:
6,394
7Moreno A, Cervera C, Fortún J, Blanes M, Montejo E,
Abradelo M, Len O, Rafecas A, Martín-Davila P, TorreCisneros J, Salcedo M, Cordero E, Lozano R, Pérez
I, Rimola A, Miró JM, OLT-HIV FIPSE Cohort Investigators. Epidemiology and outcome of infections in
human immunodeficiency virus/hepatitis C virus-coinfected liver transplant recipients: a FIPSE/GESIDA
prospective cohort study. Liver Transplantation. 2012
Jan; 18(1): 70-81. IF: 3,386
8Llansola M, Cantero JL, Hita-Yañez E, Mirones-Maldonado MJ, Piedrafita B, Ahabrach H, Errami M, Agusti
A, Felipo V. Progressive reduction of sleep time and
quality in rats with hepatic encephalopathy caused by
portacaval shunts. Neuroscience. 2012 Jan 10; 201:
199-208. IF: 3,38
9Felipo V, Urios A, García-Torres ML, El Mlili N, del
Olmo JA, Civera M, Ortega J, Ferrandez A, MartínezValls J, Cassinello N, Montoliu C. Alterations in Adipocytokines and cGMP Homeostasis in Morbid Obesity Patients Reverse After Bariatric Surgery. Obesity.
2012 Aug 15. IF: 4,284
Scientific activity
RESEARCH
Title: Estudio mediante resonancia magnética de alteraciones cerebrales en pacientes con cirrosis hepática. Utilidad en el diagnóstico de la encefalopatía hepática mínima. Identificación de marcadores periféricos.
Principal Investigator: Carmina Montoliu Félix
Beneficiary institution: Fundación de Investigación
Duration: 2010-2012
Title: Estudio de la alteración de la capacidad de conducción de vehículos en pacientes con cirrosis hepática. Identificación de posibles indicadores psicométricos y neurofisiológicos.
Principal Investigator: Vicente Felipo Orts (Carmina
Montoliu, Miguel Ángel Serra, Abdallah Wassel, José
Manuel Rodrigo as Collaborating Researchers)
Funding body: Fundación Abertis
Beneficiary institution: Centro de Investigación Príncipe Felipe
Duration: 2010-2012
Reference: Expediente 2010/001
Title: Determinación del flujo sanguíneo en diferentes
áreas cerebrales de pacientes cirróticos. Correlación
con alteraciones neurológicas. Evaluación de su utilidad en el diagnóstico de la encefalopatía hepática
mínima.
Funding body: Grupo ERESA
Beneficiary institution: Fundación Investigación
Duration: 2010-2012
Title: Capacidad de conducción de vehículos durante
el tratamiento antiviral de la infección crónica por virus
C de la Hepatitis. Relación con tests psicológicos y
mecanismos bioquímicos inmunomoduladores.
Principal Investigator: Juan Ángel del Olmo Puchalt
Funding body: Fundación de la Investigación Médica
Duration: 2009-2012
Title: Estudio mediante resonancia magnética de alteraciones cerebrales en pacientes con cirrosis hepática. Utilidad en el diagnóstico de la encefalopatía hepática mínima. Identificación de marcadores periféricos.
Valenciana
Duration: 2012
Title: Estudio mediante resonancia magnética de alteraciones cerebrales en pacientes con cirrosis hepática. Utilidad en el diagnóstico de la encefalopatía
mínima.
Valenciana
Duration: 2012
Reference: 282957
Title: DENAMIC—Developmental neurotoxicity assessment of mixtures in children Call (part) identifier
FP7-ENV-2011.
Principal Investigator: Vicente Felipo Orts (Carmina
Montoliu as collaborating researcher)
Funding body: European Commission
Beneficiary institution: Centro de Investigación Príncipe Felipe
Duration: 2011-2015
Reference: CSD2008-00005
Title: The Spanish Ion Channel Initiative Proyecto
CONSOLIDER.
4
129
Scientific activity
Principal Investigator: Antonio Ferrer Montiel (Carmina Montoliu as associated researcher)
Funding body: Ministerio de Ciencia e Innovación
Duration: 2009-2013
130
4
Scientific activity
Research Group on Inflammation
PI: Esteban Morcillo Sánchez (Quality Unit Hospital Clínico Universitario of Valencia / Department of Pharmacology
University of Valencia) and María Jesús Sanz Ferrando (Department of Pharmacology University of Valencia).
Collaborating Researchers: Laura Piqueras Ruiz (INCLIVA), Lara Milián Medina (University), Cristina Rius Leiva (University), Herminia González Navarro (INCLIVA), Patricia Almudéver Folch (University).
Predoctoral Researchers: Elena Gabarda Martínez (University).
Technicians: Virginia López García (University), Amelia González Ramón (University), Laura Núñez Arrufat (INCLIVA).
Strategic aims
• Studies on tobacco smoke effect on primary cultures of differential human epithelial cells (ALI) and on its functional activity. This studies have allowed to identify new mollecular mechanisms implied in COPD ethiopathology and have generated
several publications on the subject.
• The effect of the systemic inflammation produced by COPD in territories that are distant from the lung and its link to
cardiovascular diseases. Regarding this, the exposure of human umbilical cord artery endothelial cells to the extract of
tobacco smoke (TS) causes the expression of fractalkine (CX3CL1) and the adhesion of mononuclear monocytes. Monocytes and Limphocytes from patients with COPD showed a bigger expression of this chemokine’s receptor (CX3CR1)
and an increase of the leukocyte adherence to the arterial endothelium stimulated with TS extract.
• Molecular mechanisms that take part in the interaction between mononuclear cells and arterioles and venules inducted
by Angiotensin-II (Ang-II). It has been proven that the blockage of the fractalkine axis (CX (3) CL1)-receptor of Fractalkine
(CX (3) CR1) significantly reduces the “in vivo” and “ex vivo” leukocyte adhesion through Ang-II. Furthermore, it has been
possible to identify Nox5, the kinases ERK 1/2 and p38 and the transcription factor NF-kB as mediators in this response.
• Studies on nuclear receptors of the X (RXR) retinoid and its role in vascular inflammation and angiogenesis in the human
endothelium.
• Role of locus Ink4/Arf in age-related glucose intolerance and insulin resistance. A moderate increase in the expression of
locus improves the age-related loss of insulin sensitivity through an improvement of the signaling mediated by IRS2 and
IRS1 in liver, and the increase of glucose in peripheral tissues.
• Study on the new molecular, biochemical, cellular and genetic mechanisms implied in COPD’s etiopathology, in both
pulmonary and systemic levels.
• Study and characterization of vascular inflammation inducted by some risk factors for atherosclerosis: angiotensin-II,
menopause, tobacco smoke, in the vulnerability of the atheroma plaque in metabolic syndrome and insulin resistance.
• Study of the role of retinoid X (RXR) receptors in vascular inflammation and angiogenesis.
• Study of locus SuperInk4/Arf and hepatic lipase’s role in age-related insulin resistance and atherosclerosis.
4
131
Scientific activity
PUBLICATIONS
Original articles
1Milara J, Navarro R, Juan G, Peiró T, Serrano A, Ramón M, Morcillo E, Cortijo J. Sphingosine-1-phosphate is increased in patients with idiopathic pulmonary
fibrosis and mediates epithelial to mesenchymal transition. Thorax. 2012 Feb; 67(2): 147-56. IF: 6,84
2Aparici M, Gómez-Angelats M, Vilella D, Otal R, Carcasona C, Viñals M, Ramos I, Gavaldà A, De Alba J,
Gras J, Cortijo J, Morcillo E, Puig C, Ryder H, Beleta J, Miralpeix M. Pharmacological characterization of
abediterol, a novel inhaled beta(2)-adrenoceptor agonist with long duration of action and a favorable safety
profile in preclinical models. The Journal of pharmacology and experimental therapeutics. 2012 Aug; 342(2):
497-509. IF: 3,828
cigarette smoke-induced endothelin receptor expression in pulmonary arteries. European Respiratory
Journal. 2012 Apr; 39(4): 927-38. IF: 5,895
9Dasí F, Navarro-García MM, Jiménez-Heredia M, Magraner J, Viña JR, Pallardó FV, Cervantes A, Morcillo
10Milara
J, Serrano A, Peiró T, Artigues E, Gavaldà A,
Miralpeix M, Morcillo EJ, Cortijo J. Aclidinium inhibits
cigarette smoke-induced lung fibroblast to myofibroblast transition. European Respiratory Journal. 2012
Sep 27. IF: 5,895
RESEARCH
3Milara J, Serrano A, Peiró T, Gavaldà A, Miralpeix M,
Morcillo EJ, Cortijo J. Aclidinium inhibits human lung
fibroblast to myofibroblast transition. Thorax. 2012
Mar; 67(3): 229-37. IF: 6,84
132
4
4Mata M, Pallardo F, Morcillo EJ, Cortijo J. Piclamilast
inhibits the pro-apoptotic and anti-proliferative responses of A549 cells exposed to H(2)O(2) via mechanisms
involving AP-1 activation. Free Radical Research.
2012 May; 46(5): 690-9. IF: 2,878
5Sanz MJ, Albertos F, Otero E, Juez M, Morcillo EJ,
Piqueras L. Retinoid X receptor agonists impair arterial mononuclear cell recruitment through peroxisome
proliferator-activated receptor-Y activation. Journal of
Immunology. 2012 Jul 1; 189(1): 411-24. IF: 5,788
6Sanz MJ, Kubes P. Neutrophil-active chemokines in in
vivo imaging of neutrophil trafficking. European Journal of Immunology. 2012 Feb; 42(2): 278-83. IF: 5,103
7Sorianello E, Soriano FX, Fernández-Pascual S, Sancho A, Naon D, Vila-Caballer M, González-Navarro H,
Portugal J, Andrés V, Palacín M, Zorzano A. The promoter activity of human Mfn2 depends on Sp1 in vascular smooth muscle cells. Cardiovascular Research.
2012 Apr 1; 94(1): 38-47. IF: 6,064
8Milara
J, Gabarda E, Juan G, Ortiz JL, Guijarro R,
Martorell M, Morcillo EJ, Cortijo J. Bosentan inhibits
Title: Red de Inflamación y enfermedades reumáticas
RIER.
Principal Investigator: María Jesús Sanz Ferrando
Duration: 2009-2012
Title: Estudio de los mecanismos moleculares y celulares en la disfunción endotelial asociada a enfermedades con inflamación sistémica que podrían inducir
desórdenes cardiovasculares.
Duration: 2012-2014
Title: Pharmacological modulation of airway and pulmonary vascular remodeling: new drug targets in human and animal models.
Scientific activity
Principal Investigator: Esteban Morcillo Sánchez
Duration: 2010-2012
Title: CIBER Enfermedades Respiratorias.
Principal Investigator: Esteban Morcillo Sánchez
Duration: 2007-2013
Reference: CP10/00555
Title: Papel de la Lipasa Hepática en el desarrollo de
la aterosclerosis inducida por diabetes mellitus tipo 2 y
síndrome metabólico.
Principal Investigator: Herminia González Navarro
Duration: 2011-2013
Title:InstitutoSuperiordeInvestigacionesCientíficas
INCLIVA
(Esteban Morcillo as collaborating researcher)
Valenciana
Duration: 2011-2012
4
133
Scientific activity
Research Group on Cellular and Organic Physiopathology of Oxidative Stress
PI: Federico Vicente Pallardó Calatayud (Department of Physiology University of Valencia).
Collaborating Researchers: Francisco Dasí Fernández (INCLIVA), José Luis García Giménez (University / CIBERer), Jelena Markovic (INCLIVA), Amparo Gimeno Monrós (University).
Predoctoral Researchers: Carme Pérez Quilis (University), Marta Seco Cervera (University / CIBERer).
Technicians: Isabel Esmoris Méndez (University / CIBERer), Ana María Velázquez Ledesma (University).
Strategic aims
134
4
• Publishing on new post-translational modifications in histones (carboxylation and poly-(ADP)-ribosylation), during cell
proliferation.
• Publishing of epigenetic clinical applications.
• The PCT for the 2D-TAU OxyWestern blot technique for the determination of carboxylated histones (PCT/ES2012/070406)
has been obtained.
• Epigenetic regulation of cell proliferation by nuclear glutathione.
• Identifying of new post-translational modifications in histones related to cell redox environment.
• Physiopathology of oxidative stress in the Lafora disease.
• Characterization of thioredoxin and glutaredoxin role in Friedreich ataxia.
• Search for miRNAs as diagnosis and prognosis of Friedreich ataxia evolution markers.
• Oxidative profile in Kindler Syndrome fibroblasts.
• Regulation of the cell cycle by GSH in Down syndrome.
Emerging Researcher
José Luis García Giménez (Department of Physiology University of Valencia / CIBERer)
My research interest is focused on the study of the epigenetic deregulation and its implication in
the physiopathology of several rare diseases (e.g. Friedreich ataxia and dyskeratosis congenita).
Furthermore, I am interested in the identification of the redox-related events that control the
chromatin compaction and the epigenetic machinery. Currently, I am investigating the impact of
several novel histone redox-related PTMs on cell physiology and gene regulation.
Finally, our group try to identify epigenetic biomarkers for diagnosis and prognosis of sepsis
gravis and septic shock.
Scientific activity
PUBLICATIONS
Original articles
1Sanchis-Gomar F, Lippi G, Mayero S, Perez-Quilis C,
García-Giménez JL. Irisin: a new potential hormonal
target for treatment of obesity and type II diabetes.
Journal of Diabetes. 2012 Sep; 4(3): 196.
2García-Giménez
JL, Ledesma AM, Esmoris I, Romá-Mateo C, Sanz P, Viña J, Pallardó FV. Histone
carbonylation occurs in proliferating cells. Free Radical Biology & Medicine. 2012 Apr 15; 52(8): 1453-64.
IF: 5,423
3García-Giménez JL, Sanchis-Gomar F, Lippi G, Mena
S, Ivars D, Gómez-Cabrera MC, Viña J, Pallardó FV.
Epigenetic biomarkers: A new perspective in laboratory
diagnostics. Clinical Chimica Acta. 2012 Oct 9; 413(1920): 1576-82. IF: 2,535
4Sanchis-Gomar F, Garcia-Gimenez JL, Perez-Quilis
C, Gómez-Cabrera MC, Pallardo FV, Lippi G. Physical exercise as an epigenetic modulator. Eustress,
the “positive stress” as an effector of gene expression.
Journal of Strength and Conditioning Research. 2012
May 3. IF: 1,831
5Pagano
G, Talamanca AA, Castello G, Pallardó FV,
Zatterale A, Degan P. Oxidative stress in Fanconi
anaemia: from cells and molecules towards prospects
in clinical management. Biological Chemistry. 2012
Jan 1; 393(1-2): 11-21. IF: 2,965
graner J, Viña JR, Pallardó FV, Cervantes A, Morcillo
9García-Giménez JL, Markovic J, Dasí F, Queval G,
Foyer CH, Pallardó FV. Nuclear glutathione. Biochimica Biophysica Acta. 2012 Oct 13.
10March-Villalba
JA, Martínez-Jabaloyas JM, Herrero MJ, Santamaria J, Aliño SF, Dasí F. Cell-free circulating plasma hTERT mRNA is a useful marker for
prostate cancer diagnosis and is associated with poor
prognosis tumor characteristics. PLoS One. 2012;
7(8): e43470. IF: 4,092
11Puig-Silla
M, Dasí-Fernández F, Montiel-Company
JM, Almerich-Silla JM. Prevalence of fimA genotypes
of Porphyromonas gingivalis and other periodontal
bacteria in a Spanish population with chronic periodontitis. Medicina Oral, Patología Oral and Cirugía Bucal.
2012 Nov 1; 17(6): e1047-53. IF: 1,13
Patents
Inventors: José Luis García-Giménez and Federico
Vicente Pallardó.
Title: Method for identifying carbonylated histones
Application number: PCT/ES2012/070406
Priority country: Spain
6March-Villalba
JA, Martínez-Jabaloyas JM, Herrero
MJ, Santamaría J, Aliño SF, Dasí F. Plasma hTERT
mRNA discriminates between clinically localized and
locally advanced disease and is a predictor of recurrence in prostate cancer patients. Expert Opinion on
Biological Therapy. 2012 Jun; 12 Suppl 1: S69-77. IF:
3,505
7Badia MC, Lloret A, Giraldo E, Dasí F, Olaso G, Alonso
MD, Viña J. Lymphocytes from Young Healthy Persons
Carrying the ApoE4 Allele Overexpress Stress-Related
Proteins Involved in the Pathophysiology of Alzheimer’s
Disease. Journal of Alzheimer’s Disease. 2012 Aug 22.
IF: 3,745
8Dasí F, Navarro-García MM, Jiménez-Heredia M, Ma-
RESEARCH
Title: CIBER de Enfermedades Raras (CIBERer).
Principal Investigator: Federico Vicente Pallardó Calatayud
Duration: 2007-2013
4
135
Scientific activity
Reference: AIB2010-SE-00333
Title: Citometría de imagen en la evaluación de la homeostasis redox en patologías humanas.
Duration: 2011-2012
Principal Investigator: Federico Vicente Pallardó Calatayud
Funding body: Plan Nacional de Investigación Científica, Desarrollo e Innovación Tecnológica
Duration: 2011-2012
Total budget: €3.065.198
Reference: TREAT-CMT
Title: Translational Research, Experimental Medicine
and Therapeutics on Charcot-Marie-Tooth Disease
(TREAT-CMT).
Principal Investigator: Francesc Palau (Federico Vicente Pallardó, José Luis García and Jelena Markovic
as collaborating researchers)
Beneficiary institution: CIBERER
Duration: 2011-2015
136
4
Title: Estudio de la utilidad clínica de la determinación
del perfil de estrés oxidativo, en sangre y en condensado de aire exhalado, en pacientes con déficit de alfa
1 antitripsina.
Principal Investigator: Amparo Escribano Montaner
(Francisco Dasí as collaborating researcher)
Funding body: Sociedad Valenciana de Neumología
SVN/FNCV
Duration: 2011-2013
INCLIVA
(Federico Pallardó as collaborating researcher)
Valenciana
Confocal microscopy image. Location of thioredoxin 1 (red), of 19S proteasome
subunit (green) and of the core (blue).
Scientific activity
Research Group on Oxidative Pathology
PI: Guillermo Sáez Tormo (Department of Biochemistry and Molecular Biology University of Valencia).
Collaborating Researchers: Antonio Iradi Casal (University), Concha Cerdá Micó (University), Silvia Victoria Borrego
Oliva (University), Benjamin Climent Díaz (University).
Predoctoral Researchers: Julia Sánchez Tormo (University), Marta Fandos Sánchez (University), Leticia Bagán Debón (University).
Technicians: Carmen Tormos Muñoz (University).
4
Strategic aims
• To value the effect of Mediterranean diet supplemented with olive oil or dried fruits over the Oxidative Stress (OS) and
cardiovascular risk indicators.
• To identify the polymorphisms in the DNA reparing enzymes that predict the individual susceptibility to genetic unstableness and its relation with the pathogeny of metabolic, cardiovascular and neoplasic diseases.
• To identify the molecules and signalling routes induced by Oxidative Stress (OS) as a pathogenic mechanism of metabolic and degenerative diseases.
• Study of the role of OS as a physiopathological mechanism of cardiovascular diseases.
• Study of the signaling routes dependent on p53 in patients with cardiovascular evolution pathologies, in order to identify
the differences between the grades of expression in different genes, especially those in control of repairing the genetic
material.
• Study of OS role in the pathology of neoplastic diseases, as well as the possible validation of its molecular oxidative
products as clinical markers.
137
Scientific activity
PUBLICATIONS
RESEARCH
Original articles
1Collado R, Oliver I, Tormos C, Egea M, Miguel A, Cerdá C, Ivars D, Borrego S, Carbonell F, Sáez GT. Early
ROS-mediated DNA damage and oxidative stress biomarkers in Monoclonal B Lymphocytosis. Cancer Letters. 2012 Apr 28; 317(2): 144-9. IF: 4,238
2Martínez-González
MÁ, Corella D, Salas-Salvadó J,
Ros E, Covas MI, Fiol M, Wärnberg J, Arós F, RuízGutiérrez V, Lamuela-Raventós RM, Lapetra J, Muñoz
MÁ, Martínez JA, Sáez G, Serra-Majem L, Pintó X,
Mitjavila MT, Tur JA, Portillo Mdel P, Estruch R, PREDIMED Study Investigators. Cohort profile: design and
methods of the PREDIMED study. International Journal of Epidemiology. 2012 Apr; 41(2): 377-85. IF: 6,414
3Medina-Remón A, Vallverdú-Queralt A, Arranz S, Ros
138
4
E, Martínez-González MA, Sacanella E, Covas MI,
Corella D, Salas-Salvadó J, Gómez-Gracia E, RuizGutiérrez V, Lapetra J, García-Valdueza M, Arós F,
Saez GT, Serra-Majem L, Pinto X, Vinyoles E, Estruch
R, Lamuela-Raventos RM. Gazpacho consumption is
associated with lower blood pressure and reduced hypertension in a high cardiovascular risk cohort. Crosssectional study of the PREDIMED trial. Nutrition, Metabolism and Cardiovascular Diseases. 2012 Nov 10.
4Mitjavila
MT, Fandos M, Salas-Salvadó J, Covas MI,
Borrego S, Estruch R, Lamuela-Raventós R, Corella
D, Martínez-Gonzalez MA, Sánchez JM, Bulló M, Fitó
M, Tormos C, Cerdá C, Casillas R, Moreno JJ, Iradi A,
Zaragoza C, Chaves J, Sáez GT. The Mediterranean
diet improves the systemic lipid and DNA oxidative damage in metabolic syndrome individuals. A randomized, controlled, trial. Clinical Nutrition. 2012 Aug 31. IF:
3,731
5Ortega-Azorín C, Sorlí JV, Asensio EM, Coltell O, Martínez-González MÁ, Salas-Salvadó J, Covas MI, Arós
F, Lapetra J, Serra-Majem L, Gómez-Gracia E, Fiol M,
Sáez-Tormo G, Pintó X, Muñoz MA, Ros E, Ordovás
JM, Estruch R, Corella D. Associations of the FTO
rs9939609 and the MC4R rs17782313 polymorphisms
with type 2 diabetes are modulated by diet, being higher when adherence to the Mediterranean diet pattern
is low. Cardiovascular Diabetology. 2012 Nov 6; 11:
137. IF: 3,346
Title: Mecanismos de señalización molecular dependientes de p53 y su modulación por estrés oxidativo en
la etopatogenia de enfermedades cardiovasculares.
Principal Investigator: Guillermo Sáez Tormo
Duration: 2011-2013
Title: Valoración de estrés oxidativo en la población
de alto riesgo cardiovascular. Efecto de la intervención
con dieta mediterránea. Red Temática de Investigación Cooperativa: PREDIMED. Alimentación Saludable en la Prevención Primaria de Enfermedades Crónicas.
Duration: 2007-2012
Title: Mecanismos de señalización molecular dependientes de p53 y su modulación por estrés oxidativo en
la etiopatogenia de enfermedades cardiovasculares.
Valenciana
Duration: 2012
Scientific activity
Research Group on Psychiatry and Neurodegenerative Diseases
PI: Julio Sanjuán Arias (Department of Psychiatry Hospital Clínico Universitario of Valencia / Department of Medicine
Collaborating Researchers: Carmen Leal Cercos (Hospital / CIBERSAM), Mercedes Renovell Farré (Hospital), José
Carlos González Piqueras (Hospital / CIBERSAM), Eduardo Jesús Aguilar García-Iturrospe (Hospital / CIBERSAM),
Esther Lorente Rovira (Hospital / CIBERSAM), Ana Luengo Martín (Hospital / CIBERSAM), Rafael Sales Orts (Hospital), María Isabel Leal (Hospital), María José Escartí Fabra (Hospital / CIBERSAM), María Dolores Moltó Ruiz (University / CIBERSAM), Marien Gadea Domenech (University / CIBERSAM), Gracián García Martí (CIBERSAM), Juan
Nácher Roselló (University / CIBERSAM), Manuel Jover Martínez (Hospital / CIBERSAM), Francisco Olucha Bordonau
(University / CIBERSAM), Blanca Llácer Iborra (University / CIBERSAM).
Predoctoral Researchers: José Luis Ivorra (University), Javier Gilabert (University / CIBERSAM).
Administratives: Inmaculada Pérez (University / CIBERSAM).
Strategic aims
• Perfection and enlargement of a common data base for multicenter Studies (CIBERSAM).
• Search of Neuroimaging Biomarkers for Psychosis.
• Development of animal models in Serious Mental Illness and neurodegenerative diseases.
• Efficiency of the Cognitive Therapy in Psychosis persistent hallucinations.
• Study of risk Polymorphisms in Serious Mental Illness.
• Models of prediction and treatment of the first psychotic episodes.
• Identifying risk polymorphisms in Psychosis and Affective Disorders.
• Epigenetic Studies (functional expression) of candidate genes in Psychosis and Mental Illness.
• Study on animal models in Serious Mental Illness.
• Generating models of neurodegenerative diseases (Friedreich ataxia) on invertebrate animals (Drosophila).
• Study on mutations in neurodegenerative monogenic diseases.
• Identifying of genetic and environmental risk factors in affective and psichotic disorders.
• Identifying of abnormal patterns in neuroimage (morphometry, functional, spectroscopy) in psychotic patients.
• Design and coordination of clinical, genetic and neuroimage data bases oriented to performing multicenter projects.
• Deepening into Psychosis’ phenomenology.
• Study on the genetic and environmental factors in childhood emotional development.
• Study on the efficiency of psycho-social intervention techniques in Serious Mental Illness.
4
139
Scientific activity
PUBLICATIONS
Original articles
1Sanjúan
J, Haro JM, Mauriño J, Díez T, Ballesteros
J. Validation of the Spanish version of the Subjective
Well-being under Neuroleptic Scale (SWN-K) in patients with schizophrenia. Medicina Clínica. 2012 Feb
25; 138(4): 151-4. IF: 1,385
2Carrera N, Arrojo M, Sanjuán J, Ramos-Ríos R, Paz
E, Suárez-Rama JJ, Páramo M, Agra S, Brenlla J,
Martínez S, Rivero O, Collier DA, Palotie A, Cichon S,
Nöthen MM, Rietschel M, Rujescu D, Stefansson H,
Steinberg S, Sigurdsson E, Clair DS, Tosato S, Werge T, Stefansson K, González JC, Valero J, GutiérrezZotes A, Labad. Association study of nonsynonymous
single nucleotide polymorphisms in schizophrenia.
Biological Psychiatry. 2012 Jan 15; 71(2): 169-77. IF:
8,283
3Guirado R, Sanchez-Matarredona D, Varea E, Crespo
140
4
C, Blasco-Ibanez JM, Nacher J. Chronic fluoxetine
treatment in middle-aged rats induces changes in the
expression of plasticity-related molecules and in neurogenesis. BMC Neuroscience. 2012 Jan 5; 13(1): 5.
IF: 3,042
4Varea E, Guirado R, Gilabert-Juan J, Martí U, CastilloGómez E, Blasco-Ibáñez JM, Crespo C, Nacher J.
Expression of PSA-NCAM and synaptic proteins in
the amygdala of psychiatric disorder patients. Journal
of Psychiatric Research. 2012 Feb; 46(2): 189-97. IF:
4,664
5Hernández
S, Gilabert-Juan J, Blasco-Ibáñez JM,
Crespo C, Nácher J, Varea E. Altered expression of
neuropeptides in the primary somatosensory cortex of
the Down syndrome model Ts65Dn. Neuropeptides.
2012 Feb; 46(1): 29-37. IF: 1,553
6Magraner MJ, Bosca I, Simó-Castelló M, García-Martí
G, Alberich-Bayarri A, Coret F, Alvarez-Cermeño JC,
Martí-Bonmatí L, Villar LM, Casanova B. Brain atrophy and lesion load are related to CSF lipid-specific
IgM oligoclonal bands in clinically isolated syndromes.
Neuroradiology. 2012 Jan; 54(1): 5-12. IF: 2,824
7Cañete-Nicolás
C, Hernández-Viadel M, BellidoRodríguez C, Lera-Calatayud G, Asensio-Pascual P,
Pérez-Prieto JF , Calabuig-Crespo R, Leal-Cercós C.
Involuntary outpatient treatment (iot) for severe mental
patients: current situation in Spain. Actas Españolas
de Psiquiatría. 2012 Jan-Feb; 40(1): 27-33. IF: 0,589
8Brüne M, Belsky J, Fabrega H, Feierman HR, Gilbert
P, Glantz K, Polimeni J, Price JS, Sanjuan J, Sullivan
R, Troisi A, Wilson DR. The crisis of psychiatry - insights and prospects from evolutionary theory. World
Psychiatry. 2012 Feb; 11(1): 55-7. IF: 6,233
9García-Martí G, Aguilar EJ, Martí-Bonmatí L, Escartí
MJ, Sanjuán J. Multimodal morphometry and functional magnetic resonance imaging in schizophrenia and
auditory hallucinations. World Journal of Radiology.
2012 Apr 28; 4(4): 159-66.
10Rubio
JM, Sanjuán J, Flórez-Salamanca L, Cuesta
MJ. Examining the course of hallucinatory experiences in children and adolescents: a systematic review.
Schizophrenia Research. 2012 Jul; 138(2-3): 248-54.
IF: 4,748
11Martínez-Cengotitabengoa
M, Mac-Dowell KS, Leza
JC, Micó JA, Fernandez M, Echevarría E, Sanjuan J,
Elorza J, González-Pinto A. Cognitive impairment is
related to oxidative stress and chemokine levels in first
psychotic episodes. Schizophrenia Research. 2012
May; 137(1-3): 66-72. IF: 4,748
12Corripio I, Ferreira A, Portella MJ, Pérez V, Escartí MJ,
Del Valle Camacho M, Sauras RB, Alonso A, Grasa
EM, Carrió I, Catafau AM, Alvarez E. The role of striatal dopamine D2 receptors in the occurrence of extrapyramidal side effects: iodine-123-iodobenzamide
single photon emission computed tomography study.
Psychiatry Research. 2012 Jan 30; 201(1): 73-7. IF:
2,524
13Gilabert-Juan J, Moltó MD, Nacher J. Post-weaning
social isolation rearing influences the expression of
molecules related to inhibitory neurotransmission and
structural plasticity in the amygdala of adult rats. Brain
Research. 2012 Apr 11; 1448: 129-36. IF: 2,728
14Bonfanti
L, Nacher J. New scenarios for neuronal
structural plasticity in non-neurogenic brain parenchyma: the case of cortical layer II immature neurons. Progress in Neurobiology. 2012 Jul; 98(1): 1-15. IF: 8,874
15Liberia T, Blasco-Ibáñez JM, Nácher J, Varea E, Lanciego JL, Crespo C. Two types of periglomerular cells
Scientific activity
in the olfactory bulb of the macaque monkey (Macaca
fascicularis). Brain Structure and Function. 2012 Jun
12. IF: 5,628
16Liberia T, Blasco-Ibáñez JM, Nácher J, Varea E, Zwafink V, Crespo C. Characterization of a population of
tyrosine hydroxylase-containing interneurons in the
external plexiform layer of the rat olfactory bulb. Neuroscience. 2012 Aug 16; 217: 140-53. IF: 3,38
17Lera Calatayud G, Herrero Sebastián N, Aguilar García-Iturrospe E, González Piqueras JC, Sanjuán
Arias J, Leal Cercós C. Relationship between insight,
violence and diagnoses in psychotic patients. Revista
de Psiquiatría y Salud Mental. 2012 Jan; 5(1): 43-7.
18Olucha-Bordonau FE, Otero-García M, Sánchez-Pérez AM, Núñez A, Ma S, Gundlach AL. Distribution and
targets of the relaxin-3 innervation of the septal area in
the rat. Journal of Comparative Neurology. 2012 Jun
15; 520(9): 1903-39. IF: 3,808
sis. Molecular Psychiatry. 2012 Nov 20. IF: 13,668
24Sanchez-Perez AM, Garcia-Aviles A, Gasco HA, Sanjuan J, Olucha-Bordonau FE. Effects of methylphenidate on anxiety. Revista de Neurología. 2012 Oct 16;
55(8): 499-506. IF: 1,218
25Gilabert-Juan J, Varea E, Guirado R, Blasco-Ibáñez
JM, Crespo C, Nácher J. Alterations in the expression
of PSA-NCAM and synaptic proteins in the dorsolateral prefrontal cortex of psychiatric disorder patients.
Neuroscience Letters. 2012 Nov 14; 530(1): 97-102.
IF: 2,105
26Rojo Moreno L, Plumed Domingo J, Conesa Burguet
L, Vaz Leal F, Diaz Marsá M, Rojo-Bofill L, Livianos Aldana L. Eating disorders: Considerations on nosology,
etiology and treatment in the XXI century. Revista de
Psiquiatría y Salud Mental. 2012 Jul; 5(3): 197-204.
Letter
19Giusti Mde L, Pistorio M, Lozano MJ, Tejerizo GA, Sa-
1Martín-Santos R, Gelabert E, Subirà S, Gutierrez-Zo-
las ME, Martini MC, López JL, Draghi WO, Del Papa
MF, Pérez-Mendoza D, Sanjuán J, Lagares A. Genetic and functional characterization of a yet-unclassified
rhizobial Dtr (DNA-transfer-and-replication) region
from a ubiquitous plasmid conjugal system present in
Sinorhizobium meliloti, in Sinorhizobium medicae, and
in other nonrhizobial Gram-negative bacteria. Plasmid.
2012 May; 67(3): 199-210. IF: 1,516
tes A, Langorh K, Jover M, Torrens M, Guillamat R,
Mayoral F, Canellas F, Iborra JL, Gratacos M, Costas
J, Gornemann I, Navinés R, Guitart M, Roca M, DE
Frutos R, Vilella E, Valdés M, Esteve LG, Sanjuan J.
Research letter: is neuroticism a risk factor for postpartum depression?. Psychological Medicine. 2012 Jul;
42(7): 1559-65. IF: 6,159
20Ayuso-Mateos
JL, Baca-García E, Bobes J, Giner J,
Giner L, Pérez V, Sáiz PA, Saiz Ruiz J, Grupo RECOMS. Recommendations for the prevention and management of suicidal behaviour. Revista de Psiquiatría
y Salud Mental. 2012 Jan-Mar; 5(1): 8-23. 2012 Feb 15.
21Gilabert-Juan J, Castillo-Gómez E, Guirado R, Moltó MD, Nacher J. Chronic stress alters inhibitory networks in the medial prefrontal cortex of adult mice.
Brain Structuctura & Function. 2012 Nov 21. IF: 5,628
22McCall T, Weil ZM, Nacher J, Bloss EB, El Marouf A,
Rutishauser U, McEwen BS. Depletion of polysialic
acid from neural cell adhesion molecule (PSA-NCAM)
increases CA3 dendritic arborization and increases
vulnerability to excitotoxicity. Experimental Neurology.
2012 Dec 7. IF: 4,699
23Steinberg S, de Jong S, Mattheisen M, Sanjuán J, et al.
Common variant at 16p11.2 conferring risk of psycho-
THESIS
1Thesis title: Trastorno de aprendizjaje inespecífico y
su relación con el peso bajo/normal al nacer: una visión neuropsicológica.
Doctoral candidate: María Pilar Lacalle Alba
Director(s): María Engracia Gadea Domenech and
Raúl Espert Tortajada
Thesis defense date: 2012
2Thesis title: Neuronal structural plasticity of the rodent
telencephalon: role of PSA-NCAM and modulation by
the antidepressant fluoxetine.
Doctoral candidate: Ramón Guirado Guillén
Director (s): Juan Salvador Nácher Roselló
4
141
Scientific activity
RESEARCH
Reference: EU-GEI 241909
Title: Gene-Environment Interactions (EU-GEI).
Principal Investigator: Julio Sanjuán Arias
Duration: 2010-2015
Title: Alucinaciones crónicas en la psicosis: expresión
génica y técnica multimodal EEG/fMRI.
Duration: 2011-2013
142
4
Title: e-Enseñanza y desarrollo de un programa psicoeducativo basado en la evidencia en primeros episodios psicóticos.
Principal Investigator: Esther Lorente Rovira
Hospital Clínico Universitario de Valencia, Hospital
Santiago Apóstol de Vitoria, Hospital Universitario de
Bellvitge, Universidad del País Vasco, Hospital Clínic
de Barcelona.
Duration: 2011-2013
Reference: PIM2010ERN-00577/NEUCONNE
Title: Nuevas estrategias para el tratamiento de la esquizofrenia basadas en la variación genética de la molécula neural de adhesión celular NCAM y las enzimas
implicadas en sus modificaciones postraduccionales.
Reference: BFU2009-12284/BFI
Title: Papel de la forma polisializada de la molécula
neural de adhesión celular (PSA-NCAM) en la plasticidad estructural de la corteza cerebral adulta. Regulación por dopamina e implicación en la esquizofrenia.
Principal Investigator: Juan Salvador Nácher Roselló
Duration: 2010-2012
Reference: 520785
Title: Effects of juvenile and chronic stress on the
structure and connectivity of neural circuits.
Funding body: Ècole Polytechnique Fédérale de Lausanne
Duration: 2011-2014
Title: Desarrollo de marcadores biológicos y estrategias terapéuticas en el trastorno mental grave.
Valenciana
Hospital Clínico Valencia
Duration: 2012-2015
Title: Determinantes clínicos y neurobiológicos de segundos episodios de esquizofrenia. Estudio longitudinal de primeros episodios psicóticos.
Principal Investigator:
García-Iturrospe
Eduardo
Jesús
Aguilar
Funding body: Instituto Salud Carlos III
Beneficiary institution: Hospital Clínico Valencia
Funding body: Ministerio Ciencia e Innovación
Duration: 2012-2014
Duration: 2011-2013
Title: CIBER de Enfermedades Mentales (CIBERSAM)
Scientific activity
Duration: 2008-2013
Reference: 510935-TEMPUS-1-2010
Title: Implementing a Scientific International Master
for Biotechnology and Neuroscience i South Mediterranean Area (I.S.I.S)-TEMPUS-IV.
Principal investigator: Marc Landry (Francisco Olucha Bordonau as PI Valencian area, Julio Sanjuán
Arias as collaborating research)
Beneficiary institution: Universitat de Valencia
Duration: 2010-2013
4
143
Scientific activity
Research Group on Respiratory Problems in Neuromuscular Diseases
PI: Emilio Servera Pieras (Department of Pneumology Hospital Clínico Universitario of Valencia / Department of Physiotherapy University of Valencia).
Collaborating Researchers: Jesús Sancho Chinesta (Hospital), María Pilar Barreto Martín (University), José Blanquer
Olivas (Hospital), Julio Marín Pardo (University), Pilar Bañuls Polo (Hospital), Manuela Marín González (Hospital), María
Luisa Briones Urtiega (Hospital), María Jesús Zafra Pirés (Hospital), María Belén Safont Muñoz (INCLIVA), María Cruz
González Villaescusa (Hospital), José Vicente Ferreres Franco (Hospital).
Predoctoral Researchers: José Luis Díaz Cordobés (University).
144
4
Strategic aims
• To demonstrate that, for patients with Amyotrophic Lateral Sclerosis (ALS) when domiciliary treated with Non Invasive
Ventilation (NIV), volumetric Cyclades turns out to be more effective than presometric Cyclades.
• To identify those indicators which allow predicting the incapability to keep spontaneous breathing during acute exacerbations in patients with ALS while in clinical instability.
• To establish the determining role of bulb affection and fan asynchronies in NIV failure during acute exacerbation in patients with ALS.
• To show the usefulness of a psychological intervention program over emotional distress in ALS patients and their carers.
• To contribute to show the relevance of identifying the etiologic agent in epidemiology genetic studies in sepsis.
• To improve knowledge on stadification performed to neuromuscular patients, in order to anticipate shared decisions and
adjust respiratory therapeutic measurements.
• To improve knowledge related to respiratory muscles help and substitution techniques in neuromuscular patients, paying
special attention to the ones that prolong life without suffering.
• To improve knowledge related to the handling of psycho-emotional needs in neuromuscular patients and their carers.
• To improve knowledge related to the role of genetic polymorphisms in susceptibility, severity and predisposition to bacteremia in the community-acquired pneumonia.
• To value the efficiency in dyspnea handling showed in an appointment with the Department of Pneumonology.
Scientific activity
PUBLICATIONS
Original articles
1Martín-Loeches I, Solé-Violán J, Rodríguez de Castro F,
García-Laorden MI, Borderías L, Blanquer J, Rajas O,
Briones ML, Aspa J, Herrera-Ramos E, Marcos-Ramos
JA, Sologuren I, González-Quevedo N, Ferrer-Agüero
JM, Noda J, Rodríguez-Gallego C. Variants at the promoter of the interleukin-6 gene are associated with severity and outcome of pneumococcal community-acquired
pneumonia. Intensive Care Medicine. 2012 Feb; 38(2):
256-62. IF: 5,399
2Gimenez M, Saavedra P, Martin N, Polu JM, López D,
Gómez A, Servera E. Bilevel Exercise Training and
Directed Breathing Relieves Exertional Dyspnea for
Male Smokers. American Journal of Physical Medicine
& Rehabilitation. 2012 Jun 29. IF: 1,581
3Laserna
E, Sibila O, Aguilar PR, Mortensen EM, Anzueto A, Blanquer JM, Sanz F, Rello J, Marcos PJ,
Velez MI, Aziz N, Restrepo MI. Hypocapnia and hypercapnia are predictors for ICU admission and mortality
in hospitalized patients with community-acquired pneumonia. Chest. 2012 Nov; 142(5): 1193-9. IF: 5,25
4Delgado-Rodríguez M, Castilla J, Godoy P, Martín V,
Soldevila N, Alonso J, Astray J, Baricot M, Cantón R,
Castro A, Gónzález-Candelas F, Mayoral JM, Quintana JM, Pumarola T, Tamames S, Sáez M, Domínguez
A, CIBERESP Cases and Controls in Pandemic
Influenza Working Group. Prognosis of hospitalized
patients with 2009 H1N1 influenza in Spain: influence
of neuraminidase inhibitors. Journal of Antimicrobial
Chemotherapy. 2012 Jul; 67(7): 1739-45. IF: 5,068
5Godoy P, Castilla J, Delgado-Rodríguez M, Martín V,
Castro A, González-Candelas F, Mayoral JM, Quintana JM, Pumarola T, Tamames S, Domínguez A, CIBERESP Cases and Controls in Pandemic Influenza
Working Group, Spain. Effectiveness of hand hygiene and provision of information in preventing influenza
cases requiring hospitalization. Preventive Medicine.
2012 Jun; 54(6): 434-9. IF: 3,216
6Launes
C, García-García JJ, Martínez-Planas A, Moraga F, Astigarraga I, Arístegui J, Korta J, Salado C,
Quintana JM, Soldevila N, Domínguez A, CIBERESP
Cases and Controls in Pandemic Influenza Working
Group, Spain. 2009 H1N1: risk factors for hospitalization in a matched case-control study. European Journal
of Pediatrics. 2012 Jul; 171(7): 1127-31. IF: 1,879
7González-Candelas
F, Astray J, Alonso J, Castro A,
Cantón R, Galán JC, Garin O, Sáez M, Soldevila N,
Baricot M, Castilla J, Godoy P, Delgado-Rodríguez M,
Martín V, Mayoral JM, Pumarola T, Quintana JM, Tamames S, Domínguez A, CIBERESP Cases and Controls in Pandemic Influenza Working Group. Sociodemographic factors and clinical conditions associated
to hospitalization in influenza A (H1N1) 2009 virus infected patients in Spain, 2009-2010. PLoS One. 2012;
7(3): e33139. IF: 4,092
8Lorente L, Iceta R, Martín MM, López-Gallardo E, Solé-Violán J, Blanquer J, Labarta L, Díaz C, Jiménez A,
Montoya J, Ruiz-Pesini E. Survival and mitochondrial
function in septic patients according to mitochondrial
DNA haplogroup. Critical Care. 2012 Jan 17; 16(1):
R10. IF: 4,607
9Diaz E, Martin-Loeches I, Canadell L, Vidaur L, Suarez D, Socias L, Estella A, Gil Rueda B, Guerrero
JE, Valverdú-Vidal M, Vergara JC, López-Pueyo MJ,
Magret M, Recio T, López D, Rello J, Rodriguez A,
H1N1 SEMICYUC-CIBERES-REIPI Working Group
(GETGAG). Corticosteroid therapy in patients with primary viral pneumonia due to pandemic (H1N1) 2009
influenza. Journal of Infection. 2012 Mar 64(3): 311-8.
IF: 4,126
10Picazo JJ, Alonso LM, Arístegui J, Bayas JM, Sanz J,
Del Amo P, Cobos JL, Rodríguez-Salazar J, SánchezPastor M, de la Cámara R, Carratalá J, Cañada JL,
González-Del Castillo J, Aldaz P, Pérez-Escanilla F,
Barberán J, Rodríguez A, Vigil-Escribano D, EspinosaArranz J, Blanquer J, González-Romo F. Consensus
document on vaccination against influenza in health
care workers. Revista Española de Quimioterapia.
2012 Sep; 25(3): 226-39. IF: 0,81
11Domínguez A, Castilla J, Godoy P, Delgado-Rodríguez
M, Martín V, Saez M, Soldevila N, Quintana JM, Mayoral JM, Astray J, González-Candelas F, Cantón R,
Tamames S, Castro A, Baricot M, Alonso J, Pumarola
T, CIBERESP Cases and Controls in Pandemic Influenza Working Group Spain. Effectiveness of pandemic and seasonal influenza vaccines in preventing
pandemic influenza-associated hospitalization. Vaccine. 2012 Aug 17; 30(38): 5644-50. IF: 3,766
4
145
Scientific activity
12Capelastegui A, Quintana JM, Bilbao A, España PP, Garin O, Alonso J, Astray J, Cantón R, Castilla J, Castro A,
Delgado-Rodríguez M, Godoy P, Gónzález-Candelas F,
Martín V, Mayoral JM, Pumarola T, Tamames S, Soldevila
N, Baricot M, Domínguez A, CIBERESP Cases and Controls in Pandemic Influenza Working Group, Spain.
Score to identify the severity of adult patients with influenza A (H1N1) 2009 virus infection at hospital admission.
European Journal of Clinical Microbiology & Infectious
Diseases. 2012 Oct; 31(10): 2693-701. IF: 2,859
Reference: PSI2010-19426
Title: Beneficios del programa de soporte para familiares de pacientes al final de la vida. Estudio Multicéntrico.
Principal Investigator: Pilar Barreto Martín
Beneficiary institution: Fundación Hospital Dr. Negría
Duration: 2011-2013
13Pozo-Rodríguez
F, López-Campos JL, Alvarez-Martínez CJ, Castro-Acosta A, Agüero R, Hueto J, Hernández-Hernández J, Barrón M, Abraira V, Forte A, Sanchez Nieto JM, Lopez-Gabaldón E, Cosío BG, Agustí
A, AUDIPOC Study Group. Clinical audit of COPD
patients requiring hospital admissions in Spain: AUDIPOC study. PLoS One. 2012; 7(7): e42156. IF: 4,092
14Milara J, Armengot M, Bañuls P, Tenor H, Beume R,
Artigues E, Cortijo J. Roflumilast. N-oxide, a PDE4 inhibitor, improves cilia motility and ciliated human bronchial epithelial cells compromised by cigarette smoke
in vitro. British Journal of Pharmacology. 2012 Aug;
166(8): 2243-62. IF: 4,409
Title: Estudio de los mecanismos moleculares y celulares en la disfunción endotelial asociada a enfermedades con inflamación sistémica que podrían inducir
desórdenes cardiovasculares.
(Emilio Servera and Mª Cruz González as collaborating researchers)
Duration: 2012-2014
146
4
THESIS
1Thesis title: Violencia en relaciones de pareja jóvenes.
Doctoral candidate: María Jesús Hernández Jiménez
Director(s): María Jesús Barreto Martín
RESEARCH
Reference: AP105592012
Title: Estudio de necesidades susceptibles de intervención psicológica en familiares de pacientes al final
de la vida.
Principal Investigator: Pilar Barreto Martín
Duration: 2011-2013
Title: Variabilidad genética en la señalización medada por los TLRs/IL-1R en enfermedades respiratorias:
neumonía comunitaria y alergia respiratoria.
Principal Investigator: José Carlos Rodríguez Gallego (José Blanquer and Mª Luisa Briones as collaborating researchers)
Beneficiary institution: Fundación Hospital Dr. Negría
Duration: 2010-2013
Title: Pharmacological modulation of airway and pulmonary vascular remodeling: new drug targets in human and animal models.
Principal Investigator: Esteban Morcillo Sánchez (Mª
Cruz González a collaborating researcher)
Duration: 2010-2012
Scientific activity
Research Group on Tissular Biochemistry
PI: Juan R. Viña (Department of Biochemistry and Molecular Biology University of Valencia).
Collaborating Researchers: Luis Torres Asensi (University), Elena Ruiz García-Trevijano (University), Rosa Zaragozá
Colom (INCLIVA), Eva Serna García (University), Desamparados Roda Pérez (INCLIVA), Vicente Miralles Fernández
(University), Ana Bosch Campos (INCLIVA).
Predoctoral Researchers: Teresa Arnandis Chinesta (University), Iván Ferrer Vicens (University).
Technician: Concha García de Mier (University).
Strategic aims
• To confirm that calpaines have a dual role in the tisular restructuring of the mammary gland after the pregnancy/nursing
cycle period. On one hand, these proteases are involved in the acinar epithelial cells’ programmed cell death, which
implies formerly proved changes in the lysosomes and mitochondria. In this exercise, the experiments performed also
involve the nucleus of the epithelial cells as an especifical calpaines’ target during this process. Besides that, it has been
shown that calpain 1 cooperates in the differentiation of adipocytes required for the remodeling of the mammary gland
after pregnancy/lactancy.
• Study of the regulation of multiple signaling vias that converge in the modulation of different biologic processes as for
example cell proliferation, cycle stop, cell differentiation and apoptosis. Especially relevant in this processes modulation
are the epigenetic mechanisms that control the genic expression and partially explain the differential regulation of the
genes expression in response to different stimuli. The group tries to identify the signals that make up the response to a
great variety of stimuli and are involved in the chromatine’s structure regulation and the accessibility of specific transcription factors to different genic promoters.
• The mammary gland as a physiological model for the study of programmed cell death.
• The mammary tissues metabolism and its regulation.
• Studies on epigenomic and proteins acetylation in colon cancer tumoral lines with mutated KRAS.
Emerging Researcher
Rosa Zaragozá Colom (INCLIVA).
The research line focuses on the study of mechanisms that regulate tissue restructuring and programmed cell death in the mammary gland and the neoplastic process and development of the
mammary tissue. It is also studied the role of calpaines in the involution of the mammary gland
and breast cancer tumoral lines, in order to demonstrate its role in cell adhesion and tumoral cells
invasivity.
4
147
Scientific activity
PUBLICATIONS
Original articles
Editorial
1Lluch A,
Bosch A. Evolution of tumour biology upon
progression. Do we know our enemy?. Clinical & Translational Oncology. 2012 Jun; 14(6): 399-400. IF: 1,327
1Caffarel MM, Zaragoza R, Pensa S, Li J, Green AR,
Watson CJ. Constitutive activation of JAK2 in mammary epithelium elevates Stat5 signalling, promotes
alveologenesis and resistance to cell death, and contributes to tumourigenesis. Cell Death and Differentation. 2012 Mar; 19(3): 511-22. IF: 8,849
2Bodi V, Sanchis J, Morales JM, Marrachelli VG, Nunez
J, Forteza MJ, Chaustre F, Gómez C, Mainar L, Minana G, Rumiz E, Husser O, Noguera I, Diaz A, Moratal
D, Carratalá A, Bosch X, Llacer A, Chorro FJ, Viña JR,
ischemia by nuclear magnetic resonance spectroscopy of peripheral blood serum: a translational study based on transient coronary occlusion models. Journal
of the American College of Cardiology. 2012 May 1;
59(18): 1629-41. IF: 14,156
3Radyuk SN, Gambini J, Borras C, Serna E, Klichko VI,
148
4
Viña J, Orr WC. Age-dependent changes in the transcription profile of long-lived Drosophila over-expressing glutamate cysteine ligase. Mechanisms of Ageing
and Development. 2012 Jun; 133(6): 401-13. IF: 3,439
4Arnandis T, Ferrer-Vicens I, García-Trevijano ER, Miralles VJ, García C, Torres L, Viña JR, Zaragozá R.
Calpains mediate epithelial-cell death during mammary
gland involution: mitochondria and lysosomal destabilization. Cell Death and Differerentation. 2012 Sep;
19(9): 1536-48. IF: 8,849
5Eroles P, Bosch A, Pérez-Fidalgo JA, Lluch A. Molecular biology in breast cancer: intrinsic subtypes and signaling pathways. Cancer Treatment Reviews. 2012 Oct;
38(6): 698-707. IF: 6,054
6Dasí F, Navarro-García MM, Jiménez-Heredia M, Magraner J, Viña JR, Pallardó FV et, Cervantes A, Morcillo
RESEARCH
Title: El NF-kappaB como nodo de regulación en la
involución de la glándula mamaria tras la lactancia. Implicaciones biomédicas.
Principal Investigator: Juan R. Viña
Duration: 2011-2013
Title: Papel del NO y del NFkappaB en la remodelación tisular de la glándula mamaria tras la lactancia:
implicaciones biomédicas.
Principal Investigator: Juan R. Viña
Valenciana
Duration: 2010-2012
Title: Papel del óxido nítrico en los mecanismos epigenéticos de control de la respuesta inflamatoria. Estudios experimentales y posibles implicaciones en pacientes con cirrosis alcohólica.
Principal Investigator: Elena Ruiz García-Trevijano
Duration: 2010-2012
EGFR. Estudio epigenómico y de acetilación de proteínas en líneas celulares KRAS mutado y salvaje, y
su evaluación en pacientes con cáncer de colon.
Scientific activity
(Luis Torres and Elena Ruiz as collaborating researches)
Funding body: Fundación Gent per Gent
Duration: 2009-2012
Title: Modulación de los niveles de VEGFR1a/VEGF
en cáncer de mama tratado con doxorubicina.
Principal Investigator: Ana Lluch Hernández (Juan
R. Viña and Rosa Zaragozá as collaborating researches)
Duration: 2009-2012
Cross section from mammary gland at 24 hours after weaning. Antibodies
against Capn1 (green) and Histone H3 (red) were used. Nuclei were stained
with Hoechst (blue). The image show numerous apoptotic cells shed into the
alveolar lumen. Scale bar: 30 µm.
Title: InstitutoSuperiordeInvestigacionesCientíficas
INCLIVA
(Juan R. Viña as collaborating researcher)
Valenciana
Duration: 2011-2012
4
149
Scientific activity
Research Group on Aging and Physical Activity
PI: José Viña Ribes (Department of Physiology University of Valencia).
Collaborating Researchers: Consuelo Borrás Blasco (University), María Carmen Gómez Cabrera (University), Ana
Lloret Alcañiz (University), Juan Gambini Buchón (University), Gloria Olaso González (University), Esther Giraldo Reboloso (University), Consuelo Escrivá López (University).
Predoctoral Researchers: Fabián Sanchís Gomar (University), Rebeca García Vallés (University), Beatriz Ferrando Forés (University), Helios Pareja Galiano (University), Kheira Mohamed (University), José Viña Almunia (University), Helena
Cabo Plaza (University), Cristina Mas Bargues (University), Vicent Bonet Beltrán (University).
150
4
Strategic aims
• Aging line: it has been made a comparison among the expression profiles of micro RNA in 33 centenaries, 80 octogenarians and 80 young individuals through the expression of 15,644 mature micro RNAs, 2,334 snoRNA and scaRNA in
peripheral blood mononuclear cells. It has been observed that centenaries tend to over express small RNAs not codifying
as microRNAs and scaRNAs, which explains their exceptional ability to maintain homeostasis even at extreme ages.
• Physical activity line:
- it has been determined that the voluntary practice of physical activity does not prolong life but does prevent fragility and
Sarcopenia in an animal model.
- an increase on muscular mitochondrial biogenesis has been identified as a key parameter in the prevention of fragility
and Sarcopenia caused by physical activity.
- it has been shown that the induction of neurotrophic factors (BDNF and IGF-1) by physical exercise and its role in the
prevention of fragility and sarcopenia.
- it has been proved the induction of antioxidant enzymes by physical activity and its role in the prevention of fragility and
sarcopenia.
- it has been studied and dismissed the role of pioglitazone as a doping substance in physical activity.
• Alzheimer’s disease physiopathology line: it has been studied the role of ubiquitin ligase APC/cdh1 in the physiopathological mechanism of Alzheimer’s disease. It has been proven that cdh1 diminishes in cells treated with the beta-amyloid
peptide and, therefore, the APC/chd1 complex is not formed. This leads to a non-break down of the cyclin B and proves
that, in effect, its levels go up. This could be the cause for the reentrance in the cell cycle suffered by Alzheimer’s neurons.
• It has been shown that the glutaminase enzyme is neither degraded by APC/cdh1, which leads to an increase in the
levels of glutamate exported by the neurons. Glutamate is exotoxic and, therefore, it could be the cause for the entrance
into apoptosis observed in this neurodegenerative disease.
Scientific activity
• Aging: identification of the genes associated with aging, especially genes that are specific in centenary people. Implication of the estrogens and phytoestrogens in the prevention of age-related damage.
• Physical activity: identification of the mechanisms by which physical activity is good for health. Identification of the mechanisms by which physical activity helps preventing senile sarcopenia. Identification of the possible doping agents in
the professional practice of physical activity.
• Physiopathology of the Alzheimer’s disease: identification of the mechanisms by which free radicals, originators of the
oxidative stress are used to unleash cell signals that lead to cell death in Alzheimer disease.
Emerging Researcher
Consuelo Borrás Blasco (Department of Physiology University of Valencia).
This research line is focused on the study of the possible role of gender oxidative stress differences on the different type II diabetes prevalence between males and females. Moreover, it
is known that the risk of suffering this disease increases in menopausal women. Therefore we
also are studying the role of estrogens in the protection against the disease and the possible
mechanisms underlying this protective effect.
Emerging Researcher
María Carmen Gómez Cabrera (Department of Physiology University of Valencia).
The main aim of this research is to study the beneficial effects of physical activity in the
prevention and treatment of several pathologies and more specifically Alzheimer’s disease,
senile sarcopenia and frailty.
4
PUBLICATIONS
Original articles
1Hinchado MD, Giraldo E, Ortega E. Adrenoreceptors
are involved in the stimulation of neutrophils by exercise-induced circulating concentrations of Hsp72: cAMP
as a potential “intracellular danger signal”. Journal of
Cellular Physiology. 2012 Feb; 227(2): 604-8. IF: 3,874
2Sanchis-Gomar F, Lippi G. Telmisartan as metabolic
modulator: a new perspective in sports doping?. Journal of Strength and Conditioning Research. 2012 Mar;
26(3): 608-10. IF: 1,831
3Gómez-Cabrera
MC, Ristow M, Viña J. Antioxidant
supplements in exercise: worse than useless?. American Journal of Physiology, Endocrinol and Metabolism. 2012 Feb; 302(4): E476-7; author reply E478-9.
IF: 4,746
4Sanchis-Gomar F, Lippi G, Mayero S, Perez-Quilis C,
García-Giménez JL. Irisin: a new potential hormonal
target for treatment of obesity and type II diabetes.
Journal of Diabetes. 2012 Sep; 4(3): 196.
5García-Giménez JL, Ledesma AM, Esmoris I, RomáMateo C, Sanz P, Viña J, Pallardó FV. Histone carbonylation occurs in proliferating cells. Free Radical
Biology and Medicine. 2012 Apr 15; 52(8): 1453-64.
IF: 5,423
6Peñarrocha M, Viña J, Maestre L, Peñarrocha D, Balaguer J. Guided implant surgery with modification of
the technique involving the raising of a semicircular
miniflap: A preliminary study. Medicina Oral, Patología
Oral y Cirugía Bucal. 2012 May 1. IF: 1,13
7Radyuk SN, Gambini J, Borras C, Serna E, Klichko VI,
Viña J, Orr WC. Age-dependent changes in the transcription profile of long-lived Drosophila over-expressing
glutamate cysteine ligase. Mechanisms of Ageing and
Development. 2012 Jun; 133(6): 401-13. IF: 3,439
151
Scientific activity
8Martinez-Bello VE, Sanchis-Gomar F, Romagnoli M,
15Lippi G, Banfi G, Botrè F, de la Torre X, De Vita F, Gó-
Derbre F, Gómez-Cabrera MC, Viña J. Three weeks
of erythropoietin treatment hampers skeletal muscle
mitochondrial biogenesis in rats. Journal of Physiology
and Biochemistry. 2012 May 25. IF: 1,711
mez-Cabrera MC, Maffulli N, Marchioro L, Pacifici R,
Sanchis-Gomar F, Schena F, Plebani M. Laboratory
medicine and sports: between Scylla and Charybdis.
Clinical Chemistry and Laboratory Medicine. 2012 Feb
28; 50(8): 1309-16. IF: 2,15
9García-Giménez
JL, Sanchis-Gomar F, Lippi G,
Mena S, Ivars D, Gómez-Cabrera MC, Viña J, Pallardó
FV. Epigenetic biomarkers: A new perspective in laboratory diagnostics. Clinica Chimica Acta. 2012 Oct 9;
413(19-20): 1576-82. IF: 2,535
10Otalora BB, Popovic N, Gambini J, Popovic M, Viña
J, Bonet-Costa V, Reiter RJ, Camello PJ, Rol MÁ, Madrid JA. Circadian System Functionality, Hippocampal
Oxidative Stress, and Spatial Memory in the APPswe/
PS1dE9 Transgenic Model of Alzheimer Disease:
Effects of Melatonin or Ramelteon. Chronobiology International. 2012 Aug; 29(7): 822-34. IF: 4,028
11
152
4
Gómez-Cabrera MC, Sanchis-Gomar F, Garcia-Valles R, Pareja-Galeano H, Gambini J, Borras C, Viña
J. Mitochondria as sources and targets of damage in
cellular aging. Clinical Chemistry and Laboratory Medicine. 2012 Feb 1; 50(8): 1287-95. IF: 2,15
12Pareja-Galeano H, Brioche T, Sanchís-Gomar F, Escrivá C, Dromant M, Gómez-Cabrera MC, Viña J.
Effects of physical exercise on cognitive alterations
and oxidative stress in an APP/PSN1 transgenic model
of Alzheimer’s disease. Revista Española de Geriatría
y Gerontología. 2012 Aug 9.
13
Rodríguez-Mañas L, Féart C, Mann G, Viña J, Chatterji S, Chodzko-Zajko W, Gonzalez-Colaço Harmand
M, Bergman H, Carcaillon L, Nicholson C, Scuteri A,
Sinclair A, Pelaez M, Van der Cammen T, Beland F,
Bickenbach J, Delamarche P, Ferrucci L, Fried LP,
Gutiérrez-Robledo LM, Rockwood K, Rodríguez Artalejo F, Serviddio G, Vega E, on behalf of the FODCC group (Appendix 1). Searching for an Operational
Definition of Frailty: A Delphi Method Based Consensus Statement. The Frailty Operative Definition-Consensus Conference Project. Journals of Gerontology.
Series A, Biological Sciences and Medical Sciences.
2012 Apr 16. IF: 4,598
14Viña J, Sanchis-Gomar F, Martinez-Bello V, GómezCabrera M. Exercise acts as a drug; the pharmacological benefits of exercise. British Journal of Pharmacology. 2012 Sep; 167(1): 1-12. IF: 4,409
16Sanchis-Gomar F, Garcia-Gimenez
JL, Perez-Quilis
C, Gómez-Cabrera MC, Pallardo FV, Lippi G. Physical exercise as an epigenetic modulator. Eustress,
the “positive stress” as an effector of gene expression.
Journal of Strength and Conditioning Research. 2012
May 3. IF: 1,831
17Lippi G, Plebani M, Sanchis-Gomar F, Banfi G. Current limitations and future perspectives of the Athlete
Blood Passport. European Journal of Applied Physiology. 2012 Mar 23. IF: 2,147
18Viña-Almunia
J, Maestre-Ferrín L, Alegre-Domingo
T, Peñarrocha-Diago MA. Survival of implants placed
with the osteotome technique: An update. Medicina
Oral, Patología Oral y Cirugía Bucal. 2012 May 1. IF:
1,13
19Badia MC, Lloret A, Giraldo E, Dasí F, Olaso G, Alonso MD, Viña J. Lymphocytes from Young Healthy Persons Carrying the ApoE4 Allele Overexpress StressRelated Proteins Involved in the Pathophysiology of
Alzheimer’s Disease. Journal of Alzheimers Disease.
2012 Aug 22. IF: 3,745
20Sanchis-Gomar
F, Viña J, Lippi G. Intermittent hypobaric hypoxia applicability in myocardial infarction
prevention and recovery. Journal of Cellular and Molecular Medicine. 2012 May; 16(5): 1150-4. IF: 4,125
21Derbré F, Gómez-Cabrera MC, Nascimento AL, Sanchis-Gomar F, Martinez-Bello VE, Tresguerres JA,
Fuentes T, Gratas-Delamarche A, Monsalve M, Viña J.
Age associated low mitochondrial biogenesis may be
explained by lack of response of PGC-1? to exercise
training. Age. 2012 Jun; 34(3): 669-79. IF: 3,948
22Lippi
G, Sanchis-Gomar F, Banfi G. Anti-“negativedoping” testing: a new perspective in anti-doping research?. European Journal of Applied Physiology.
2012 Jun; 112(6): 2383-4. IF: 2,147
23Martinez-Bello VE, Sanchis-Gomar F, Martinez-Bello
D, Olaso-Gonzalez G, Gómez-Cabrera MC, Viña
Scientific activity
J. Vitamin C Supplementation Does not Improve Hypoxia-Induced Erythropoiesis. High Altitude Medicine
& Biology. 2012 Dec; 13(4): 269-74. IF: 1,771
24Serna E, Gambini J, Borras C, Mohammed K, Belenguer A, Sanchis P, Avellana JA, Rodriguez-Mañas L,
Viña J. Centenarians, but not octogenarians, up-regulate the expression of microRNAs. Scientific Reports.
2012; 2: 961. Epub 2012 Dec 11.
25Derbre
F, Ferrando B, Gómez-Cabrera MC, Sanchis-Gomar F, Martinez-Bello VE, Olaso-Gonzalez
G, Diaz A, Gratas-Delamarche A, Cerda M, Viña J.
Inhibition of xanthine oxidase by allopurinol prevents
skeletal muscle atrophy: role of p38 MAPKinase and
E3 ubiquitin ligases. PLoS One. 2012; 7(10): e46668.
Epub 2012 Oct 5. IF: 4,092
26Sanchis-Gomar
F, Cortell-Ballester J, Pareja-Galeano H, Banfi G, Lippi G. Hemoglobin Point-of-Care
Testing: The HemoCue System. Journal of Laboratory
Automation. 2012 Sep 6.
27Lippi
G, Sanchis-Gomar F, Salvagno GL, Aloe R,
Schena F, Guidi GC. Variation of serum and urinary
neutrophil gelatinase associated lipocalin (NGAL) after
strenuous physical exercise. Clinical Chemistry and Laboratory Medicine. 2012 Feb 14; 50(9): 1585-9. IF: 2,15
28Lippi
G, Sanchis-Gomar F, Cervellin G. Rest heart
rate and mortality: More physical exercise for the rabbit?. International Journal of Cardiology. 2012 Sep 12.
IF: 7,078
29Sanchis-Gomar F, Banfi G, Pareja-Galeano H, Martinez-Bello V, Lippi G. Anemia, heart failure and exercise training. International Journal of Cardiology. 2012
Sep 29. IF: 7,078
30Lombardi G, Banfi G, Lippi G, Sanchis-Gomar F. Ex
expected 2012 Olympics public health effect. Perspectives in Public Health. 2012 Mar; 132(2): 59.
3Sanchis-Gomar F, Lippi G. Hb(mass) for anti-doping
purposes should be assessed in combination with hemoglobin and blood volume. International Journal of
Sports Medicine. 2012 Jun; 33(6): 502. IF: 2,433
4Sanchis-Gomar F, Banfi G, Lippi G. Plasticizer detection in urine samples after autologous blood transfusion. Transfusion. 2012 Mar; 52(3):680; author reply
680-1. IF: 3,217
5Sanchis-Gomar
F. The skeletal muscle-metabolism
axis in prostate-cancer therapy. New England Journal
of Medicine. 2012 Dec 6; 367(23): 2257-8. IF: 53,298
RESEARCH
Reference: 35 NEURO
Title: Identificación de nuevos biomarcadores periféricos de deterioro cognitivo ligero y de enfermedad de
Alzheimer.
Principal Investigator: José Viña Ribes
Entidad Beneficiary institution: Universitat de València
Duration: 2011-2012
Title: Modulación de los genes de longevidad y su importancia en la prevención de enfermedades asociadas al envejecimiento.
vivo erythrocyte generation and blood doping. Blood
Transfusion. 2012 Oct 10; 1-3. IF: 2,099
Letters
Duration: 2011-2013
1Sanchis-Gomar F, Lippi G. Front-of-Package Nutrition
Labeling and Obesity Implications. American Journal of
Preventive Medicine. 2012 Jan; 42(1): e1. IF: 4,044
2Sanchis-Gomar F, Martinez-Bello VE, Pareja-Galeano H, Lippi G. The financial crisis implications on the
Title: Papel de los radicales libres en la biología de las
células madre. Importancia en el desarrollo del envejecimiento.
4
153
Scientific activity
Valenciana
INCLIVA
(José Viña as collaborating researcher)
Duration: 2010-2012
Reference: HEALTH.2010.2.2.2-5
Title: Frailty operative definition-consensus conference “FOD-CC”.
Duration: 2011-2013
Reference: ISCIII2006-RED13-027
envejecimiento y fragilidad (RETICEF).
Duration: 2007-2012
154
4
Reference: 4/2013
Title: Utility of OMIC-Based biomarkers in characterizing older individuals at risk for frailty, its progression
to disability and general consequences to health and
well-being - THE FRAILOMIC INITIATIVE (FRAILOMIC).
Duration: 2012-2015
Title: CIBERER (CIBER de Enfermedades Raras).
Principal Investigator: Federico Vicente Pallardó Calatayud (Ana Lloret as collaborating researcher)
Duration: 2007-2013
Valenciana
Duration: 2011-2012
Scientific activity
Research Group on Anesthesiology and Reanimation
PI: Francisco Javier Belda Nácher (Department of Anaesthesia Hospital Clínico Universitario of Valencia / Department
of Surgery University of Valencia).
Collaborating Researchers: Marina Soro Domingo (Hospital), Gerardo Aguilar Aguilar (Hospital), Carlos Ferrando
Ortolá (Hospital), José García de la Asunción (Hospital), Francisco Martí Cánoves (Hospital), Miguel García Raimundo (Hospital), Arturo Carratalá Calvo (Hospital), Jaime Pérez-Griera (Hospital), Beatriz Garrigues Olivé (Hospital),
Juan Vicente Llau Pitarch (Hospital), Raquel Ferrandis Comes (Hospital), Rafael Badenes Quiles (Hospital), Armando
Martuenda Paulino (Hospital), María Luis García Pérez (Hospital), Juan Carlos Tornero Tornero (Hospital), Benigno
Escamilla Cañete (Hospital), María Luisa Laredo Alcázar (Hospital).
Strategic aims
• Determining the most physiological anesthetics and an optimum administering way in order to obtain a better protection
for the organs and the fewer secondary post-surgery effects.
• Identification of factors associated with a higher mortality rate in patients submitted to non-cardiac major surgery.
• Identifying the molecular plasmatic factors that act locally and remotely in the pre and Post-remote amendment by
ischemia reperfusion during the surgery.
• Description of the pharmacokinetic properties of diverse antibiotics in critical patients with altered kidney function.
• Consolidation of new hemotherapy strategies in the peri-surgery period.
• In anesthesia: gases used in anesthesia: halogenated agents, xenon and oxygen; anesthetics effects: oxidative stress
and organs protection in surgeries performed with ischemia reperfusion.
• In critical care: the ventilatory handling of patients includes the mechanical ventilation and a coadjuvant treatment (ways
for weaning, drugs with immunomodulator effects, etc.).
• Way of administering the anesthetic agents (for surgery anesthetics and sedation in critical care) where new disposable
devices, alternative to vaporizers, are being looked into.
• Development of the hemodynamic monitoring into a less invasive technique and its employment in the field of patients
intervened with cardiac surgery or admitted into the critical care units.
• Study and development of drugs and instrumental that allow quantifying or intervening in the different hemostatic vias, in
a double aspect: prevention of thrombotic diseases and avoiding hemorrhages in the post-surgery period.
• Study and development of ways to detect an infection, specially fungal and viral infections, as well as the ways to prevent them.
• Development of the neurologic monitoring for its employment in neurocritical patients.
• Development of new strategies and drugs for pain treatment.
• Study of the Aquaporin expression 1 and 5 in an experimental model of acute pulmonary damage by mechanical ventilation in rats.
4
155
Scientific activity
PUBLICATIONS
Original articles
1Ferrandis
R, Belda FJ, Garcia-Raimundo M, Soro
M, Martí F, Montoya FJ, Cortés V, Bahamonde JA.
Airway pressure curve: a good tool to measure neural
inspiratory time?. Minerva anestesiológica. 2012 Jan
Volume: 78 Issue: 1 Pages: 54-62. IF: 2,656
2Sánchez-Miralles A, Castellanos G, Badenes R, Conejero R. Abdominal compartment syndrome and acute intestinal distress syndrome. Medicina intensiva.
2012 Jan 11. IF: 1,072
3Aguilar
G, Carbonell JA, Ferrando C, Badenes R,
Belda FJ. Echinocandins in a critically ill patient during
continuous venovenous renal replacement. Revista
Iberoamericana de Micología. 2012 Apr Volume: 29
Issue: 2 Pages: 85-9. IF: 1,156
4García-de-la-Asunción
156
4
J, Perez-Solaz A, Carrau M,
Belda FJ, Perez-Griera J, Garriges B. Different oxidative stress marker levels in blood from the operated
knee or the antecubital vein in patients undergoing knee
surgery: A tourniquet-induced ischemia-reperfusion
model. Redox Report. 2012; 17(5): 194-9. IF: 1,732
5Brochard L, Martin GS, Blanch L, Pelosi P, Belda FJ,
Jubran A, Gattinoni L, Mancebo J, Ranieri VM, Richard
JC, Gommers D, Vieillard-Baron A, Pesenti A, Jaber
S, Stenqvist O, Vincent JL. Clinical review: Respiratory monitoring in the ICU - a consensus of 16. Critical
Care. 2012 Apr 26; 16(2): 219. IF: 4,607
6Llau JV, Gil-Garay E, Castellet E, en nombre de los
investigadores del estudio ENOXACOR. Thromboprophylaxis with enoxaparin for total knee replacement:
An observational, retrospective and multicentre study
comparing starting the treatment before and after the
operation. Revista Española de Anestesiología y Reanimación. 2012 Jun; 59(6): 306-14.
7Llau JV, Ferrandis R, Castillo J, de Andrés J, Gomar
C, Gómez-Luque A, Hidalgo F, Torres LM, en representación de los participantes en el Foro de Consenso
de la ESRA-España sobre «Fármacos que alteran la
hemostasia». Management of direct action oral anticoagulants in the peri-operative period and invasive
techniques. Revista Española de Anestesiología y Re-
animación. 2012 Jun; 59(6): 321-30.
8Colomina MJ, Díez Lobo A, Garutti I, Gómez-Luque A,
Llau JV, Pita E. Perioperative use of prothrombin complex concentrates. Minerva Anestesiologica. 2012 Mar;
78(3): 358-68. IF: 2,656
9Alvarez-Lerma F, Soriano MC, Rodríguez M, Catalán
M, Llorente AM, Vidart N, Garitacelaya M, Maraví E,
Fernández E, Alvarado F, López M, Alvarez-Sánchez
B, Espinosa J, Quintana E, Study Group of Liposomal Amphotericin B in the ICU. Impact of liposomal
amphotericin B on renal function in critically ill patients
with renal function impairment. Revista Española de
Quimioterapia. 2012 Sep; 25(3): 206-15. IF: 0,81
10Ferrando C, Aguilar G, Belda FJ. Extravascular lung
water does not increase in hypovolemic patients after
a fluid-loading protocol guided by the stroke volume
variation. Critical Care Research and Practice. 2012;
437659.
11Soro M, Gallego L, Silva V, Ballester MT, Lloréns J, Alvariño A, García-Perez ML, Pastor E, Aguilar G, Martí
FJ, Carratalá A, Belda FJ. Cardioprotective effect of
sevoflurane and propofol during anaesthesia and the
postoperative period in coronary bypass graft surgery:
a double-blind randomised study. European Journal of
Anaesthesiology. 2012 Dec; 29(12): 561-9. IF: 2,231
12Ferrando
C, Carbonell JA, Aguilar G, Badenes R,
Belda FJ. Intracranial hypertension related to sedation with sevoflurane using the AnaConDa(®) device
in a patient with severe traumatic brain injury. Revista Española de Anestesiología y Reanimación. 2012
Aug 21.
13Muedra V, Llau JV, Llagunes J, Paniagua P, Veiras S,
Fernández-López AR, Diago C, Hidalgo F, Gil J, Valiño
C, Moret E, Gómez L, Pajares A, Prada BD. Postoperative Costs Associated With Outcomes After Cardiac
Surgery With Extracorporeal Circulation: Role of Antithrombin Levels. Journal of Cardiothoracic and Vascular Anesthesia. 2012 Oct 25. IF: 1,64
14Coburn M, Sanders RD, Maze M, Rossaint R, HIPELD
Investigators. The Hip Fracture Surgery in Elderly Patients (HIPELD) study: protocol for a randomized, multicenter controlled trial evaluating the effect of xenon on
postoperative delirium in older patients undergoing hip
fracture surgery. Trials. 2012 Sep 27; 13: 180. IF: 2,496
Scientific activity
15Ingelmo
I, Fábregas N, Rama P, Rubio R, Badenes
R, Sola LV, Krauchi OR, Honorato C, Palazón JH, Ledesma MJ. Encuesta sobre el tratamiento anestesiológico de los pacientes sometidos a neurocirugía de
fosa posterior. Revista Española de Anestesiología y
Reanimación. 2012; 59: 118-126.
16Pearse PM, Moreno RP,
Bauer P, Pelosi P, Metnitz P,
Spies C, Vallet B, Vincent JL, Hoeft A, Rhodes A, for
the European Surgical Outcomes Study (EuSOS)
group for the Trials groups of the European Society
of Intensive Care Medicine and the European Society of Anaesthesiology. Mortality after surgery in
Europe: a 7 day cohort study. Lancet. 2012; 380: 10591065. IF: 38,278
17Turpie AG, Kreutz R, Llau J, Norrving B, Hass S. Management consensus guidance for the use of rivaroxaban - an oral direct factor Xa inhibitor. Thrombosis and
Haemostasis. 2012; 108: 876-886. IF: 5,044
THESIS
1Thesis title: Estudio de toxicidad hepática y renal causada por la administración de sevoflurano 2,5% durante procedimientos sedativos de larga duración en
modelo animal.
RESEARCH
Reference: GANCMV-2011. Number EudraCT: 2011002603
Title: Tratamiento anticipado con ganciclovir de la infección activa por el citomegalovirus (CMV) en el paciente crítico en ventilación mecánica con sepsis grave o shock séptico.
Principal Investigator: Gerardo Aguilar Aguilar
Funding body: Ministerio de Sanidad, Servicios Sociales e Igualdad
Beneficiary institution: Fundación para la Investigación del Hospital Clínico Universitario de Valencia
Duration: 2012-2016
Title: Identificación de nuevos biomarcadores periféricos de deterioro cognitivo ligero y de enfermedad de
Alzheimer.
Principal Investigator: José Viña (Jose García de la
Asunción as collaborating researcher)
Beneficiary institution: Fundación para la Investigación del Hospital Clínico Universitario de Valencia
Doctoral candidate: Lucía Gallego Ligorit
Duration: 2011-2013
Director(s): Francisco Javier Belda and Marina Soro
Domingo
2Thesis title: Estudio de la respuesta inflamatoria en
diferentes estrategias de cirugía de revascularizacion
coronaria.
Doctoral candidate: Irene León Carsi
Director(s): Joaquín Ortega Serrano and Rosario Vicente
4
157
Scientific activity
Research Group on Translational Genomics
PI: Rubén Darío Artero Allepuz (Department of Genetics University of Valencia).
Collaborating Researchers: Manuel Pérez Alonso (University), Mª Beatriz Llamusí Troísi (University).
Predoctoral Researchers: Ariadna Bargiela Schönbrunn (University), Estefanía Cerro Herreros (University), Piotr
Konieczny (University).
Strategic aims
• To begin working in the development of new therapeutic strategies based on the use of RNA molecules as drugs as well
as in the discovery of disease biomarkers.
158
4
• To participate in a European research project, for which a current E-rare project aiming at deciphering the molecular basis
of the cardiac dysfunction in myotonic dystrophy will serve as initial promoting consortium.
The current research lines for the group of Translational Genomics are the following:
• Use of miRNAs as therapeutic targets and progression markers in Myotonic Dystrophia.
• Analysis of the post-transcriptional regulation of the muscleblind gene and identification of myotonic dystrophy biomarkers.
• Development of a Drosophila model for the discovery of inhibitors of protein-protein interactions.
• Study of the causes for cardiac alterations in Myotonic Dystrophia.
• Study of the transcriptional regulation of muscleblind, a gen involved in several diseases including, Myotonic Dystrophy
among them.
• Study of the molecular mechanisms associated with Spinal Muscular Atrophy and the search for potential therapies.
Patents
Inventors: M Carmen Alvárez, Arturo López Castel,
Irma García, Manuel Pérez Alonso, Rubén Darío Artero, José R. Tormo, Diego Cortés
RESEARCH
Title: Identificación de RNAs de suero sanguíneo
como biomarcadores de progresión de distrofia miotónica.
Title: Phenanthrene derivatives for use as medicaments
Principal Investigator: Rubén Artero Allepuz
Application number: EP12197087
Priority date: 2012
Scientific activity
Duration: 2012-2014
Reference: GrisoliaP/2012/068
Principal Investigator: Nuria Paricio Ortiz (Rubén Artero as collaborating researcher)
Valenciana
Title: Un modelo de atrofia muscular espinal en Drosophila para el descubrimiento de fármacos in vivo.
Funding body: Conselleria d´Educació, Generalitat
Valenciana
Duration: 2012-2015
Duration: 2010-2013
Title: Nuevas dianas terapéuticas para la distrofia
miotónica: análisis de microRNAs en dos modelos
animales de la enfermedad.
Funding body: Fundación Ramón Areces
Title: Programa Gerónimo Forteza para la contratación de personal de apoyo para grupos de calidad
contrastada.
Funding body: Conselleria d´Educació, Generalitat
Valenciana
Duration: 2010-2013
Title: Regulación de muscleblind: módulos reguladores de la transcripción en cis y señales potenciales de
localización nuclear.
Duration: 2012
Reference: BIO2011-15081-E
Title: Descubrimiento de inhibidores de interacciones
proteína-proteína en Drosophila.
Duration: 2010-2012
Reference: UV-INV_AE11-40093
Title: Mecanismo de toxicidad a expansiones CTG:
nuevos componentes y su relevancia biomédica.
Duration: 2012-2014
Principal Investigator: Manuel Pérez Alonso
Funding body: Universitat de València
Title: Development of novel treatments for myotonic
dystrophy: in vivo drug discovery.
Funding body: Fundación La Marató de TV3
Hospital Clínica Valencia
Duration: 2011-2014
Title: Aproximaciones genéticas para el estudio de patologías humanas y del desarrollo en Drosophila.
Duration: 2010-2012
4
159
Scientific activity
4.1.4.
Research
on
Reproductive
Medicine
Area
4
161
Scientific activity
Research Group on Women Health
PI: Antonio Cano Sánchez (Department of Pediatrics, Obstetrics and Gynecology University of Valencia).
Collaborating Researchers: Juan José Tarín Folgado (University), Paz Laporta Martín (Hospital), Lucía Sanz Salvador (University), Leonor Fernández-Murga (University), Arantxa Hervás Lorente (University), María Cinta García
Martínez (University).
Predoctoral Researchers: Rosa Aliaga Corachán (University).
Strategic aims
162
4
• The strengthening of the research group on postmenopausal osteosporosis biology with the Instituto de Biomedicina de
Valencia. Contributions to Instituto de Investigación del Hospital Marqués de Valdecilla and to el URFOA-IMIM, Parc de
Salut del Mar of the Hospital del Mar de Barcelona.
• Consolidation of the clinical group in women health, with projects in the endometriosis area (role of the microRNA), gonadal protection during chemotherapy in young women and protection before ovaric hyperstimulation and hemorrhagic
luteal body with GnRH antagonists.
Main lines of Research
• Postmenopausal osteoporosis: role of the calcium sensor receptor in the osteo formation and osteoclastogenesis.
• Gonadal protection in pre-menopausal women treated with chemotherapy.
• Endometriosis: Role of the microRNA and regulators of vascularization and pain mechanisms.
• Initial aterogenesis and gonadal steroids.
• Vitamin D in women’s health.
PUBLICATIONS
Original articles
1Riancho JA, Liu Y, Sainz J, García-Pérez MA, Olmos
JM, Bolado-Carrancio A, Valero C, Pérez-López J,
Cano A, Yang T, Sañudo C, Deng HW, Rodríguez-Rey
JC. Nuclear receptor NR5A2 and bone: gene expres-
sion and association with bone mineral density. European Journal of Endocrinology. 2012 Jan; 166(1): 6975. IF: 3,423
2Pineda B, Hermenegildo C, Tarín JJ, Cano A, GarcíaPérez MA. Effects of administration of hormone therapy or raloxifene on the immune system and on biochemical markers of bone remodeling. Menopause. 2012
Mar; 19(3): 319-27. IF: 3,758
Scientific activity
3Fernández-Murga L, Hermenegildo C, Tarín JJ, García-Pérez MA, Cano A. Endometrial response to concurrent treatment with vaginal progesterone and transdermal estradiol. Climacteric. 2012 Feb 9. IF: 1,986
4Blümel
JE, Cano A, Mezones-Holguín E, Barón G,
Bencosme A, Benítez Z, Bravo LM, Calle A, Flores D,
Espinoza MT, Gómez G, Hernández-Bueno JA, Laribezcoa F, Martino M, Lima S, Monterrosa A, Mostajo
D, Ojeda E, Onatra W, Sánchez H, Tserotas K, Vallejo
MS, Witis S, Zúñiga MC, Chedraui P. A multinational
study of sleep disorders during female mid-life. Maturitas. 2012 Aug; 72(4): 359-66. IF: 2,767
5Cañete
P, Monllor A, Pineda A, Hernández R, Tarín
JJ, Cano A. Levels of heat shock protein 27 in placentae from small for gestational age newborns. Gynecologic and Obstetric Investigation. 2012; 73(3): 248-51.
IF: 1,276
6Cano A,
Estévez J, Usandizaga R, Gallo JL, Guinot
M, Delgado JL, Castellanos E, Moral E, Nieto C, del
Prado JM, Ferrer J. The therapeutic effect of a new
ultra low concentration estriol gel formulation (0.005%
estriol vaginal gel) on symptoms and signs of postmenopausal vaginal atrophy: results from a pivotal phase
III study. Menopause. 2012 Aug 20. IF: 3,758
7Artero A, Tarín JJ, Cano A. The adverse effects of estrogen and selective estrogen receptor modulators on
hemostasis and thrombosis. Seminars in Thrombosis
and Hemostasis. 2012 Nov; 38(8): 797-807. IF: 4,524
8Baró F, Cano A, Sánchez-Borrego R, Ferrer J, González-Rodríguez SP, Neyro JL, Rodríguez-Bueno E,
Sancho C, Inaraja V, Fernández C, Corral C. Frequency of FRAX risk factors in osteopenic postmenopausal women with and without history of fragility fracture.
Menopause. 2012. 19: 1193-9. IF: 3,758
9Salvador-Carulla L, OlsonWalsh C, Alonso F, Gómez
R, de Teresa C, Cabo-Soler JR, Cano A, Ruiz M. eVITAL: A Preliminary Taxonomy and Electronic Toolkit of
Health-Related Habits and Lifestyle. Scientific World
Journal. 2012. Epub 2012 Apr 1.
10Blanco-Molina MA, Lozano M, Cano A, Cristobal I, Pallardo LP, Lete I. Progestin-only contraception and venous thromboembolism. Thrombosis Research. 2012.
129:e257-62. IF: 2,44
RESEARCH
Title: Efecto del envejecimiento reproductivo materno
sobre los perfiles de expresión génica de los individuos descendientes: ovocito versus medio ambiente
materno.
Principal Investigator: Juan José Tarín Folgado
Duration: 2010-2012
Title: Receptor sensor del calcio y osteoformación.
Principal Investigator: Antonio Cano Sánchez
Duration: 2010-2012
Title: Identificación de genes del sistema inmune implicados en la osteoporosis posmenopáusica.
(Nuria Abril and Rosa Aliaga as collaborating Researchers)
Duration: 2010-2012
4
163
Scientific activity
Research Group on Male Infertility and Embrionary Stimulation
PI: José Remohí Jiménez (IVI University Institute / Department of Pediatrics, Obstetrics and Gynecology University of
Valencia).
Collaborating Researchers: Amparo Ruiz Jorro (IUIVI), Carmen Rubio Lluesa (IUIVI), Jaime Ferro Camargo (IUIVI),
José Antonio Martínez Conejero (IUIVI), Marcos Meseguer Escrivá (IUIVI), Nicolás Garrido Puchalt (IUIVI).
Predoctoral Researchers: Rocío Rivera Egea (IUIVI), Nerea Sota Echarri (IUIVI).
164
4
Strategic aims
• Study of the correlations between the recombination and total length of the sinaptonemic complex, both in the control
group, constituted by men with proven fertility, and in the group of study on patients with secretory azoospermia with
unknown causes.
• Related to the Study on seminal respiration as a diagnosis method, it has been validated the reproducibility of the measured O2 levels in semen samples from infertile patients, and it has also been established the necessary experimental
conditions in order to obtain concluding results with this technique, optimizing the concentration of spermatozoids and
the time taken for the analysis.
• A study on the genetic causes for male infertility: Studies on meiosis, chromosomal anomalies in spermatozoids and
genes that are possibly related to male infertility.
• Study on seminal respiration as a new diagnosis method for male fertility potential through micro-respiration.
Emerging Researcher
Nicolás Garrido Puchalt (IVI University Institute).
In this research line about male fertility, factors related to sperm physiology are intended
to be discovered. Using assisted reproduction techniques and several instrumental tools,
the genetic, proteomic and metabolomic profiles (in the latter, mainly lipid composition),
DNA integrity and oxygen uptake are determined in order to analyze the relevance of these parameters and improve the diagnosis and the design of new optimal sperm selection
techniques to achieve pregnancy.
Scientific activity
Emerging Researcher
Marcos Meseguer Escrivá (IVI University Institute).
This group has developed a new technology, based in new equipment (Embryoscope) that
allows embryo analysis without using an invasive technique. The processes in our laboratory
have changed, since it is not needed to take out the embryos from the incubator to be observed, and we have more information of each embryo since it takes continuous pictures of the
embryo development that allows select those that have major implantation rate according to
its morphokinetic patterns. In this way it achieves a much more stable incubation.
Capturing images is done in multiple focal planes and pre-programmed time intervals. The
sum of each embryo frame generates a recording that displays the embryonic development
continuously. It represents a major conceptual advance in the quality assessment by assessing embryonic developmental processes against embryo stages. We have also established a
new marker that indicates success in implantation which is based on oxygen consumption. By
adding a micro sensor (nano sensor detecting oxygen consumption) in embryo culture media
we get additional information about embryos to select them for transfer 48 or 72 hours after “in
vitro” fecundation. The preliminary studies showed that it can increase up to 20% the chance
of success of assisted reproductive technology.
PUBLICATIONS
Original articles
1Muñoz
E, Bosch E, Fernandez I, Portela S, Ortiz G,
Remohi J, Pellicer A. The Role of LH in Ovarian Stimulation. Current Pharmaceutical Biotechnology. 2012
Mar 1; 13(3): 409-16. IF: 2,805
2Cobo A, Bellver J, de Los Santos MJ, Remohí J. Viral
screening of spent culture media and liquid nitrogen
samples of oocytes and embryos from hepatitis B,
hepatitis C, and human immunodeficiency virus chronically infected women undergoing in vitro fertilization
cycles. Fertility and Sterility. 2012 Jan; 97(1): 74-8.
IF: 3,775
3Garrido N, Pellicer A, Niederberger C. Testing the water before swimming: satisfying the need for clinical
trials of devices, media, and instruments before their
use in assisted reproduction laboratories. Fertility and
Sterility. 2012 Feb; 97(2): 245-6. IF: 3,775
4Cobo A, de Los Santos MJ, Castellò D, Gámiz P, Campos P, Remohí J. Outcomes of vitrified early cleavagestage and blastocyst-stage embryos in a cryopreservation program: evaluation of 3,150 warming cycles.
Fertility and Sterility. 2012 Aug 3. IF: 3,775
5Garrido N, Bellver J, Remohí J, Alamá P, Pellicer A.
Cumulative newborn rates increase with the total number of transferred embryos according to an analysis
of 15,792 ovum donation cycles. Fertility and Sterilility.
2012 Aug; 98(2): 341-346.e2. IF: 3,775
6Al-Asmar
N, Peinado V, Vera M, Remohí J, Pellicer
A, Simón C, Hassold T, Rubio C. Chromosomal abnormalities in embryos from couples with a previous
aneuploid miscarriage. Fertility and Sterility. 2012 Jul;
98(1): 145-50. IF: 3,775
7Rienzi L, Cobo A, Paffoni A, Scarduelli C, Capalbo A,
Vajta G, Remohí J, Ragni G, Ubaldi FM. Consistent and
predictable delivery rates after oocyte vitrification: an
observational longitudinal cohort multicentric study. Human Reproduction. 2012 Jun; 27(6): 1606-12. IF: 4,475
8Altmäe S, Martinez-Conejero JA, Esteban FJ, RuizAlonso M, Stavreus-Evers A, Horcajadas JA, Salumets
A. MicroRNAs miR-30b, miR-30d, and miR-494 Regulate Human Endometrial Receptivity. Reproductive
Sciences. 2012 Aug 17. IF: 2,444
9Evans GE, Martínez-Conejero JA, Phillipson GT, Simón C, McNoe LA, Sykes PH, Horcajadas JA, Lam
EY, Print CG, Sin IL, Evans JJ. Gene and protein expression signature of endometrial glandular and stromal compartments during the window of implantation.
Fertilily and Sterility. 2012 Jun; 97(6): 1365-73.e1-2.
IF: 3,775
10Vialard F, Simoni G, Gomes DM, Abourra A, De Toffol
S, Bru F, Martinez Romero MC, Nitsch L, Bouhanna
P, Marcato L, Popowski T, Grimi B, Martínez-Conejero JA, Benzacken B, Genesio R, Grati FR. Prenatal
BACs-on-Beads™: the prospective experience of five
prenatal diagnosis laboratories. Prenatal Diagnosis.
2012 Apr; 32(4): 329-35. IF: 2,106
4
165
Scientific activity
Online. 2012 Apr; 24(4): 424-32. IF: 2,042
18Riboldi
M, Rubio C, Pellicer A, Gil-Salom M, Simón
C. In vitro production of haploid cells after coculture of
CD49f+ with Sertoli cells from testicular sperm extraction in nonobstructive azoospermic patients. Fertility
and Sterility. 2012 Jun 23. IF: 3,775
19Mas A, Cervelló I, Gil-Sanchis C, Faus A, Ferro J, PeTriple sperm FISH: CEP X Spectrum Green, CEP Y Spectrum Orange, CEP
18 Spectrum Aqua
11De los Santos MJ, García-Láez V, Beltrán-Torregrosa
D, Horcajadas JA, Martínez-Conejero JA, Esteban
FJ, Pellicer A, Labarta E. Hormonal and molecular
characterization of follicular fluid, cumulus cells and
oocytes from pre-ovulatory follicles in stimulated and
unstimulated cycles. Human Reproduction. 2012 Jun;
27(6): 1596-605. IF: 4,475
4
20Labarta E, Bosch E, Alamá P, Rubio C, Rodrigo L, Pellicer A. Moderate Ovarian Stimulation Does Not Increase
the Incidence of Human Embryo Chromosomal Abnormalities in in Vitro Fertilization Cycles. Journal of Clinical
Endocrinology and Metabolism. 2012 Aug 3. IF: 5,967
12Cruz M, Garrido N, Herrero J, Pérez-Cano I, Muñoz
21Rubio C, Bellver J, Rodrigo L, Bosch E, Mercader A,
M, Meseguer M. Timing of cell division in human cleavage-stage embryos is linked with blastocyst formation
and quality. Reproductive Biomedicine Online. 2012
Jul 7. IF: 2,042
Vidal C, De Los Santos MJ, Giles J, Labarta E, Domingo J, Crespo J, Remohí J, Pellicer A, Simón C. Preimplantation genetic screening using fluorescence in situ
hybridization in patients with repetitive implantation
failure and advanced maternal age: two randomized
trials. Fertility and Sterility. 2012 Dec 20. IF: 3,775
13Muñoz
166
llicer A, Simón C. Identification and characterization
of the human leiomyoma side population as putative
tumor-initiating cells. Fertility and Sterility. 2012 May
23. IF: 3,775
M, Cruz M, Humaidan P, Garrido N, PérezCano I, Meseguer M. Dose of recombinant FSH and
oestradiol concentration on day of HCG affect embryo
development kinetics. Reproductive Biomedicine Online. 2012 Jul 4. IF: 2,042
14Tejera A,
Herrero J, Viloria T, Romero JL, Gamiz P,
Meseguer M. Time-dependent O(2) consumption patterns determined optimal time ranges for selecting viable human embryos. Fertility and Sterility. 2012 Jul 24.
IF: 3,575
15Meseguer
M, Kruhne U, Laursen S. Full in vitro fertilization laboratory mechanization: toward robotic assisted reproduction?. Fertility and Sterility. 2012 Jun;
97(6): 1277-86. IF: 3,775
16Camprubí
C, Pladevall M, Grossmann M, Garrido N,
Pons M, Blanco J. Semen samples showing an increased rate of spermatozoa with imprinting errors have a
negligible effect in the outcome of assisted reproduction
techniques. Epigenetics. 2012 Oct 1; 7(10). IF: 4,318
17Cobo A, Garrido N, Crespo J, José R, Pellicer A. Accumulation of oocytes: a new strategy for managing
low-responder patients. Reproductive Biomedicine
22Garrido N, Pellicer A, Niederberger C. Testing the water before swimming: satisfying the need for clinical
trials of devices, media, and instruments before their
use in assisted reproduction laboratories. Fertility and
Sterility. 2012 Feb; 97(2): 245-6. IF: 3,775
23Meseguer M, Rubio I, Cruz M, Basile N, Marcos J, Requena A. Embryo incubation and selection in a timelapse monitoring system improves pregnancy outcome
compared with a standard incubator: a retrospective
cohort study. Fertility and Sterility. 2012 Dec; 98(6):
1481-1489.e10. IF: 3,775
24Rubio I, Kuhlmann R, Agerholm I, Kirk J, Herrero J, Escribá MJ, Bellver J, Meseguer M. Limited implantation
success of direct-cleaved human zygotes: a time-lapse
study. Fertility and Sterility. 2012 Dec; 98(6): 1458-63.
IF: 3,775
25Altmäe S, Martinez-Conejero JA, Esteban FJ, RuizAlonso M, Stavreus-Evers A, Horcajadas JA, Salumets
A. MicroRNAs miR-30b, miR-30d, and miR-494 Regulate Human Endometrial Receptivity. Reproductive
Sciences. 2012 Aug 17. IF: 2,444
Scientific activity
Meiotic prophase progression I. MLH1: points recombination; CREST centromere; SCP3: synaptonemal complex.
Letters
1 Vila-Vives JM, Martínez-Conejero JA, Pellicer A. Effect of
adenomyosis on implantation. Reproductive Biomedicine
Online. 2012 May; 24(5):584; author reply 585. IF: 2,042
2 Garrido N, Bellver J, Rubio C, Pellicer A. Hepatitis B
virus in human oocytes and embryos. Human Reproduction. 2012 Apr; 27(4): 1227-8; author reply 1228-9.
IF: 4,475
Title: Estudio de la respiración seminal como nuevo
método diagnóstico del potencial fértil del varón mediante la microrespiración.
Principal Investigator: Nicolás Garrido Puchalt
Beneficiary institution: INCLIVA-IUIVI
THESIS
1 Thesis title: Transcritómica de la infertilidad masculina.
Doctoral candidate: Sandra García Herrero
Director(s): Nicolás Garrido Puchalt and Marcos Meseguer Escrivá
RESEARCH
Title: Estudio de anomalías meióticas y citogenéticas
en biopsias testiculares de varones azoospérmicos.
Despistajes de mutaciones génicas asociadas a errores sinápticos y alteraciones en la recombinación.
Principal Investigator: José Alejandro Remohí Jiménez
Beneficiary institution: Fundación IVI
Duration: 2010-2012
4
167
Scientific activity
Research Group on Stem Cells Applied to Reproduction, Embryo Viability and
Endometrial Receptivity
PI: Carlos Simón Vallés (IVI University Institute / Department of Pediatrics, Obstetrics and Gynecology University of
Valencia).
Collaborating Researchers: Amparo Mercador Bayarri (IUIVI), Ana Cristina Cerveró Sanz (IUIVI), María José de los
Santos Molina (IUIVI), Ernesto Bosch Aparicio (IUIVI), Francisco Domínguez Hernández (IUIVI), Felip Vilella Mitjana
(IUIVI), Xavier Santamaria Costa (IUIVI), Raúl Gómez Gallego (IUIVI), Irene Cervelló Alcaraz, (University), José Vicente
Medrano (University), Ana Martínez Arroyo (University), Diana Valbuena Perilla (IUIVI), David Blesa Jarque (IUIVI).
Predoctoral Researchers: Tamara Garrido Gómez (IUIVI), Claudia Gil Sanchis (IUIVI), Leslie Ramírez Lima (IUIVI),
Juan Manuel Moreno Moya (IUIVI), Hortensia Ferrero Cháfer (IUIVI), Carmen García Pascual (IUIVI), Aymara Mas
Perucho (University).
168
4
Technicians: Sebastián Martínez Escribano (IUIVI), Alicia Quiñonero Villora (IUIVI), Eva Gómez Sánchez (University).
Strategic aims
• Once isolated the candidate colony for somatic stem cells in the human endometrium and other reproductive tissues, this
work focuses on getting to know the origin of this cell colony and looking for possible markers.
• It has been completed the publication of the study where normal embryos and embryos with trisomy 21 are compared,
causing the appearance of certain metabolic markers that differentiate both embryos and can be measured in the culture
environment where these embryos grow.
• Development of a new non-invasive tool based on a lipid profile for the diagnosis of the endometrial receptivity.
• Adult stem cells in the Human endometrium.
• Embryo viability.
• Endometrial receptivity.
Emerging Researcher
Irene Cervelló Alcaraz (Department of Pediatrics, Obstetrics and Gynecology University of
Valencia).
This line of research develops the identification, characterization and isolation of somatic
stem cells in the endometrium. A colony of endometrial stem cells has been identified in human and murine models, the regenerative potential of these cells has been proven and there
is an ongoing research on the existence of Lgr5 marker in the endometrial human tissue in
order to know the only marker for this cells.
Scientific activity
Emerging Researcher
Felip Vilella Mitjana (IVI University Institute)
The research line of Endometrial Receptivity is based on the study of endometrial secretions.
Using the secretomic approach we can describe new molecules that can be correlated with
the days of the menstrual cycle and may be involved in obtaining the window of implantation
period, opening a new field of study for the analysis of the changes in the endometrium during
the menstrual cycle.
PUBLICATIONS
Original articles
1Muñoz E, Bosch E, Fernandez I, Portela S, Ortiz G,
Remohi J, Pellicer A. The Role of LH in Ovarian Stimulation. Current Pharmaceutical Biotechnology. 2012
Mar 1; 13(3): 409-16. IF: 2,805
2Wang
H, Pilla F, Anderson S, Martínez-Escribano S,
Herrer I, Moreno-Moya JM, Musti S, Bocca S, Oehninger S, Horcajadas JA. A novel model of human
implantation: 3D endometrium-like culture system
to study attachment of human trophoblast (Jar) cell
spheroids. Molecular Human Reproduction. 2012 Jan;
18(1): 33-43. IF: 3,852
3Cobo A, Bellver J, de Los Santos MJ, Remohí J. Viral screening of spent culture media and liquid nitrogen
samples of oocytes and embryos from hepatitis B, hepatitis C, and human immunodeficiency virus chronically
infected women undergoing in vitro fertilization cycles.
Fertility and Sterility. 2012 Jan; 97(1): 74-8. IF: 3,775
4García-Velasco
JA, Kupesic S, Pellicer A, Bourgain
C, Simón C, Mrazek M, Devroey P, Arce JC. Follicular and endocrine profiles associated with different
GnRH-antagonist regimens: a randomized controlled
trial. Reproductive Biomedicine Online. 2012 Feb;
24(2): 153-62. IF: 2,042
5Valbuena
D, Póo ME, Aguilar-Gallardo C, Martinez S,
Cobo AC, Pellicer A, Simón C. Comparison of Cryotip vs.
Cryotop for mouse and human blastomere vitrification.
Fertility and Sterility. 2012 Jan; 97(1): 209-17. IF: 3,775
6Cobo
A, de Los Santos MJ, Castellò D, Gámiz P,
Campos P, Remohí J. Outcomes of vitrified early
cleavage-stage and blastocyst-stage embryos in a cryopreservation program: evaluation of 3,150 warming
cycles. Fertility and Sterility. 2012 Nov; 98(5): 1138-46.
e1. IF: 3,775
7Al-Asmar
N, Peinado V, Vera M, Remohí J, Pellicer
A, Simón C, Hassold T, Rubio C. Chromosomal abnormalities in embryos from couples with a previous
aneuploid miscarriage. Fertility and Sterility. 2012 Jul;
98(1): 145-50. IF: 3,775
8Evans GE, Martínez-Conejero JA, Phillipson GT, Simón
C, McNoe LA, Sykes PH, Horcajadas JA, Lam EY, Print
CG, Sin IL, Evans JJ. Gene and protein expression signature of endometrial glandular and stromal compartments
during the window of implantation. Fertility and Sterility.
2012 Jun; 97(6): 1365-73.e1-2. IF: 3,775
9De los Santos MJ, García-Láez V, Beltrán-Torregrosa
D, Horcajadas JA, Martínez-Conejero JA, Esteban FJ,
Pellicer A, Labarta E. Hormonal and molecular characterization of follicular fluid, cumulus cells and oocytes
from pre-ovulatory follicles in stimulated and unstimulated cycles. Human Reproduction. 2012 Jun; 27(6):
1596-605. IF: 4,475
10Riboldi
M, Rubio C, Pellicer A, Gil-Salom M, Simón
C. In vitro production of haploid cells after coculture of
CD49f+ with Sertoli cells from testicular sperm extraction in nonobstructive azoospermic patients. Fertility
and Sterility. 2012 Jun 23; 98(3): 580-90. IF: 3,775
11Simón C. Somatic stem cells and tissue engineering
shed light on unsolved clinical issues in reproductive
medicine: in stem cells we trust. Fertility and Sterility.
2012 Jul; 98(1): 1-2. IF: 3,775
12Garrido-Gómez T, Dominguez F, Quiñonero A, Estella C, Vilella F, Pellicer A, Simon C. Annexin A2 is
critical for embryo adhesiveness to the human endometrium by RhoA activation through F-actin regulation.
FASEB Journal. 2012 May 29; 26(9): 3715-27. IF: 5,712
13Ruiz-Alonso M, Blesa D, Simón C. The genomics of
the human endometrium. Biochimical et Biophysica
Acta. 2012 May 24 ; 1822(12): 1931-42.
14Mas A, Cervelló I, Gil-Sanchis C, Faus A, Ferro J, Pellicer A, Simón C. Identification and characterization
of the human leiomyoma side population as putative
tumor-initiating cells. Fertility and Sterility. 2012 May
23; 98(3): 741-751.e6. IF: 3,775
4
169
Scientific activity
15Galán A, Simón C. Human embryonic stem cells derived in xeno-free conditions. Methods in Molecular Biology. 2012; 873: 13-32.
16Ferrero
H, Delgado-Rosas F, Garcia-Pascual CM,
Monterde M, Zimmermann RC, Simón C, Pellicer A,
Gómez R. Efficiency and purity provided by the existing methods for the isolation of luteinized granulosa
cells: a comparative study. Human Reproduction. 2012
Jun; 27(6): 1781-9. IF: 4,475
17Estella C, Herrer I, Atkinson SP, Quiñonero A, Martínez
S, Pellicer A, Simón C. Inhibition of histone deacetylase activity in human endometrial stromal cells promotes
extracellular matrix remodelling and limits embryo invasion. PLoS One. 2012; 7(1): e30508. IF: 4,092
18Cervelló I, Gil-Sanchis C, Mas A, Faus A, Sanz J, Moscardó F, Higueras G, Sanz MA, Pellicer A, Simón C.
Bone marrow-derived cells from male donors do not
contribute to the endometrial side population of the recipient. PLoS One. 2012; 7(1): e30260. IF: 4,092
19Escrich
L, Grau N, de Los Santos MJ, Romero JL,
Pellicer A, Escribá MJ. The dynamics of in vitro maturation of germinal vesicle oocytes. Fertility and Sterility.
2012 Nov; 98(5): 1147-51. IF: 3,775
170
4
20Labarta
E, Bosch E, Alamá P, Rubio C, Rodrigo L,
Pellicer A. Moderate Ovarian Stimulation Does Not Increase the Incidence of Human Embryo Chromosomal
Abnormalities in in Vitro Fertilization Cycles. Journal
of Clinical Endocrinology and Metabolism. 2012 Oct;
97(10): E1987-94. IF: 5,967
21Estella C, Herrer I, Moreno-Moya JM, Quiñonero A,
Martínez S, Pellicer A, Simón C. miRNA Signature and
Dicer Requirement during Human Endometrial Stromal Decidualization In Vitro. PLoS One. 2012; 7(7):
e41080. IF: 4,092
22Rubio C, Bellver J, Rodrigo L, Bosch E, Mercader A,
Vidal C, De Los Santos MJ, Giles J, Labarta E, Domingo J, Crespo J, Remohí J, Pellicer A, Simón C.
Preimplantation genetic screening using fluorescence
in situ hybridization in patients with repetitive implantation failure and advanced maternal age: two randomized trials. Fertility and Sterility. 2012 Dec 20. IF: 3,775
Reconstruction of Human Endometrial Tissue from Side Population Cells.
Identification of Side Population (SP) cells in the human endometrium (upper
panel). Lower panel; macroscopic image, H&E staining and positive expression of human progesterone receptor (green signals) in new glands reconstructed in an animal model showing regenerated tissue after a subcutaneous
injection of SP cells.
rrasco L, Jönsson T, Pineda-Lucena A, Ballesteros A,
Domínguez F, Simón C. Differential metabolic profiling of non-pure trisomy 21 human preimplantation
embryos. Fertility and Sterility. 2012 Nov; 98(5): 11571164.e2. IF: 3,775
25Aguilar-Gallardo C, Rutledge EC, Martínez-Arroyo AM,
Hidalgo JJ, Domingo S, Simón C. Overcoming challenges of ovarian cancer stem cells: novel therapeutic
approaches. Stem Cell Reviews. 2012 Sep; 8(3): 9941010. IF: 3,739
26Medrano
JV, Ramathal C, Nguyen HN, Simon C,
Reijo Pera RA. Divergent RNA-binding proteins, DAZL
and VASA, induce meiotic progression in human germ
cells derived in vitro. Stem Cells. 2012; 30(3): 441-51.
IF: 7,781
27Niakan KK, Han J, Pedersen RA, Simon C, Pera RA.
Human pre-implantation embryo development. Development. 2012; 139(5): 829-41. IF: 6,596
28Paule
S, Aljofan M, Simon C, Rombauts LJ, Nie G.
Cleavage of endometrial a-integrins into their functional forms is mediated by proprotein convertase 5/6.
Human Reproduction. 2012; 27(9): 2766-74. IF: 4,475
Letter
1Bosch E. Can we skip weekends in GnRH antagonist
cycles without compromising the final outcome?. Fertility and Sterility. 2012 Jun; 97(6): 1299-300. IF: 3,775
23Santamaria X, Massasa EE, Taylor HS. Migration of
cells from experimental endometriosis to the uterine endometrium. Endocrinology. 2012 Nov; 153(11):
5566-74. IF: 4,459
24Sánchez-Ribas I, Riqueros M, Vime P, Puchades-Ca-
THESIS
1Thesis
mano.
title: Estudio proteómico del endometrio hu-
Scientific activity
Doctoral candidate: Tamara Garrido Gómez
Director(s): Carlos Simón Vallés and Francisco Domínguez Hernández
2Thesis title: Endometrial study of a novel in vivo em-
bryo culture device.
Doctoral candidate: Manuel Fernández Sánchez
Director(s): Antonio Pellicer Martínez, José Antonio
Horcajadas Almansa and Carlos Simón Vallés
3Thesis title: Inducción de la meiosis en células germi-
nales obtenidas in vitro a partir de células madre pluripotentes humanas mediante expresión ectópica de las
proteínas de unión al RNA DAZL y VASA.
Doctoral candidate: José Vicente Medrano Plaza
Director(s): Carlos Simón Vallés
4Thesis
title: Estudio del receptor 2 de la dopamina
en ovario humano y efecto de su modulación sobre el
síndrome de hiperestimulación ovárica.
Doctoral candidate: Francisco Manuel Delgado Rosas
Director(s): Antonio Pellicer Martínez, Francisco Gaytan Luna and Raúl Gómez Gallego
5Thesis
title: Identificación, caracterización y aislamiento de células madre somáticas en los miomas
humanos.
Doctoral candidate: Aymara Mas Perucho
Director(s): Carlos Simón Vallés and Irene Cervelló
Alcaraz
6Thesis title: Mecanismos epigenéticos en las células
estromales endometriales.
Doctoral candidate: Isabel Herrer Mambrona
Director(s): Carlos Simón Vallés and Carlos Estella
Sagrado
ovárica controlada
Application number: EP12382032.6
RESEARCH
Reference: 08/09
Title: Caracterización de las células madre neoplásicas en el cáncer de endometrio. Implicaciones patogénicas, pronósticas y terapeúticas.
Principal Investigator: Carlos Simón Vallés
Beneficiary institution: Fundación IVI
Duration: 2009-2012
Title: Aislamiento y caracterización de la población de
células madre somáticas endometriales en la endometriosis: implicaciones patogénicas y terapeúticas.
Valenciana
Duration: 2008-2012
Reference: EC11/299
Title: Nuevas terapias en el abordaje del Síndrome de
Asherman y atrofia endometrial basadas en transplante autólogo de células madre de médula ósea.
Duration: 2012-2013
Title: Red de Terapia Celular.
Patents
Duration: 2008-2011
Inventors: Carlos Simón, David Blesa and Antonio
Pellicer
Title: Diagnóstico de fallo masivo de generación de
ovocitos maduros en tratamientos de estimulación
Beneficiary institution: Fundación de la Comunidad
Valenciana Centro Investigación Príncipe Felipe
4
171
Scientific activity
4.2.Other scientific contributions from the Hospital divisions and the
Clínico-Malvarrosa Health Department
4.2.1. Admission and clinical documentation Department
National Registry of Childhood Cancer. Epidemiology of
chilhood cancer: incidence and survival of chilhood cancer in Spain, geographic, temporal, national and international variations, epidemiology of the biological characteristics that have a clinical relevance in childhood cancer.
Publications
172
4
Duration: 2011-2013
• Reference: LSSH-CT-2008-219453
Title: Europe Against Cancer: Optimisation of the Use
of Registries for Scientific Excellence in research (EUROCOURSE). “Working Package 3: Tools for improving the quality, coverage and use of cancer registration data in Europe (WP3)” y dentro el “Working Group
on the expansion of the Geographic coverage in childhood cancer registration in Europe (task 3.5)”.
Principal Investigator: Rafael Peris Bonet
Original articles
Duration: 2009-2012
1Gavin AT,
Francisci S, Foschi R, Donnelly DW, Lemmens V, Brenner H, Anderson LA, EUROCARE-4 Working Group. Oesophageal cancer survival in Europe: a
EUROCARE-4 study. Cancer Epidemiology. 2012 Dec;
36(6): 505-12. IF: 2,01
• Reference: 261474
Research projects and grants research
Title: European network for cancer in children and
adolescent (ENCCA).
Principal Investigator: Rafael Peris Bonet
Funding body: Comisión Europea, 7º Programa Marco
Duration: 2011-2015
• Reference: RD06/0020/0033
Project title: Red Temática de Investigación Cooperativa (RTICC). Grupo Clínico Asociado “Registro Nacional de Tumores Infantiles (RNTI-SEHOP)”.
Principal Investigator: Rafael Peris-Bonet
4.2.2. Allergology Unit
Duration: 2007-2012
• Reference: PI10/01617
Project title: Incidencia, supervivencia y tendencias
del cáncer en adolescentes en España: un estudio
cooperativo de 11 registros de cáncer.
Principal Investigator: Rafael Peris-Bonet
• Application of the basophil activation test (Basotest)
for the diagnosis of respiratory and brought about by
medication allergies.
• Relationship between patient’s allergenic profiles and
the efficiency of the immunotherapy with mites.
• Use of the anti-IgE (omalizumab) in the treatment for
the cutaneous allergic pathology.
• Application of the diagnosis by allergenic components
(microarrays and recombinant allergens) in the alimentary and cutaneous allergy pathology.
Scientific activity
Publications
Original articles
1Colás C, Galera H, Añibarro B, Soler R, Navarro A, Jáuregui I, Peláez A. Disease severity impairs sleep quality
in allergic rhinitis (The SOMNIAAR study). Clinical and
Experimental Allergy. 2012; 42: 1080-1087. IF: 5,032
2Martorell Aragonés A, Martorell Calatayud C, Pineda
F, Félix R, Cerdá JC, de las Marinas MD. Persistence of
allergy to goat’s milk after specific induction of tolerance
to cow’s milk. Journal of Investigational Allergology &
Clinical Immunology. 2012; 22(4):301-2. IF: 2,269
3Félix
R, Martorell C, Martorell A, Pineda F, Cerdá
JD, de las marinas MD. Induced bronchospasm after
handling of orange flavedo (zest). Journal of Allergy
and Clinical Immunology. 2012 NOV 10. IF: 2,269
4López-Hoyos M, Lizaso MT, Rodriguez JJ, Sanz ML,
Labrador-Horrillo M, Ramos R, Martin-Esteban M,
Pastro R, Hernandez MD, Casas ML, Peláez A, García BE. Quantitative Measurament of Allergen_specific
Immunoglobulin E Levels in Mass Units (ng/ml): An Interlaboratory Comparison. Journal of Allergy and Clinical Immunology. 2012 ; Vol. 22(5): 387-389. IF: 2,269
2Brignole M, Menozzi C, Moya A, Andresen D, Blanc JJ,
Krahn AD, Wieling W, Beiras X, Deharo JC, Russo V,
Tomaino M, Sutton R, International Study on Syncope of Uncertain Etiology 3 (ISSUE-3) Investigators.
Pacemaker therapy in patients with neurally mediated
syncope and documented asystole: Third International
Study on Syncope of Uncertain Etiology (ISSUE-3): a
randomized trial. Circulation. 2012 May 29; 125(21):
2566-71. IF: 14,739
3Díaz-Infante
E, Macías Gallego A, Ferrero de LomaOsorio A. Spanish Catheter Ablation Registry. 11th Official Report of the Spanish Society of Cardiology Working
Group on Electrophysiology and Arrhythmias (2011).
Revista Española de Cardiología. 2012 Aug 14. IF: 2,53
• Reference: TSI-020100-2009-332
Title: Predictores eléctricos y biológicos de remodelado ventricular en pacientes hospitalizados por disfunción sistólica del ventriculo izquierdo (VPREDICT+).
Principal Investigator: Ricardo Ruiz Granell
Funding body: Co-funded by Ministerio de Industria,
Turismo y Comercio
Duration: 2010-2012
5Olaguibel JM, Quirce S, Juliá B, Fernández C, Fortuna AM,
Molina J, Plaza V, MAGIC Study Group. Measurement
of asthma control according to Global Initiative for Asthma
guidelines: a comparison with the Asthma Control Questionnaire. Respiratory Research. 2012 Jun 22; 13: 50.
4.2.4. Department of General Surgery // Visceral Surgery
4.2.3. Cardiac stimulation Unit
• Coloproctologic surgery: quality standards in coloproctology, 3D endorrectal ultrasound, sacral neuromodulation, perianal fistula surgery.
Publications
Original articles
1Izquierdo M, Ruiz-Granell R, Ferrero A, Martínez A, Sánchez-Gomez J, Bonanad C, Mascarell B Morell S GarcíaCivera R. Ablation or conservative management of electrical storm due to monomorphic ventricular tachycardia:
differences in outcome. Europace. 2012 Jun 13. IF: 1,98
• Hepatic-biliary surgery: acute pancreatitis, genic transfection, duodenus pancreatectomy.
• Endocrinus surgery: laparoscopy, suprarrenal tumors,
Study on recurrences in tyroideal surgery, intraoperative localization, parathyroid adenomas.
• Bariatric and Metabolic surgery: physiopathology of
post surgical alterations.
• Mammary surgery: use of the fibrin sealers in the postsurgical seroma.
- Esophageal-gastric surgery: mutations in GIST tu-
4
173
Scientific activity
mors, over expression of HER2 and HER3 in gastric
tumors, post-surgical QT in advanced gastric cancer.
Publications
Original articles
1Felipo V, Urios A, Montesinos E, Molina I, Garcia-Torres ML, Civera M, Olmo JA, Ortega J, Martinez-Valls
J, Serra MA, Cassinello N, Wassel, A Jordá E, Montoliu C. Contribution of hyperammonemia and inflammatory factors to cognitive impairment in minimal hepatic
27(1): 51-8. IF: 2,198
2Escobar J, Pereda J, Arduini A, Sandoval J, Moreno ML,
Pérez S, Sabater L, Aparisi L, Cassinello N, Hidalgo J,
Joosten LA, Vento M, López-Rodas G, Sastre J. Oxidative and nitrosative stress in acute pancreatitis. Modulation by pentoxifylline and oxypurinol. Biochemical
Pharmacology. 2012 Jan 1; 83(1): 122-30. IF: 4,705
3Ortega J, Ortega-Evangelio G, Cassinello N, Sebas174
4
tia V. What Are Obese Patients Able to Eat after Rouxen-Y Gastric Bypass?. Obesity Facts. 2012; 5(3): 33948. IF: 1,856
4Ortega-Serrano
J. Commentary on “A standard approach to expose the recurrent laryngeal nerve during
endoscopic thyroidectomy”. Journal of Laparoendosc
& Advanced Surgical Techniques A. 2012 Apr; 22(3):
264. IF: 1,198
5Molina Rodríguez JL, Martí Obiol R, López Mozos F,
Ortega Serrano J. Superior mesenteric artery syndrome. Cirugía Española. 2012 Jan; 90(1): 53. IF: 0,874
6Herrero MJ, Sabater L, Guenechea G, Sendra L, Montilla AI, Abargues R, Navarro V, Ariño SF. DNA delivery to ‘ex vivo’ human liver segments. Gene Therapy.
2012 May; 19(5): 504-12. IF: 3,71
7Fernández-Cruz
L, Sabater L, Fabregat J, Boggi U.
Complications after pancreaticoduodenectomy. Cirugía Española. 2012 Apr; 90(4): 222-32. IF: 0,874
8Ortega J, Cassinello N, Baltasar A, Torres AJ. Recommendations for the peri-operative management of bariatric surgery patients: results of a national survey. Ci-
rugía Española. 2012 Jun-Jul; 90(6): 355-62. IF: 0,874
9Planells Roig M, Garcia Espinosa R, Cervera Delgado
M, Navarro Vicente F, Carrau Giner M, Sanahuja Santafé A, Arnal Bertomeu C. Ambulatory laparoscopic
cholecystectomy. A cohort study of 1,600 consecutive
cases. Cirugía Española. 2012 Dec 13. IF: 0,874
10Ortega
J, Fernandez-Canet R, Alvarez-Valdeita S,
Cassinello N, Jose Baguena-Puigcerver M. Predictors
of psychological symptoms in morbidly obese patients
after gastric bypass surgery. Surgery for Obesity and
Related Disease. 2012 Nov; 8(6): 770-6. IF: 3,929
11Moro-Valdezate
D, Buch-Villa E, Peiró S, MoralesMonsalve MD, Caballero-Gárate A, Martínez-Agulló
A, Checa-Ayet ,F Ortega-Serrano J. Factors associated with health-related quality of life in a cohort of
Spanish breast cancer patients. Breast Cancer. 2012
Aug 28. IF: 1,363
12Garcés-Albir M, Marti-Obiol R, López-Mozos F, Calabuig-Fariñas S, Navarro-Ros S, Ortega-Serrano J.
Results on prognostic value of mutations in localized
gastrointestinal stromal tumors (GIST) in one single
center. Revista Española de Enfermedades Digestivas. 2012 Sep; 104(8): 405-410. IF: 1,548
13Pereda
J, Pérez S, Escobar J, Arduini A, Asensi M,
Serviddio G, Sabater L, Aparisi L, Sastre J. Obese
rats exhibit high levels of fat necrosis and isoprostanes
in taurocholate-induced acute pancreatitis. PLoS One.
2012; 7(9): e44383. IF: 4,092
14Planells Roig M, Cervera Delgado M, Garcia Espinosa R, Navarro Vicente F, Sanahuja Santafé A. Evaluation of the gastrointestinal quality of life index as a
system to prioritize patients on the waiting list for laparoscopic cholecystectomy. Cirugía Española. 2012
Nov 12. IF: 0,874
15Garcés-Albir M,
García-Botello S, Esclapez-Valero P,
Sanahuja-Santafé A, Raga-Vázquez J, Espi-Macías
A, Ortega-Serrano J. Quantifying the extent of fistulotomy. How much sphincter can we safely divide? A
three-dimensional endosonographic study. International Journal of Colorectal Disease. 2012; 27: 1109–
1116. IF: 2,385
16Herreros MD, Garcia-Arranz M, Guadalajara H, De-LaQuintana P, Garcia-Olmo D, the FATT Collaborative
Scientific activity
Group. Autologous Expanded Adipose-Derived Stem
Cells for the Treatment of Complex Cryptoglandular
Perianal Fistulas: A Phase III Randomized Clinical
Trial (FATT 1: Fistula Advanced Therapy Trial 1) and
Long-term Evaluation. Diseases of the Colon & Rectum. 2012; 55(7): 762–772.
Letter
1Garcés
Albir M, López Mozos F, Martí Cuñat E,
Martí Obiol R, Ortega Serrano J. Mesenteric hepatic
portal pneumatosis: is it always an ominous diagnosis?. Cirugía Española. 2012 Jun 2. IF: 0,874
2Báguena
G, Calvete J, Caballero A, Burgués O,
Martinez Agulló A. Granular cell tumours: An uncommon lesion in the breast. Cirugía Española. 2012;
90(8): 537-539. IF: 0,874
nero, Susana Roselló, Desamparados Roda, Samuel
Navarro as collaborating researchers).
Duration: 2012
• Reference: CSD2007-00020
Title: Papel funcional del estrés oxidativo y nitrosativo
en grandes sistemas biológicos.
Principal Investigator: Santiago Lamas Peláez (Juan
Sastre as the person incharge of the Grupo de Gastroenterología Experimental and Luis Sabater as collaborating researchers)
Funding body: Ministerio de Educación, Cultura y Deporte
Beneficiary institution: CSIC Centro de Investigaciones Biológicas
Duration: 2007-2012
• Title: Identificación de perfiles de expresión en el adenocarcinoma ductal de páncreas. Implicaciones clínicas en relación con la supervivencia.
Principal Investigator: Luis Sabater Ortí
Hospital Clínico Universitario Valencia
Duration: 2010-2012
• Reference: SAF 2011-27002
Title: Terapia génica hepática mediante inyección de
DNA por cateterismo en territorio vascular estanco:
modelo preclínico en cerdo y humano.
Principal Investigator: Salvador Aliño (Luis Sabater
as collaborating researcher)
• Reference: FIS PS09/01800
Title: Demora diagnóstica y estrategias de seguimiento en el cáncer colorrectal: su influencia en el pronóstico.
Duration: 2012-2014
Principal Investigator: Alejandro Espí Macías (Luis
González and Marta Maia Boscá as collaborating researchers)
• Reference: SAF 2009-09500
Title: Identificación de dianas de estrés oxidativo y nitrosativo claves en la Pancreatitis aguda en obesidad
experimental.
Principal Investigator: Juan Sastre Belloch (Luis Sabater as collaborating researcher)
Duration: 2010-2013
• Title: Aplicación de la resonancia magnética de difusión y
perfusión en la estadificación preoperatoria del cáncer del
recto: detección de ganglios metastáticos y evaluación de
la respuesta a la quimio-radioterapia neoadyuvante.
Principal Investigator: Alejandro Espí Macías (Daniel Monleón, Salvador Campos, Álvaro García-Gra-
Duration: 2010-2012
4
175
Scientific activity
4.2.5. Department of Dermatology
Lines focused on Malignant Melanoma and Psoriasis.
• Performing of a test in patients with moderate and severe
psoriasis with adalimumab.
• Related to melanocritical injuries, both benignant and malignant (melanoma), several studies have been open.
6González Rodríguez AJ, Gutiérrez Paredes EM, Molina Gallardo I, Jordá Cuevas E. A rapidly expanding
mass of the first toe. International Journal of Dermatology. 2012 Nov; 51(11): 1343-4. IF: 1,142
7Gavrilova M, Martin-Gorgojo A, Ruiz-Domenech C,
Alonso-Salvador MD, Gomez-Mateo Mdel C, JordaCuevas E. Unilateral facial ulceration. Archives of Dermatology. 2012 May; 148(5): 641-6. IF: 3,888
- determining of clinical-pathologyc and molecular parameters involved in the spontaneous regression of cutaneous melanocytic lesions.
8Martín JM, Bella-Navarro R, Jordá E. Vascular pat-
Publications
Original articles
4
dá Cuevas E. Pityriasis lichenoides chronica associated
with herpes simplex virus type 2. Case Reports in Dermatological Medicine. 2012; 2012: 737428.
- epidemyologic surveys on chronic sun-exposure in patients with precedents of malignant melanoma.
- determination of cytokines that intervene in the melanoma dissemination and methastasis.
176
5González Rodríguez AJ, Montesinos Villaescusa E, Jor-
1Reig I, Monteagudo C, Gámez L, Martí N, Martín JM,
Jorda E. Follicular mucinosis with loss of ephelides.
International Journal of Dermatology. 2012 Mar; 51(3):
332-4. IF: 1,142
2González-Rodríguez
AJ, Gutiérrez-Paredes EM,
Revert Fernández A, Jordá-Cuevas E. Allergic Contact Dermatitis to Benzocaine: The Importance of Concomitant Positive Patch Test Results. Actas Dermosifiliográficas. 2012 Apr 30.
3Cochrane SA, Salt LJ, Wantling E, Rogers A, Coutts
J, Ballmer-Weber BK, Fritsche P, Fernández-Rivas M,
Reig I, Knulst A, Le TM, Asero R, Beyer K, Golding M,
Crevel R, Clare Mills EN, Mackie AR. Development of
a standardized low-dose double-blind placebo-controlled challenge vehicle for the EuroPrevall project. Allergy. 2012 Jan; 67(1): 107-13. IF: 6,271
4Alonso-Castro L, Boixeda P, Reig I, de Daniel-Rodríguez C, Fleta-Asín B, Jaén-Olasolo P. Carbon dioxide
laser treatment of epidermal nevi: response and longterm follow-up. Actas Dermosifiliográficas. 2012 Dec;
103(10): 910-8.
terns in dermoscopy. Actas Dermosifiliográficas. 2012
Jun; 103(5): 357-75.
9López
V, Jordá E, Monteagudo C. Birt-Hogg-Dubé
Syndrome: An Update. Actas Dermosifiliográficas.
2012 Apr; 103(3): 198-206.
10Martín JM, Monteagudo C, Bella R, Reig I, Jordá E.
Complete Regression of a Melanocytic Nevus under
Intense Pulsed Light Therapy for Axillary Hair Removal
in a Cosmetic Center. Dermatology. 2012; 224(3): 1937. IF: 2,053
11Felipo V, Urios A, Montesinos E, Molina I, Garcia-Torres ML, Civera M, Olmo JA, Ortega J, Martinez-Valls
J, Serra MA, Cassinello N, Wassel A, Jordá E, Montoliu C. Contribution of hyperammonemia and inflammatory factors to cognitive impairment in minimal hepatic
27(1): 51-8. IF: 2,198
12Monteagudo
C, Ramos D, Pellín-Carcelén A, Gil R,
Callaghan RC, Martín JM, Alonso V, Murgui A, Navarro L, Calabuig S, López-Guerrero JA, Jordá E, Pellín
A. CCL27-CCR10 and CXCL12-CXCR4 chemokine
ligand-receptor mRNA expression ratio: new predictive
factors of tumor progression in cutaneous malignant
melanoma. Clinical & Experimental Metastasis. 2012
Aug; 29(6): 625-37. IF: 3,524
Letters
1Gutiérrez-Paredes
E, López-Castillo V, Revert-Fernández A, Jordá-Cuevas E. Nevus Oligemicus on the
Breasts: A Report of 2 Cases. Actas Dermosifiliográficas. 2012 Jan 26.
Scientific activity
2Bella-Navarro
R, Alonso-Usero V, Gutiérrez Paredes EM, Jordá-Cuevas E. Persistent labial edema
secondary to hemifacial spasm. Actas Dermosifiliográficas. 2012 Mar; 103(2): 157-8.
3Gutiérrez-Paredes E, González-Rodríguez A, Molina-Gallardo I, Jordá-Cuevas E. Neutrophilic dermatosis on postmastectomy lymphedema. Actas Dermosifiliográficas. 2012 Sep; 103(7): 649-51.
4Gutiérrez
Paredes E, Bella Navarro R, Montesinos
Villaescusa E, Jordá Cuevas E. Porokeratosis of Mibelli: A New Indication for Photodynamic Therapy?.
Actas Dermosifiliográficas. 2012 Oct 23.
5Bella-Navarro R, Martí-Fajardo N, Martín-Hernández
JM, Jordá-Cuevas E. Follicular mucinosis in childhood: a case report and review of the literature. Actas
Dermosifiliográficas. 2012 May; 103(4): 335-6.
6Martín-Gorgojo
A, Alonso-Usero V, Gavrilova M,
Jordá-Cuevas E. Dermatosis Neglecta or Terra Firma-Forme Dermatosis. Actas Dermosifiliográficas.
2012 Dec; 103(10): 932-934.
7Gavrilova M, Martin JM, Martin-Gorgojo A, JordaCuevas E. Follicular acneiform eruption induced by
bevacizumab. Dermatology Online Journal. 2012 Sep
15; 18(9): 15.
8López V, Alonso V, Jordá E. Efficacy of topical imiquimod 5% in a patient with chronic radiodermatitis on the
hands. Actas Dermosifiliográficas. 2012 Jun; 103(5):
441-2.
9Martí
N, Alonso V, Jordá E. Encephalocraniocutaneous lipomatosis and didymosis aplasticopsilolipara.
Actas Dermosifiliográficas. 2012 May; 103(4): 341-2.
10López V, Ricart JM, López I, Martín JM, Marton D, Ortega C, Costa S. Vascular malformation of the glans
penis successfully treated with Nd: YAG laser. Dermatology Online Journal. 2012; 18: 16.
Principal Investigator: Gloria Ribas Despuig (Isabel
Pinazo, Esperanza Jordá, Zaira Mª Pellicer, Antonio Javier González as collaborating researchers)
Beneficiary institution: Fundación Investigación Hospital
Clínico Universitario de Valencia
Duration: 2011-2013
• Reference: AP-032/10
Title: Determinación de parámetros clínico-patológicos y
moleculares implicados en la regresión espontánea de las
neoplasias melanocíticas cutáneas.
Principal Investigator: Carlos Monteagudo (JM Marín as
collaborating researcher)
Funding body: Conselleria de Sanitat – EVESP
Beneficiary institution: Fundación de la Comunidad Valenciana Centro de Investigación Príncipe Felipe
Duration: 2010-2012
4.2.6. Department of Gastroenterology
and Digestive diseases
Publications
Original articles
1Felipo V, Urios A, Montesinos E, Molina I, Garcia-Torres
ML, Civera M, Olmo JA, Ortega J, Martinez-Valls J, Serra
MA, Cassinello N, Wassel A, Jordá E, Montoliu C. Contribution of hyperammonemia and inflammatory factors to
cognitive impairment in minimal hepatic encephalopathy.
Metabolic Brain Disease. 2012 Mar; 27(1): 51-8. IF: 2,198
Editorial
Title: Impacto de la susceptibilidad genética y de la
exposición solar sobre los niveles de vitamina D en
pacientes con melanoma.
1Mínguez Pérez M, García-Granero E. Usefulness of anal
ultrasonography in anal fistula. Revista Española de Enfermedades Digestivas. 2006 Aug; 98(8): 563-72. IF: 1,548
4
177
Scientific activity
4.2.7. Department of Gastroenterology
and Hepatology
• Gastroenterology Division: Gastrointestinal bleeding;
Acute Pancreatitis, Inflammatory bowel disease; Digestive motor diseases; Non-malignant rectal-anal
Pathology.
• Hepatology Division: Hepatic Encephalopathy. Clinical, diagnostic and biochemical aspects; Non-alcoholic
steatohepatitis. Clinical, diagnostic and therapeutic aspects; Hepatitis virus: epidemiologic, therapeutic and
immunoprofilaxis aspects.
Publications
Original articles
1Felipo V, Urios A, Montesinos E, Molina I, Garcia-Torres
178
4
ML, Civera M, Olmo JA, Ortega J, Martinez-Valls J, Serra
MA, Cassinello N, Wassel A, Jordá E, Montoliu C. Contribution of hyperammonemia and inflammatory factors to
cognitive impairment in minimal hepatic encephalopathy.
Metabolic Brain Disease. 2012 Mar; 27(1): 51-8. IF: 2,198
• Reference: Expediente 2010/001
Title: Determinación del flujo sanguíneo en diferentes
áreas cerebrales de pacientes cirróticos. Correlación
con alteraciones neurológicas. Evaluación de su utilidad en el diagnóstico de la encefalopatía hepática
mínima.
Principal Investigator: Carmina Montoliu Félix (Miguel Ángel Serra Desfilis, Abdallah Wassel, José Manuel Rodrigo as collaborating researchers)
Duration: 2010-2012
• Title: Estudio de la alteración de la capacidad de conducción de vehículos en pacientes con cirrosis hepática. Identificación de posibles indicadores psicométricos y neurofisiológicos.
Principal Investigator: Vicente Felipo (Carmina Montoliu, Miguel Ángel Serra, Abdallah Wassel, José Manuel Rodrigo as collaborating researchers)
Funding body: Fundación Abertis
Duration: 2010-2012
Editorial
1Mínguez
• Reference: BFU2009-12909
Pérez M, García-Granero E. Usefulness of
anal ultrasonography in anal fistula. Revista Española
de Enfermedades Digestivas. 2006 Aug; 98(8): 56372. IF: 1,548
• Title: Capacidad de conducción de vehículos durante
el tratamiento antiviral de la infección crónica por virus
C de la hepatitis. Relación con test psicológicos y mecanismos bioquímicos inmunomoduladores.
Title: Factores endoteliales en la obesidad mórbida
con estatosis o esteatohepatitis no alcohólica.
Principal Investigator: José María Vila Salinas (Paloma Lluch as collaborating researcher)
Duration: 2010-2012
Principal Investigator: Juan Angel del Olmo Puchalt
Duration: 2009-2012
4.2.8. Department of Pharmacy
• Pharmacological evaluations on oncology treatments.
Scientific activity
• Reference: EC10-318
Title: Tratamiento anticipado con ganciclovir de la infección activa por el citomegalovirus (CMV) en el paciente crítico en ventilación mecánica con sepsis grave
o shock séptico.
Principal Investigator: Teresa Torrecilla Junyent
Duration: 2011-2015
4.2.10. Department of Biochemistry and Clinical Analysis
• Non-invasive prenatal genetic diagnosis: extraction of fetal
DNA from the maternal plasma. Quantification and validation of this technique.
• Profile of RNA expression in limphocytes after oral overload with unsaturated fat in two insulin-resistant models:
abdominal obesity and type 2 diabetes.
• Implication of polymorphisms in PCR and System IL-18
genes in the modulation of the insulin-resistance risk and
the development of arteriosclerosis.
• Receptive sensor for calcium and osteoformation.
4.2.9. Department of Gynecology and
Obstetrics
Publications
Publications
Original articles
1Castillo JC, Dolz M, Moreno J, Gijón L, Ferrer R, Ferrero E, Bonilla-Musoles F. Triggering with GnRH agonist
in oocyte-donation cycles: oestradiol monitoring is not
necessary during ovarian stimulation. Reproductive Biomedicine Online. 2012 Feb; 24(2): 247-50. IF: 2,042
2Bonilla-Musoles
F, Castillo JC, Caballero O, PérezPanades J, Bonilla F Jr, Dolz M, Osborne N. Predicting ovarian reserve and reproductive outcome using
antimüllerian hormone (AMH) and antral follicle count
(AFC) in patients with previous assisted reproduction
technique (ART) failure. Clinical and Experimental
Obstetrics & Gynecology. 2012; 39(1): 13-8. IF: 0,429
Letters
1Raga
F, Bonilla-Musoles F, Castillo JC. SonoAVC:
a new tool in early diagnosis of patent urachus with
bladder prolapse. Ultrasound in obstetrics & gynecology. 2012 Feb; 39(2): 241-2. IF: 3,007
2Solves P, Perales A, Fillol M, Bonilla-Musoles F, Mirabet V. Cord blood quality after vaginal and cesarean deliveries. Transfusion. 2012 Sep; 52(9): 2064-6. IF: 3,217
Original articles
1Núñez J, Núñez E, Sanchis J, Bodí V, Fonarow GC,
Miñana G, Palau P, Bertomeu-González V, Carratalá
A, Mainar L, Chorro FJ, Llàcer A. Antigen carbohydrate
125 and brain natriuretic peptide serial measurements
for risk stratification following an episode of acute heart
failure. International Journal of Cardiology. 2012 Aug
9; 159(1): 21-8. IF: 7,078
2Codoñer-Franch
P, Tavárez-Alonso S, Simó-Jordá R,
Laporta-Martín P, Carratalá-Calvo A, Alonso-Iglesias E.
Vitamin D status is linked to biomarkers of oxidative stress,
inflammation, and endothelial activation in obese children.
Journal of Pediatrics. 2012 Nov; 161(5): 848-54. IF: 4,115
3 García de la Asunción J, Perez Solaz A, Carrau M, Belda
FJ, Perez Griera J, Garriges B. Different oxidative stress
marker levels in blood from the operated knee or the antecubital vein in patients undergoing knee surgery: A tourniquet-induced ischemia–reperfusion model. Redox Report.
2012 vol 17 no 5. IF: 1,732
4 Torregrosa I, Montoliu C, Urios A, Elmlili N, Puchades MJ,
Solís MA, Sanjuán R, Blasco ML, Ramos C, Tomás P, Ribes J,Carratalá A, Juan I, Miguel A. Early biomarkers of
acute kidney failure after heart angiography or heart surgery in patients with acute coronary syndrome or acute
heart failure. Nefrología. 2012; 32(1): 44-52. IF: 1,00
4
179
Scientific activity
5 Bodi V, Sanchis J, Morales JM, Marrachelli VG, Nunez J,
Forteza MJ, Chaustre F, Gomez C, Mainar L, Minana G,
Rumiz E, Husser O, Noguera I, Diaz A, Moratal D, Carratalá A, Bosch X, Llacer A, Chorro FJ, Viña JR, Monleon
D. Metabolomic profile of human myocardial ischemia by
nuclear magnetic resonance spectroscopy of peripheral
blood serum: a translational study based on transient coronary occlusion models. Journal of the American College
of Cardiology. 2012 May 1; 59(18): 1629-41. IF: 1,456
6 Soro M, Gallego L, Silva V, Ballester MT, Lloréns J, Alvariño A, García-Perez ML, Pastor E, Aguilar G, Martí FJ,
Carratalá A, Belda FJ. Cardioprotective effect of sevoflurane and propofol during anaesthesia and the postoperative period in coronary bypass graft surgery: a double-blind
randomised study. European Journal of Anaesthesiology.
2012 Sep 6. IF: 2,231
7 Sanchis J, Bardají A, Bosch X, Loma-Osorio P, Marín F,
Sánchez PL, Núñez J, Carratalá A, Barrabés JA. Usefulness of high-sensitivity troponin T for the evaluation
of patients with acute chest pain and no or minimal myocardial damage. American Heart Journal. 2012 Aug;
164(2): 194-200.e1. IF: 4,651
delos con resistencia a la insulina: obesidad abdominal y diabetes tipo 2.
Principal Investigator: Juan Francisco Ascaso Gimilio
(Arturo Carratalá as collaborating researcher)
Beneficiary institution: Fundación Investigación Hospital Clínico Universitario de Valencia
Duration: 2011-2013
• Reference: PS09/01687
Title: Receptor sensor del calcio y osteoformación.
Principal Investigator: Antonio Cano Sánchez (Paz Laporta as collaborating researcher)
Funding body: Ministerio de Sanidad, Servicios Sociales
e Igualdad
Duration: 2010-2012
8 Monge-Argilés JA, Sánchez-Payá J, Muñoz-Ruiz C, Pam180
4
pliega-Pérez A, Gómez-López MJ, Rodríguez Borja E,
Montoya-Gutiérrez J, Leiva-Santana C. Patients with mild
cognitive impairment and a reduced CSF Ab(1 – 42) protein progress rapidly to Alzheimer´s disease. Neurología
2012 Jan; 27(1):28-33. IF: 0,79
4.2.11.Department of Maxillofacial surgery
• Reference: FIBLEX08/04
Title: Implicaciones del estrés oxidativo en la esterilidad
masculina: análisis de marcadores bioquímicos en plasma
seminal y su asociación con parámetros del seminograma
y la capacitación espermática.
Principal Investigator: Mª Consuelo Tormo Díaz (Celia
Villalba as collaborating researcher)
• Research for the development of added-value implantations through the additive manufacture for the sociosanitary sector.
• Research on the approaching via for installing a neuromodulator in the sphenopalatine ganglion oriented to
the treatment of Cluster cefaleas.
• Research on planning in Dentofacial Deformities.
Funding body: Fundación para la Investigación Biomédica del Hospital General Universitario de Elche
• Research on cervical metastatic adenopathies: diagnostic study.
Beneficiary institution: Fundación Investigación Hospital Clínico Universitario de Valencia
• Research on materials involved in ostium regeneration.
Duration: 2012
Title: Perfil de expresión de ARN en linfomonocitos
tras sobrecarga oral con grasa insaturada en dos mo-
• Research on prosthesis reconstruction in the ATM:
oral infection and Cancer.
Publications
Scientific activity
Original articles
metabolism in the Acute Coronary Syndrom in cooperation with the Nephrology Service.
1Puche M, Guijarro-Martínez R, Pérez-Herrezuelo G,
Miragall L, Iglesias ME, Martínez-Costa C. The hypothetical role of congenital hypotonia in the development of early coronoid hyperplasia. Journal of Craniomaxillofacial Surgery. 2012 Sep; 40(6): e155-8. IF: 1,643
2Hernández-Alfaro F, Guijarro-Martínez R. Endoscopically assisted tunnel approach for minimally invasive
corticotomies: a preliminary report. Journal of Periodontology. 2012 May; 83(5): 574-80. IF: 2,602
3Hernández-Alfaro F, Ruiz-Magaz V, Chatakun P, Guijarro-Martínez R. Mandibular reconstruction with tissue engineering in multiple recurrent ameloblastoma.
International Journal of Periodontics & Restorative
Dentistry. 2012 Jun; 32(3): e82-6. IF: 1,197
4Triaca A, Brusco D, Guijarro-Martínez R. Nasal wall
lateralization: a novel technique to improve nasal
airway obstruction. British Journal of Oral and Maxillofacial Surgery. 2012 Feb 18. IF: 1,95
5Guijarro-Martínez
R, Hernández-Alfaro F. Management of maxillofacial hard and soft tissue discrepancy
in Möbius sequence: clinical report and review of the
literature. Journal of Craniomaxillofacial Surgery. 2012
Jan; 40(1):11-6. IF: 1,643
6Bagan J, Sheth CC, Soria JM, Margaix M, Bagan L.
Bisphosphonates-related osteonecrosis of the jaws:
a preliminary study of salivary interleukins. Journal of
Oral Patholology & Medicine. 2012 Nov 15. IF: 1,628
4.2.12. Department of Critical Care
Publications
Original articles
1Torregrosa I, Montoliu C, Urios A, Elmlili N, Puchades
MJ, Solís MA, Sanjuán R, Blasco ML, Ramos C, Tomás P, Ribes J, Carratalá A, Juan I, Miguel A . Early
biomarkers of acute kidney failure after heart angiography or heart surgery in patients with acute coronary
syndrome or acute heart failure. Nefrologia. 2012;
32(1): 44-52. IF: 1,00
2Juan-García I, Puchades MJ, Sanjuán R, Torregrosa I,
Solís MÁ, González M, Blasco M, Martínez A, Miguel A.
Echocardiographic impact of hydration status in dialysis
patients. Nefrologia. 2012; 32(1): 94-102. IF: 1,00
3Martín-Loeches I, Sole-Violán J, Rodríguez De Castro
F, García-Laorden MI, Borderías L, Blanquer J, Rajas O Briones Ml, Aspa J, Herrera-Ramos E, MarcosRamos JA, Sologuren I, González-Quevedo N, FerrerAgüero JM, Noda J, Rodríguez-Gallego C. Variants at
the promoter of the interleukin-6 gene are associated
with severity and outcome of pneumococcal community-acquired pneumonia. Intensive Care Medicine.
2012; 38(2): 256-62. IF: 5,399
4Lorente L, Iceta R, Martín Mm, López-Gallardo E, SoleViolán J, Blanquer J, Labarta L, Díaz C, Jiménez A, Montoya J, Ruiz-Pesini E. Survival and mitochondrial function
in septic patients according to mitochondrial DNA haplogroup. Critical Care. 2012; 16(1): R10. IF: 4,607
5Delgado-Rodríguez M, Castilla J, Godoy P, Martín V,
• Involment in the Research Study on PROCELL, in cooperation with the Cardiology Service about Acute Ischemic Cardiopathy.
• Involment in the TAO Research Study in cooperation
with the Cardiology Service about Acute Ischemic Cardiopathy.
• Research on glucid metabolism in the Acute Coronary
Syndrome.
• Research on the phosphorus-calcium and vitamin D
Castro A, Gónzález-Candelas F, Mayoral JM, Quintana JM, Pumarola T, Tamames S, Sáez M, Domínguez
A, CIBERESP Cases and Controls in Pandemic Influenza Working Group. Prognosis of hospitalized
patients with 2009 H1N1 influenza in Spain: influence
of neuraminidase inhibitors. Journal of Antimicrobial
Chemotherapy. 2012 Jul; 67(7): 1739-45. IF: 5,068
6Díaz E, Martín-Loeches I, Canadell L, Vidaur L, Suárez D, Socias L, Estella A, Gil Rueda B, Guerrero JE,
Valverdú-Vidal M, Vergara JC, López-Pueyo MJ, Magret M, Recio T, López D, Rello J, Rodríguez A, H1N1
4
181
Scientific activity
SEMICYUC-CIBERES-REIPI Working Group (GETGAG). Corticosteroid therapy in patients with primary
viral pneumonia due to pandemic (H1N1) 2009 influenza. Journal of Infection. 2012; 64(3): 311-8. IF: 4,126
7Laserna E,
Sibila O, Aguilar P, Mortensen E, Anzueto
A, Blanquer J, Sanz F, Rello J, Marcos Pj, Velez Mi,
Aziz N, Restrepo MI. Hypocapnia and hypercapnia are
predictors for ICU admission and mortality in hospitalized patients with community-acquired pneumonia.
Chest. 2012; 142(5): 1193-9. IF: 5,25
8Picazo
J, Alonso L, Aristegui J, Bayas J, Sanz J, Del
Amo P, Cobos J, Rodríguez-Salazar J, Sánchez-Pastor
M, De La Cámara R, Carratalá J, Cañada J, GonzálezDel Castillo J, Aldaz P, Pérez-Escanilla F, Barberán J,
Rodríguez A, Vigil-Escribano D, Espinosa J, Blanquer J,
González-Romo F. Consensus document on vaccination
against influenza in health care workers. Revista Española de Quimioterapia. 2012; 25(3): 226-39. IF: 0,81
182
4
12Launes
C, García-García J, Martínez-Planas A, Moraga F, Astigarraga I, Arístegui J, Korta J, Salado C,
Quintana JM, Soldevila N, Domínguez A, CIBERESP
Cases and Controls in Pandemic Influenza Working Group. 2009 H1N1: risk factors for hospitalization in a matched case-control study. European journal
of pediatrics. 2012; 171(7): 1127-31. IF: 1,879
13González-Candelas
F, Astray J, Alonso J, Castro A,
Cantón R, Galán JC, Garin O, Sáez M, Soldevila N,
Baricot M, Castilla J, Godoy P, Delgado-Rodríguez
M,Martín V, Mayoral JM, Pumarola T, Quintana JM,
Tamames S, Domínguez A, CIBERESP Cases And
Controls In Pandemic Influenza Working Group.
Sociodemographic factors and clinical conditions associated to hospitalization in influenza A (H1N1) 2009
virus infected patients in Spain, 2009-2010. PLoS
One. 2012; 7(3). Epub 2012 Mar 7. IF: 4,092
Letter
9Domínguez A, Castilla J, Godoy P, Delgado-Rodríguez
M, Martín V, Saez M, Soldevila N, Quintana JM, Mayoral JM, Astray J, González-Candelas F, Cantón R,
Tamames S, Castro A, Baricot M, Alonso J, Pumarola
T, CIBERESP Cases and Controls in Pandemic Influenza Working Group Spain. Effectiveness of pandemic and seasonal influenza vaccines in preventing
pandemic influenza-associated hospitalization. Vaccine. 2012; 30(38): 5644-50. IF: 3,766
222(1): 295-7. IF: 3,794
10Godoy P, Castilla J, Delgado-Rodríguez M, Martín V,
Castro A, González-Candelas F, Mayoral JM,Quintana
JM, Pumarola T, Tamames S, Domínguez A, CIBERESP Cases and Controls in Pandemic Influenza
Working Group, Spain. Effectiveness of hand hygiene and provision of information in preventing influenza
cases requiring hospitalization. Preventine Medicine.
2012; 54(6): 434-9. IF: 3,216
11Capelastegui A, Quintana J, Bilbao A,
España PP, Garin O, Alonso J, Astray J, Cantón R, Castilla J, Castro A,
Delgado-Rodríguez M, Godoy P, Gónzález-Candelas F,
Martín V, Mayoral JM, Pumarola T, Tamames S, Soldevila N, Baricot M, Domínguez A, CIBERESP Cases
and Controls in Pandemic InfluenzaWorking Group,
Spain. Score to identify the severity of adult patients
with influenza A (H1N1) 2009 virus infection at hospital
admission. European journal of clinical microbiology &
infectious diseases. 2012; 31(10): 2693-701. IF: 2,859
Thesis
1Thesis
title: Control metabólico e infeccioso en pacientes críticos mediante la administración de una dieta enteral específica para diabetes suplementada con
glutamina.
Doctoral candidate: Mª del Mar Juan Díaz
Director(s): Alfonso Mesejo Arizmendi and Juan Francisco Ascaso Gimilio
2Thesis title: Influencia de los biomarcadores de lesión
cerebral BNP, DD, MMP-9 y S-100B y de marcadores
de la inflamación en el pronóstico de la hemorragia
cerebral espontánea en fase aguda.
Doctoral candidate: Ainhoa Serrano Lázaro
Director(s): Alfonso Mesejo Arizmendi and Josep Redón i Mas
Scientific activity
4.2.13.Department of Preventive Medicine
labelled purple tomatoes. Plant Biotechnology Journal.
2012 Apr; 10(3): 341-52. IF: 5,442
2Alcalá
• Comparative evaluation of Corporal Decontamination
protocols in patients infected/colonized by multiresistant
germs (SAMR).
L, Martín A, Marín M, Sánchez-Somolinos M,
Catalán P, Peláez, Bouza E, Spanish Clostridium
difficile Study Group. The undiagnosed cases of
Clostridium difficile infection in a whole nation: where
is the problem?. Clinical Microbiology and Infection.
2012 Jul; 18(7): E204-13. IF: 4,54
• Avoidable hospitalization and evaluation on the prevention of cardiovascular diseases.
3Midgley SE, Bányai K, Buesa J, Halaihel N, Hjulsager
• Habits modification after a health education intervention
in a population in risk of suffering colorectal cancer.
• Evaluation of the effect of sistematized evaluation processes and planification in nursing care on patient’s security.
Publications
CK, Jakab F, Kaplon J, Larsen LE, Monini M, PoljšakPrijatelj M, Pothier P, Ruggeri FM, Steyer A, Koopmans
M, Böttiger B. Diversity and zoonotic potential of rotaviruses in swine and cattle across Europe. Veterinary
Microbiology. 2012 May 4; 156(3-4): 238-45. IF: 3,327
Letter
Original articles
1 Martínez Morel HR, Nebot Marzal CM, Sánchez Torres
S, Ortí Lucas RM. The risk of nosocomial infection in
informed consent documents. Gaceta Sanitaria. 2012
Oct 16. IF: 1,326
222(1): 295-7. IF: 3,794
Thesis
1Thesis title: Análisis filogenético de los genes VP7 y
4.2.14. Department of Microbiology
NSP4 de cepas de rotavirus de niños con gastroenteritis en Valencia y Castellón.
Doctoral candidate: Carlos J Téllez Castillo
• Molecular epidemic of rotavirus and norovirus.
• Production of pseudo viral particles of norovirus and
analysis of epitopes recognized by monoclonal bodies.
Director(s): Francisco Javier Buesa Gómez
• Functional nourishment in infections by enteroviruses.
• Reference: PI 09/02065
• Maternal nursing’s role in the protection before norovirus infections.
Title: Calicivirus humanos causantes de gastroenteritis: análisis de prevalencia, epidemiología molecular e
interacciones virus-receptor.
Publications
Principal Investigator: Francisco Javier Buesa Gómez
Original articles
1Juárez P, Presa S, Espí J, Pineda B, Antón MT, Moreno V, Buesa J, Granell A, Orzaez D. Neutralizing
antibodies against rotavirus produced in transgenically
Duration: 2010-2012
4
183
Scientific activity
Sanchis J, Bodi V, Nuñez E, Puchades MJ, Palau P,
Merlos P, Llacer A, Miguel A. A Continuous ambulatory
peritoneal dialysis as a therapeutic alternative in patients
with advanced congestive heart failure. European Journal of Heart Failure. 2012; 14(5): 540-548. IF: 4,896
• Reference: CSD2007-00063
Title: Nuevos ingredientes de alimentos funcionales
para mejorar la salud.
Principal Investigator: Francisco Tomás Barberán
(José Vicente Gil as collaborating researcher)
Funding body: Ministerio de Educación, Cultura y
Deporte
4Torregrosa
I, Montoliu C, Urios A, Emilili N, Juan I,
Puchades MJ, Solis MA, Sanjuan R, Blasco ML, Ramos C, Tomás P, Ribes J, Carratalá A, Miguel A. Biomarcadores precoces de fracaso renal agudo tras la
angiografía coronaria o cirugía cardiaca en pacientes
con síndrome coronario o fallo cardiaco agudos. Nefrologia. 2012; 32(1): 44-52. IF: 1,00
Beneficiary institution: Centro de Edafología y Biología Aplicada del Segura
Duration: 2008-2012
4.2.15. Nefrology Service
• A Study on the oxydative stress that was started on
patients with dialysis is nowadays continued together
with the nutritional study in patients with chronic kidney
disease in stages 3, 4 and 5.
• Study on predictive markers of acute renal failure after a cardiac surgery and hemodynamic study (N-gal,
KIM-1, cistatine).
184
4
• The effect of peritoneal dialysis on patients with refractory cardiac insufficiency.
• Study on hepcidin and inflammation markers in patients treated with dialysis and its implication in these
patients’ anemia.
Publications
Original articles
1Juan-García I, Puchades MJ, Sanjuán R, Torregrosa
I, Solís MÁ, González M, Blasco M, Martínez A, Miguel
A. Echocardiographic impact of hydration status in dialysis patients. Nefrologia. 2012; 32(1): 94-102. IF: 1,00
2Herrero-Calvo JA, González-Parra E, Pérez-García R,
Tornero-Molina F, Grupo de Estudio Español Sobre
Anticoagulación en Hemodiálisis. Spanish study of
anticoagulation in haemodialysis. Nefrologia. 2012;
32(2): 143-52. IF: 1,00
3Nuñez
J, González M, Miñana G, Garcia Ramón R,
5
Nuñez J, González M, Miñana G, García Ramón R,
Sanchis J, Bodi V , Puchades MJ, Palau P, Merlos
P, Mascarell B, Miguel A. Continuos ambulatory peritoneal dialysys and clinical outcomes in patients with
refactory congestive heart failure. Revista Española de
Cardiología. 2012; 65: 986-95. IF: 2,53
Thesis
1Thesis title: Integración de la bioimpedancia multifrecuencia, parámetros ecocardiográficos y bioquímicos en la voloración y manejo del estado de hidratación de pacientes
en diálisis.
Doctoral candidate: Isabel Juan García
Director(s): Juan Alfonso Miguel Carrasc and Rafael Sanjuán Máñez
Title: Valor de Cistatina, NGAL, KIM-1, L-FABP e Interleukina-18 como marcadores precoces de insuficiencia renal
aguda en pacientes sometidos a cirugía y cateterismo cardiacos.
Principal Investigator: Juan Alfonso Miguel Carrascosa
Beneficiary institution: Fundación Investigación Hospital
Clínico Universitario de Valencia
Duration: 2011-2013
Scientific activity
between inflammatory activity and brain atrophy in natalizumab treated patients. European Journal of Radiology. 2012 Mar 3. IF: 2,606
4.2.16. Neurology Service
Publications
8 Linde M, Gustavsson A, Stovner LJ, Steiner TJ, Barré
J, Katsarava Z, Lainez JM, Lampl C, Lantéri-Minet M,
Rastenyte D, Ruiz de la Torre E, Tassorelli C, Andrée
C. The cost of headache disorders in Europe: the Eurolight project. European Journal of Neurology. 2012
May; 19(5): 703-11. IF: 3,692
Original articles
1Landgrebe M, Azevedo A, Baguley D, Bauer C, Cacace
A, Coelho C, Dornhoffer J, Figueiredo R, Flor H, Hajak
G, van de Heyning P, Hiller W, Khedr E, Kleinjung T, Koller M, Lainez JM, Londero A, Martin WH, Mennemeier
M, Piccirillo J, De Ridder D, Rupprecht R, Searchfield G,
Vanneste S, Zeman F, Langguth B. Methodological aspects of clinical trials in tinnitus: A proposal for an international standard. Journal of Psychosomatic Research.
2012 Aug; 73(2): 112-21. IF: 3,296
2Dávalos A, Alvarez-Sabín J, Castillo J, Díez-Tejedor E,
Ferro J, Martínez-Vila E, Serena J, Segura T, Cruz VT,
Masjuan J, Cobo E, Secades JJ, International Citicoline Trial on acUte Stroke (ICTUS) trial investigators. Citicoline in the treatment of acute ischaemic
stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet. 2012 Jul
28; 380(9839): 349-57. IF: 38,278
3Bas E, Van De Water TR, Gupta C, Dinh J, Vu L, Mar-
9 Färkkilä M, Diener HC, Géraud G, Láinez M, Schoenen
J, Harner N, Pilgrim A, Reuter U, COL MIG-202 study
group. Efficacy and tolerability of lasmiditan, an oral
5-HT(1F) receptor agonist, for the acute treatment of
migraine: a phase 2 randomised, placebo-controlled,
parallel-group, dose-ranging study. Lancet Neurology.
2012 May; 11(5): 405-13. IF: 23,462
10 Cubo E, Benito-León J, Coronell C, Armesto D, ANIMO
Study Group. Clinical correlates of apathy in patients recently diagnosed with Parkinson’s disease: the ANIMO
study. Neuroepidemiology. 2012; 38(1): 48-55. IF: 2,305
11
12
Benito-León J, Cubo E, Coronell C, ANIMO Study
Group. Impact of apathy on health-related quality of
life in recently diagnosed Parkinson’s disease: the
ANIMO study. Movement Disorders. 2012 Feb; 27(2):
211-8. IF: 4,505
13
Castelló M, Boscá I, Pérez-Miralles FC, Burgal M, Casanova B. Neuronal antigens recognized by cerebrospinal
fluid IgM in multiple sclerosis. Journal of Neuroimmunology. 2012 Jun 15; 247(1-2): 63-9. IF: 2,959
Blanco M, Vivancos-Mora J, Castillo J, registro EPICES. Compliance with the measures for preventing
vascular risk factors in hospitalised patients with acute
stroke. Analysis of a national multi-centre registry: EPICES registry (III). Revista de Neurología. 2012 May 1;
54(9): 523-9.
14
Comi G, Jeffery D, Kappos L, Montalban X, Boyko
A, Rocca MA, Filippi M, ALLEGRO Study Group.
Placebo-controlled trial of oral laquinimod for multiple
sclerosis. New England Journal of Medicine. 2012 Mar
15; 366(11): 1000-9. IF: 53,298
Arias-Rivas S, Vivancos-Mora J, Castillo J, investigadores del registro Epices. Epidemiology of the
subtypes of stroke in hospitalised patients attended by
neurologists: results of the EPICES registry (I). Revista
de Neurología. 2012 Apr 1; 54(7): 385-93.
15
Castillo J, Vivancos-Mora J, registro EPICES. Hospital arrival times and delay before acute stroke patients receive neurological care. Analysis of a national
tínez-Soriano F, Láinez JM, Marco J. Efficacy of three
drugs for protecting against gentamicin-induced hair
cell and hearing losses. British Journal of Pharmacology. 2012 Jul; 166(6): 1888-904. IF: 4,409
4Magraner
MJ, Coret F, Casanova B. The effect of
intravenous immunoglobulin on neuromyelitis optica.
Neurologia. 2012 Jul 27. IF: 0,79
5Beltrán E, Hernández A, Lafuente EM, Coret F, Simó-
6
7
Molinuevo JL, Hernández B, Grupo de Trabajo del
Estudio TRACE. Assessment of the information provided by the medical specialist on Alzheimer’s disease
and that retained by the patient caregivers. Neurologia. 2012 Oct; 27(8): 453-71. IF: 0,79
Magraner M, Coret F, Casanova B. The relationship
4
185
Scientific activity
multi-centre registry: EPICES registry (II). Revista de
Neurología. 2012 Apr 16; 54(8): 461-7.
4.2.18. Otolaryngology Service
• Reference: FP-ENV-2008-226873
Title: Las tecnologías de la comunicación, el medio
ambiente y el cáncer del sistema nervioso central en
la juventud.
Principal Investigator: María Manuela Morales (José
Miguel Láinez as collaborating researchers)
Publications
Original articles
1García-Callejo FJ, Marco-Algarra J, Pla-Gil I, MonzóGandía R, Juantegui-Azpilicueta M, Martínez-Beneyto
P. Pathologic erythrocyte deformability in patients with
sudden sensorineural hearing loss. Acta Otorrinolaringológica Española. 2012 Jul; 63(4): 249-257.
Beneficiary institution: CREAL (Centre de Recerca
en Epidemiología Ambiental)
Duration: 2009-2012
2 Muñoz-Fernández N, Morant-Ventura A, Achiques MT,
Dualde-Beltrán D, Garcia-Callejo FJ, Monrroy-Parada
MV, Pitarch I, Latorre E, Marco-Algarra J. Evolution of
otosclerosis to cochlear implantation. Acta Otorrinolaringológica Española. 2012 Jul; 63(4): 265-271.
4.2.17. Ophthalmology Service
3 Conill Tobías N, Paula Vernetta CD, García Callejo FJ,
Marco Algarra J. Objective tinnitus from palatal myoclonus. Use of botulinum toxin: a case report. Acta Otorrinolaringológica Española. 2012 Sep; 63(5): 391-392.
• Development of the Splenectomy.
• Development of the Canaloplasty.
186
4
Publications
4 García Callejo FJ, Fernández NM, López NS, González PM. Inflammatory pseudotumor of the tonsil. Acta
Otorrinolaringológica Española. 2012 Jan-Feb; 63(1):
62-4.
Original articles
1
2
Shields CL, Kancherla S, Patel J, Vijayvargiya P, Suriano MM, Kolbus E, Badami A, Sharma P, Jacobs E,
Voluck M, Zhang Z, Kansal R, Shields PW, Bianciotto
CG, Shields JA. Clinical survey of 3680 iris tumors
based on patient age at presentation. Ophthalmology.
2012 Feb; 119(2): 407-14. IF: 5,454
Vila-Arteaga J, Stirbu O, Suriano M, Vila-Mascarell
E. A New Technique for Diode Laser Cyclophotocoagulation. Journal of Glaucoma. 2012 Oct 10. IF: 1,776
5
Muñoz-Fernández N, Morant-Ventura A, Achiques
MT, Dualde-Beltrán D, Garcia-Callejo FJ, MonrroyParada MV, Pitarch I, Latorre E, Marco-Algarra J.
Evolution of otosclerosis to cochlear implantation. Acta
Otorrinolaringológica Española. 2012 Jul-Aug; 63(4):
265-71.
6
Monzó-Gandía R, García-Callejo FJ, Calatayud-Blas
AM, Calvo-González J. Laryngeal leishmaniasis. A
case report. Acta Otorrinolaringológica Española. 2012
Oct 29.
7 Bas E, Van De Water TR, Gupta C, Dinh J, Vu L, Martínez-Soriano F, Láinez JM, Marco J. Efficacy of three
drugs for protecting against gentamicin-induced hair
cell and hearing losses. British Journal of Pharmacology. 2012 Jul; 166(6): 1888-904. IF: 4,409
Scientific activity
4.2.19. Pediatric Service
centre epidemiological study. European Respiratory
Journal. 2012; 40: 1502-1507. IF: 5,895
7Nagel
Original articles
G, Weinmayr G, Flohr C, Kleiner A, Strachan
DP, Isaac Phase Two Study Group. Association of
pertussis and measles infections and immunizations
with asthma and allergic sensitization in ISAAC Phase
Two. Pediatriatric Allergy and Immunology. 2012 Dec;
23(8): 737-46. IF: 2,459
1Puche M, Guijarro-Martínez R, Pérez-Herrezuelo G,
Publications
Miragall L, Iglesias ME, Martínez-Costa C. The hypothetical role of congenital hypotonia in the development of early coronoid hyperplasia. Journal of Craniomaxillofacial Surgery. 2012 Sep; 40(6): e155-8. IF:
1,643
2Rives
S, Estella J, Camós M, García-Miguel P, Verdeguer A, Couselo JM, Tasso M, Molina J, Gómez P,
Fernández-Delgado R, Navajas A, Badell I, grupo
cooperativo SHOP (Sociedad Española de HematoOncología Pediátrica). T-cell pediatric acute lymphoblastic leukemia: analysis of survival and prognostic
factors in 4 consecutive protocols of the Spanish cooperative study group SHOP. Medicina Clinica. 2012 Jul
7; 139(4): 141-9. IF: 1,385
3
4
5
Flohr C, Nagel G, Weinmayr G, Kleiner A, Williams
HC, Aït-Khaled N, Strachan DP, ISAAC Phase Two
Study Group. Tuberculosis, bacillus Calmette-Guérin
vaccination, and allergic disease: findings from the International Study of Asthma and Allergies in Childhood
Phase Two. Pediatric Allergy Immunology. 2012 Jun;
23(4): 324-31. IF: 2,459
Morata Alba J, Alpera Lacruz R. Guillain-Barré syndrome and anti-ganglioside antibodies. Anales de Pediatría. 2012 Oct 16. IF: 0,77
• Reference: AP-094/11
Title: Análisis del riesgo de úlceras por presión en
neonatos hospitalizados mediante una nueva escala
de valoración.
Principal Investigator: Pablo García Molina
Funding body: Generalitat Valenciana
Duration: 2011-2012
• Title: Estudio básico sobre el consumo de productos
fermentados con prebióticos de horchata de chufa valenciana en el estreñimiento funcional y diarrea vírica
en la población infantil.
Principal Investigator: Cecilia Martínez Costa
Funding body: Alimentos funcionales y de origen tradicional
Duration: 2011-2012
Strippoli Mpf, Frischer T, Barbato A, Snijders D, Maurer E, Lucas Jsa, Eber E, Karadag B, Pohunek P, Zivkovic Z, Escribano A, O’callaghan C, Bush A, Kuehni
Ce. Management of primary ciliary dyskinesia in Europe: recommendations and clinical practice. European
Respiratory Journal. 2012 Jun; 39 (6):1482-1491. IF:
5,895
6 Pérez-Ruiz E, Caro P, Pérez-Frías J, Cols M, Barrio I,
Torrent A, García Ma, Asensio O, Pastor Md, Luna C,
Torres J, Osona B, Salcedo A, Escribano A, Cortell I,
Gaboli M, Valenzuela A, Alvarez E, Velasco R, García
E. Paediatric patients with a tracheostomy: a multi-
Title: Estudio de la utilidad clinica del perfil de estrés
oxidativo y de la expresión de MIRNAS, en sangre y
en condensado de aire exhalado en pacientes con déficit de alfa-1 antitripsina.
Principal Investigator: Francisco Dasí Fernández
Duration: 2012-2014
4
187
Scientific activity
• Title: Evaluación de la función mitocondrial en leucocitos de pacientes con déficit de alfa-1 antitripsina.
Principal Investigator: Francisco Dasí Fernández
Funding body: Ayuda Intramural para grupos de Investigadores emergentes 2012. Fundación Investigación Hospital Clínico de Valencia
• Reference: PS09/02065
Research projects and grants for research
Duration: 2012
Title: Calicivirus humanos causantes de gastroenteritis: análisis de la prevalencia, epidemiología molecular
e interacciones virus-receptor.
Principal Investigator: Javier Buesa Gómez (Cecilia
Martínez Costa as collaborating researcher)
Duration: 2010-2012
4
2Noelia
Muñoz Fernández, Antonio Morant-Ventura,
Maria Teresa Achiques, Delfina Dualde-Beltrán, F.
Javier García-Callejo, María Victoria Monrroy-Parada,
Ignacia Pitarch, Emilia Latorre, Jaime Marco-Algarra.
Evolución en la otoesclerosis hacia la implantación
coclear. Acta Otorrinolaringologica Española. 2012; 63
(4): 265-271.
188
lective Aurora A kinase inhibitor – in patients with advanced solid tumors. Clinical Cancer Research. 2012,
18 (17): 4764-74. IF: 7,742
4.2.20.Radiology and Diagnosis Service
• Treatment of the Asherman Syndrome through uterine
stem cells injections.
• Ablation the sympathetic peri-renal plexus performed
through radiofrequency, in patients with refractory hypertension in several lines of pharmacologic treatment
and with systolic cardiac dysfunction.
Publications
Original articles
1Cervantes
A, Elez E, Roda D, Ecsedy J, Macarulla T, Venkatakrishnan K, Roselló S, Andreu J, Jung
JA, Sanchis-Garcia JM, Piera A, Blasco I, Maños L,
Pérez-Fidalgo JA, Fingert H, Baselga J, Tabernero J.
Phase 1 pharmacokinetic and pharmacodynamic study of alisertib (MLN8237) – an investigational, oral, se-
• Reference: FP-ENV-2008-226873
Title: Las tecnologías de la comunicación, el medio
ambiente y el cáncer del sistema nervioso central en
la juventud.
Principal Investigator: María Manuela Morales (Delfina Dualde as collaborating research)
Duration: 2009-2012
• Reference: EPI-CT
Title: Estudio de cohorte de niños con exposición
diagnóstica sustancial a radiaciones ionizantes.
Principal Investigator: Elisabeth Cardis (Julio Palmero as collaborating researcher)
Duration: 2012-2015
• Reference: EC11/299
Title: Tratamiento del Síndrome Asherman mediante
inyección en arterias uterinas de células madre.
Principal Investigator: Carlos Simón (Julio Palmero,
Francisco Gil, Cristina Arbona, Francisco Raga as collaborating researchers)
Duration: 2012-2014
Scientific activity
4.2.21. Ortopedic Surgery and
Traumatology Service
Duration: 2010-2013
Publications
Original articles
1 Clérigues V, Guillén MI, Gomar F, Alcaraz MJ. Haem
oxygenase-1 counteracts the effects of interleukin-1?
oninflammatoryandsenescencemarkersincartilagesubchondral bone explants from osteoarthritic patients.
Clinical Science. 2012 Mar 1; 122(5): 239-50. IF: 4,317
• Reference: RD06/0013/2001-RETICEF
Title: GrupoFarmacologíadelaInflamación.
Principal Investigator: Mª José Alcaraz Tormo (Francisco Gomar Sancho as collaborating researchers)
Duration: 2009-2012
2 Clérigues V, Guillén MI, Castejón MA, Gomar F, Mirabet V, Alcaraz MJ. Heme oxygenase-1 mediates
protective effects on inflammatory, catabolic and senescence responses induced by interleukin-1? in osteoarthritic osteoblasts. Biochemical Pharmacology.
2012 Feb 1; 83(3): 395-405. IF: 4,705
3 Lassen MR, Fisher W, Mouret P, Agnelli G, George D,
Kakkar A, Mismetti P, Turpie AG, SAVE Investigators.
Semuloparin for prevention of venous thromboembolism after major orthopedic surgery: results from three
randomized clinical trials, SAVE-HIP1, SAVE-HIP2
and SAVE-KNEE. Journal of Thrombosis and Haemostasis. 2012 May; 10(5): 822-32. IF: 5,731
Thesis
1 Thesis title: Desarrollo de un método no lesivo, basado en la proyección de luz estructurada, para la valoración y ayuda al diagnóstico de las deformidades del
raquis.
Doctoral candidate: Francisco Javier López de la O
Director(s): M. Fe Mínguez Rey
Research projects and grants for research
Title: Estrés oxidativo celular y su relación con la osteonecrosis femoral idiopática.
Principal Investigator: Francisco Gomar Sancho
4
189
190
2
5
2
Clinical
trials
and other
studies
19
5
191
Clinical trials and others studies
5.1. Activity of the Ethical Committee in Clinical Research (ECCR)
INCLIVA Health Research Institute –through its Ethical Committee in Clinical Research (ECCR) – manages the clinical
studies (trials, observational studies, and research projects) of the Hospital Clínico Universitario and the Health Department
Valencia Clínico-Malvarrosa. Furthermore, as an Health Research Institute, it is able to complete new drug and medical product development phases.
As a result of its activity along 2012, the ECCR has processed a total of 114 studies (clinical trials and observational studies): 111 assessed, 110 positively valued, and none denied; 3 are in the course of assessment and 1 pending of approval.
Total of studies presented to ECCR
Not assessed studies by ECCR
114
3
Assessed studies by ECCR
111
Approved studies by ECCR
110
Not approved studies by ECCR
0
Pending of approval studies
1
Number of studies presented to ECCR
5
193
The distribution of these trials by phase is: Phase I: 14, Phase II: 25, Phase III: 33, Phase IV: 2, Observational studies: 36,
others: 4. The following table shows the number of clinical trials and other studies according to their typology.
PHASE
Nº
%
Phase I
14
12,3
Phase II
25
21,9
Phase III
33
28,9
Phase IV
2
1,8
Observational
36
31,6
Others
4
3,5
Total
114
100.0
Number of trials per phase
194
5
The Service of Medical Oncology and Haematology is at the top regarding the presentation of clinical trials. It is followed
by the services of Internal Medicine, Anesthesia and Reanimation, Cardiology, and Neurology. These five services make over
75% of the total processed trials. The following table shows the number of trials presented per service and its percentage.
SERVICE
Number of PI’s
%
Anesthesia and Reanimation
7
6.2
Cardiology
6
5.3
Endocrinology
3
2.6
Digestive Medicine
4
3.5
Internal Medicine
9
7.9
Neurology
6
5.3
Medical Oncology and Haematology
58
50.9
Pediatrics
4
3.5
Psychiatry
3
2.6
Unit of Infectious Diseases
3
2.6
Others
9
7.9
Guardianship of other centers
2
1.7
Total
114
100
Number of trials per service
5
195
The PI distribution shown below indicates that the Service of Medical Oncology and Haematology has 13 PI involved in
clinical trial. It is followed by the Services of Pediatrics and Cardiology with 4. Anesthesia and Reanimation, Internal Medicine and Neurology have 3 PI involved. Services of Endocrinology, Digestive Medicine, and Psychiatry close the table with 2
researchers each one.
SERVICE
196
5
Number of PI’s
%
3
6.8
Cardiology
4
9.1
Endocrinology
2
4.6
Digestive Medicine
2
4.6
Internal Medicine
3
6.8
Neurology
3
6.8
Medical Oncology and Hematology
13
29.5
Pediatrics
4
9.1
Psychiatry
2
4.6
Others
8
18
Total
44
100
Regarding the distribution of studies per promoter, 18 trials are considered Independent Clinical Research (trials from
associations, groups, foundations, and private individuals), and the rest of them have been promoted by the pharmaceutical
industry. When comparing these data with the one from 2011 (19 trials) the figures speak once again about the support to
non-commercial research.
PROMOTER
Nº
PROMOTER
Nº
Abbott Laboratories, S.A.
3
Inserm-ARNS
1
Amgen Inc
3
Independent Clinical Research
18
Ariad Pharmaceuticals, Inc
1
Janssen-Cilag
2
AstraZeneca AB
3
Jennerex Inc
1
Autonomic Technologies
1
Laboratorios Esteve S.A.
3
Baxter Innovations GmbH
1
Lilly S.A.
1
Bayer Hispania S.L.
2
MedImmune LLC
1
BHR Pharma, LLC
1
Medthronic
2
Bial- Industrial Farmacéutica S.A
1
Merck
3
Boehringer Ingelheim España S.A.
2
Merck Sharp&Dohme
3
Boston Scientific
1
Millennium Pharmaceuticals, Inc.
1
Bristol-Myers Squibb International Corporation
1
Mundipharma Pharmaceuticals S.L.
2
Celgene Corporation
2
Nektar Therapeutics
1
Celgene S.L.
2
Nestec Ltd
1
Cochlear Bone Anchored solutions AB
1
Novartis Farmacéutica S.A.
11
DAIICHI SANKYO EUROPE GmbH
1
Novo nordisk
2
Deutsche CLL-Studiengroup
1
Pfizer
2
F. Hoffmann-La Roche Ltd.
6
Pharma Mar S.A.
1
FGK Representative Service GmbH, München
(Germany)
1
Roche Farma S.A.
3
Genentech, Inc.
5
Samsung Electronics Co. Ltd.
1
Gilead Sciences Europe Ltd
1
Sanofi-aventis S.A
5
GlaxoSmithkline S.A.
3
Taiho Pharma USA, Inc
1
Grünenthal
2
Vaxon Biotech
1
Hollister Iberica SA
1
Vivia Biotech
1
5
197
5.2. Assessment activity during last 5 years
The table below confirms the importance of the Committee’s activity during the last five years. The number of studies processed yearly increases not only in the institutional field but also at a national level.
Year
Processed Studies
2007
86
2008
80
2009
77
2010
89
2011
106
2012
110
Number of processed studies
198
5
The ECCR acts as a National Reference Committee issuing a unique report of assessment in the multicentric trials detailed below.
Year
Processed Studies
2007
5
2008
5
2009
7
2010
6
2011
10
2012
7
One of the strategic aims of INCLIVA is to drive and promote translational research: during the period 2008-2012, the number of
Phase I and Phase II trials remains stable or has increased as shown in the table and graph below.
PHASE
2007
2008
2009
2010
2011
2012
Phase I
2
12
10
9
6
14
Phase II
23
23
19
22
30
25
Phase III
34
31
24
28
26
33
Phase IV
10
6
7
6
10
2
Observational
14
8
11
16
31
36
Others
3
0
6
3
3
4
Evolution of clinical trial distribution by phase
5
199
5.3. Ongoing studies in the Health Department Valencia Clínico-Malvarrosa
During 2012, 310 clinical trials have been active. The distribution of clinical trials per service analyzed below uses a semilogarithmic scale due to the great difference between the Service of Medical Oncology and Haematology, and the rest of the
Department’s services.
SERVICE
Nº
13
Cardiology
13
Endocrinology
7
Digestive Medicine
14
Internal Medicine
14
Neurology
11
Medical Oncology and Haematology
Pediatry
6
Psychiatry
5
Unit of Allergy
4
Unit of Infectious Diseases
11
Primary Health Care
12
Urology
6
Others
9
Total
200
5
182
310
The results of the distribution of trials and other studies depending on their typology are the following:
PHASE
Nº
Clinical Trials Phase I
33
Clinical Trials Phase II
89
Clinical Trials Phase III
104
Clinical Trials Phase IV
21
Observational Studies
56
Others
7
Total
310
5
201
6
2
Initiatives
for
research
promotion
20
6
203
Initiatives of research promotion
6.1. Grants for secondments in centers of excellence
As every year, the Institute has announced its Grants for research secondments in centers of excellence, to allow the staff
of the Hospital Clínico to acquire new knowledge and clinical techniques. The awarded researchers and the assigned training
centers are shown in the following table:
Teresa Arnandis Chinesta
Laboratorio Naxionale del Consorzio Interuniversitario per le Biotecnologie (Italy)
Clara Bononad Lozano
Hospital La Paz, Madrid
Laura Botella Maciá
Hospital Beneficencia Portuguesa, Sao Paulo (Portugal)
José Antonio Carbonell López
Hospital John Hopkins, Baltimore (USA)
Nelson Díez Calzadilla
London Bridge Hospital, London (United Kingdom)
Meritxell Forte Vila
New York University School of Medicine, New York (USA)
David Fuster Molina
Brugmann University Hospital, Brussels (Belgium)
Álvaro García-Granero García-Fuster
Hospital North Clinic Minnesota, Minnesota (USA)
Raúl Gómez Gallego
Centro Nacional de Investigaciones Oncológicas CNIO, Madrid
Andrea Gutiérrez Valcárcel
Hospital Mount Sinai, New York (USA)
Ignacio López Blasco
American College of Radiology, Maryland (USA)
María Jesús Montero Hernández
Cleveland Clinic, Cleveland (USA)
Juan Montoro Gómez
University of Washington and Seattle Cancer Care Alliance, Seattle (USA)
6
205
6.2. Training and Teaching Activities
Training Program
The Institute has continued developing, along this year, the Training Program for its professionals with seminars and courses, in order to make progress in the constant improvement.
In particular, courses, seminars and educational conferences have been developed during the year 2012 in the following
categories:
Courses
•RESEARCH TRAINING PROGRAM FOR INTERN AND RESIDENT DOCTORS – In progress. October 2011 - June
2013, October 2012 - June 2014.”
•VI COURSE ON PEDIATRICS MECHANICAL VENTILATION. 7, 8 and 9 June.
•5th HANDS-ON COURSE ON NEUROSURGICAL APPROACHES: CEREBRAL ANEURYSM. 10, 11, 12, and 13
July.
•BREAST CANCER TREATMENT IMPROVEMENTS “OPTIMIZING AND ADAPTING TREATMENTS ACCORDING
TO TUMOR BIOLOGY”. 24 and 25 April 2012.
•EXCELLENCE IN THE RESPIRATORY TREATING UNIT OF THE PULMONARY SERVICE. 25 May, 26 October, 16
November 2012.
•17th COURSE ON MECHANICAL VENTILATION. 7, 8 and 9 March 2012.”
•ADVANCED COURSE ON THERAPY WITH CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII) AND
CONTINUOUS GLUCOSE MONITORING: OPTIMIZING TREATMENT WITH CSII IN CLINICAL PRACTICE. 23
September, 21 October, 11 November, 16 December 2011, 20 January, 24 February and 23 March 2012.”
•III COURSE ON RESEARCH IN PRIMARY HEALTH CARE. 6, 8, 15, 22 and 29 November, and 13 December 2012.
•II ADVANCED COURSE ON DIABETIC EDUCATION. 25 and 30 October, 6, 13 and 20 November 2012.
206
6
•COURSE OF CPR AND AUTOMATED DEFIBRILLATION. 17 and 18 December 2012.
Seminars
•“Toward optimal selection for treatment with anti-angiogenesis and with anti-EGFR drugs: identification of mechanisms of cancer cell sensitivity and resistance.” 18 April.
Prof. Fortunato Ciardiello Full Professor of Medical Oncology Head Laboratory of Experimental Therapeutics, Head
Division of Medical Oncology, Second University of Naples, Italy.
•“Role of the HGF-MET axis in cancer: NSCLC as a model”. 22 June.
Dr. George R Blumenschein, MD Anderson Cancer Center, Houston TX.
•“The Biology of Cancer of Unknown Primary: Where do we stand today?. 19 September.
Proff. Nicholas Pavlidis, MD Professor of Medical Oncology, School of Medicine, University of Ioannina Greece.
•“Lipids, immunity, and atherosclerosis: Ancient Concepts and new prospects”. 22 November.
Dr. M. Castro Cabezas, MD, PhD Internist-endocrinologist/vascular specialist Chair Medical Staff SFG St Franciscus
Gasthuis Rotterdam Dpt. of Internal Medicine Center for Diabetes and Vascular Medicine STZ Center of Expertise.
Conferences
•II CONFERENCE OF THE GROUP OF EXPERIMENTAL CARDIAC ELECTROPHYSIOLOGY (GRELCA) AND BIOMEDICAL ENGINEERING. 30 January 2012.
•CONFERENCE ABOUT DEPARTMENT EVALUATION OF THE CODE STROKE 2012. 10 February 2012.
•III CONFERENCE ABOUT RESEARCH IN PRIMARY HEALTH CARE. 28 November 2012.
•IV VALENCIAN CONFERENCE “TOBBACO USE AND BREATHING”. 8 November 2012.
•CONFERENCE ABOUT TRAINING IN DIABETES. 14 and 15 December 2012.
•CONFERENCE “MANAGEMENT AND INNOVATION IN INSTITUTES OF HEALTH RESEARCH”. 8 November
2012.
•III CONFERENCE OF THE GROUP OF EXPERIMENTAL CARDIAC ELECTROPHYSIOLOGY (GRELCA) AND
BIOMEDICAL ENGINEERING. 20 December 2012.
Other events and activities
•ONCOLOGY AND GYNECOLOGY PRECEPTORSHIP. 8, 9 and 10 March 2012.
•SEMINAR “MULTICOLOR FLOW CYTOMETRY: ANALYSIS AND SORTING”. 25 May 2012.
•SEMINAR Jorge Gayoso “Biological bases and clinical experience in haploidentical hematopoietic transplants”. 20
June 2012.
•WORKSHOP ABOUT ASSERTIVE COMMUNICATION. 12 and 13 November 2012.
6
207
Other activities in which INCLIVA participates
•OFFICIAL MASTER IN BIOINFORMATICS. October 2012 – June 2013.
Universitat de València, INCLIVA and CIPF.
•MASTER OF CLINICAL STUDIES AND TRIALS. November 2012 – June 2013.
Universitat de València.
Doctoral thesis
The teaching activities, in which the researchers attached to this institution also participate, are represented by the 35 doctoral theses defended in 2012.
208
6
PhD Student
Thesis Title
Reading date
Thesis Director
Pedro Font,
María Teresa
Efecto de la sobrecarga oral con grasa insaturada
sobre los marcadores de estrés oxidativo e inflamación. Estudios de lipemia postprandial en sujetos
con hipercolesterolemia familiar heterocigota
01/23/2012
Real Collado, José
Tomás; Carmena
Rodríguez, Rafael
González Segura, Ana
Caracterización de tumores del sistema nervioso
central mediante el análisis de imágenes de microscopía de resonancia magnética nuclear
01/23/2012
Monleón Salvadó,
Daniel; González
Darder, José Manuel;
Cerdá Nicolás, Miguel
Palau Sampio, Patricia
Estrategia invasiva en el síndrome coronario agudo
sin elevación del segmento ST. Aspectos pronósticos. Análisis en población infrarrepresentada en estudios controlados
02/10/2012
Nuñez Villota, Julio;
Sanchis Forés, Juan;
Such Belenguer, Luis
Laguna Fernández,
Andrés
Modificación de la expresión génica en células endoteliales humanas por factores aterogénicos y ateroprotectores
02/24/2012
Hermenegildo
Caudevilla, Carlos
Medrano Plaza,
José Vicente
Inducción de la meiosis en células germinales obtenidas in vitro a partir de células madre pluripotentes
humanas mediante expresión ectópica de las proteínas de unión al RNA DAZL y VASA
03/01/2012
Simón Vallés, Carlos
Téllez Castillo,
Carlos J
Análisis filogenético de los genes VP7 y NSP4 de
cepas de rotavirus de niños con gastroenteritis en
Valencia y Castellón
03/28/2012
Buesa Gómez,
Francisco Javier
Blas García, Ana
Mecanismos celulares y moleculares implicados en
la hepatotoxicidad inducida por efavirenz
03/30/2012
Esplugues Mota, Juan
Vicente; Apostolova
Atanasovska, Nadezda
Ibarrola Villava, Maider
Búsqueda de genes de susceptibilidad a melanoma
esporádico: análisis de las rutas de pigmentación y
reparación del ADN y en procesos de estrés oxidativo
03/30/2012
Ribas Despuig, Gloria
PhD Student
Miñana Escrivá, Gema
Thesis Title
Marcador tumoral antígeno carbohidrato 125 como
marcador biológico en la insuficiencia cardiaca
Reading date
Thesis Director
04/03/2012
Chorro Gascó,
Francisco Javier; Núñez
Villota, Julio
Ruiz Marzal, Fernando
Prune belly versus válvulas uretrales posteriores,
estudio comparativo retrosprectivo 2D-3D
04/27/2012
Bonilla Musoles,
Fernando; Bonilla
Bartret, Francisco
José; Raga Bauxauli,
Francisco
Cebrián Cuenca,
Ana Mª
Estudio epidemiológico de incidencia y análisis de
costes de herpes zóster y neuralgia posherpética en
atención primaria en la Comunidad Valenciana
05/04/2012
Navarro Pérez, Jorge;
Díez Domingo, Javier
Oltra Sempere, María
Rosa
Monitorización ambulatoria de la presión arterial: valor pronóstico en el seguimiento de pacientes con
hipertensión arterial resistente
05/07/2012
Redón Mas, Josep;
Pascual Izuel, Jose
Maria
Lacalle Alba,
María Pilar
Trastorno de aprendizaje inespecífico y su relación
con el peso bajo/normal al nacer: una visión neuropsicológica
05/16/2012
Gadea Domenech,
María Engracia; Espert
Tortajada, Raúl
Juan García, Isabel
Integración de la bioimpedancia multifrecuencia,
parámetros ecocardiográficos y bioquímicos en la
valoración y manejo del estado de hidratación de
pacientes en diálisis
05/17/2012
Miguel Carrasco, Juan
Alfonso; Sanjuán
Máñez, Rafael
Guirado Guillén,
Ramón
Neuronal structural plasticity of the rodent telencephalon: role of PSA-NCAM and modulation by the
antidepressant fluoxetine
05/24/2012
Nácher Roselló, Juan
Salvador
05/29/2012
Simón Vallés, Carlos;
Domínguez Hernández,
Francisco
Garrido Gómez,
Tamara
Estudio proteómico del endometrio humano
Fernández Sánchez,
Manuel
Endometrial study of a novel in vivo embryo culture
device
06/01/2012
Pellicer Martínez,
Antonio; Horcajadas
Almansa, José Antonio;
Simón Vallés, Carlos
Díaz Díaz, Beatriz
Efecto del ejercicio físico crónico sobre las características de la fibrilación ventricular, la refractariedad y el proceso de activación miocárdica durante
la arritmia, en el corazón normalmente oxigenado y
tras isquemia regional aguda
06/08/2012
Such Belenguer, Luis;
Such Miquel, Luis
Parra Giraldo, Germán
Estudio de los efectos del entrenamiento físico sobre
algunas propiedades electrofisiológicas miocárdicas
ventriculares, mediante el análisis de la fibrilación
ventricular inducida. Una investigación en corazón
aislado de conejo
06/08/2012
Such Belenguer, Luis;
Such Miquel, Luis
6
209
PhD Student
210
6
Thesis Title
Reading date
Thesis Director
Serrano Lázaro,
Ainhoa
Influencia de los biomarcadores de lesión cerebral
BNP, DD, MMP-9 y S-100 y de marcadores de la
inflamación, en el pronóstico de la hemorragia cerebral espontánea en fase aguda
06/19/2012
Mesejo Arizmendi,
Alfonso; Redón Mas,
Josep
Juan Díaz,
María Del Mar
Control metabólico e infeccioso en pacientes críticos
mediante la administración de una dieta enteral específica para diabetes suplementada con glutamina
06/19/2012
Mesejo Arizmendi,
Alfonso; Ascaso Gimilio,
Juan F
Delgado Rosas,
Francisco Manuel
Estudio del receptor 2 de la dopamina en ovario humano y efecto de su modulación sobre el síndrome
de hiperestimulación ovárica
06/26/2012
Pellicer Martínez,
Antonio; Gaytán Luna,
Francisco; Gómez
Gallego, Raúl
López De La O,
Francisco Javier
Desarrollo de un método no lesivo, basado en la
proyección de luz estructurada, para la valoración y
ayuda al diagnóstico de las deformidades del raquis
07/04/2012
Cibrián Ortiz, Rosa;
Mínguez Rey, M. Fe;
Salvador Palmer, María
Rosario
Khodayar Pardo,
Parisá
Capacidad protectora de la leche materna frente a
las infecciones por norovirus
07/18/2012
Martínez Costa,
Cecilia; Buesa Gómez,
Francisco Javier
Guill Ibáñez, Antonio
Estudio de los efectos electrofisiológicos de la modificación local de la temperatura en un modelo experimental de corazón aislado mediante un electrodo
específico de alta densidad con modulación térmica
07/20/2012
Tormos Ferrando,
Álvaro; Chorro Gascó,
Francisco Javier; Millet
Roig, José
07/23/2012
Catalá Pizarro,
Montserrat; Rojo
Moreno, Juan
Bonafé Monzó, Neus
Valoración de los efectos clínicos del óxido nitroso
Borraz Gracia, Soraya
Nutrición artificial domiciliaria mediante gastrostomía. Análisis de la respuesta nutricional y de la
aceptación familiar del procedimiento
07/30/2012
Martínez Costa, Cecilia;
Calderón Garrido,
Caterina; Pedrón Giner,
Consuelo
Bañuls Morant, Celia
Esteroles vegetales en bebidas lácteas: efecto sobre
el perfil lipídico y estimación de su biodisponibilidad
09/13/2012
Lagarda Blanch, María
Jesús; Hernández
Mijares, Antonio
Alfaro Rubio, Alberto
Estudio estructural de la mucosa respiratoria post
intubación orotraqueal
10/03/2012
Carda Batalla, María
Del Carmen; Armengot
Carceller, Miguel
Herrer Mambrona,
Isabel
Mecanismos epigenéticos en las células endometriales estromales durante el proceso de decidualización
10/16/2012
Estella Sagrado,
Carlos; Simón Vallés,
Carlos
Hernández Jiménez,
María Jesús
Violencia en relaciones de pareja jóvenes
11/13/2012
Barreto Martín, Pilar
PhD Student
Thesis Title
Reading date
Thesis Director
León Carsí, Irene
Estudio de la respuesta inflamatoria en diferentes
estrategias de cirugía de revascularización coronaria
11/19/2012
Ortega Serrano,
Joaquín; Vicente
Guillén, Rosario
Más Perucho, Aymara
Identificación, caracterización y aislamiento de células madre somáticas en los miomas humanos
11/30/2012
Simón Vallés, Carlos;
Cervelló Alcaraz, Irene
García Herrero,
Sandra
Transcritómica de la infertilidad masculina
12/04/2012
Meseguer Escrivá,
Marcos; Garrido
Puchalt, Nicolás
Gallego Ligorit, Lucía
Toxicidad hepática y renal causada por la administración de sevoflurano 2,5% durante procedimientos
sedativos de larga duración, en modelo animal
12/14/2012
Belda Nácher,
Francisco Javier; Soro
Domingo, Marina
6
211
7
2
INCLIVA
in
figures
21
7
213
INCLIVA in figures
7.1 Dissemination of scientific activity
Since its creation, INCLIVA has shown a gradual increase in the number of scientific publications generated. The indicators
of research quality such as the participation in international journals or the impact factor prove a clear upward trend: the number of indexed works in Medline database has been 512 along the year 2012, figures that represent a 4% over the number of
publications from the previous year.
The following tables and figures show the trend in the last years, and the number and quality of the published manuscripts.
YEAR
NUMBER OF ARTICLES
(PMID)
TOTAL IMPACT FACTOR
AVERAGE IMPACT FACTOR
2007
286
1079,569
3,77
2008
268
1306,366
4,87
2009
310
1225,780
3,95
2010
434
1791,476
4,13
2011
491
1962,977
4,00
2012
512
2059,85
4,02
Cumulative impact factor evolution
Number of articles
214
7
INCLIVA in figures
It should be highlighted that the 82% of works published in indexed journals belong to the quartiles 1 and 2 of their corresponding thematic categories. The distribution by quartiles of journals within their thematic categories is shown below:
INDICATOR
VALUE
Publications
512
Cumulative Impact Factor (IF)
2059
Average Impact Factor
4,02
Publications with IF>7
45
First decile publications
118
International Collaborations
153
Quartile distribution
7.2 Networks of cooperative research
The Carlos III Health Institute (Instituto de Salud Carlos III) develops – through the General Sub-management of Networks
and Centers for the Cooperative Research – the creation of Research Network Structures as RETICS (Thematic Networks in
Cooperative Clinical Research) or CIBER (Centres for Biomedical Network Research). INCLIVA participates in many of these
research structures through its associated groups.
The following table shows the participation in networks according to the line prioritized by the center and by the principal
investigator of the network group publication.
7
215
INCLIVA in figures
Research Area
INCLIVA PI
Scientific Proposal
File
Carlos Hermenegildo Caudevilla
HERACLES network
RD06/0009/0005
Rafael Carmena Rodríguez
CIBERdem
CB07/08/0018
Juan Sanchis Forés
HERACLES network
RD06/0009/1001
Francisco Javier Chorro Gascó
REDINSOR network
RD06/0003/0010
Empar Lurbe i Ferrer
CIBERobn
CB06/03/0039
Ana Lluch Hernández
RETICC
RD06/0020/0080
Samuel Navarro Fos
RETICC
RD06/0020/0102
Esteban Morcillo Sánchez
RIER network
RD08/0075/0016
María Jesús Sanz
CIBERes
CB06/06/0027
Federico V. Pallardó Calatayud
CIBERrer
CB06/07/0073
José Viña Ribes
RETICEF network
2006-RED13-027
Julio Sanjuán Arias
CIBERsam
CB07/09/0006
Guillermo Sáez Tormo
PREDIMED network
RD06/0045/0006
Antonio Hernández-Mijares
CIBERehd
CB06/04/0071
Reproductive Medicine
Carlos Simón Vallés
Network of Cell Therapy
RD06/0010/1006
Others
Rafael Peris Bonet
RETICC
RD06/0020/0033
Cardiovascular
Oncology
Metabolism and Organ
Damage
Other initiatives of the Carlos III Health Institute (Instituto de Salud Carlos III), in which INCLIVA also participates, are as
follows:
The National Biobank Network (Red Nacional de Biobancos), whose mission is to storage and manage the samples for
216
7
research. It is to join the Biobanking and Biomolecular Resources Research Infrastructure (BBMR).
The CAIBER iniciative (Consorcio de Apoyo a la Investigación Biomédica en Red), headed by Dr. Andrés Cervantes, that is
a qualified network for clinical trials which study the most relevant health problems for the Spanish population, such as cancer,
rare diseases, neurological and mental diseases, chronic or cardiovascular diseases. The Institution’s director is Dr. Ruipérez.
INCLIVA in figures
7.3. National and international scientific collaborations
One of the main factors of success for an institution devoted to biomedical research is the development of its potential for
the establishment of scientific collaborations of quality.
It is listed below the main research centers that collaborate actively with researchers from INCLIVA in the development of
scientific projects.
NATIONAL COLLABORATIONS (by Spanish autonomous communities)
ANDALUCÍA
• Hospital Universitario Carlos Haya, Málaga
• Hospital Universitario Reina Sofía, Córdoba
• Hospital Universitario de Valme, Sevilla
• Hospital Universitario Virgen del Rocío, Sevilla
• Hospital Virgen de las Nieves, Granada
• Universidad de Granada, Granada
• Universidad Pablo de Olavide, Sevilla
CANTABRIA
• Instituto de Formación e Investigación Marqués Valdecilla (IFIMAV), Santander
CATALUÑA
• Hospital Clínic, Barcelona
• Hospital Duran i Reynals, Barcelona
• Hospital Santa Creu i Sant Pau, Barcelona
• Hospital Universitari del Mar, Barcelona
• Hospital Vall d’Hebrón, Barcelona
• Hospital Verge de la Cinta, Tortosa, Tarragona
• Institut d’Alta Tecnología-PRBB de Barcelona
• Institut Hospital del Mar d’Investigacions Mèdiques (IMIM), Barcelona
• Institut d’Investigacions Biomédiques August Pi i Sunyer (IDIBAPS), Barcelona
• Institut de Recerca Biomédica, Lleida
• Universitat Autonòma de Barcelona, Barcelona
COMUNIDAD VALENCIANA
• Consejo Superior de Investigaciones Médicas e Instituto de Biomedicina de Valencia (CSIC-IBV), Valencia
• Hospital Arnau de Vilanova, Valencia
• Consorcio Hospital General Universitario de Valencia, Valencia
• Hospital Universitario Dr Peset, Valencia
• Hospital Universitari i Politècnic La Fe, Valencia
7
217
INCLIVA in figures
• Instituto Valenciano de Oncología (IVO), Valencia
• VCL Campus de Excelencia, Valencia
• Universitat Jaime I, Castellón
• Universitat Politècnica de València, Valencia
• Universitat de València, Valencia
• Centro de Investigación Príncipe Felipe, Valencia
• Fundación Oftalmológica del Mediterráneo, Valencia
CASTILLA LA MANCHA
• Hospital General Universitario de Ciudad Real, Ciudad Real
• Universidad de Castilla-La Mancha
CASTILLA LEÓN
• Hospital Universitario Río Hortega de Valladolid, Valladolid
• Universidad de Valladolid, Valladolid
GALICIA
• Universidade de Santiago de Compostela, Santiago de Compostela
• Complexo Hospitalario Universitario de Santiago, Santiago de Compostela
MADRID
• Centro de Biología Molecular Severo Ochoa, CSIC-UAM, Madrid
• Centro de Investigaciones Biológicas, CSIC, Madrid
• Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid
• Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid
• CSIC-Universidad Autónoma de Madrid CSIC-CNB, Madrid
• Fundación Jiménez-Díaz, Madrid
• Hospital Clínico San Carlos, Madrid
• Hospital Ramón y Cajal, Madrid
• Hospital Universitario Gregorio Marañón, Madrid
• Hospital Universitario La Princesa, Madrid
• Instituto de Salud Carlos III, Madrid
• Universidad Autónoma de Madrid, Madrid
• Universidad Complutense de Madrid, Madrid
PAÍS VASCO
• Hospital Universitario de Donostia, San Sebastián
218
7
• Universidad del País Vasco
INCLIVA in figures
INTERNATIONAL COLLABORATIONS (by countries)
GERMANY
• Aachen University Hospital, Aachen
• Justus-Liebig-Universität Gießen, Giessen
• Universität Hamburg, Hamburg
• Universität Würzburg, Würzburg
BELGIUM
• Ghent University Hospital, Ghent
• University of Leuven, Leuven
BRASIL
• Universidad de Sao Paulo, Riberao Preto, Sao Paulo
CANADA
• Dalhousie University, Nova Scotia
• Hamilton Health Sciences and McMaster University, Hamilton
• University of Calgary, Calgary
DENMARK
• University of Southern Denmark, Odense
ESTONIA
• Tartu Ülikool, Tartu
FRANCE
• Centre Hospitalier Universitaire de Saint-Étienne, Loire
• Groupe Hospitalier Pitié-Salpêtrière, Paris
• Hôpital Bichat Claude Bernard, Paris
• Institut de la Génétique et de la Biologie Moléculaire et Cellulaire (IGBMC), Strasbourg
• International Agency for Research on Cancer (IARC), Lyon
IRELAND
• University College Dublin, Dublin
ITALY
• International Center for Genetic Engineering and Biotechnology (ICGEB), Trieste
• Istituto Nazionale Tumori di Milano, Milano
• ITN Cancer Research Center, Mercogliano
• Università degli Studi di Milano-Bicocca, Milano
7
219
INCLIVA in figures
• Università degli Studi di Palermo, Palermo
• Università di Torino, Torino
JAPAN
• Keio University, Tokyo
MOROCCO
• Universidad Abdelmalik Essaadi-Tetuan, Tetuán
NORWAY
• NorLux Neuro-Oncology Laboratory, University of Bergen, Bergen
NETHERLANDS
• Academic Medical Center, Amsterdam
• Comprehensive Cancer Center & Erasmus MC, Rotterdam
• Maastricht University, Maastricht
• Nijmegen Medical Center, Nijmegen
• Universitair Medisch Centrum Utrecht, Utrecht
PUERTO RICO
• Centro de Cáncer Auxilio Mutuo, San Juan
UNITED KINGDOM
• Cambridge University Hospitals NHS Foundation Trust, Cambridge
• The European Bioinformatics Institute - European Molecular Biology Laboratory. EMBL-EBI, Cambridge
• Imperial College, London
• King’s College, London
• London School of Hygiene & Tropical Medicine, London
• MRC Laboratory of Molecular Biology, Cambridge
• National Institute for Biological. Standards and Control (NIBSC), Potters Bar
• Newcastle University, Newcastle
• University of Glasgow, Glasgow
• University of Leeds, Leeds
• William Harvey Research Institute, London
• Wolfson Institute, London
UNITED STATES
220
7
• Harvard School of Public Health, Boston
• MD Anderson Cancer Center, Houston
• Mount Sinai School of Medicine, New York
• Rosalin Franklin University, Chicago
INCLIVA in figures
• Stritch School of Medicine - Loyola University Chicago, Chicago
• University of California, San Francisco
• University of Medicine and Dentistry of New Jersey, New Jersey
• University of North Carolina at Chapel Hill, Chapel Hill
• University of Texas, Austin
• Washington State University, Pullman
RUSSIA
• Institute of Theoretical and Experimental Biophysics, Moscow
SWEDEN
• Göteborgs universitet, Göteborg
• Sahlgrenska University Hospital, Göteborg
• Universitetssjukhuset MAS, Malmö
• University of Uppsala, Uppsala
7.4 Knowledge transfer
With the mission of “driving, promoting, coordinating, and executing a research of quality, incorporating the basic and clinical aspects of the research process, with the aim of contributing to the improvement of citizens’ health and quality of life”,
INCLIVA is fully committed to innovation in health and to the transfer of the knowledge generated to both the National Health
System and the industrial sector.
Knowledge transfer to the Health System
Clinical guidelines are one of the best indicators of transference from research to clinical practice improvement. The following table shows the published guidelines in which authors attached to INCLIVA have participated.
7
221
INCLIVA in figures
PROMOTING JOURNAL
OR ORGANIZATION
RESEARCHER INVOLVED
Revista Española de Anestesiología y Reanimación. 2012;
59:3-24
F Iturri, C Honorato, I Ingelmo, N Fàbregas, P Rama, R
Valero, F Buisán, E Vázquez, AM Verger, R Badenes,
L Valencia and Section of Neuroscience from the
Sociedad Española de Anestesiología, Reanimación y
Terapéutica del Dolor
Clinical guideline of
neuroanesthesiology in
surgery of fenestra.
Considerations
and post-surgical
neuroanesthesiological
behaviour
Revista Española de Anestesiología y Reanimación. 2012;
59:25-37
I Ingelmo, F Iturri, N Fàbregas, C Honorato, P Rama, R
Valero, F Buisán, E Vázquez, AM Verger, R Badenes,
L Valencia, J Hernández and Section of Neuroscience
from the Sociedad Española de Anestesiología,
Reanimación y Terapéutica del Dolor
Guidelines of Antibiotic
Treatment for the Critical
Patient in the Resuscitation
Units
Sociedad Española de Anestesiología, Reanimación y Terapéutica del Dolor. Consensus
Meeting, Valencia, 1 June 2012
Gerardo Aguilar and Group GTIPO-SEDAR
EPICO: Educational Project
for the Critical Patient: Panel
of Experts. Consensus
Meeting: Approval of Action
Measures in patients
suspected of having invasive
Candidiasis
Consensus Meeting, Madrid
20 June 2012 promoted by the
Asociación Española de Micología (AEM)
Aguilar G and Working group EPICO
Menoguideline osteoporosis
from the Asociación Española
para el Estudio de la
Menopausia
Revista Española para el
Estudio de la Menopausia, DL.
B: 18.824-2012. 2012, Pages:
1-44.
Antonio Cano Sánchez
Clinical Therapeutic Protocols
of Endocrinology
Médica Esteve, ISBN:
9788469981320. 2012, Pages:
1-474
Antonio Hernández Mijares,
Marcelino Gómez Balaguer
Hypothalamus-Hypophysis
Functional Evaluation
Médica Esteve. 2012, Pages:
10-25
Carlos Salvador Suárez,
Antonio Hernández Mijares
Multiple Endocrine Neoplasias
Médica Esteve. 2012, Pages:
444-460
Marina T Bergoglio,
Antonio Hernández Mijares
Cardiovascular preventive
recommendations
Atención Primaria. 2012, Volumen: 44 Supl 1: 3-15
A Maiques, C Brotons, F Villar,
J Navarro, JM Lobos, R Ortega, et al.
TITLE
Clinical guideline of
neuroanesthesiology in
surgery of fenestra.
Pre-surgical considerations
and intra-surgical
neuroanesthesiological use
222
7
INCLIVA in figures
TITLE
PROMOTING JOURNAL
OR ORGANIZATION
RESEARCHER INVOLVED
Guideline of Neuroimaging
Biomarkers for Schizophrenia
Edika Med Madrid, ISBN 97884-7877-730-3, 2012
L Marti-Bonmati, J Sanjuán, G Garcia (coord)
Respiratory therapies and
neuromuscular care of patients with respiratory involvement
Manual de Procedimientos
SEPAR, ISBN 84-7989-152-1.
2012
C Cabrera, F Del Campo, S Díaz, J Escarrabill, V Casolivé, JL García, J Sancho, C Zamarrón
Normative on the
management of respiratory
complications in patients with
neuromuscular disease
SEPAR, ISBN 97884-940708-22. 2012
E Farrero, A Antón, CJ Egea, MJ Almaraz, J Masa, I
Utrabo, M Calle, H Verea, E Servera, L Jara, E Barrot,
V Casolivé
Guideline of clinical care
practice in B-cell Chronic
Lymphocytic Leukemia
GELP, ISBN 978-84-695-68088. 2012: 1-65
Anabel Teruel, María José Terol, Mafer Palmero, María
Ángeles Ruiz, Encarna Monzó, Aurelio López, Isidro
Jarque, María José Fernández, Alfonso García, Félix
Carbonell, Rafael Andreu
Guidelines of national
consensus for the
Management of B-cell Chronic
Lymphocytic Leukemia
GELLC, Springer SBM Spain,
2012
José A. García Marco, Pilar Giraldo Castellano, Javier
López Jiménez, Eduardo Ríos Herranz, José Luis Sastre Moral, Mª José Terol Casterá, Francesc Bosch
Spanish Guidelines of
diagnosis and treatment of
MDS and CMML. Treatment
of high-risk MDS.
Hematologica (Spanish ed.).
2012; 97, Suppl 5: 5-58
Guillermo Sanz, David Valcárcel, Consuelo del Cañizo,
Javier de la Serna, María Díez-Campelo, Mar Tormo,
Salut Brunet, Joan Bargay, María Luz Amigo, Valle
Gómez, Teresa Bernal, Patricia Font, María Jesús Arilla,
Mónica Ballesteros, María Calbacho, Fernando Ramos,
Nuria Hernanz, Santiago Bonanad, José Cervera, Lourdes Florensa, Blanca Xicoy
ESH position paper: renal
denervation - an interventional
therapy of resistant
hypertension
Journal of Hypertension. 2012;
30: 837-841
RE Schmieder, J Redón, G Grassi, SE Kjeldsen, G
Mancia, K Narkiewicz, G Parati, L Ruilope, P van de
Borne, C Tsioufis
Knowledge transfer to industry
The number of patents developed in 2012 – a total of 5 – also benefits the ability to innovate, whose aim is the Knowledge
transfer. At the moment, the licenses detailed below have been requested:
Inventors: M Carmen Alvárez, Arturo López, Irma García, Manuel Pérez, Rubén D. Artero, José R. Tormo and Diego Cortés
Title: Phenanthrene derivatives for use as medicaments
Number of Application: EP12197087
Priority Country: Spain
Priority Date: 2012
Entity-holder: Valentia BioPharma
7
223
INCLIVA in figures
Inventors: Carmen Carda, Gloria Gallego, José Luis Gómez and Joan Carles Monllau
Title: Device for fixing a macroporous material to regenerate joint cartilages
Number of Application: P201131625
Priority Date: 10/10/2011
Entity-holder: UPV (52%) UV (24%) FIRHSCSP (24%)
Inventors: Carlos Simón, David Blesa and Antonio Pellicer
Title: Diagnosis of massive failure in the generation of mature oocytes in treatments of controlled ovarian stimulation
Number of Application: EP12382032.6
Priority Country: Europe
Entity-holder: IVIOMICS S.L.
Inventors: José Luis García-Giménez and Federico V. Pallardó
Title: Procedure of Identification of carbonized Histones
Number of Application: PCT/ES2012/070406
Entity-holder: CIBERER-UV
Inventors: Felipe J Chaves, Ana B. García-García and Sebastián Blesa
Title: Methods for DNA rearrengements analysis
Number of Application: 300077376
Entity-holder: Fundación de Investigación Clínico de Valencia-INCLIVA
224
7
7
225
Avda. Menéndez Pelayo, 4 accesorio
46010 Valencia
www.incliva.es
[email protected]

memoria 2012

Transcription

Similar documents

El 16 Ruzafa Valencia Spain

Useful advises to help you protect your Child From domestic

Life changes, the household changes Useful advises to help you

Certificate of Registration Crissair, Inc.

10 Marina Terra - Seaside Realty

DITA VON TEESE, NOVEMBER 2005 SPANK ME, 2002 VINNIE

Houston AIM Updates - AIM-IRS Houston

ICCD report - Childhood Cancer International